
<html lang="en"     class="pb-page"  data-request-id="304b07d9-ded9-4301-a4b3-f396e6f76069"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00611;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management" /></meta><meta name="dc.Creator" content="Alessandro  Bonifazi" /></meta><meta name="dc.Creator" content="Francisco O.  Battiti" /></meta><meta name="dc.Creator" content="Julie  Sanchez" /></meta><meta name="dc.Creator" content="Saheem A.  Zaidi" /></meta><meta name="dc.Creator" content="Eric  Bow" /></meta><meta name="dc.Creator" content="Mariia  Makarova" /></meta><meta name="dc.Creator" content="Jianjing  Cao" /></meta><meta name="dc.Creator" content="Anver Basha  Shaik" /></meta><meta name="dc.Creator" content="Agnieszka  Sulima" /></meta><meta name="dc.Creator" content="Kenner C.  Rice" /></meta><meta name="dc.Creator" content="Vsevolod  Katritch" /></meta><meta name="dc.Creator" content="Meritxell  Canals" /></meta><meta name="dc.Creator" content="J. Robert  Lane" /></meta><meta name="dc.Creator" content="Amy Hauck  Newman" /></meta><meta name="dc.Description" content="The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains μ-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liabilit..." /></meta><meta name="Description" content="The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains μ-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liabilit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 20, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00611" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00611" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00611" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00611" /></link>
        
    
    

<title>Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00611" /></meta><meta property="og:title" content="Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0023.jpeg" /></meta><meta property="og:description" content="The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains μ-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liability. We recently demonstrated that targeting the dopamine D3 receptor (D3R) with highly selective antagonists/partial agonists can reduce opioid self-administration and reinstatement to drug seeking in rodent models without diminishing antinociceptive effects. The identification of the D3R as a target for the treatment of opioid use disorders prompted the idea of generating a class of ligands presenting bitopic or bivalent structures, allowing the dual-target binding of the MOR and D3R. Structure–activity relationship studies using computationally aided drug design and in vitro binding assays led to the identification of potent dual-target leads (23, 28, and 40), based on different structural templates and scaffolds, with moderate (sub-micromolar) to high (low nanomolar/sub-nanomolar) binding affinities. Bioluminescence resonance energy transfer-based functional studies revealed MOR agonist–D3R antagonist/partial agonist efficacies that suggest potential for maintaining analgesia with reduced opioid-abuse liability." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00611"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00611">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00611&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00611&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00611&amp;href=/doi/10.1021/acs.jmedchem.1c00611" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 7778-7808</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00578" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00644" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Dual-Target μ-Opioid Receptor and Dopamine D<sub>3</sub> Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Alessandro Bonifazi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alessandro Bonifazi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2d4c41485e5e4c43495f42034f4243444b4c57441f6d434445034a425b"><span class="__cf_email__" data-cfemail="7d1c11180e0e1c13190f12531f1213141b1c07144f3d131415531a120b">[email protected]</span></a>. Phone: (443)-740-2897. Fax: (443)-740-2111.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alessandro++Bonifazi">Alessandro Bonifazi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7306-0114" title="Orcid link">https://orcid.org/0000-0002-7306-0114</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francisco O. Battiti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francisco O. Battiti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francisco+O.++Battiti">Francisco O. Battiti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Sanchez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Sanchez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Sanchez">Julie Sanchez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Saheem A. Zaidi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Saheem A. Zaidi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bridge Institute, Michelson Center for Convergent Bioscience, Department of Chemistry, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Saheem+A.++Zaidi">Saheem A. Zaidi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Bow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Bow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Bow">Eric Bow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariia Makarova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariia Makarova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariia++Makarova">Mariia Makarova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianjing Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjing Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjing++Cao">Jianjing Cao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anver Basha Shaik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anver Basha Shaik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anver+Basha++Shaik">Anver Basha Shaik</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9894-5544" title="Orcid link">https://orcid.org/0000-0001-9894-5544</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agnieszka Sulima</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agnieszka Sulima</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agnieszka++Sulima">Agnieszka Sulima</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenner C. Rice</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenner C. Rice</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenner+C.++Rice">Kenner C. Rice</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vsevolod Katritch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vsevolod Katritch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bridge Institute, Michelson Center for Convergent Bioscience, Department of Chemistry, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vsevolod++Katritch">Vsevolod Katritch</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3883-4505" title="Orcid link">https://orcid.org/0000-0003-3883-4505</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Meritxell Canals</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meritxell Canals</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meritxell++Canals">Meritxell Canals</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7942-5006" title="Orcid link">https://orcid.org/0000-0002-7942-5006</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Robert Lane</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Robert Lane</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Robert++Lane">J. Robert Lane</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7361-7875" title="Orcid link">https://orcid.org/0000-0002-7361-7875</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Amy Hauck Newman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Hauck Newman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#90f1fef5e7fdf1fed0f9fee4e2f1befef9f4f1befef9f8bef7ffe6"><span class="__cf_email__" data-cfemail="88e9e6edffe5e9e6c8e1e6fcfae9a6e6e1ece9a6e6e1e0a6efe7fe">[email protected]</span></a>. Phone: (443)-740-2887. Fax: (443)-740-2111.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy+Hauck++Newman">Amy Hauck Newman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9065-4072" title="Orcid link">https://orcid.org/0000-0001-9065-4072</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00611&amp;href=/doi/10.1021%2Facs.jmedchem.1c00611" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 7778–7808</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 20, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 April 2021</li><li><span class="item_label"><b>Published</b> online</span>20 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00611" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00611</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7778%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlessandro%2BBonifazi%252C%2BFrancisco%2BO.%2BBattiti%252C%2BJulie%2BSanchez%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D11%26contentID%3Dacs.jmedchem.1c00611%26title%3DNovel%2BDual-Target%2B%25CE%25BC-Opioid%2BReceptor%2Band%2BDopamine%2BD3%2BReceptor%2BLigands%2Bas%2BPotential%2BNonaddictive%2BPharmacotherapeutics%2Bfor%2BPain%2BManagement%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7808%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00611"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1100</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00611" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alessandro&quot;,&quot;last_name&quot;:&quot;Bonifazi&quot;},{&quot;first_name&quot;:&quot;Francisco&quot;,&quot;last_name&quot;:&quot;O. Battiti&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Sanchez&quot;},{&quot;first_name&quot;:&quot;Saheem&quot;,&quot;last_name&quot;:&quot;A. Zaidi&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Bow&quot;},{&quot;first_name&quot;:&quot;Mariia&quot;,&quot;last_name&quot;:&quot;Makarova&quot;},{&quot;first_name&quot;:&quot;Jianjing&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Anver&quot;,&quot;last_name&quot;:&quot;Basha Shaik&quot;},{&quot;first_name&quot;:&quot;Agnieszka&quot;,&quot;last_name&quot;:&quot;Sulima&quot;},{&quot;first_name&quot;:&quot;Kenner&quot;,&quot;last_name&quot;:&quot;C. Rice&quot;},{&quot;first_name&quot;:&quot;Vsevolod&quot;,&quot;last_name&quot;:&quot;Katritch&quot;},{&quot;first_name&quot;:&quot;Meritxell&quot;,&quot;last_name&quot;:&quot;Canals&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Robert Lane&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Hauck Newman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7778-7808&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00611&quot;},&quot;abstract&quot;:&quot;The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains μ-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liability. We recently demonstrated that targeting the dopamine D3 receptor (D3R) with highly selective antagonists/partial agonists can reduce opioid self-administration and reinstatement to drug seeking in rodent models without diminishing antinociceptive effects. The identification of the D3R as a target for the treatment of opioid use disorders prompted the idea of generating a class of ligands presenting bitopic or bivalent structures, allowing the dual-target binding of the MOR and D3R. Structure–activity relationship studies using computationally aided drug design and in vitro binding assays led to the identification of potent dual-target leads (23, 28, and 40), based on different structural templates and scaffolds, with moderate (sub-micromolar) to high (low nanomolar/sub-nanomolar) binding affinities. Bioluminescen&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00611&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00611" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00611&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00611" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00611&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00611" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00611&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00611&amp;href=/doi/10.1021/acs.jmedchem.1c00611" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00611" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00611" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00611%26sid%3Dliteratum%253Aachs%26pmid%3D34011153%26genre%3Darticle%26aulast%3DBonifazi%26date%3D2021%26atitle%3DNovel%2BDual-Target%2B%25CE%25BC-Opioid%2BReceptor%2Band%2BDopamine%2BD3%2BReceptor%2BLigands%2Bas%2BPotential%2BNonaddictive%2BPharmacotherapeutics%2Bfor%2BPain%2BManagement%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D11%26spage%3D7778%26epage%3D7808%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/jmcmar.2021.64.issue-11/20210610/jmcmar.2021.64.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains μ-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liability. We recently demonstrated that targeting the dopamine D<sub>3</sub> receptor (D<sub>3</sub>R) with highly selective antagonists/partial agonists can reduce opioid self-administration and reinstatement to drug seeking in rodent models without diminishing antinociceptive effects. The identification of the D<sub>3</sub>R as a target for the treatment of opioid use disorders prompted the idea of generating a class of ligands presenting bitopic or bivalent structures, allowing the dual-target binding of the MOR and D<sub>3</sub>R. Structure–activity relationship studies using computationally aided drug design and <i>in vitro</i> binding assays led to the identification of potent dual-target leads (<b>23</b>, <b>28</b>, and <b>40</b>), based on different structural templates and scaffolds, with moderate (sub-micromolar) to high (low nanomolar/sub-nanomolar) binding affinities. Bioluminescence resonance energy transfer-based functional studies revealed MOR agonist–D<sub>3</sub>R antagonist/partial agonist efficacies that suggest potential for maintaining analgesia with reduced opioid-abuse liability.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the last decade, the United States has faced a devastating opioid epidemic with an estimate of over 130 people dying from opioid overdose every day.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The misuse and often consequent addiction to opioids (<i>e.g.</i>, prescription pain relievers and synthetic opioids, in general) are a serious national health, social, and economic emergency. Coupled with the SARS-CoV-2 pandemic, the mortality rate involving opioid overdose is increasing, and the need for new therapeutic strategies is more urgent than ever.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> According to recent reports,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> >20% of patients being treated for chronic pain will misuse their opioid prescriptions<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and 8–12% develop opioid use disorders (OUD).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Ultimately, an estimated 5% of patients are reported to transition from misuse of prescription opioids to heroin<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> or other synthetic opioids.</div><div class="NLM_p">The National Institutes of Health (NIH) launched the Helping to End Addiction Long-Term (HEAL) initiative to promote and support innovative research addressing this national health emergency. Moreover, the National Institute on Drug Abuse (NIDA) recently proposed a list of the “ten most wanted” medication development strategies to tackle the opioid epidemic/crisis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Among them, the dopamine D<sub>3</sub> receptor (D<sub>3</sub>R) antagonists and partial agonists are a “new” proposed class of ligands as therapeutics to attenuate opioid self-administration.</div><div class="NLM_p">In the past, D<sub>3</sub>R-selective antagonists, such as <b>GSK598809</b>, have been investigated as potential treatments for psychostimulant use disorder (<i>e.g.</i>, cocaine);<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> however, the potentiation of hypertensive effects observed in dogs produced by cocaine in the presence of this selective D<sub>3</sub>R antagonist prevented further development<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and suggested that this may be a class effect. We recently demonstrated that our novel D<sub>3</sub>R antagonists and partial agonists look promising for the treatment of OUD.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Highly selective antagonists, such as <b>VK4-116 (1)</b> and <b>VK4-40 (2)</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), attenuate oxycodone self-administration and reinstatement to drug seeking, without compromising oxycodone’s antinociceptive effects, in rodents. Importantly, these D<sub>3</sub>R antagonists/partial agonists do not potentiate the cardiovascular effects induced by cocaine or oxycodone in rats.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In combination, these studies support the development of D<sub>3</sub>R antagonists/partial agonists to reduce the risk of opioid misuse and the consequent development of OUD.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug design based on structural modification of canonical synthons inspired by agonists, antagonists, and partial agonists selectively targeting the MOR and D<sub>3</sub>R. Orange boxes denote bivalent templates, and green boxes denote bitopic templates. Variables <b>A</b>, <b>B</b>, and <b>C</b> correspond to the aromatic substitutions seen in compounds <b>1</b>, <b>2</b>, <b>7</b>, <b>10</b>, or <b>11</b>. The general <b>Ar</b> group corresponds to the aromatic substituents in compounds <b>7</b>, <b>9</b>, <b>10</b>, and <b>11</b>. General <b>R</b><sup><b>1</b></sup> and <b>R</b><sup><b>2</b></sup> groups represent H, Me, or OH or (O). Variables <b>Y</b> and <b>Z</b> represent C or N, and variable <b>X</b> is H, OMe, or OH or (O).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Until now, the main target for pain-management therapies and drug development has been the opioid system, in particular, the μ-opioid receptors (MORs), belonging to the G-protein coupled receptors (GPCR) family. However, due to the abuse liability and development of tolerance associated with the most common MOR agonists used in pain therapy, including chronic pain, for which opioid agonists are largely ineffective in the long term,<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> research efforts have been directed toward identifying specific physiological responses associated with MOR agonists’ cellular activation pathways. Functionally biased agonists have been posited to reduce the side effect profile of classic opioid analgesics and augment their utility not only as analgesics but also in the treatment of OUD.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22">(19−22)</a></div><div class="NLM_p">Design, synthesis, and pharmacological characterization of signaling-pathway-biased agonists targeting the MORs allowed the identification of highly selective G-protein-biased agonists, with limited activation of β-arrestin pathways, highlighting different physiological effects mediated by each independent pathway.<a onclick="showRef(event, 'ref19 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref23">(19,23)</a> It has been suggested that the MOR G-protein pathway seems to be the predominant mediator of the analgesic effects of MOR agonists; meanwhile, it has been posited that the simultaneous hindering of β-arrestin recruitment might reduce the respiratory depression and other side effects, such as constipation, associated with opioid-like drugs.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28">(24−28)</a> However, this has been a topic of intensive investigation, and recently, it has been reported that classical MOR agonists, such as <b>morphine</b> and <b>fentanyl</b>, induce dose-dependent respiratory depression and constipation in β-arrestin-2 knock-out mice, similar to what is observed in wild-type mice.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> Subsequent pharmacological evaluation has also shown that MOR G-protein-biased agonists still have abuse potential.<a onclick="showRef(event, 'ref29 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref29 ref32 ref33 ref34">(29,32−34)</a> It is still unclear whether the optimal outcome and pharmacotherapeutic potential of MOR agonists can be gained through selective activation of a particular downstream signaling pathway (functional selectivity) or whether an optimal level partial agonism at multiple pathways may instead provide a route for the development of safer opioids.<a onclick="showRef(event, 'ref31 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref35">(31,35)</a> Independent of the signaling pathways and cellular mechanisms associated with respiratory depression and constipation, abuse liability remains as a serious concern that must be addressed with different drug design approaches.</div><div class="NLM_p">The recognition of D<sub>3</sub>R antagonism/partial agonism as an alternative and nonopioid approach for treatment of OUD, modulating the abuse potential of common prescription opioids (<i>e.g.</i>, oxycodone),<a onclick="showRef(event, 'ref12 ref13 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref15">(12,13,15)</a> combined with the well-established antinociceptive properties of MOR agonists, prompted the idea of generating a novel class of dual-target ligands directed to both the MOR and D<sub>3</sub>R (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In theory, compounds that are both MOR agonists/partial agonists and D<sub>3</sub>R antagonist/partial agonists would have analgesic activity without concomitant abuse liability. Our approach aimed at maintaining the analgesic effects of the classic MOR agonists, while reducing the rewarding properties and subsequent abuse liability as a result of D<sub>3</sub>R antagonism. This drug design may lead to the development of safer dual-target drugs, bridging the most promising pharmacological effects of two classes of molecules/targets previously developed independently. Of note, our drug design was to develop new small molecules endowed with differing ranges of affinities for both targets, independently modulating their physiology/pharmacology rather than toward simultaneous binding of the MOR and D<sub>3</sub>R when in close proximity or in a heteromeric conformation. Nevertheless, if MOR–D<sub>3</sub>R heteromers are demonstrated to exist and are physiologically relevant, these molecules may be interesting tools to probe their pharmacology.</div><div class="NLM_p">Furthermore, several well-known MOR agonists, such as <b>loperamide (3)</b> (peripherally limited potent MOR agonist, FDA-approved for antidiarrhea treatment) and <b>diphenoxylate (4)</b>, share similar structural motifs with the highly potent nonselective D<sub>2</sub>R/D<sub>3</sub>R antagonist <b>haloperidol (5)</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Substituted phenyl-piperazine and/or phenyl-piperidine synthons, common to both classes of ligands, can exploit the structural similarities between MOR and D<sub>3</sub>R proteins, thus achieving dual-target binding. Of note, a similar approach was taken previously toward more effective peripherally limited analgesics, based on loperamide, although implementing a bivalent or bitopic drug design or binding to the D<sub>3</sub>R was not described or presumably intended.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Moreover, <b>methadone (6)</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) also showed low micromolar D<sub>2</sub>R and D<sub>3</sub>R affinity in our binding assays (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), supporting the hypothesis that some of its structural fragments could be used to target not only the MOR orthosteric binding site (OBS) but the D<sub>2</sub>R and D<sub>3</sub>R as well. Unlike <b>6</b>, the synthetic opioid <b>fentanyl</b>, with its completely different structural features, showed an interesting moderate affinity for the dopamine D<sub>4</sub>R subtype but total lack of recognition for either the D<sub>2</sub>R or D<sub>3</sub>R (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This template was not considered in our drug design for this reason and also because, recently, bivalent ligands using fentanyl have been reported to lack antinociceptive activity.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Radioligand Competition Binding Affinity Data for All the MOR Diphenyl PP Analogues Based on <b>3</b>, <b>4</b>, and <b>6</b> at hMOR and hD<sub>2</sub>-like Receptor Subtypes<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0020.gif" alt="" id="gr19" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0021.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All the affinity values are expressed as <i>K</i><sub>i</sub> ± standard error of the mean (SEM), derived from IC<sub>50</sub> values using the Cheng–Prusoff equation,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and calculated as the mean of at least three independent experiments (<i>n</i> = number of independent experiments), each performed in triplicate. ND = not determined.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">No inhibition of specific radioligand binding was observed at the highest tested concentration in one to three independent experiments, each performed in triplicate.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last"><i>K</i><sub>i</sub> value obtained from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>.</p></div></div><div></div></div><div class="NLM_p">Due to the limited availability of reported structure–activity relationships (SARs) for dual-target MOR–D<sub>3</sub>R ligands,<a onclick="showRef(event, 'ref38 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref38 ref40 ref41 ref42">(38,40−42)</a> we used a fragment-based drug design approach, supported by molecular docking, computer-aided drug design (CADD), and extensive <i>in vitro</i> pharmacology to guide SAR, hit optimization, and lead identification.</div><div class="NLM_p">Herein, we refer to bivalent dual-target analogues when an MOR agonist primary pharmacophore (PP) is tethered with a D<sub>3</sub>R antagonist PP; both can bind their respective OBS, eliciting their corresponding opioid agonist and dopaminergic antagonist effects. Consistent with our definition of bitopic ligands,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> we classify these new analogues as bitopic when they incorporate an MOR agonist PP, targeting its corresponding OBS that also has structural features suitable for D<sub>3</sub>R OBS recognition, tethered to a D<sub>3</sub>R secondary pharmacophore (SP), identifying the D<sub>3</sub>R secondary binding pocket (SBP).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Of note, this D<sub>3</sub>R SP may also elicit binding interactions within the MOR SBP. All new compounds represent carefully designed linkers, as tethering fragments, with specific SAR focusing on the linkers’ regiochemistry, stereochemistry, and substituents.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p last">All newly synthesized analogues were tested for their on-target and off-target affinities at the MOR, D<sub>2</sub>R, D<sub>3</sub>R, and D<sub>4</sub>R, in a combination of agonist and antagonist radioligand competition binding assays. Compounds selected as hits, for their promising dual-target and sub-micromolar affinities, were further evaluated in functional bioluminescence resonance energy transfer (BRET) studies to assess their agonist and/or antagonist potencies for the target of interest and possible functional selectivity (biased agonism) for specific signaling pathways.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">This novel class of compounds can be subdivided, as depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A–C, in three general templates: (A) the <i>N</i>,<i>N</i>-dimethyl-2,2-diphenylacetamide, 2,2-diphenylacetonitrile, and 1,1-diphenylbutan-2-one MOR PPs, derived from <b>3</b>, <b>4</b>, and <b>6</b>, respectively (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), were tethered with suitably substituted PPs, inspired by selective and nonselective D<sub>3</sub>R antagonists [<i>e.g.</i>, <b>1</b>, <b>2</b>, <b>PG648 (7)</b>, <b>eticlopride (8)</b> and <b>SB269,652 (9)</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>], <i>via</i> a short ethyl linker chain; (B) the same MOR OBS-binding agonist PPs were linked with D<sub>3</sub>R OBS antagonist PPs <i>via</i> a longer and more complex butyl linker, substituted with a 3-hydroxyl group, or the piperazine or pyrrolidine basic function in several regiochemical combinations; and (C) the MOR agonist PPs were replaced with the more rigid, stereochemically complex, and hindered ethyl-2-(-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ylidene)acetate and 5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ol PP (<b>10</b> and <b>11</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), with structural features reminiscent of previously published D<sub>3</sub>R ligands<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> that we have found to have low micromolar affinity for the MOR as well. This new MOR PP presented key functional groups for extending linkers of multiple lengths, substitutions, rigidity and chirality, and tethering D<sub>3</sub>R PPs (for bivalent dual-target compounds) or D<sub>3</sub>R SPs (<i>e.g.</i>, 2-indoleamide for bitopic dual-target compounds). When possible and appropriate, a complete resolution of the chiral centers at PP, SP, or linkers was performed, and the stereochemical properties of the new analogues have been taken into consideration when generating detailed SAR.</div><div class="NLM_p">The first series of compounds with the 2,2-diphenylbutanenitrile as the MOR PP, inspired by <b>4</b>, were prepared as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Starting from the commercially available 4-bromo-2,2-diphenylbutanenitrile, simple N-alkylation under basic conditions yielded the first group of bivalent MOR–D<sub>3</sub>R hybrids, where the D<sub>3</sub>R PP was represented by 2-phenylethan-1-amine (<b>12</b>), 1-(2,3-dichlorophenyl)piperazine (<b>13</b>), 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (<b>14</b>), and 4-amino-1-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-2-ol (<b>15</b>). This provided initial SAR deduction, by increasing the structural complexity of the D<sub>3</sub>R PP and simultaneously modifying the linker length and substitution. To investigate the optimal regiochemistry for introducing the linker and D<sub>3</sub>R PP, compound <b>18</b> was prepared, where the butyl-4-(2,3-dichlorophenyl)piperazine synthon was introduced to replace the nitrile, while maintaining the MOR 4-(dimethylamino)-2,2-diphenylbutanamide moiety, as seen in both <b>3</b> and <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In detail, 4-bromo-2,2-diphenylbutanenitrile was first N-alkylated with dimethylamine hydrochloride (Me<sub>2</sub>NH·HCl) under basic conditions, followed by hydrolysis of the nitrile in the presence of 48% HBr (aq solution) to yield the HBr salt of amino acid <b>17</b>. Subsequent amidation mediated by EDC, HOBt, and 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> yielded the desired product <b>18</b>. Despite the importance of the α-methyl group of <b>6</b> being well reported in the literature,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> favoring the optimal binding pose within the MOR OBS, we decided to study the SAR of structurally simplified analogues. Thus, <i>via</i> simple Grignard addition to the nitrile <b>16</b>, we prepared the desmethyl-methadone <b>19</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Appropriate primary or secondary amine, K<sub>2</sub>CO<sub>3</sub>, and acetonitrile (ACN), 130 °C, overnight, 8–53%; (b) Me<sub>2</sub>NH·HCl, K<sub>2</sub>CO<sub>3</sub>, and ACN, 130 °C, overnight, 79%; (c) HBr 48% in H<sub>2</sub>O, 100 °C, overnight; (d) <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (EDC), 1-hydroxybenzotriazole hydrate (HOBt), 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><i>N</i>,<i>N</i>-diisopropylethylamine (Hünig’s base, DIPEA), and dichloromethane (DCM), 25 °C, overnight, 6%; and (e) ethyl magnesium bromide (EtMgBr) 3 M in diethyl ether (Et<sub>2</sub>O), toluene, 0 to 110 °C, 3 h, 59%.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, in order to investigate the structural requirement of the D<sub>3</sub>R pharmacophore, in particular, the effect of replacing the basic butyl-4-(2,3-dichlorophenyl)piperazine, with the corresponding amide analogue, HCTU mediated amide coupling of 5-((<i>tert</i>-butoxycarbonyl)amino)pentanoic acid, followed by removal of the Boc-protecting group, and consequent mono N-alkylation with 4-bromo-2,2-diphenylbutanenitrile afforded the desired product <b>21</b>. The longer 5 carbon atom linker, instead of the canonical butyl chain, was chosen because of the increased rigidity of the cyclic amide function and need for extending the tethered PP to an optimal distance.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 1-(2,3-Dichlorophenyl)piperazine, 2-(6-chloro-1-<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), and DCM, 25 °C, 3 h, 59%; (b) trifluoroacetic acid (TFA) and DCM, 25 °C, 24 h; and (c) 4-bromo-2,2-diphenylbutanenitrile, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight, 3% (over two steps).</p></p></figure><div class="NLM_p">The switch from 2,2-diphenylbutanenitrile (<b>4</b>-like analogues) to <i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>3</b>-like analogues) as the MOR PP was achieved, as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Starting from the commercially available <i>N</i>-(3,3-diphenyldihydrofuran-2(3<i>H</i>)-ylidene)-<i>N</i>-methylmethanaminium bromide, simple ring opening with the appropriate primary or secondary amines afforded compounds <b>22</b>, presenting the <b>6</b>-like dimethylamino function, <b>23</b>, where the 2,3-dichlorophenyl piperazine D<sub>3</sub>R scaffold was introduced, as well as <b>24</b>, whose 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile is another common D<sub>2</sub>R/D<sub>3</sub>R antagonist PP fragment, present in well-characterized ligands, such as <b>9</b>.<a onclick="showRef(event, 'ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52">(49−52)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Appropriate secondary amine, K<sub>2</sub>CO<sub>3</sub>, DIPEA (for <b>23</b> and <b>24</b>), ACN, and <i>tert</i>-butyl methyl ether (TBME), reflux, 24 h, 16–91%; (b) 2 N NaOH in H<sub>2</sub>O, 25 °C, 5 min, 100%; (c) Dess–Martin periodinane (DMP), DCM, 0 to 25 °C, 1 h, 60%; and (d) appropriate primary or secondary amine, catalytic acetic acid (cat. AcOH), sodium triacetoxyborohydride (STAB), and 1,2-dichloroethane (DCE), 25 °C, 2.5 h, 12–100%.</p></p></figure><div class="NLM_p">To investigate the effect of the linker length and substitution on the bivalent hybrid analogues, <i>N</i>-(3,3-diphenyldihydrofuran-2(3<i>H</i>)-ylidene)-<i>N</i>-methylmethanaminium bromide was simply washed with 2 N NaOH in H<sub>2</sub>O and extracted with DCM to obtain the alcohol intermediate <b>25</b>, which was then oxidized to the aldehyde using DMP and then mono-N-alkylated <i>via</i> reductive amination conditions with the appropriate primary and secondary amines. This small library of compounds (<b>27</b>, <b>28</b>, <b>29</b>, <b>30</b>, <b>31</b>, and <b>32</b>) covered a large structural variety of canonical D<sub>3</sub>R antagonist PPs, as well as butyl and hydroxyl substituted linkers, known for increasing D<sub>3</sub>R subtype selectivity.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p">Compound <b>34</b>, containing the 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile pharmacophore was synthesized according to <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, <i>via</i> preparation of intermediate <b>33</b> and reductive amination with <b>26</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, cat. KI, ACN, 82 °C, overnight; (b) hydrazine (NH<sub>2</sub>NH<sub>2</sub>) and ethanol (EtOH), 80 °C, 3 h, 94% (over 2 steps); and (c) <i>N</i>,<i>N</i>-dimethyl-4-oxo-2,2-diphenylbutanamide (<b>26</b>), cat. AcOH, STAB, and DCE, 25 °C, 2.5 h, 46%.</p></p></figure><div class="NLM_p">In order to expand the library toward different D<sub>3</sub>R PPs, the canonical piperazine and 1,2,3,4-tetrahydroisoquinoline, inspired by selective D<sub>3</sub>R antagonists and partial agonists (<b>1</b>, <b>2</b>, <b>7</b>, and <b>9</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) were replaced in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> with the highly decorated phenyl-<i>N</i>-(pyrrolidin-2-ylmethyl)benzamide derived from the eticlopride pharmacophore (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Alkylation of (<i>S</i>)-nor-eticlopride (obtained from the NIDA Drug Supply Program) with 4-bromo-2,2-diphenylbutanenitrile yielded compound <b>35</b>, introducing the 2,2-diphenyl-nitrile MOR PP, tethered by an ethyl linker. Meanwhile, the formation of intermediate <b>36</b> allowed the synthesis of analogue <b>37</b>, tethered <i>via</i> the longer butyl-amino linker.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight; (b) NH<sub>2</sub>NH<sub>2</sub> and EtOH, 80 °C, 3 h, 36% (over two steps); and (c) K<sub>2</sub>CO<sub>3</sub> and ACN, 130 °C, overnight, 10–23%.</p></p></figure><div class="NLM_p">Analogous to the approach described above for the phenylpiperazine series, we investigated the replacement of the diphenyl nitrile MOR PP, with the <b>3</b>-like <i>N</i>,<i>N</i>-dimethylamide functional group for the <b>8</b>-based bivalent analogues. In <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, the substituted benzoic acid intermediate was prepared following previous literature procedures.<a onclick="showRef(event, 'ref14 ref54'); return false;" href="javascript:void(0);" class="ref ref14 ref54">(14,54)</a> The benzoic acid was coupled with 2-(4-(2-(aminomethyl)pyrrolidin-1-yl)butyl)isoindoline-1,3-dione, which was freshly prepared <i>in situ via</i> selective Boc-deprotection of <b>38</b>, prior to the HCTU-mediated amide coupling. The phthalimide group in intermediate <b>39</b> was removed, and the resulting primary amine was mono-N-alkylated <i>via</i> reductive amination to yield <b>40</b> as the racemic mixture.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight, 85%; (b) TFA and DCM, 25 °C, 3 h; (c) HCTU and DCM, 25 °C, 48 h, 26%; (d) NH<sub>2</sub>NH<sub>2</sub> and EtOH, 80 °C, 3 h; and (e) cat. AcOH, STAB, and DCE, 25 °C, 12 h, 21% (over two steps).</p></p></figure><div class="NLM_p">In this case, we decided to synthesize the racemic mixture, starting from the commercially available <i>tert</i>-butyl (pyrrolidin-2-ylmethyl)carbamate, because although <b>8</b> favors the (<i>S</i>) absolute configuration at the pyrrolidine ring, we did not want to exclude the possibility of different stereochemical requirements for this bivalent analogue, as we have seen in another series of bivalent/bitopic D<sub>3</sub>R ligands.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">SAR for an alternative MOR PP, with a 3,3-diphenyl substituted pyrrolidine, was investigated through the synthesis of analogues in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. The common starting material 4-bromo-2,2-diphenylbutanenitrile was reacted with lithium aluminum hydride (LAH) to give the primary amine and consequent ring-closure in a one-pot step. Intermediate <b>41</b> was either methylated <i>via</i> treatment with methyl chloroformate followed by <i>in situ</i> LAH reduction to afford <b>42</b> or reacted with propionyl chloride to yield the cyclic amide synthon <b>43</b>. This rather simple PP allowed us to evaluate the effect of structural rigidity in <b>6</b>- and <b>3</b>-like MOR PPs and the effect of replacing the protonatable cyclic amine to a cyclic amide. To prepare the bivalent analogue <b>46</b>, <b>41</b> was initially acylated with 2-chloroacetyl chloride. Subsequent alkylation of racemic <i>tert</i>-butyl (pyrrolidin-2-ylmethyl)carbamate yielded <b>45</b>. Finally, Boc-deprotection and amide coupling afforded the desired product.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) LAH and tetrahydrofuran (THF), 0 to 25 °C, 15 h, 40%; (b) 2-chloroacetyl chloride, DIPEA, and THF, 0 to 25 °C, 1 h; (c) cat. KI, K<sub>2</sub>CO<sub>3</sub> and ACN, 82 °C, 3 h, 74% (over two steps); (d) TFA and DCM, 25 °C, 2 h; (e) HCTU, DIPEA, and DCM, 25 °C, 3 h, 15% (over two steps); (f) methyl chloroformate, DIPEA, and DCM, 25 °C, 1 h; (g) LAH and THF, 0 to 25 °C, 56% (over two steps); and (h) propionyl chloride, DIPEA, and DCM, 40 °C, overnight, 29%.</p></p></figure><div class="NLM_p">As consistently observed in previous work,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> when generating bitopic or bivalent ligand SAR, it is essential to study structural requirements not only for the PP and/or SP but also for regiochemistry and stereochemistry of the linkers, which can play a crucial role in their biological activity.</div><div class="NLM_p">In <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>, we approached a modification of the regiochemistry for the pyrrolidine D<sub>3</sub>R PP scaffold. The final compound <b>48</b> presents the MOR diphenyl-<i>N</i>,<i>N</i>-dimethyl amide PP tethered to the D<sub>3</sub>R PP, <i>via</i> a butyl ether linker fused in position-4 of the pyrrolidine nucleus, in a rel-trans stereochemistry configuration with respect to the <b>8</b> amide PP appended in position-2. This was easily introduced as shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>, starting from <b>47</b><i>via</i> reductive amination and Boc-deprotection to ultimately yield <b>48</b>.</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Cat. AcOH, STAB, and DCE, 25 °C, 4 h; (b) TFA and DCM, 25 °C, overnight, 8.5% (over two steps).</p></p></figure><div class="NLM_p">Extensive <i>in silico</i> docking studies and optimization (see the section below) were directed toward improving the dual-target affinity of these new MOR–D<sub>3</sub>R analogues and guided us to the synthesis of <b>51</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). In particular, the hydroxy substitution of the MOR diphenyl PP was based on the <i>in silico</i> observation that the <i>meta</i>-hydroxy groups will engage a water-mediated hydrogen bond network observed in several known opioid ligands while being well tolerated by the D<sub>3</sub>R SP binding site.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Titanium tetrachloride (TiCl<sub>4</sub>), triethylamine (TEA), and DCM, 0 to 25 °C, overnight, 58%; (b) 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine, cat. AcOH, STAB, and DCE, 25 °C, 4 h, 88%; (c) H<sub>2</sub> (50 psi), Pd/C (20% wt), and EtOH, 25 °C, 12 h; (d) HBr 33% in AcOH; 118 °C, 48 h, 13–31%; (e) 1-(2-chloro-3-ethylphenyl)piperazine,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> cat. AcOH, STAB, and DCE, 25 °C, 4 h, 88%; and (f) H<sub>2</sub> (30 psi), Pd/C (20% wt), and EtOAc/EtOH (2:1), 25 °C, 3 h, 75%.</p></p></figure><div class="NLM_p">Homologation of the commercially available bis(3-methoxyphenyl)methanone in the presence of TiCl<sub>4</sub> and TEA<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> allowed the formation of the α,β-unsaturated aldehyde <b>49</b>. Reductive amination in the presence of 2,3-dichlorophenyl piperazine yielded <b>50</b>, which was hydrogenated in the presence of Pd/C. The crude mixture was then subsequently O-demethylated with 33% HBr in AcOH (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).</div><div class="NLM_p">High-resolution mass spectroscopy (HRMS) and NMR analyses revealed the loss of both chlorine atoms in final product <b>51</b>. Retrospective analyses of the previous synthetic steps and intermediates showed that the loss of both chlorine atoms occurred during hydrogenation while reducing the styrenyl olefin. Unfortunately, dehalogenation and concomitant hydrogenation appear to occur faster than the reduction of the desired olefin. Despite replacing Pd/C with PtO<sub>2</sub>, the solvent (from EtOH to EtOAc), and H<sub>2</sub> pressure (from 50 to 15–20 psi), the same reaction outcome was observed. Nevertheless, we proceeded in testing <b>51</b>, as a proof of concept to validate the biological activity of the newly proposed bis-phenol PP to target the MOR.</div><div class="NLM_p">The 1-(2-chloro-3-ethylphenyl)piperazine scaffold proved to be resistant to hydrogenation conditions<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and was introduced as the D<sub>3</sub>R PP tethered to the MOR bis-phenol scaffold (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Intermediate <b>52</b> was readily prepared by reductive amination, followed by milder hydrogenation conditions (30 psi H<sub>2</sub>, using a mixture of EtOAc/EtOH 3:1 as a solvent, for 3 h of total reaction time) to obtain the saturated analogue <b>53</b>. Partial and total O-demethylation was again achieved in the presence of 33% HBr in AcOH, and respective products <b>54</b> (obtained and tested as the racemic mixture) and <b>55</b> were isolated and tested <i>in vitro</i>.</div><div class="NLM_p">To further expand SAR on the MOR PP, in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>, we synthesized a new library of bitopic analogues presenting different phenylmorphan nuclei as PPs to target the MOR and the well-known 2-indoleamide SP to target D<sub>3</sub>R SBP. We were motivated to use this combination of pharmacophores because phenylmorphans are a well-characterized scaffold for obtaining highly potent and selective MOR ligands,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and they also structurally resemble phenyl/pyridine morpholino moieties that we extensively studied as D<sub>3</sub>R OBS ligands.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Moreover, we recently demonstrated how the pyridine morpholine scaffold designed as a D<sub>3</sub>R PP can also be structurally tweaked <i>via</i> the bitopic approach and linker tethering to target other families of GPCRs, including the MOR.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> This suggested that simple structural modification of the phenylmorphan scaffold might also exploit affinity for both targets and ultimately be suitable for the generation of bitopic and bivalent hybrids for both the MOR and D<sub>3</sub>R.</div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 10. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> cat. AcOH, STAB, and DCE, 25 °C, 1.5 h, 26–88%; (b) <i>trans</i>-<i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> cat. AcOH, STAB, and DCE, 25 °C, 1.5 h, 65%; and (c) preparative enantioselective high-performance liquid chromatography (HPLC), ChiralPak AD-H column.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>, <b>56</b> was N-alkylated <i>via</i> reductive amination with <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and <i>trans</i>-<i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> to obtain <b>57</b> and <b>58</b>, respectively. We have previously published<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> the importance of the rigid cyclopropyl linker to achieve unique pharmacological profiles, and its stereochemistry is essential in modulating favorable poses for D<sub>3</sub>R target recognition, binding affinity, selectivity, and functional efficacy. Thus, both trans enantiomers of <b>58</b> were resolved <i>via</i> preparative chiral HPLC (<b>58a</b> and <b>58b</b>) and pharmacologically evaluated. Due to the lack of significant differences between their biological profiles we did not proceed any further in assigning the absolute configuration of each <i>trans</i>-cyclopropyl enantiomers for these analogues.</div><div class="NLM_p"><i>In silico</i> docking predicted that replacing the ethyl acrylate on the phenylmorphan ring with a less sterically hindered group (<i>e.g.</i>, ketone or hydroxyl group) would be tolerated within the MOR OBS and could increase the affinity of the new hybrids for the D<sub>3</sub>R. Moreover, since the bitopic analogues <b>57</b> and <b>58</b> showed high affinity for the MOR, but moderate to low binding at D<sub>2</sub>-like receptors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), we aimed to study and invert the stereochemistry of the phenylmorphan ring, while simultaneously evaluating all the possible stereochemical combinations with the hydroxyl group. We synthesized both diastereoisomers <b>61</b> and <b>62</b>, starting from the fully resolved <b>59</b> and <b>60</b>, to study not only the effect of the hydroxyl substitution but of its stereochemistry too, in the dual-target binding profile.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Radioligand Competition Binding Affinity Data, for All the MOR-Substituted Phenylmorphan PP Analogues, at the hMOR and hD<sub>2</sub>-like Receptor Subtypes<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0022.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All the affinity values are expressed as <i>K</i><sub>i</sub> ± SEM, derived from IC<sub>50</sub> values using the Cheng–Prusoff equation,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and calculated as the mean of at least three independent experiments (<i>n</i> = number of independent experiments), each performed in triplicate. ND = not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">No inhibition of specific radioligand binding was observed at the highest tested concentration in one to three independent experiments, each performed in triplicate.</p></div></div><div></div></div><div class="NLM_p">Finally, as shown in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>, we prepared the bivalent analogue of this phenylmorphan series, <b>65</b>, presenting both the MOR PP and the canonical D<sub>3</sub>R PP 2,3-dichlorophenyl piperazine for D<sub>3</sub>R OBS, instead of the 2-indoleamide for SBP binding. The alcohol intermediate <b>63</b> was prepared starting from 1-(2,3-dichlorophenyl)piperazine hydrochloride and 2-bromoethan-1-ol, under basic conditions. Tosylation of the hydroxy group and subsequent nucleophilic substitution with <b>56</b> yielded the desired product <b>65</b>.</div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 11. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 2-Bromoethan-1-ol, K<sub>2</sub>CO<sub>3</sub>, cat. KI, and ACN, 82 °C, overnight, 60%; (b) <i>p</i>-toluenesulfonyl chloride (<i>p</i>-TsCl), DIPEA, and DCM, 25 °C, overnight, 36%; (c) NaHCO<sub>3</sub> and ACN, 82 °C, 6 h, 43%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Molecular Docking and CADD</h3><div class="NLM_p">We employed structure-based molecular modeling methods to guide the rational design of our dual-target compounds. All atom docking studies on the inactive-state D<sub>3</sub>R (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and active-state MOR (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> were performed, followed by local optimization of receptor–ligand interactions <i>via</i> energy-based Monte Carlo minimization protocols<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> using ICM-Pro (Molsoft LLC). <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> shows optimized binding modes of <b>5</b> and <b>3</b> inside the D<sub>3</sub>R and MOR, respectively, indicating salt bridge interactions between basic nitrogen and conserved D<sup>3.32</sup> of the receptors. The fluorophenyl butanone moiety of <b>5</b> occupies the OBS between TM3, TM5, and TM6 in the D<sub>3</sub>R, lined by hydrophobic residues such as V111<sup>3.33</sup>, V189<sup>5.39</sup>, F345<sup>6.51</sup>, F346<sup>6.52</sup>, and H349<sup>6.55</sup>. In the MOR, the diphenyl butanamide moiety of <b>3</b> also occupies the OBS pocket similar to canonical MOR ligands such as morphine and methadone, interacting with residues Y150<sup>3.33</sup>, M153<sup>3.35</sup>, V238<sup>5.42</sup>, W295<sup>6.48</sup>, I298<sup>6.51</sup>, H299<sup>6.52</sup>, V302<sup>6.55</sup>, W320<sup>7.35</sup>, I324<sup>7.39</sup>, and Y328<sup>7.43</sup>. Although the chlorophenyl and hydroxy substituents on the piperidine rings are common for both <b>5</b> and <b>3</b>, these moieties occupy distinct SBPs and interact with different residues in their cognate receptors. Attempts at cross-docking these ligands, that is, dock <b>5</b> to the MOR and <b>3</b> to the D<sub>3</sub>R, were unsuccessful, corroborating selectivity of the PPs to their corresponding OBS pockets.</div><figure id="fig2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of <b>5</b> (orange sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) binding mode of <b>3</b> (green sticks) inside the MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows an overlay of MOR and D<sub>3</sub>R docking modes of <b>23</b>, a compound with the <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide PP of the MOR tethered to a 2,3-dichlorophenyl-piperazine PP of canonical D<sub>3</sub>R antagonists/partial agonists. In docking to the MOR (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), we observed a perfect fit of the MOR PP in the corresponding OBS, while the D<sub>3</sub>R PP of <b>23</b> was accommodated in the secondary site of the MOR. In the D<sub>3</sub>R, the lack of flexibility of the N-linked 2,3-dichlorophenyl of <b>23</b> prevented this D<sub>3</sub>R PP from reaching its OBS site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). However, the 2,3-dichlorophenyl moiety still comfortably fits the hydrophobic pocket lined by V111<sup>3.33</sup>, W342<sup>6.48</sup>, F345<sup>6.51</sup>, F346<sup>6.52</sup>, and H349<sup>6.55</sup>. The MOR PP moiety of <b>23</b>, <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide, is placed in a hydrophobic region of the D<sub>3</sub>R surrounded by V86<sup>2.61</sup>, L89<sup>2.64</sup>, C103<sup>3.25</sup>, F106<sup>3.28</sup>, C181<sup>ECL2</sup>, Y365<sup>7.35</sup>, and T369<sup>7.39</sup> and makes additional interactions resulting in comparable docking scores for the MOR and D<sub>3</sub>R, supporting the synthesis of this compound.</div><figure id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding modes of <b>23</b> (green) and <b>5</b> (orange) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) docking mode of <b>23</b> (green) and <b>13</b> (orange) inside the MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast, despite D<sub>3</sub>R SAR that supported introduction of the butyl linker between the tethered <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide or 2,2-diphenylbutanenitrile MOR PP and the 2,3-dichlorophenyl-piperazine, as seen in compounds such as <b>14</b> and <b>28</b>, this design had no effect on the placement of the compounds in the OBS of the D<sub>3</sub>R, while the corresponding SP motif moves further toward the extracellular region, away from the hydrophobic residues of TM2, TM3, and ECL2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of <b>14</b> (orange sticks) and <b>28</b> (green sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>meta</i>-hydroxy compounds were designed to avail the water-mediated hydrogen bonding network close to H299<sup>6.52</sup> and Y150<sup>3.33</sup> in the MOR, such as <b>51</b>, <b>54</b>, and <b>55</b> indeed indicate the presence of those predicted hydrogen bonds, while the 2-chloro-3-ethyl-substituted phenyl-piperazine D<sub>3</sub>R PP motif is tolerated in the voluminous and solvent-accessible MOR pocket (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">Figure S1</a>). Furthermore, the highly decorated <b>8</b>-based D<sub>3</sub>R PP of compounds <b>40</b> and <b>48</b> are placed expectedly in the OBS of the D<sub>3</sub>R, and like the substituted phenyl analogues, the <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide motif occupies hydrophobic subpockets between TM2, TM3, ECL2, and TM7 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>40</b> (orange sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The conformationally restricted ethyl-2-(-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ylidene)acetate MOR PP motif of <b>10</b> expectedly docks in the MOR hydrophobic pocket formed between TM3–TM5–TM6–TM7, and 3-hydroxyphenyl forms water-mediated hydrogen bonding interactions with H299<sup>6.52</sup> and Y150<sup>3.33</sup>. The ethyl phenyl tail of <b>10</b> shares the same hydrophobic subpocket between TM2 and TM3 engaged by <b>fentanyl</b>-like compounds. The docking mode of <b>65</b> overlaps completely with the binding mode of <b>10</b>, except the fact that extended 2,3-dichlorophenyl piperazine of <b>65</b> moves slightly toward the extracellular region and is placed in the subpocket between TM2–TM3–ECL2. The 2,3-dichlorophenyl piperazine of <b>65</b> is docked in the OBS of the D<sub>3</sub>R, while the ethyl-2-(-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ylidene)acetate moiety is placed in the hydrophobic SBP region (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>65</b> (orange sticks) and <b>10</b> (green sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Binding Studies and SARs</h3><div class="NLM_p">All the newly synthesized compounds were tested for their binding affinities at the hMOR (in competition with [<sup>3</sup>H]-DAMGO), hD<sub>2</sub>R, hD<sub>3</sub>R, and hD<sub>4</sub>R [in competition with [<sup>3</sup>H]-<i>N</i>-methylspiperone ([<sup>3</sup>H]-NMSP) for all the hD<sub>2</sub>-like subtypes]. Moreover, a subset of selected hits were further studied at hD<sub>2</sub>R and hD<sub>3</sub>R using the agonist [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT as the competing radioisotope. We have previously observed and reported that differences in affinity due to the radioligand being an agonist or antagonist can predict functional efficacy profiles for the tested compounds.<a onclick="showRef(event, 'ref45 ref60'); return false;" href="javascript:void(0);" class="ref ref45 ref60">(45,60)</a></div><div class="NLM_p">In <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the binding data are reported for the first series of MOR–D<sub>3</sub>R hybrid analogues, based on, <b>3</b>-, <b>4</b>-, and <b>6</b>-like PPs. Reference compounds, including <b>fentanyl</b>, <b>3</b>, <b>4</b>, <b>5</b>, and <b>6</b>, are reported in the table for useful comparisons. Among the reference compounds, it was interesting to observe how <b>3</b>, a well-known potent MOR agonist, despite presenting an SP identical to the D<sub>2</sub>-like antagonist <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), binds with low micromolar affinity to all the D<sub>2</sub>-like subtypes, as predicted in the CADD studies. <b>Fentanyl</b>, <b>4</b>, and <b>6</b> all have low nanomolar affinities for the MOR, as expected and consistent with the literature.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a><b>Fentanyl</b>, however, presents moderate affinity for D<sub>4</sub>R (<i>K</i><sub>i</sub> = 554 nM), while being inactive at both the D<sub>2</sub>R and D<sub>3</sub>R (<i>K</i><sub>i</sub>s > 10,000 nM); meanwhile, <b>6</b> is endowed with a preferential low micromolar affinity for the D<sub>3</sub>R, being completely inactive at D<sub>2</sub>R and >10-fold selective over D<sub>4</sub>R. These data highlight how subtle structural changes in well-characterized MOR agonists can induce different binding profiles and subtype selectivity for the D<sub>2</sub>-like dopamine receptors and that binding affinities can be directed toward dual-target profiles with well-designed structural modifications.</div><div class="NLM_p">The docking studies showed that the MOR PP motifs (<i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide and 2,2-diphenylbutanenitrile) occupy primarily hydrophobic pockets in both the D<sub>3</sub>R and MOR. In the case of the MOR, this pocket formed between TM3, TM5, TM6, and TM7 is an accumulation of three subpockets lined by (a) V238<sup>5.42</sup>, M153<sup>3.33</sup>, H299<sup>6.52</sup>, I298<sup>6.51</sup>, and V302<sup>6.55</sup>, (b) M153<sup>3.33</sup>, W295<sup>6.48</sup>, and Y328<sup>7.43</sup>, and (c) W320<sup>7.35</sup>, I324<sup>7.39</sup>, I298<sup>6.51</sup>, and V302<sup>6.55</sup>. In the D<sub>3</sub>R, these MOR PP motifs occupy a hydrophobic SBP between TM2, TM3, and ECL2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). In general, replacing the nitrile group with the <b>3</b>-like <i>N</i>,<i>N</i>-dimethylamide synthon significantly increased the affinity profiles of all the analogues. In particular, <b>23</b> presents one of the highest MOR affinities among all the new analogues (MOR <i>K</i><sub>i</sub> = 0.832 nM), and despite the shorter linker, which is generally less favorable for D<sub>2</sub>-like receptors affinity, we still obtained a potent D<sub>2</sub>-like ligand (D<sub>2</sub>R <i>K</i><sub>i</sub> = 74.7 nM, D<sub>3</sub>R <i>K</i><sub>i</sub> = 171 nM, and D<sub>4</sub>R <i>K</i><sub>i</sub> = 102 nM). A similar nanomolar binding profile across the D<sub>2</sub>R and D<sub>3</sub>R was also confirmed when <b>23</b> was tested in the presence of [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT. The analogous nitrile compound, <b>13</b>, showed reduced MOR binding (∼320-fold; <i>K</i><sub>i</sub> = 266 nM) and reduced D<sub>3</sub>R binding (∼13-fold; <i>K</i><sub>i</sub> = 2240 nM).</div><div class="NLM_p">The docking studies of butyl-linked compounds show that in the D<sub>3</sub>R, the <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide and 2,2-diphenylbutanenitrile MOR PP motifs move further toward the extracellular region, away from the hydrophobic residues of TM2, TM3, and ECL2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Perhaps, because of this conformational change, <i>N</i>,<i>N</i>-dimethylamide to cyano substitutions on the extended linker molecules such as <b>14</b> (D<sub>2</sub>R <i>K</i><sub>i</sub> = 149 nM and D<sub>3</sub>R <i>K</i><sub>i</sub> = 132 nM) are better tolerated at the D<sub>3</sub>R than the shorter linker compounds such as <b>13</b> (D<sub>2</sub>R <i>K</i><sub>i</sub> = 2630 nM and D<sub>3</sub>R <i>K</i><sub>i</sub> = 2240 nM). As in the D<sub>3</sub>R, the extended linker compounds are reasonably well tolerated inside the MOR. However, in contrast to its binding profile at the D<sub>3</sub>R, even the extended linker molecule with nitrile substitutions <b>14</b> shows reduced MOR binding (<i>K</i><sub>i</sub> = 490 nM). This was also observed with the nitrile analogues, <b>35</b> and <b>37</b>. Compound <b>28</b>, an analogous compound with substituted <i>N</i>,<i>N</i>-dimethylamide in the MOR PP motif, shows significant improvement in both D<sub>3</sub>R affinity (<i>K</i><sub>i</sub> = 39.2 nM) and MOR binding (<i>K</i><sub>i</sub> = 23.8 nM). This was the first hit analogue in this series to show a low nanomolar dual-target affinity for both the MOR and the D<sub>2</sub>-like receptors. In contrast, compound <b>18</b> showed similarly high affinity for the D<sub>2</sub>-like receptors, but MOR affinity was diminished (<i>K</i><sub>i</sub> = 1470 nM), whereas compounds <b>15</b>, <b>19</b>, <b>21</b>, <b>24</b>, and <b>27</b> showed the opposite profile, having higher affinities for the MOR than the D<sub>2</sub>R or D<sub>3</sub>R. Compounds <b>16</b> and <b>22</b> were poorly active at all receptors tested, reflecting an inability to bind the OBS of either MOR or the D<sub>2</sub>-like receptors.</div><div class="NLM_p">Introduction of the hydroxy substituent in the butylamine linker (compounds <b>29</b> and <b>32</b>), as well as replacement of the 2,3-dichlorophenyl piperazine, with the 2-chloro-3-ethyl-phenylpiperazine (compounds <b>31</b> and <b>32</b>) either maintained or slightly decreased the overall affinity for all the D<sub>2</sub>-like receptor subtypes, when compared to <b>28</b> and shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">Figure S2</a>. The introduction of 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile as the D<sub>3</sub>R PP (<b>34</b>) decreased affinity for the D<sub>2</sub>-like receptors into the micromolar range. None of the diphenyl-pyrrolidine analogues (compounds <b>42</b>, <b>43</b>, and <b>46</b>) were active. However, the only bivalent compound <b>46</b> did have moderate affinity for the D<sub>3</sub>R (<i>K</i><sub>i</sub> = 288 nM).<named-content content-type="anchor" rid="tbl1" type="simple"></named-content><named-content content-type="anchor" rid="tbl2" type="simple"></named-content></div><div class="NLM_p">Removal of either nitrile or amide functions from the diphenyl MOR PP and introduction of the <i>meta</i>-hydroxy substituents to the bis-phenyl system, <b>51</b>, were tolerated as suggested from the docking predictions (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">Figure S1</a>). Despite the presence of a simple unsubstituted phenylpiperazine pharmacophore, <b>51</b> still maintained moderate affinities at both the MOR (<i>K</i><sub>i</sub> = 213 nM) and D<sub>3</sub>R (<i>K</i><sub>i</sub> = 249 nM).</div><div class="NLM_p">When the bis-<i>meta</i>-phenol MOR PP was used in combination with the 2-chloro,3-ethyl-phenylpiperazine D<sub>3</sub>R PP, tethered <i>via</i> the shorter (two methylene units) linker (<b>55</b>), moderate affinity for all the targets of interest was maintained, but this analogue was not significantly different from the longer linker analogue <b>51</b>. The presence of the <i>meta</i>-hydroxy substituents also retained D<sub>2</sub>-like affinity for <b>55</b>, similar to that observed for <b>23</b> and <b>30</b> (containing the <b>3</b>-like MOR PP). In a continuation of a trend noted previously, we observed a significant loss of affinity at the MOR, with <b>55</b> presenting a binding <i>K</i><sub>i</sub> >300-fold less than <b>30</b> and <b>23</b>. These results suggest that while the bis-phenol MOR PP is well tolerated as an alternative to the more canonical <b>3</b>-like di-phenyl-<i>N</i>,<i>N</i>-dimethylamide, the binding profile is still dependent on the linker length, rigidity, and overall substitutions on the D<sub>3</sub>R PP as well.</div><div class="NLM_p">In agreement with the CADD, the meta-substitutions in bis-phenyl-containing compounds are important for MOR recognition. The methoxy analogues result in partial loss of MOR affinity with a general binding profile of <b>53</b> (di-methoxy) < <b>54</b> (mono-methoxy) ∼ <b>55</b> (di-hydroxy). This, however, does not apply for D<sub>2</sub>-like binding, where all three analogues show moderate affinities for all the subtypes independent of <i>meta</i>-methoxy or <i>meta</i>-hydroxy substitutions on the bis-phenyl rings, interestingly with higher affinities at D<sub>4</sub>R.</div><div class="NLM_p">Shifting from a phenylpiperazine-based D<sub>3</sub>R PP to a highly decorated <b>8</b>-based D<sub>3</sub>R PP, to develop SAR around the pyrrolidine scaffold, <b>40</b>, containing a racemic pyrrolidin-2-ylmethyl-amide linker, and <b>48</b>, presenting a butyl ether linker chain in position 4 of the <i>trans</i>-pyrrolidine nucleus, were synthesized. Compound <b>48</b> showed the highest D<sub>2</sub>R/D<sub>3</sub>R affinity among all the new analogues (D<sub>2</sub>R <i>K</i><sub>i</sub> = 9.41 nM; D<sub>3</sub>R <i>K</i><sub>i</sub> = 2.21 nM); however, the regio- and stereochemistry of the substituted pyrrolidine ring was detrimental for MOR binding, with a <i>K</i><sub>i</sub> of 559 nM.<named-content content-type="anchor" rid="fig7" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content> On the other hand, <b>40</b> emerged as our third lead, alongside <b>23</b> and <b>28</b>, with its almost identical affinities for both the MOR (<i>K</i><sub>i</sub> = 106 nM) and D<sub>3</sub>R (<i>K</i><sub>i</sub> = 135 nM), ∼4- and ∼25-fold selectivity over D<sub>2</sub>R and D<sub>4</sub>R, respectively. This profile distinguished <b>40</b> as one of the most promising dual-target MOR–D<sub>3</sub>R compounds in the series.</div><div class="NLM_p">The binding data for the phenylmorphan analogues are reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compounds <b>10</b>, <b>11</b>, and the nor-analogues <b>56</b>, <b>59</b>, and <b>60</b> were tested as reference compounds, since most of them were key MOR PP building blocks for our bivalent and bitopic drug design. Compound <b>10</b> showed the highest MOR affinity as an OBS PP, with <i>K</i><sub>i</sub> = 0.633 nM, similar to the affinities of <b>3</b> and the hybrid bivalent analogue, <b>23</b>. Interestingly, <b>10</b> also showed moderately low micromolar and sub-micromolar affinities for the D<sub>2</sub>R and D<sub>3</sub>R, supporting the hypothesis that the phenylmorphan ring structurally resembles more flexible phenyl-morpholino moieties, canonical scaffolds for D<sub>3</sub>R ligands.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">Docking studies suggested that the steric clash between the ethyl acrylate group and the backbone of the D<sub>3</sub>R receptor would limit and potentially challenge the development of bitopic ligands <b>57</b> and <b>58</b> targeting D<sub>3</sub>R, despite being tolerated in the MOR OBS. Indeed, bitopic analogues <b>57</b> and <b>58</b> and the resolved enantiomers <b>58a</b> and <b>58b</b> all showed high affinities at the MOR (<i>K</i><sub>i</sub>s ranging from 13.5 to 57 nM) but micromolar <i>K</i><sub>i</sub>s for all the D<sub>2</sub>-like subtypes, independent of linker rigidity or stereochemistry. The shorter bivalent analogue <b>65</b> with a simple ethyl linker chain (<i>n</i> = 2) was predicted by docking studies to be the optimal spacer to resolve steric clashes of the MOR PP motif in the D<sub>3</sub>R; <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Indeed, tethering the MOR phenylmorphan PP and the D<sub>3</sub>R 2,3-dichlorophenyl piperazine PP presented one of the most interesting dual-target candidates (<b>65</b>) with equivalent affinities at the MOR (<i>K</i><sub>i</sub> = 92.7 nM) and D<sub>3</sub>R (<i>K</i><sub>i</sub> = 139 nM).</div><div class="NLM_p">Replacement of the sterically hindered ethyl acrylate group with a smaller hydroxy substituent allowed validation of the docking observation that a small substituent would significantly improve D<sub>3</sub>R binding. Overall, <b>61</b> and <b>62</b> adopt the same docking as <b>65</b> inside the MOR but lose hydrophobic interactions of the ethyl acrylate moiety with M153<sup>3.36</sup> and Y328<sup>7.43</sup> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">Figure S3</a>). The hydrogen-bonding interactions between the 9-OH and Y328<sup>7.43</sup> provide limited compensation for <b>62</b>. However, for <b>61</b>, this hydrogen bond is accompanied by negative interactions due to proximity of the carboxylate oxygen of D149<sup>3.32</sup> (3.2 Å compared to 4.5 Å of S-chiral <b>62</b>). Furthermore, <b>61</b> and <b>62</b> adopt an interesting conformation inside the D<sub>3</sub>R with the indole carboxamide ring situated in the OBS. In the absence of positively charged nitrogen, the nitrogen of the amide forms a hydrogen bond with the D110<sup>3.32</sup> residue. Interestingly, the 9-OH is placed very close to the backbone of TM7 for <b>62</b> and TM2 for <b>61</b>. Therefore, the substitution of this position with ethyl acrylate would cause steric clashes with the D<sub>3</sub>R, as indicated by the loss of affinity of <b>57</b>. Bitopic analogue <b>62</b>, with all the resolved stereochemical configurations around the phenylmorphan moiety inverted with respect to <b>57</b>, showed a D<sub>3</sub>R <i>K</i><sub>i</sub> of 79.6 nM, ∼172-fold improved affinity with respect to the ethyl acrylate analogue <b>57</b>, maintaining a moderate affinity (<i>K</i><sub>i</sub> = 464 nM) for the MOR.</div><div class="NLM_p">Across all the tested compounds, no significant differences were observed in the D<sub>2</sub>-like affinities determined using [<sup>3</sup>H]-NMSP, and [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT binding assays were observed, unlike our previous observations for efficacious agonist ligands,<a onclick="showRef(event, 'ref43 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref45">(43,45)</a> consistent with our hypothesis that all the new analogues are likely antagonists or low-efficacy partial agonists at the D<sub>3</sub>R.</div><div class="NLM_p last">Based on their binding profiles, a select group of hits were tested in functional assays to determine their agonist and antagonist potencies for the multiple GPCR-related signaling pathways, as well as to validate and confirm the MOR agonism and D<sub>3</sub>R antagonism/partial agonism profile, we were seeking with these new hybrid molecules.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> BRET Functional Studies at the MOR and D<sub>3</sub>R</h3><div class="NLM_p">With the binding studies and SAR established, we then characterized the action of selected ligands to signal through both the MOR and D<sub>3</sub>R; these results are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The action of these ligands was assessed through arrestin-3 (or β-arrestin-2) recruitment at MOR and G-protein activation (GPA) at MOR (Gα<sub>i2</sub>) and D<sub>3</sub>R (Gα<sub>oA</sub>) assays. In addition, the ability of the ligands to induce the active state of the MOR was determined by measuring recruitment of a conformationally selective nanobody that recognizes and binds to the active conformation of the MOR, nanobody 33 (Nb33).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Seven of the newly synthesized MOR–D<sub>3</sub>R hybrids (<b>14</b>, <b>23</b>, <b>28</b>, <b>40</b>, <b>57</b>, <b>58a</b>, and <b>58b</b>) were tested together with <b>10</b>. The efficacious agonists <b>DAMGO</b> (D-Ala2, N-MePhe4, and Gly5-ol-enkephalin), <b>quinpirole</b>, and <b>dopamine</b> were used as reference agonists to normalize data at the MOR and D<sub>3</sub>R. We included the MOR partial agonist <b>morphine</b> to illustrate the relative coupling efficiency and amplification of the different assays (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,B,D). Both known antagonists, <b>naloxone</b> (MOR) and <b>5</b> (D<sub>3</sub>R), inhibited agonist-stimulated GPA in a concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C,F).</div><figure id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Functional profiles of selected MOR–D<sub>3</sub>R hybrids. Each panel shows a different signaling readout: (A) Nb33 recruitment at the MOR, (B) MOR-mediated Gα<sub>i2</sub> protein activation, (C) antagonism at the MOR using GPA in the presence of 100 nM DAMGO, (D) arrestin-3 recruitment at the MOR in the presence of overexpressed GRK2, (E) D<sub>3</sub>R-mediated Gα<sub>oA</sub> protein activation, and (F) antagonism at the D<sub>3</sub>R using GPA in the presence of 3 nM quinpirole. In order to ensure that test ligands achieved maximal receptor occupancy possible before agonist addition, all ligands were added to the cells 3 h prior to activating the D<sub>3</sub>R with quinpirole and measuring BRET signals with the exception of <b>5</b>. Dotted lines represent fits where the bottom asymptote was constrained to be 0%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potencies and Efficacies at the MOR and D<sub>3</sub>R<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">MOR Nb33 recruitment</th><th class="rowsep1 colsep0" colspan="3" align="center">MOR G<sub>i2</sub> activation</th><th class="rowsep1 colsep0" colspan="2" align="center">MOR arr3 recruitment (+GRK2)</th><th class="rowsep1 colsep0" colspan="3" align="center">D<sub>3</sub>R G<sub>oA</sub> activation</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> ± SEM (%)</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> ± SEM (%)</th><th class="colsep0 rowsep0" align="center">pIC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> ± SEM (%)</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub> ± SEM [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> ± SEM (%)</th><th class="colsep0 rowsep0" align="center">pIC<sub>50</sub> ± SEM [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>DAMGO</b></td><td class="colsep0 rowsep0" align="left">7.02 ± 0.04 [95.9] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">8.83 ± 0.03 [1.50] (<i>n</i> = 9)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.97 ± 0.03 [11.1] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>morphine</b></td><td class="colsep0 rowsep0" align="left">6.38 ± 0.05 [416] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">73.4 ± 1.7</td><td class="colsep0 rowsep0" align="left">8.06 ± 0.03 [8.66] (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">97.4 ± 1.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.10 ± 0.04 [79.8] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">92.1 ± 1.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>naloxone</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.52 ± 0.1 [305] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>quinpirole</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.62 ± 0.05 [2.39] (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>dopamine</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9.05 ± 0.05 [0.896] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">88.0 ± 1.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>haloperidol (5)</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.46 ± 0.07 [3.49] (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">7.51 ± 0.10 [31.3] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">33.3 ± 1.2</td><td class="colsep0 rowsep0" align="left">8.28 ± 0.05 [5.29] (<i>n</i> = 9)</td><td class="colsep0 rowsep0" align="left">91.9 ± 1.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.70 ± 0.07 [20.0] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">69.3 ± 1.7</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.70 ± 0.06 [1997] (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">4.98 ± 0.29 [10,530] (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">114.9 ± 39.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">6.78 ± 0.15 [165] (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">63.8 ± 4.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">6.58 ± 0.06 [266] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">95.5 ± 2.7</td><td class="colsep0 rowsep0" align="left">7.91 ± 0.06 [12.3] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">100.8 ± 2.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7.08 ± 0.03 [83.3] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">102.7 ± 1.3</td><td class="colsep0 rowsep0" align="left">6.13 ± 0.16 [747] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">20.2 ± 2.1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.96 ± 0.09 [1107] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">44.5 ± 2.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">7.58 ± 0.16 [26.4] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">55.0 ± 3.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">5.67 ± 0.20 [2136] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">16.6 ± 2.1</td><td class="colsep0 rowsep0" align="left">6.68 ± 0.08 [211] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">84.4 ± 2.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.32 ± 0.11 [484] (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">25.3 ± 1.3</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.82 ± 0.15 [1515] (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.45 ± 0.05 [3522] (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>5 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58a</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.68 ± 0.05 [2102] (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.83 ± 0.08 [1498] (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">110.6 ± 6.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58b</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">5.24 ± 0.06 [5770] (<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">45.6% of DA at 10 μM (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All data represent the mean of at least three independent experiments (<i>n</i> = number of independent experiments), each performed in duplicate. Potency values are expressed as pEC<sub>50</sub> ± SEM with the corresponding EC<sub>50</sub> in nM in brackets. Efficacy values are calculated as a percentage of a reference ligand (DAMGO or quinpirole for the MOR and D<sub>3</sub>R, respectively) and expressed as <i>E</i><sub>max</sub> ± SEM (%). NA = not active, and the compound presents no agonist activity at the highest tested concentration.</p></div></div></div><div class="NLM_p">The three substituted phenylmorphan MOR PP analogues (<b>57</b>, <b>58a</b>, and <b>58b</b>), despite showing improved affinities for the MOR compared to <b>56</b>, did not activate the MOR in any of the three pathways tested (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,B,D). Thus, we tested the ability of these bitopic compounds to inhibit the action of 100 nM of <b>DAMGO</b> in the GPA i2 assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C, all three ligands were able to inhibit <b>DAMGO</b>-mediated GPA to the same extent as <b>naloxone</b> albeit with lower potencies. When tested at the D<sub>3</sub>R, <b>57</b> failed to demonstrate any D<sub>3</sub>R activity (up to 10 μM, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E,F), which is likely due to the low affinity of this compound for this receptor (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compounds <b>58a</b> and <b>58b</b> showed agonist activity at the D<sub>3</sub>R but with low (micromolar) potencies that reflect their affinity for the D<sub>3</sub>R (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Thus, these two phenylmorphan hybrids display MOR antagonism and D<sub>3</sub>R agonism, rather than the MOR agonist/D<sub>3</sub>R antagonist or partial agonist profile we targeted.</div><div class="NLM_p">In contrast, all four MOR diphenyl PP analogues tested (<b>14</b>, <b>23</b>, <b>28</b>, and <b>40</b>) showed agonist activity at the MOR, with <b>23</b> being the most potent and efficacious compound. Compound <b>14</b> showed low-potency MOR agonism that could only be detected at the highest concentration used of 10 μM in the most amplified and sensitive GPA i2 assay. <b>40</b> displayed higher potency and efficacy in assays of MOR activation than <b>28</b>, with <b>28</b> displaying no detectable agonism in the less-amplified Nb33 and arrestin-3 recruitment assays but an <i>E</i><sub>max</sub> of 50% that of <b>DAMGO</b> in the GPA i2 assay. Compound <b>40</b> gave a robust response (<i>E</i><sub>max</sub> = 84.4% of DAMGO) in the GPA i2 assay but much weaker responses in the arrestin and Nb33 assays, indicating that it is a less-efficacious partial agonist than <b>morphine</b>. All four bivalent compounds share a similar MOR diphenyl PP based on <b>3</b> and <b>4</b>, the <i>N</i>,<i>N</i>-dimethyl-diphenylbutanamide PP being more favorable than the diphenylbutanenitrile PP for MOR agonism. The major structural differences are present in the D<sub>3</sub>R PP and the type and length of the linker between the two pharmacophores: a shorter linker being more favorable for MOR agonism. In general, across the series of compounds and <b>morphine</b>, we observe higher maximal effects (<i>E</i><sub>max</sub>) and potencies in the GPA i2 assay as compared to that in the arrestin-3 recruitment and Nb33 assays. Such a behavior is consistent with the action of partial agonists at signaling endpoints with different levels of amplification and coupling efficiency of the pathway. In agreement with this, when these data were analyzed using the Black and Leff operational model of agonism and assessed for biased agonism using <b>DAMGO</b> as the reference ligand, none of the compounds displayed significant bias between these two pathways relative to the action of <b>DAMGO</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">Table S2</a>).</div><div class="NLM_p last">When these four MOR diphenyl PP ligands were tested for their ability to activate the D<sub>3</sub>R (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E,F), <b>14</b> and <b>28</b> showed similar efficacies (64 and 55% of dopamine, respectively), with <b>28</b> being the most potent compound in agreement with their relative affinities (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Although <b>14</b> and <b>40</b> display similar affinities for D<sub>3</sub>R, <b>40</b> acted as an antagonist with micromolar potency (IC<sub>50</sub> = 1.5 μM), whereas <b>14</b> acted as a robust partial agonist (<i>E</i><sub>max</sub> = 63.8% of quinpirole). Finally, <b>23</b>, which was the most potent MOR agonist and shares the same D<sub>3</sub>R PP structure as <b>28</b> but with a shorter linker, displayed weak partial agonism (<i>E</i><sub>max</sub> = 20% of quinpirole) at the D<sub>3</sub>R and sub-micromolar potency consistent with its binding affinity.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The data obtained highlight a series of hit to lead candidates as MOR–D<sub>3</sub>R dual-target ligands. We have synthesized multiple combinations of bivalent or bitopic ligands based on carefully designed structural modifications and <i>in silico</i>-guided SAR around the MOR PP, D<sub>3</sub>R PP, and SP, as well as linkers, with a particular focus on regio- and stereochemistry. Importantly, we have identified compounds with a range of sub-nanomolar to sub-micromolar binding affinities for each receptor of interest and thus provide a new approach to modulate the pharmacological profiles of highly selective MOR agonists through concomitant dual-target D<sub>3</sub>R antagonism.</div><div class="NLM_p last">The functional studies revealed three lead analogues, <b>23</b>, <b>28</b> and <b>40</b>, which are partial agonists at the MOR and partial agonists or antagonists at the D<sub>3</sub>R. We and others have suggested that low intrinsic efficacy could explain the improved therapeutic window observed on the most recent MOR agonists, such as <b>PZM21</b> and <b>TRV-130</b>,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and our three lead compounds fit this desired functional profile with the added feature of D<sub>3</sub>R low-efficacy partial agonism or antagonism, which may prove beneficial in avoiding the addictive liability of opioid receptor-targeted drugs. Furthermore, evaluation and thus a better understanding of the desired kinetic profiles at both targets for the optimal pharmacological effect will be crucial in the development of future generations of dual-target MOR–D<sub>3</sub>R ligands. Indeed, current drug design is focused on improving drug-like characteristics and blood–brain barrier penetrability as the current lead compounds have central nervous system multiparameter optimization<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> scores of ∼2 and are predicted to be peripherally limited. This indeed was what Komoto and colleagues<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> found with their loperamide analogues, which is perhaps unsurprising. Nevertheless, with the proof-of-concept in hand, we have laid the groundwork for an alternative pharmacological approach, using bivalent drug design to engage both the MOR and D<sub>3</sub>R in the pursuit of a novel class of opioid analgesics with lower abuse potential.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p">All chemicals and solvents were purchased from chemical suppliers unless otherwise stated and used without further purification. All melting points were determined (when obtainable) on an OptiMelt automated melting point system and are uncorrected. Reactions were not yield optimized. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian Mercury Plus 400 instrument. Proton chemical shifts are reported as parts per million (δ ppm) relative to tetramethylsilane (0.00 ppm) as an internal standard or to deuterated solvents. Coupling constants are measured in Hertz. Chemical shifts for <sup>13</sup>C NMR spectra are reported as parts per million (δ ppm) relative to deuterated CHCl<sub>3</sub> or deuterated MeOH (CDCl<sub>3</sub> 77.5 ppm and CD<sub>3</sub>OD 49.3 ppm). Chemical shifts, multiplicities, and coupling constants (<i>J</i>) have been reported and calculated using VnmrJ Agilent-NMR 400MR or MNova 9.0 software. Gas chromatography–mass spectrometry (GC/MS) data were acquired (where obtainable) using an Agilent Technologies (Santa Clara, CA) 7890B GC equipped with an HP-5MS column (cross-linked 5% PH ME siloxane, 30 m × 0.25 mm i.d. × 0.25 μm film thickness) and a 5977B mass-selective ion detector in the electron-impact mode. Ultrapure-grade helium was used as the carrier gas at a flow rate of 1.2 mL/min. The injection port and transfer line temperatures were 250 and 280 °C, respectively, and the oven temperature gradient used was as follows: the initial temperature (70 °C) was held for 1 min and then increased to 300 °C at 20 °C/min and maintained at 300 °C for 4 min, with a total run time of 16.5 min. Column chromatography was performed using a Teledyne Isco CombiFlash RF flash chromatography system or a Teledyne Isco EZ-Prep chromatography system. Preparative thin-layer chromatography was performed on Analtech silica gel plates (1000 μm). When % DMA is reported as the eluting system, it stands for % of methanol in DCM, in the presence of 0.5–1% NH<sub>4</sub>OH. Preparative chiral HPLC was performed using a Teledyne Isco EZ-Prep chromatography system with the diode array detector (DAD) and ELS detectors. HPLC analysis was performed using an Agilent Technologies 1260 Infinity system coupled with the DAD. For each analytical HPLC run, multiple DAD λ absorbance signals were measured in the range of 210–280 nm. Separation of the analyte, purity, and enantiomeric/diastereomeric excess determinations were achieved at 40 °C using the methods reported in each detailed reaction description. Preparative and analytical HPLC columns were purchased from Daicel Corporation or Phenomenex. HPLC methods and conditions are reported in the descriptions of the chemical reactions where they were applied. Microanalyses were performed by Atlantic Microlab, Inc. (Norcross, GA) and agree with ±0.4% of calculated values. HRMS (mass error within 5 ppm) and MS/MS fragmentation analysis were performed on an LTQ-Orbitrap Velos (Thermo Scientific, San Jose, CA) coupled with an ESI source in the positive-ion mode to confirm the assigned structures and regiochemistry. Unless otherwise stated, all the test compounds were evaluated to be >95% pure on the basis of combustion analysis, NMR, GC/MS, and HPLC-DAD. The detailed analytical results are reported in the characterization of each final compound.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 4-(Phenethylamino)-2,2-diphenylbutanenitrile (<b>12</b>)</h4><div class="NLM_p last">A suspension of 4-bromo-2,2-diphenylbutanenitrile (500 mg, 1.67 mmol), 2-phenylethan-1-amine (605 mg, 5 mmol), and K<sub>2</sub>CO<sub>3</sub> (230 mg, from 1.67 mmol up to 10 equiv) in ACN (50 mL) was heated at 130 °C in a sealed vessel overnight. The mixture was filtered, the solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 15% DMA. The desired product was obtained as colorless oil (300 mg, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.18 (m, 15H), 3.74 (t, <i>J</i> = 7.1 Hz, 2H), 3.07 (t, <i>J</i> = 6.2 Hz, 2H), 2.95 (t, <i>J</i> = 7.2 Hz, 2H), 2.60 (t, <i>J</i> = 6.2 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.34, 142.74, 139.55, 128.86, 128.57, 128.46, 128.38, 128.36, 128.12, 126.98, 126.18, 61.47, 53.40, 46.66, 46.18, 37.35, 33.47. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>24</sub>H<sub>24</sub>N<sub>2</sub> + H<sup>+</sup>): calcd, 341.20123; found, 341.20048 (error −0.7 ppm). CHN (C<sub>24</sub>H<sub>24</sub>N<sub>2</sub> + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + H<sub>2</sub>O) Calcd: C, 65.71; H, 5.92; N, 5.68. Found: C, 65.76; H, 5.77; N, 5.57. mp: salt too hygroscopic to determine the melting point.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-2,2-diphenylbutanenitrile (<b>13</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from 1-(2,3-dichlorophenyl)piperazine (250 mg, 0.9 mmol) and 4-bromo-2,2-diphenylbutanenitrile (350 mg, 1.17 mmol). The desired product was purified by flash chromatography eluting with hexanes/ethyl acetate (hex/EtOAc 5:5) and obtained as colorless oil (30 mg, 7.5% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45–7.23 (m, 10H), 7.19–7.08 (m, 2H), 6.94 (dd, <i>J</i> = 6.8, 2.8 Hz, 1H), 3.04 (br s, 4H), 2.65 (dd, <i>J</i> = 10.5, 4.3 Hz, 6H), 2.57–2.49 (m, 2H). The free base was converted into the corresponding oxalate salt. CHN (C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>Cl<sub>2</sub> + H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 0.25H<sub>2</sub>O) Calcd: C, 61.71; H, 5.09; N, 7.71. Found: C, 61.67; H, 5.09; N, 7.85. mp: 202–207 °C.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 4-((4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)amino)-2,2-diphenylbutanenitrile (<b>14</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (200 mg, 0.7 mmol) and 4-bromo-2,2-diphenylbutanenitrile (105 mg, 0.35 mmol). The desired product was purified by flash chromatography eluting with 15% DMA and obtained as colorless oil (58 mg, 31% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37–7.29 (m, 10H), 7.29–7.18 (m, 2H), 6.95 (dd, <i>J</i> = 6.4, 3.2 Hz, 1H), 4.84 (br s, 1H), 3.52 (t, <i>J</i> = 7.2 Hz, 2H), 3.26 (t, <i>J</i> = 6.2 Hz, 2H), 3.05 (t, <i>J</i> = 4.8 Hz, 4H), 2.71 (t, <i>J</i> = 6.2 Hz, 2H), 2.59 (br s, 4H), 2.44 (dd, <i>J</i> = 8.2, 6.7 Hz, 2H), 1.70–1.53 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.46, 151.32, 142.37, 133.99, 128.51, 128.45, 127.48, 127.39, 127.15, 124.48, 118.56, 61.65, 58.24, 53.24, 51.31, 46.34, 44.72, 37.36, 25.14, 24.26. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>30</sub>H<sub>34</sub>N<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 521.22333; found, 521.22363 (error 0.3 ppm). CHN (C<sub>30</sub>H<sub>34</sub>N<sub>4</sub>Cl<sub>2</sub> + 3H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 0.5H<sub>2</sub>O) Calcd: C, 54.01; H, 5.16; N, 7.00. Found: C, 53.97; H, 5.33; N, 7.15. mp: salt decomposes above 80 °C.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 4-((4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)amino)-2,2-diphenylbutanenitrile (<b>15</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from 4-amino-1-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-2-ol<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (223 mg, 0.7 mmol) and 4-bromo-2,2-diphenylbutanenitrile (105 mg, 0.35 mmol). The desired product was purified by flash chromatography eluting with 15% DMA and obtained as colorless oil (53 mg, 28% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.32 (m, 6H), 7.24–7.10 (m, 6H), 6.95 (dd, <i>J</i> = 7.2, 2.3 Hz, 1H), 4.22–4.06 (m, 3H), 3.75–3.67 (m, 2H), 3.12 (br s, 4H), 2.96 (tt, <i>J</i> = 8.1, 4.2 Hz, 4H), 2.76 (d, <i>J</i> = 10.7 Hz, 2H), 2.67 (dd, <i>J</i> = 12.5, 3.2 Hz, 1H), 2.61–2.50 (m, 1H), 2.01 (s, 1H), 1.82 (ddd, <i>J</i> = 16.4, 13.9, 7.1 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.96, 150.78, 138.44, 138.40, 134.10, 129.50, 129.48, 128.91, 128.89, 127.88, 127.78, 127.58, 127.43, 124.83, 118.64, 64.45, 63.72, 62.31, 53.36, 50.83, 50.62, 45.63, 37.82, 31.51. HRMS (C<sub>30</sub>H<sub>34</sub>ON<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 537.21824; found, 537.21935 (error 1 ppm). HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 4.944 min, purity >94.3% (absorbance at 254 nm). HPLC analysis method B: Chiralpak OZ-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 9.072 and 10.862 min, purity >95%, er 43:57 (absorbance at 254 nm).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 4-(Dimethylamino)-2,2-diphenylbutanenitrile (<b>16</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from dimethylamine hydrochloride (2.0 g, 25 mmol) and 4-bromo-2,2-diphenylbutanenitrile (5.0 g, 16.7 mmol). The desired product was purified by flash chromatography eluting with 5% DMA and obtained as colorless oil (3.5 g, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66–6.75 (m, 10H), 2.68–2.50 (m, 2H), 2.50–2.33 (m, 2H), 2.25 (s, 6H). GC/MS (EI), Rt 10.499 min; 264.1 (M<sup>+</sup>), purity >95%. The free base was converted into the corresponding oxalate salt. CHN (C<sub>18</sub>H<sub>20</sub>N<sub>2</sub> + H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>) Calcd: C, 67.78; H, 6.26; N, 7.90. Found: C, 67.66; H, 6.43; N, 7.96. mp: 163–169 °C.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 3-Carboxy-<i>N</i>,<i>N</i>-dimethyl-3,3-diphenylpropan-1-aminium Bromide (<b>17</b>)</h4><div class="NLM_p last">Compound <b>16</b> (2 g, 7.6 mmol) was dissolved in 48% HBr aq solution (50 mL) and stirred under reflux overnight. The solution was concentrated to half-volume and decanted, and the residue was washed multiple times with Et<sub>2</sub>O. The dried crude material was used in the next step without further purification.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(dimethylamino)-2,2-diphenylbutanamide (<b>18</b>)</h4><div class="NLM_p last">A solution of <b>17</b> (460 mg, 1.26 mmol), EDC hydrochloride (240 mg, 1.26 mmol), HOBt (170 mg, 1.26 mmol), and DIPEA (2.2 mL; 12.6 mmol) in DCM (20 mL) was stirred at room temperature (RT) for 1 h, followed by dropwise addition of 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (380 mg, 1.26 mmol) in DCM (20 mL). The mixture was stirred at RT overnight, the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as yellow oil (40 mg, 6% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.20 (m, 10H), 7.18–7.08 (m, 2H), 6.94 (dd, <i>J</i> = 6.6, 3.0 Hz, 1H), 6.74 (br s, 1H), 3.31–3.14 (m, 2H), 3.03 (br s, 4H), 2.62–2.53 (m, 6H), 2.40–2.27 (m, 2H), 2.19 (m, 8H), 1.53–1.36 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.99, 151.26, 143.81, 133.99, 128.74, 128.25, 127.47, 127.40, 126.81, 124.51, 118.55, 60.22, 58.03, 55.98, 53.23, 51.28, 45.53, 45.42, 44.87, 39.71, 36.80, 29.40, 27.36, 24.09. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>32</sub>H<sub>40</sub>ON<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 567.26519; found, 567.26524 (error 1.3 ppm). CHN (C<sub>32</sub>H<sub>40</sub>ON<sub>4</sub>Cl<sub>2</sub> + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 3H<sub>2</sub>O) Calcd: C, 53.93; H, 6.29; N, 6.99. Found: C, 53.89; H, 5.90; N, 7.31. mp: salt too hygroscopic to determine melting point.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-(Dimethylamino)-4,4-diphenylhexan-3-one (<b>19</b>)</h4><div class="NLM_p last">Ethyl magnesium bromide (3 M solution in diethyl ether, 10 mmol) was added dropwise to a solution of <b>16</b> (2.0 g, 7.5 mmol) in toluene (30 mL) at 0 °C. The mixture was slowly warmed to RT and then stirred at reflux for 3 h. The reaction was quenched with 10 mL of 2 N HCl (aq solution) at 0 °C and stirred at reflux for 30 min. The suspension was basified with 2 N NaOH at 0 °C, the toluene was removed under vacuum, and the aqueous phase was extracted with DCM/2-PrOH (3:1). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried under vacuum to afford the crude material, which was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as colorless oil (1.3 g, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.51–7.06 (m, 10H), 2.52 (m, 2H), 2.30 (m, 2H), 2.15 (d, <i>J</i> = 0.9 Hz, 6H), 1.95 (m, 2H), 0.88 (td, <i>J</i> = 7.3, 0.9 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 211.02, 141.48, 129.14, 128.26, 126.94, 65.04, 55.67, 45.52, 35.41, 32.47, 9.05. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>20</sub>H<sub>25</sub>NO + H<sup>+</sup>): calcd, 296.20089; found, 296.20150 (error 0.4 ppm). CHN (C<sub>20</sub>H<sub>25</sub>NO + H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>) Calcd: C, 68.55; H, 7.06; N, 3.63. Found: C, 68.51; H, 7.15; N, 3.62. mp: 161–165 °C.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl (5-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-5-oxopentyl)carbamate (<b>20</b>)</h4><div class="NLM_p last">A solution of 5-((<i>tert</i>-butoxycarbonyl)amino)pentanoic acid (470 mg, 2.16 mmol), 1-(2,3-dichlorophenyl)piperazine (500 mg, 2.16 mmol), and HCTU (895 mg, 2.16 mmol) in DCM (25 mL) was stirred at RT for 3 h. The solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with hex/EtOAc (40/60). The desired product was obtained as yellow oil (550 mg, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.23–7.11 (m, 2H), 6.92 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 4.63 (br s, 1H), 3.79 (t, <i>J</i> = 4.9 Hz, 2H), 3.68–3.60 (m, 2H), 3.15 (q, <i>J</i> = 6.6 Hz, 2H), 3.00 (dq, <i>J</i> = 10.7, 5.2 Hz, 4H), 2.39 (t, <i>J</i> = 7.4 Hz, 2H), 1.76–1.62 (m, 2H), 1.60–1.51 (m, 2H), 1.43 (s, 9H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-((5-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-5-oxopentyl)amino)-2,2-diphenylbutanenitrile (<b>21</b>)</h4><div class="NLM_p last">TFA (1 mL, 12.8 mmol) was added to a solution of <b>20</b> (550 mg, 1.28 mmol) in DCM (10 mL). The mixture was stirred at RT for 24 h, basified with 2 N NaOH, and extracted with DCM. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and dried under vacuum to afford the crude primary amine intermediate, which was dissolved in ACN (20 mL), followed by the addition of 4-bromo-2,2-diphenylbutanenitrile (384 mg, 1.28 mmol) and K<sub>2</sub>CO<sub>3</sub> (10 equiv). The reaction mixture was stirred at reflux overnight and filtered, and the solvent was removed under vacuum. The residue was purified by flash chromatography eluting with 15% DMA, and the desired product was obtained as yellow oil (20 mg, 3% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37–7.10 (m, 12H), 6.90 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 3.78 (d, <i>J</i> = 5.8 Hz, 2H), 3.63 (t, <i>J</i> = 4.9 Hz, 2H), 3.59–3.51 (m, 2H), 3.28 (t, <i>J</i> = 6.2 Hz, 2H), 2.97 (dt, <i>J</i> = 9.3, 5.0 Hz, 4H), 2.72 (t, <i>J</i> = 6.2 Hz, 2H), 2.50–2.41 (m, 2H), 1.71 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.48, 171.42, 150.64, 142.20, 134.16, 128.51, 128.47, 128.43, 127.74, 127.50, 127.25, 125.13, 118.75, 61.72, 51.69, 51.20, 46.41, 45.80, 44.41, 41.73, 37.36, 32.69, 26.68, 22.47. HRMS (C<sub>31</sub>H<sub>34</sub>ON<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 549.21824; found, 549.21825 (error 0.0 ppm). HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 27.693 min, purity >95% (absorbance at 254 nm).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(Dimethylamino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>22</b>)</h4><div class="NLM_p last">Dimethylamine hydrochloride (1.18 g, 14.5 mmol) was added to a suspension of <i>N</i>-(3,3-diphenyldihydrofuran-2(3<i>H</i>)-ylidene)-<i>N</i>-methylmethanaminium bromide (500 mg, 1.45 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.0 g, 14.5 mmol) in TBME/ACN (25 mL/10 mL). The reaction mixture was heated in a sealed vessel for 24 h, the solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with EtOAc/MeOH (95/5). The desired product was obtained as colorless oil (70 mg, 16% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.24 (m, 10H), 2.97 (br s, 3H), 2.57–2.46 (m, 2H), 2.30 (m + br s, 2H + 9H). GC/MS (EI), Rt 11.256 min; 310.1 (M<sup>+</sup>), purity >95%. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>20</sub>H<sub>26</sub>ON<sub>2</sub> + H<sup>+</sup>): found, 311.21098 (error −2.4 ppm). CHN (C<sub>20</sub>H<sub>26</sub>ON<sub>2</sub> + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 0.75H<sub>2</sub>O) Calcd: C, 60.19; H, 6.70; N, 6.10. Found: C, 60.09; H, 6.36; N, 6.13. mp: 174–178 °C.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>23</b>)</h4><div class="NLM_p last">1-(2,3-Dichlorophenyl)piperazine hydrochloride (400 mg, 1 mmol) was added to a suspension of <i>N</i>-(3,3-diphenyldihydrofuran-2(3<i>H</i>)-ylidene)-<i>N</i>-methylmethanaminium bromide (500 mg, 1 mmol), K<sub>2</sub>CO<sub>3</sub> (967 mg, 7 mmol), and DIPEA (1 mL, 7 mmol) in ACN (20 mL). The reaction mixture was stirred at reflux overnight, the solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 5% DMA. The desired product was obtained as colorless oil (640 mg, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46–7.34 (m, 10H), 7.34–7.20 (m, 2H), 7.15–7.03 (m, 1H), 2.97 (br s, 6H), 2.56–2.43 (m, 8H), 2.19–2.10 (m, 2H), 1.69 (s, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.41, 151.42, 140.76, 133.89, 128.35, 128.10, 127.44, 127.30, 126.70, 124.29, 118.54, 59.70, 55.71, 53.16, 51.33, 42.24. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>28</sub>H<sub>31</sub>ON<sub>3</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 496.19169; found, 496.19052 (error −2.3 ppm). CHN (C<sub>28</sub>H<sub>31</sub>ON<sub>3</sub>Cl<sub>2</sub> + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>) Calcd: C, 58.96; H, 5.43; N, 6.65. Found: C, 58.69; H, 5.33; N, 6.65. mp: 199–205 °C.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(7-Cyano-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>24</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>23</b>, starting from 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (100 mg, 0.63 mmol). The crude material was purified by flash chromatography eluting with 5% DMA, and the desired product was obtained as colorless oil (130 mg, 40% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46–7.18 (m, 12H), 7.10 (d, <i>J</i> = 7.9 Hz, 1H), 3.49 (br s, 2H), 2.98 (br s, 3H), 2.82 (t, <i>J</i> = 5.9 Hz, 2H), 2.63 (t, <i>J</i> = 5.9 Hz, 2H), 2.55–2.46 (m, 2H), 2.40–2.26 (br s, 3H), 2.26–2.17 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.44, 140.62, 140.46, 136.71, 130.29, 129.39, 129.33, 128.42, 128.39, 128.07, 126.80, 119.18, 109.08, 59.74, 55.45, 55.42, 50.18, 42.84, 29.55. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>28</sub>H<sub>29</sub>ON<sub>3</sub> + H<sup>+</sup>): calcd, 424.23834; found, 424.23765 (error −1.6 ppm). CHN (C<sub>28</sub>H<sub>29</sub>ON<sub>3</sub> + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 0.5H<sub>2</sub>O) Calcd: C, 65.60; H, 5.86; N, 7.40. Found: C, 65.76; H, 5.87; N, 7.29. mp: 178–181 °C.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>25</b>)</h4><div class="NLM_p last"><i>N</i>-(3,3-Diphenyldihydrofuran-2(3<i>H</i>)-ylidene)-<i>N</i>-methylmethanaminium bromide (700 mg, 2 mmol) was suspended in 2 N NaOH (15 mL of aq solution) and then stirred at RT for 5 min. The mixture was extracted with DCM, and the organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum to afford the pure desired product in quantitative yield, as colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.25 (m, 10H), 3.17 (q, <i>J</i> = 5.0 Hz, 2H), 3.04–2.95 (m, 3H), 2.57–2.49 (m, 2H), 2.35–2.27 (m, 3H). GC/MS (EI), Rt 11.847 min; 283.1 (M<sup>+</sup>).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>,<i>N</i>-Dimethyl-4-oxo-2,2-diphenylbutanamide (<b>26</b>)</h4><div class="NLM_p last">DMP was added portionwise to a solution of <b>25</b> (200 mg, 0.71 mmol) in DCM (10 mL) at 0 °C. The reaction mixture was slowly warmed to RT and stirred for 1 h. The suspension was washed with 10% NaHCO<sub>3</sub> (aq solution), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by flash chromatography eluting with hex/EtOAc (50/50) to afford the desired product as a white solid (120 mg, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.17 (t, <i>J</i> = 2.2 Hz, 1H), 7.46–7.25 (m, 10H), 3.11–2.99 (m, 6H), 2.33 (s, 2H). GC/MS (EI), Rt 11.744 min; 281.1 (M<sup>+</sup>).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>,<i>N</i>-Dimethyl-4-(phenethylamino)-2,2-diphenylbutanamide (<b>27</b>)</h4><div class="NLM_p last">A solution of <b>26</b> (90 mg, 0.32 mmol), 2-phenylethan-1-amine (77 mg, 0.64 mmol), and cat. AcOH in DCE (5 mL) was stirred at RT for 30 min. STAB (97 mg, 0.48 mmol) was added portionwise, and the mixture was stirred for additional 2 h. The solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 5% DMA. The desired product was obtained as colorless oil (quantitative yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39–7.10 (m, 15H), 2.96 (m, 3H), 2.75 (br s, 7H), 2.48–2.28 (m + br s, 4H + 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 176.89, 173.88, 140.40, 139.18, 128.82, 128.73, 128.54, 128.45, 128.04, 126.94, 126.22, 126.17, 60.51, 50.11, 46.28, 44.40, 43.46, 40.00, 35.13, 23.25. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>26</sub>H<sub>30</sub>ON<sub>2</sub> + H<sup>+</sup>): calcd, 387.24309; found, 387.24226 (error −2.1 ppm). CHN (C<sub>26</sub>H<sub>30</sub>ON<sub>2</sub> + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 0.1NH<sub>4</sub>OH) Calcd: C, 66.33; H, 6.43; N, 5.60. Found: C, 66.10; H, 6.61; N, 5.91. mp: 112–117 °C.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-((4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)amino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>28</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (272 mg, 0.9 mmol). The desired product was purified by flash chromatography eluting with 25% DMA and obtained as colorless oil (300 mg, 65% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41–7.33 (m, 7H), 7.28–7.26 (m, 3H), 7.15–7.13 (m, 2H), 7.00–6.90 (m, 1H), 3.05 (s, 4H), 2.98 (s, 3H), 2.62 (br s, <i>J</i> = 6.0 Hz, 3H), 2.51 (t, <i>J</i> = 6.8 Hz, 6H), 2.45–2.37 (m, 4H), 2.29 (br s, 3H), 1.62–1.49 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 178.09, 173.97, 151.17, 139.95, 133.94, 128.69, 128.65, 127.97, 127.48, 127.38, 127.15, 124.55, 118.73, 60.48, 57.93, 53.14, 51.06, 50.67, 47.97, 45.70, 43.25, 25.94, 24.19, 23.98. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>32</sub>H<sub>40</sub>ON<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 567.26519; found, 567.26458 (error −1.1 ppm). CHN (C<sub>32</sub>H<sub>40</sub>ON<sub>4</sub>Cl<sub>2</sub> + 2.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + H<sub>2</sub>O) Calcd: C, 54.82; H, 5.84; N, 6.91. Found: C, 54.89; H, 5.68; N, 6.83. mp: initial decomposition ∼119 °C, complete melting 150–160 °C.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-((4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)amino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>29</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from 4-amino-1-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-2-ol (130 mg, 0.41 mmol). The desired product was purified by flash chromatography eluting with 25% DMA and obtained as colorless oil (80 mg, 34% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 8H), 7.31–7.22 (m, 2H), 7.16–7.07 (m, 2H), 6.93 (dd, <i>J</i> = 6.5, 3.1 Hz, 1H), 3.82 (m, 1H), 3.04 (br s, 6H), 2.97 (br s, 1H), 2.83–2.67 (m, 4H), 2.59 (dt, <i>J</i> = 11.8, 6.1 Hz, 4H), 2.50–2.30 (m, 4H), 2.30–2.17 (m, 4H), 1.56–1.32 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.53, 151.32, 140.75, 140.71, 133.98, 128.38, 128.33, 128.12, 128.09, 128.04, 127.48, 127.36, 126.71, 126.68, 124.45, 118.56, 71.43, 68.18, 64.64, 62.95, 59.92, 53.04, 52.17, 51.35, 47.60, 47.30, 45.64, 43.84, 34.82, 34.04. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 11.906 and 12.953 min, purity >99%, er 38:62 (absorbance at 254 nm). HPLC analysis method B: Chiralcel OD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 12.011 min, purity >99% (absorbance at 254 nm). HPLC analysis method C: Chiralcel OZ-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 12.172 min, purity >95% (absorbance at 254 nm). The free base was converted into the corresponding oxalate salt. HRMS (C<sub>32</sub>H<sub>40</sub>O<sub>2</sub>N<sub>4</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 583.26011; found, 583.26204 (error 2.3 ppm). CHN (C<sub>32</sub>H<sub>40</sub>O<sub>2</sub>N<sub>4</sub>Cl<sub>2</sub> + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 1.5H<sub>2</sub>O) Calcd: C, 54.69; H, 5.99; N, 7.09. Found: C, 54.75; H, 5.71; N, 7.16. mp: salt decomposes above 116 °C.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>30</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from 1-(2-chloro-3-ethylphenyl)piperazine<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (120 mg, 0.53 mmol). The desired product was purified by flash chromatography eluting with 15% DMA and obtained as colorless oil (130 mg, 50% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.44–7.34 (m, 8H), 7.29 (m, 2H), 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 6.91 (ddd, <i>J</i> = 19.7, 7.8, 1.5 Hz, 2H), 3.07 (br s, 6H), 2.99 (br s, 2H), 2.74 (br s + q, 4H + 2H), 2.61–2.52 (m, 2H), 2.38 (m, 4H), 1.20 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.46, 173.36, 148.98, 143.16, 140.12, 128.63, 128.54, 128.49, 128.06, 126.98, 126.87, 124.19, 118.14, 59.68, 55.36, 52.67, 50.17, 40.52, 27.39, 22.19, 14.03. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>30</sub>H<sub>36</sub>ON<sub>3</sub>Cl + H<sup>+</sup>): found, 490.26239 (error 0.9 ppm). CHN (C<sub>30</sub>H<sub>36</sub>ON<sub>3</sub>Cl + 1.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub>) Calcd: C, 63.40; H, 6.29; N, 6.72. Found: C, 63.35; H, 6.46; N, 6.67. mp: 183–186 °C.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-((4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)butyl)amino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>31</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from 4-(4-(2-chloro-3-ethylphenyl)piperazin-1-yl)butan-1-amine (390 mg, 1.33 mmol). The desired product was purified by flash chromatography eluting with 15% DMA and obtained as colorless oil (90 mg, 12% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.30 (m, 8H), 7.30–7.21 (m, 2H), 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 6.92 (ddd, <i>J</i> = 8.1, 6.6, 1.6 Hz, 2H), 3.03 (br s, 6H), 2.97 (br s, 2H), 2.76 (q, <i>J</i> = 7.5 Hz, 2H), 2.48–2.38 (m, 4H), 2.38–2.30 (m, 6H), 2.30–2.22 (m, 4H), 1.51–1.40 (m, 2H), 1.40–1.31 (m, 2H), 1.21 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.52, 149.69, 143.14, 140.85, 128.66, 128.32, 128.07, 126.83, 126.64, 123.85, 117.99, 59.90, 58.56, 53.42, 51.55, 49.76, 47.50, 45.75, 28.20, 27.46, 24.72, 23.03, 14.09. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>34</sub>H<sub>45</sub>ON<sub>4</sub>Cl + H<sup>+</sup>): calcd, 561.33547; found, 561.33350 (error −4.4 ppm). CHN (C<sub>34</sub>H<sub>45</sub>ON<sub>4</sub>Cl + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 1.75H<sub>2</sub>O) Calcd: C, 59.06; H, 6.85; N, 7.25. Found: C, 59.09; H, 6.65; N, 7.17.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-((4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)amino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>32</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from 4-amino-1-(4-(2-chloro-3-ethylphenyl)piperazin-1-yl)butan-2-ol (166 mg, 0.53 mmol). The desired product was purified by flash chromatography eluting with 25% DMA and obtained as colorless oil (110 mg, 36% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.32 (m, 7H), 7.32–7.22 (m, 3H), 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 6.92 (ddd, <i>J</i> = 11.9, 7.8, 1.6 Hz, 2H), 3.82 (m, 1H), 3.03 (s, 6H), 2.98 (s, 2H), 2.82–2.69 (m, 5H), 2.61 (ddd, <i>J</i> = 11.7, 8.1, 5.3 Hz, 3H), 2.47–2.19 (m, 8H), 1.58–1.34 (m, 2H), 1.22 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.55, 149.65, 143.17, 140.71, 128.67, 128.39, 128.05, 126.82, 126.72, 123.88, 117.98, 67.91, 64.64, 59.97, 53.73, 51.60, 47.48, 47.22, 45.49, 34.03, 27.45, 14.07. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 8.242 and 9.055 min, purity >99%, er 37:63 (absorbance at 254 nm). HPLC analysis method B: Chiralcel OD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 8.516 and 9.788 min, purity >99%, er 57:43 (absorbance at 254 nm). HPLC analysis method C: Chiralcel OZ-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 8.886 and 9.524 min, purity >99%. er 50:50 (absorbance at 254 nm). The free base was converted into the corresponding oxalate salt. HRMS (C<sub>34</sub>H<sub>45</sub>O<sub>2</sub>N<sub>4</sub>Cl + H<sup>+</sup>): found, 577.33059 (error 0.4 ppm). CHN (C<sub>34</sub>H<sub>45</sub>O<sub>2</sub>N<sub>4</sub>Cl + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + H<sub>2</sub>O) Calcd: C, 58.87; H, 6.63; N, 7.23. Found: C, 59.06; H, 6.46; N, 7.14. mp: 126–130 °C.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(4-Aminobutyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (<b>33</b>)</h4><div class="NLM_p last">A suspension of 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (300 mg, 1.9 mmol), <i>N</i>-(4-bromobutyl)phthalimide (535 mg, 1.9 mmol), cat. KI (3.15 mg, 19 μmol), and K<sub>2</sub>CO<sub>3</sub> (2.6 g, 19 mmol) in ACN (20 mL) was stirred under reflux overnight. The reaction mixture was cooled down to RT and filtered, the solvent was removed under vacuum, and the residue was dissolved in EtOH (10 mL), followed by the addition of hydrazine (0.175 mL). The solution was stirred under reflux for 3 h, EtOH was evaporated, and the residue was diluted with 20% K<sub>2</sub>CO<sub>3</sub> aq solution and extracted with DCM. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The crude material was used in the next step without further purification (300 mg, 94% yield).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-((4-(7-Cyano-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)butyl)amino)-<i>N</i>,<i>N</i>-dimethyl-2,2-diphenylbutanamide (<b>34</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>27</b>, starting from <b>33</b> (300 mg, 1.31 mmol) and <b>26</b> (368 mg, 1.31 mmol). The desired product was purified by flash chromatography eluting with 10% DMA and obtained as colorless oil (300 mg, 46% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42–7.21 (m, 12H), 7.16 (d, <i>J</i> = 7.9 Hz, 1H), 3.57 (s, 2H), 3.47 (d, <i>J</i> = 0.7 Hz, 6H), 2.99–2.87 (m, 4H), 2.68 (t, <i>J</i> = 5.9 Hz, 2H), 2.49–2.35 (m, 7H), 1.50 (q, <i>J</i> = 7.7 Hz, 2H), 1.41 (q, <i>J</i> = 7.3 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.55, 140.74, 140.36, 136.37, 130.37, 129.50, 129.46, 128.35, 128.04, 126.69, 119.13, 109.29, 59.89, 58.00, 55.45, 50.77, 50.10, 49.57, 47.45, 45.64, 29.41, 27.93, 24.82. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>32</sub>H<sub>38</sub>ON<sub>4</sub> + H<sup>+</sup>): found, 495.31212 (error 0.5 ppm). CHN (C<sub>34</sub>H<sub>45</sub>O<sub>2</sub>N<sub>4</sub>Cl + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 1.5H<sub>2</sub>O) Calcd: C, 61.61; H, 6.46; N, 7.98. Found: C, 61.59; H, 6.36; N, 7.98. mp: salt decomposes above 134 °C.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-3-Chloro-<i>N</i>-((1-(3-cyano-3,3-diphenylpropyl)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>35</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from (<i>S</i>)-nor-eticlopride (250 mg, 0.8 mmol) and 4-bromo-2,2-diphenylbutanenitrile (240 mg, 0.8 mmol). The desired product was purified by flash chromatography eluting with hex/EtOAc (60/40) and obtained as colorless oil (98 mg, 23% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 13.78 (s, 1H), 8.74 (s, 1H), 7.44–7.19 (m, 11H), 3.86 (s, 3H), 3.62 (ddd, <i>J</i> = 14.0, 6.9, 2.6 Hz, 1H), 3.29–3.12 (m, 2H), 2.89–2.78 (m, 1H), 2.72–2.55 (m, 5H), 2.49–2.37 (m, 1H), 2.28 (q, <i>J</i> = 8.8 Hz, 1H), 1.90 (dq, <i>J</i> = 12.3, 8.1 Hz, 1H), 1.75 (t, <i>J</i> = 7.8 Hz, 2H), 1.67–1.51 (m, 1H), 1.32–1.15 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.44, 160.15, 152.40, 140.02, 139.45, 132.90, 130.91, 128.95, 128.01, 127.97, 126.64, 122.00, 116.06, 108.18, 62.15, 61.44, 54.04, 50.33, 50.08, 40.43, 38.52, 29.68, 28.12, 22.71, 22.55, 13.43. CHN (C<sub>31</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub>Cl + 0.4 hexanes) Calcd: C, 70.81; H, 7.05; N, 7.42. Found: C, 70.49; H, 7.15; N, 7.08. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: gradient from 10 to 40% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 7.799 min, purity >99%, ee >99% (absorbance at 254 nm). HPLC analysis method B: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 10% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 9.043 min, purity >99%, ee >99% (absorbance at 254 nm). HRMS (C<sub>31</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub>Cl + H<sup>+</sup>): calcd, 532.23615; found, 532.23691 (error 0.4 ppm).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-<i>N</i>-((1-(4-Aminobutyl)pyrrolidin-2-yl)methyl)-3-chloro-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>36</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>33</b>, starting from (<i>S</i>)-3-chloro-5-ethyl-6-hydroxy-2-methoxy-<i>N</i>-(pyrrolidin-2-ylmethyl)benzamide [(<i>S</i>)-nor-eticlopride 250 mg, 0.8 mmol]. The crude material was used in the next step without further purification (110 mg, 36% yield).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-3-Chloro-<i>N</i>-((1-(4-((3-cyano-3,3-diphenylpropyl)amino)butyl)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>37</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>12</b>, starting from <b>36</b> (110 mg, 0.29 mmol) and 4-bromo-2,2-diphenylbutanenitrile (78 mg, 0.26 mmol). The desired product was purified by flash chromatography eluting with 10% DMA and obtained as colorless oil (15 mg, 10% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD): δ 7.39–7.23 (m, 6H), 7.18–7.06 (m, 5H), 3.83 (s, 3H), 3.82–3.50 (m, 6H), 3.36–3.26 (m, 6H), 2.82 (p, <i>J</i> = 6.9 Hz, 2H), 2.53 (q, <i>J</i> = 7.5 Hz, 2H), 1.74 (m, 5H), 1.11 (ddd, <i>J</i> = 8.2, 7.1, 0.8 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.69, 163.12, 156.56, 143.10, 142.99, 137.03, 134.45, 132.70, 132.67, 132.08, 132.06, 131.89, 131.85, 120.19, 112.47, 67.26, 66.39, 64.97, 57.87, 54.60, 49.82, 43.72, 42.16, 31.41, 27.77, 27.47, 26.07, 25.77, 16.57. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: gradient from 10 to 40% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 22.362 min, purity >95%, ee >99% (absorbance at 254 nm). HPLC analysis method B: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 14.389 min, purity >99%, ee >99% (absorbance at 254 nm). HRMS (C<sub>35</sub>H<sub>43</sub>N<sub>4</sub>O<sub>3</sub>Cl + 2H)<sup>2+</sup>: found, 302.15901; (C<sub>35</sub>H<sub>43</sub>N<sub>4</sub>O<sub>3</sub>Cl + H<sup>+</sup>): calcd, 603.30965; found, 603.31020 (error 0.4 ppm).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>tert</i>-Butyl ((1-(4-(1,3-Dioxoisoindolin-2-yl)butyl)pyrrolidin-2-yl)methyl)carbamate (<b>38</b>)</h4><div class="NLM_p last">A suspension of <i>tert</i>-butyl (pyrrolidin-2-ylmethyl)carbamate (500 mg, 2.5 mmol), <i>N</i>-(4-bromobutyl)phthalimide (775 mg, 2.75 mmol), cat. KI (4.15 mg, 25 μmol), and K<sub>2</sub>CO<sub>3</sub> (3.45 g, 25 mmol) in ACN (20 mL) was stirred under reflux overnight. The reaction mixture was cooled down to RT and filtered, the solvent was removed under vacuum, and the desired product, presenting both <i>N</i>-Boc and <i>N</i>-phthalimide protecting groups, was purified by flash chromatography eluting with 10% DMA and obtained as yellow oil (940 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.84 (dd, <i>J</i> = 5.5, 3.0 Hz, 2H), 7.71 (dd, <i>J</i> = 5.5, 3.1 Hz, 2H), 5.00–4.95 (m, 1H), 3.77–3.64 (m, 2H), 3.27 (d, <i>J</i> = 10.9 Hz, 1H), 3.15–2.99 (m, 2H), 2.73 (dt, <i>J</i> = 11.9, 8.1 Hz, 1H), 2.47 (br s, 1H), 2.23–2.02 (m, 2H), 1.89–1.43 (m, 8H), 1.43 (s, 9H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-Chloro-<i>N</i>-((1-(4-(1,3-dioxoisoindolin-2-yl)butyl)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>39</b>)</h4><div class="NLM_p last">A solution of <b>38</b> (940 mg, 2.34 mmol) and TFA (2.5 mL) in DCM (15 mL) was stirred at RT for 3 h. The reaction was quenched with NaHCO<sub>3</sub> (sat. aq solution) and extracted with DCM/2-PrOH (3:1). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The crude material was dissolved in DCM (15 mL), followed by dropwise addition of a solution of 3-chloro-5-ethyl-6-hydroxy-2-methoxybenzoic acid<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> (647 mg, 2.81 mmol) and HCTU (1.16 g, 2.81 mmol) in DCM (15 mL). The reaction mixture was stirred at RT for 48 h, the solvent was removed under vacuum, and the crude material was purified by flash chromatography eluting with 5% DMA. The desired product was obtained as brown oil (310 mg, 26% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 13.12 (s, 1H), 9.11 (s, 1H), 7.80 (dd, <i>J</i> = 5.4, 3.0 Hz, 2H), 7.69 (dd, <i>J</i> = 5.5, 3.0 Hz, 2H), 7.26–7.15 (m, 1H), 3.96–3.78 (m, 5H), 3.72 (m, <i>J</i> = 14.0 Hz, 4H), 3.57 (br s, 1H), 3.48 (br s, 1H), 3.26 (br s, 2H), 2.66–2.51 (m, 3H), 2.22 (dt, <i>J</i> = 15.0, 7.6 Hz, 1H), 1.99 (tt, <i>J</i> = 13.4, 6.9 Hz, 2H), 1.80–1.60 (m, 3H), 1.18 (dt, <i>J</i> = 10.7, 7.5 Hz, 3H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-Chloro-<i>N</i>-((1-(4-((4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)amino)butyl)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>40</b>)</h4><div class="NLM_p last">Hydrazine (0.2 mL, 50–60% wt in H<sub>2</sub>O) was added to a solution of <b>39</b> (310 mg, 0.6 mmol) in EtOH (20 mL), and the solution was stirred at reflux for 3 h. The solvent was removed under vacuum, and the residue was diluted with 20% K<sub>2</sub>CO<sub>3</sub> aq solution and extracted with DCM. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The obtained crude material was dissolved in DCE (10 mL) and added to a solution of <b>26</b> (169 mg, 0.6 mmol) and catalytic AcOH in DCE (10 mL). The mixture was stirred for 10 min at RT, and STAB (190 mg, 0.9 mmol) was added portionwise. The reaction mixture was stirred for additional 12 h, the solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as colorless oil (80.5 mg, 21% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.79 (br s, 1H), 7.40–7.22 (m, 11H), 3.82 (s, 3H), 3.72 (dt, <i>J</i> = 12.1, 4.0 Hz, 2H), 3.28–3.19 (m, 1H), 3.14 (dt, <i>J</i> = 9.5, 4.5 Hz, 1H), 2.95 (br s, 3H), 2.74–2.52 (m, 3H), 2.47–2.35 (m, 4H), 2.25 (d, <i>J</i> = 14.1 Hz, 4H), 2.12 (q, <i>J</i> = 8.6 Hz, 3H), 1.93–1.80 (m, 1H), 1.72 (d, <i>J</i> = 7.8 Hz, 2H), 1.69–1.52 (m, 1H), 1.40 (dt, <i>J</i> = 16.4, 8.3 Hz, 4H), 1.20 (dt, <i>J</i> = 27.3, 7.3 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.62, 169.49, 160.11, 152.51, 140.71, 140.65, 132.82, 130.67, 128.37, 128.17, 128.16, 128.03, 126.72, 116.01, 108.17, 62.27, 61.41, 60.04, 54.01, 53.80, 49.38, 47.15, 45.23, 40.32, 28.10, 27.73, 26.57, 22.58, 22.51, 13.41. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 9.538 and 10.664 min, purity >99%, er 46:54 (absorbance at 254 nm). HPLC analysis method B: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 15% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 22.250 and 25.814 min, purity >99%, er 50:50 (absorbance at 254 nm). HRMS (C<sub>37</sub>H<sub>49</sub>N<sub>4</sub>O<sub>4</sub>Cl + 2H)<sup>2+</sup>: found, 325.18021; (C<sub>37</sub>H<sub>49</sub>N<sub>4</sub>O<sub>4</sub>Cl + H<sup>+</sup>): calcd, 649.35151; found, 649.35221 (error 1.0 ppm).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3,3-Diphenylpyrrolidine (<b>41</b>)</h4><div class="NLM_p last">A suspension of LAH (0.56 g, 14.8 mmol) in THF (50 mL) was cooled to 0 °C, and a solution of 4-bromo-2,2-diphenylbutanenitrile (1.5 g, 5 mmol) in THF (20 mL) was added dropwise. The mixture was stirred at RT for 15 h, quenched with MeOH (5 mL) and sat. aq NaHCO<sub>3</sub> solution (5 mL), filtered over Celite, and concentrated under vacuum. The residue was suspended in DCM and washed with sat. Na<sub>2</sub>CO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The crude material was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as yellow oil (0.450 g, 40% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.34–7.22 (m, 8H), 7.22–7.13 (m, 2H), 3.52 (s, 2H), 3.13 (t, <i>J</i> = 7.2 Hz, 2H), 2.80–2.70 (br s, 1H), 2.52 (t, <i>J</i> = 7.2 Hz, 2H). GC/MS (EI), Rt 9.987 min; 223.2 (M<sup>+</sup>).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-Methyl-3,3-diphenylpyrrolidine (<b>42</b>)</h4><div class="NLM_p last">Methyl chloroformate (85 mg, 69 μL, 0.9 mmol) was added dropwise to a solution of <b>41</b> (100 mg, 0.45 mmol) in THF (10 mL), followed by excess of DIPEA (5 equiv). The mixture was stirred at RT for 1 h, the solvent was evaporated under vacuum, and the residue was dissolved in THF (10 mL). This solution was added dropwise to a suspension of LAH (17 mg, 0.45 mmol) in THF (10 mL), at 0 °C. The mixture was warmed to RT, quenched with MeOH/2 N aq NaOH (1:1 ratio, 2 mL), and filtered over Celite, and the solvents were evaporated under vacuum. The crude material was purified by flash chromatography eluting with 10% DMA to afford the desired product as colorless oil (60 mg, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.26 (d, <i>J</i> = 4.6 Hz, 8H), 7.20–7.11 (m, 2H), 3.22 (s, 2H), 2.82 (td, <i>J</i> = 7.0, 0.6 Hz, 2H), 2.60 (dd, <i>J</i> = 7.7, 6.7 Hz, 2H), 2.42 (s, 3H). GC/MS (EI), Rt 9.650 min; 237.2 (M<sup>+</sup>), purity >99%.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-(3,3-Diphenylpyrrolidin-1-yl)propan-1-one (<b>43</b>)</h4><div class="NLM_p last">A solution of <b>41</b> (70 mg, 0.31 mmol), propionyl chloride (58 mg, 0.63 mmol), and DIPEA (5 equiv) in DCM (10 mL) was stirred under reflux overnight. The solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with hex/EtOAc (70/30). The desired product was obtained as colorless oil (25 mg, 29% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) rotamer conformations observed (60:40; rotamer A/rotamer B): δ 7.34–7.14 (m, 10H), 4.16 (s, 2H, rotamer A), 4.04 (s, 2H, rotamer B), 3.53 (t, <i>J</i> = 6.9 Hz, 2H, rotamer B), 3.42 (t, <i>J</i> = 6.7 Hz, 2H, rotamer A), 2.63 (t, <i>J</i> = 6.7 Hz, 2H, rotamer A), 2.52 (t, <i>J</i> = 6.9 Hz, 2H, rotamer B), 2.41 (q, <i>J</i> = 7.5 Hz, 2H, rotamer B), 2.26 (q, <i>J</i> = 7.5 Hz, 2H, rotamer A), 1.21 (t, <i>J</i> = 7.5 Hz, 3H, rotamer B), 1.16 (t, <i>J</i> = 7.5 Hz, 3H, rotamer A). GC/MS (EI), Rt 12.154 min; 279.1 (M<sup>+</sup>), purity >99%.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Chloro-1-(3,3-diphenylpyrrolidin-1-yl)ethan-1-one (<b>44</b>)</h4><div class="NLM_p last">2-Chloroacetyl chloride (126 mg, 1.12 mmol) was added dropwise to a solution of <b>41</b> (250 mg, 1.12 mmol) in THF (10 mL) at 0 °C, followed by dropwise addition of DIPEA (0.3 mL, 1.68 mmol). The mixture was allowed to warm to RT and stirred for 1 h. The solvent was removed under vacuum, and the residue was used in the following step without further purification. GC/MS (EI), Rt 12.740 min; 299.1 (M<sup>+</sup>).</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl ((1-(2-(3,3-Diphenylpyrrolidin-1-yl)-2-oxoethyl)pyrrolidin-2-yl)methyl)carbamate (<b>45</b>)</h4><div class="NLM_p last">A mixture of <b>44</b> (290 mg, 0.97 mmol), <i>tert</i>-butyl (pyrrolidin-2-ylmethyl)carbamate (194 mg, 0.97 mmol), KI (161 mg, 0.97 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.34 g, 9.67 mmol) in ACN (25 mL) was stirred under reflux for 3 h. The mixture was filtered, the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as yellow oil (330 mg, 74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) rotamer conformations observed: δ 7.34–7.15 (m, 10H), 5.30 (m, 1H), 3.69–3.38 (m, 4H), 3.29–2.93 (m, 3H), 2.71–2.17 (m, 4H), 1.90 (tt, <i>J</i> = 19.2, 8.6 Hz, 2H), 1.73 (m, <i>J</i> = 17.3, 8.5 Hz, 4H), 1.50–1.38 (m, 9H).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-Chloro-<i>N</i>-((1-(2-(3,3-diphenylpyrrolidin-1-yl)-2-oxoethyl)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>46</b>)</h4><div class="NLM_p last">TFA (0.3 mL) was added to a solution of <b>45</b> (330 mg, 0.71 mmol) in DCM (10 mL). The mixture was stirred at RT for 2 h, basified with NH<sub>4</sub>OH (28% aq solution), and extracted with DCM. The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum to afford the crude material, which was filtered over a silica pad, eluting and washing with 25% DMA to isolate the desired primary amine intermediate. The amine was dissolved in DCM (10 mL) and added dropwise to a solution of 3-chloro-5-ethyl-6-hydroxy-2-methoxybenzoic acid (70 mg, 0.3 mmol), HCTU (0.2 g, 0.33 mmol), and DIPEA (1.5 equiv) in DCM (10 mL). The mixture was stirred at RT for 3 h, the solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 5% DMA. The desired product was obtained as colorless oil (26 mg, 15% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) rotamer conformations observed: δ 13.68 (s, 1H), 8.82 (s, 1H), 7.31–7.12 (m, 11H), 4.23 (t, <i>J</i> = 11.0 Hz, 1H), 4.02 (dd, <i>J</i> = 26.1, 11.5 Hz, 1H), 3.85 (ds, <i>J</i> = 17.4 Hz, 3H), 3.79–3.68 (m, 1H), 3.62–3.21 (m, 6H), 2.96 (br s, 1H), 2.68–2.52 (m, 4H), 2.14–1.97 (m, 1H), 1.92–1.66 (m, 4H), 1.28–1.14 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) rotamer conformations observed: δ 169.75, 160.07, 160.04, 152.47, 152.46, 144.94, 144.88, 144.79, 133.07, 130.79, 130.77, 128.57, 128.53, 128.51, 126.67, 126.62, 126.59, 126.58, 126.52, 116.16, 116.11, 107.98, 61.57, 61.49, 56.60, 56.14, 56.12, 55.10, 54.87, 54.68, 54.45, 53.40, 52.22, 44.57, 44.39, 40.88, 40.46, 37.52, 35.57, 29.68, 28.38, 28.26, 23.05, 22.86, 22.51, 13.39. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 10% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 20.539 and 23.859 min, purity >99%, er 51:49 (absorbance at 254 nm). HRMS (C<sub>33</sub>H<sub>38</sub>N<sub>3</sub>O<sub>4</sub>Cl + H<sup>+</sup>): calcd, 576.26236; found, 576.26297 (error 1.0 ppm).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-Chloro-<i>N</i>-(((2<i>S</i>,4<i>R</i>)-4-(4-((4-(dimethylamino)-4-oxo-3,3-diphenylbutyl)amino)butoxy)pyrrolidin-2-yl)methyl)-5-ethyl-6-hydroxy-2-methoxybenzamide (<b>48</b>)</h4><div class="NLM_p last">A solution of <b>47</b> (400 mg, 0.8 mmol), <b>26</b> (225 mg, 0.8 mmol), and cat. AcOH (0.05 equiv) in DCE (20 mL) was stirred at RT for 1 h, followed by portionwise addition of STAB (339 mg, 1.6 mmol). The mixture was stirred at RT for 3 h and basified with 10% NH<sub>4</sub>OH in MeOH, the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 10% DMA. The obtained intermediate was dissolved in DCM (20 mL) and TFA (10 mL), and the solution was stirred at RT overnight. The excess of TFA was removed under vacuum, and the residue resuspended in aq NH<sub>4</sub>OH (pH 9) and extracted with DCM/2-PrOH (3:1). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford the crude material, which was purified by flash chromatography eluting with 25% DMA. The desired product was obtained as colorless oil (45 mg, 8.5% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.92 (s, 1H), 7.43–7.21 (m, 11H), 3.97 (t, <i>J</i> = 4.9 Hz, 1H), 3.89 (s, 3H), 3.57 (dq, <i>J</i> = 9.6, 4.7 Hz, 3H), 3.36 (dt, <i>J</i> = 5.8, 2.8 Hz, 3H), 3.22 (tt, <i>J</i> = 8.9, 4.5 Hz, 2H), 3.02–2.90 (m, 5H), 2.69–2.55 (m, 4H), 2.45 (dd, <i>J</i> = 21.5, 5.7 Hz, 4H), 2.30 (br s, 2H), 2.00 (dd, <i>J</i> = 13.7, 6.9 Hz, 1H), 1.70–1.50 (m, 5H), 1.31–1.14 (m, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.57, 169.21, 160.06, 152.48, 139.97, 132.89, 130.72, 128.78, 127.96, 127.93, 127.26, 116.16, 108.17, 80.67, 68.17, 61.57, 56.10, 51.78, 43.34, 36.07, 27.16, 22.50, 21.93, 13.41. HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 18.518 min, purity >95%, ee >95% (absorbance at 210 nm). The free base was converted into the corresponding oxalate salt. HRMS (C<sub>37</sub>H<sub>49</sub>N<sub>4</sub>O<sub>5</sub>Cl + 2H)<sup>2+</sup>: calcd, 333.17685; found, 333.17656 (error 0.9 ppm); (C<sub>37</sub>H<sub>49</sub>N<sub>4</sub>O<sub>5</sub>Cl + H)<sup>+</sup>: calcd, 665.34642; found, 665.34552 (error 1.4 ppm). CHN (C<sub>37</sub>H<sub>49</sub>N<sub>4</sub>O<sub>5</sub>Cl + 2H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 1.5H<sub>2</sub>O) Calcd: C, 56.45; H, 6.47; N, 6.42. Found: C, 56.25; H, 6.24; N, 6.40. mp: salt decomposes above 90 °C.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3,3-Bis(3-methoxyphenyl)acrylaldehyde (<b>49</b>)</h4><div class="NLM_p last">A solution of bis(3-methoxyphenyl)methanone (1.0 g, 4.13 mmol) and TiCl<sub>4</sub> (1.0 M solution in DCM, 16.5 mL, 16.5 mmol) in DCM was cooled to 0 °C. TEA (2.3 mL, 16.5 mmol) was added dropwise, and the mixture was warmed to RT and stirred overnight.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The reaction was quenched with sat. NH<sub>4</sub>Cl aq solution and stirred for 30 min. The mixture was extracted with DCM, and the organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude material was purified by flash chromatography eluting with hex/EtOAc (95/5). The desired product was obtained as colorless oil (645 mg, 58% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.60–9.53 (m, 1H), 7.42–7.25 (m, 2H), 7.07–6.77 (m, 6H), 6.64–6.56 (m, 1H), 3.89–3.74 (m, 6H). GC/MS (EI), Rt 11.647 min; 268.1 (M<sup>+</sup>).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(3,3-Bis(3-methoxyphenyl)allyl)-4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (<b>50</b>)</h4><div class="NLM_p last">A solution of <b>49</b> (302 mg, 1.12 mmol), 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine (340 mg, 1.12 mmol), and cat. AcOH (0.1 equiv) in DCE (20 mL) was stirred for 1 h at RT, followed by portionwise addition of STAB (715 mg, 3.37 mmol). The reaction mixture was stirred for 3 h, the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 5% DMA. The desired product was obtained as colorless oil (550 mg, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.26 (m, 1H), 7.16 (q, <i>J</i> = 7.6 Hz, 2H), 6.90–6.79 (m, 3H), 6.79–6.67 (m, 4H), 6.67–6.60 (m, 1H), 6.20–6.11 (m, 1H), 3.74 (d, <i>J</i> = 5.4 Hz, 6H), 3.38–3.33 (m, 4H), 3.08 (br s, 4H), 2.74 (m, 2H), 2.58 (br s, 2H), 2.42 (m, 2H), 1.47 (m, 2H), 1.28 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.73, 159.49, 159.43, 150.75, 142.64, 140.20, 134.01, 129.39, 129.11, 127.48, 127.47, 124.83, 122.01, 119.88, 118.71, 115.22, 113.32, 112.98, 112.85, 57.48, 55.20, 55.16, 53.39, 52.57, 52.48, 51.42, 50.27, 30.90, 23.33, 23.10, 21.27. HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 6.538 min, purity >95% (absorbance at 254 nm). HRMS (C<sub>31</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub>Cl<sub>2</sub> + H)<sup>+</sup>: calcd, 554.23356; found, 554.23390.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3,3′-(3-((4-(4-Phenylpiperazin-1-yl)butyl)amino)propane-1,1-diyl)diphenol (<b>51</b>)</h4><div class="NLM_p last">A suspension of <b>50</b> (250 mg, 0.45 mmol) and Pd/C (20% wt wet, 0.05 equiv) in EtOH (10 mL) was shaken in a Parr apparatus under 50 psi pressure of hydrogen gas for 12 h. The mixture was filtered through a pad of Celite, the solvent was evaporated under vacuum, and the residue was purified trough a pad of silica eluting with 5% DMA. This intermediate was dissolved in 33% HBr (solution in AcOH, 2 mL) and stirred under reflux for 48 h. The solvent was removed under vacuum, and the residue was basified with 10% v/v NH<sub>4</sub>OH solution in methanol. The crude material was purified by flash chromatography eluting with 25% DMA. The desired product was obtained as yellow oil (6.8 mg, 29% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.28–7.19 (m, 1H), 7.09 (t, <i>J</i> = 7.8 Hz, 2H), 6.90–6.80 (m, 2H), 6.71–6.60 (m, 4H), 6.55 (s, 2H), 5.44 (br s, 2H), 3.81 (t, <i>J</i> = 7.9 Hz, 1H), 3.09 (t, <i>J</i> = 5.0 Hz, 4H), 2.61 (s, 2H), 2.49 (dt, <i>J</i> = 11.8, 5.4 Hz, 6H), 2.25 (p, <i>J</i> = 7.5 Hz, 4H), 1.30–1.16 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.49, 157.37, 150.94, 145.43, 129.75, 129.07, 119.90, 119.43, 116.11, 114.54, 114.47, 65.83, 58.11, 52.97, 34.26, 26.57, 25.34, 24.12, 22.59, 15.25. HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes + 0.1% DEA; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 38.741 min, purity >95% (absorbance at 254 nm). HRMS (C<sub>29</sub>H<sub>37</sub>N<sub>3</sub>O<sub>2</sub> + H)<sup>+</sup>: found, 460.29628.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(3,3-Bis(3-methoxyphenyl)allyl)-4-(2-chloro-3-ethylphenyl)piperazine (<b>52</b>)</h4><div class="NLM_p last">The reaction was performed following the same procure described for <b>50</b>, starting from 1-(2-chloro-3-ethylphenyl)piperazine<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (180 mg, 0.78 mmol). The desired product was obtained as colorless oil (330 mg, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.24–7.11 (m, 3H), 7.00–6.66 (m, 8H), 6.31 (t, <i>J</i> = 7.0 Hz, 1H), 3.79 (d, <i>J</i> = 14.0 Hz, 6H), 3.34 (d, <i>J</i> = 6.9 Hz, 2H), 3.14 (br s, 4H), 3.00–2.76 (br s, 4H), 2.76 (q, <i>J</i> = 7.5 Hz, 2H), 1.21 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(3,3-Bis(3-methoxyphenyl)propyl)-4-(2-chloro-3-ethylphenyl)piperazine (<b>53</b>)</h4><div class="NLM_p last">A suspension of <b>52</b> (330 mg, 0.69 mmol) and Pd/C (20% wt wet, 0.05 equiv) in EtOAc/EtOH (10:5 mL) was shaken in a Parr apparatus under 30 psi pressure of H<sub>2</sub> for 3 h. The mixture was filtered through a pad of Celite, the solvent was evaporated under vacuum, and the desired product was obtained as colorless oil (250 mg, 75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.18 (dt, <i>J</i> = 20.9, 7.8 Hz, 3H), 6.94 (ddd, <i>J</i> = 11.1, 7.8, 1.5 Hz, 2H), 6.90–6.67 (m, 6H), 3.96–3.86 (m, 1H), 3.82–3.67 (br s, 6H), 3.10 (br s, 4H), 2.76 (br s + q, <i>J</i> = 7.5 Hz, 6H), 2.50 (dd, <i>J</i> = 9.9, 5.8 Hz, 2H), 2.06 (m, 2H), 1.29–1.15 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (C<sub>29</sub>H<sub>35</sub>ClN<sub>2</sub>O<sub>2</sub> + H)<sup>+</sup>: calcd, 479.24598; found, 479.24505 (error 1.9 ppm). The free base (50 mg) was converted into the corresponding oxalate salt. mp: salt decomposes above 100 °C.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 3-(3-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-1-(3-methoxyphenyl)propyl)phenol (<b>54</b>) and 3,3′-(3-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)propane-1,1-diyl)diphenol (<b>55</b>)</h4><div class="NLM_p last">A solution of <b>53</b> (200 mg, 0.42 mmol) in 33% HBr (solution in AcOH, 5 mL) and DCM (10 mL) was stirred under reflux for 24 h. The solvent was removed under vacuum, and the residue was basified with 28–30% v/v aq NH<sub>4</sub>OH and extracted with DCM/2-PrOH (3:1). The crude material was purified by flash chromatography eluting with 10% DMA. <b>54</b> eluted first as yellow oil (60 mg, 31% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.20–7.07 (m, 3H), 6.94 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 6.91–6.66 (m, 4H), 6.64 (d, <i>J</i> = 1.0 Hz, 1H), 6.64–6.47 (m, 2H), 3.83 (t, <i>J</i> = 7.6 Hz, 1H), 3.73 (s, 3H), 3.01 (br s, 4H), 2.76 (br s + q, <i>J</i> = 7.5 Hz, 6H), 2.49–2.36 (m, 2H), 2.35–2.15 (m, 2H), 1.36–1.17 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (C<sub>28</sub>H<sub>33</sub>ClN<sub>2</sub>O<sub>2</sub> + H)<sup>+</sup>: calcd, 465.23033; found, 465.22945 (error 1.9 ppm). <b>55</b> eluted second as a yellow oil (25 mg, 13% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.09 (td, <i>J</i> = 7.8, 2.4 Hz, 3H), 6.93 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 6.85–6.69 (m, 3H), 6.63 (ddd, <i>J</i> = 8.1, 2.5, 0.9 Hz, 2H), 6.55 (t, <i>J</i> = 1.9 Hz, 2H), 3.75 (q, <i>J</i> = 7.9 Hz, 1H), 2.97 (br s, 4H), 2.75–2.60 (br s + q, <i>J</i> = 7.6 Hz, 6H), 2.43 (br s, 2H), 2.26–2.15 (m, 2H), 1.30–1.16 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (C<sub>27</sub>H<sub>31</sub>ClN<sub>2</sub>O<sub>2</sub> + H)<sup>+</sup>: calcd, 451.21468; found, 451.21429 (error 0.9 ppm).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>trans</i>-Ethyl (<i>Z</i>)-2-((1<i>S</i>,5<i>S</i>)-2-(4-(1<i>H</i>-Indole-2-carboxamido)butyl)-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ylidene)acetate (<b>57</b>)</h4><div class="NLM_p last">A solution of <b>56</b> (20 mg, 66 μmol), <i>N</i>-(4-oxobutyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (18 mg, 80 μmol), and catalytic AcOH (0.01 equiv) in DCE (10 mL) was stirred at RT for 1 h, followed by portionwise addition of STAB (30 mg, 66 μmol). The reaction mixture was stirred for additional 30 min and basified with 10% NH<sub>4</sub>OH solution in MeOH (10 mL), the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 20% DMA. The desired product was obtained as colorless oil (30 mg, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.30 (s, 1H), 7.61 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 7.46–7.38 (m, 1H), 7.32–7.08 (m, 3H), 6.97–6.78 (m, 4H), 6.78–6.70 (m, 1H), 5.30 (s, 1H), 5.16 (d, <i>J</i> = 17.9 Hz, 2H), 4.13–3.92 (m, 2H), 3.63–3.44 (m, 2H), 3.20 (ddd, <i>J</i> = 13.2, 8.9, 4.8 Hz, 1H), 2.73 (ddt, <i>J</i> = 17.8, 12.3, 5.8 Hz, 3H), 2.46 (ddd, <i>J</i> = 14.4, 8.7, 6.0 Hz, 1H), 2.27–2.00 (m, 5H), 1.90–1.50 (m, 6H), 1.14 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.91, 166.96, 161.79, 155.61, 148.65, 136.14, 131.04, 129.25, 127.68, 124.33, 121.83, 120.55, 119.46, 115.00, 114.38, 113.60, 111.89, 102.22, 59.92, 55.45, 53.31, 48.76, 45.69, 40.19, 39.34, 38.73, 30.66, 27.22, 24.50, 20.48, 14.13. HPLC analysis method A: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 30.677 min, purity >99%, ee >99% (absorbance at 254 nm). HPLC analysis method B: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 30% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 13.495 min, purity >99%, ee >99% (absorbance at 254 nm). HRMS (C<sub>31</sub>H<sub>37</sub>O<sub>4</sub>N<sub>3</sub> + H<sup>+</sup>): calcd, 516.28568; found, 516.28475 (error −1.8 ppm).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>trans</i>-Ethyl (<i>Z</i>)-2-((2<i>S</i>,6<i>R</i>)-6-(((2-(2-(1<i>H</i>-Indole-2-carboxamido)ethyl)cyclopropyl)methyl)(ethyl)amino)-2-(3-hydroxyphenyl)-2-methylcyclohexylidene)acetate (<b>58</b>)</h4><div class="NLM_p last">The reaction was performed following the same procure described for <b>57</b>, starting from <b>56</b> (20 mg, 66 μmol) and <i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (17 mg, 66 μmol). The desired product was obtained as colorless oil (23 mg, 65% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) mixture of diastereomers observed: δ 9.33 (s, 1H, dr 60:40), 7.62 (dd, <i>J</i> = 8.1, 3.8 Hz, 1H), 7.47–7.39 (m, 1H), 7.34–7.25 (m, 1H), 7.23–7.08 (m, 2H), 6.93 (d, <i>J</i> = 10.1 Hz, 1H), 6.89–6.69 (m, 3H), 6.60 (s, 1H), 5.25–5.10 (m, 2H), 4.13–3.95 (m, 2H), 3.72–3.49 (m, 2H), 3.16 (d, <i>J</i> = 12.3 Hz, 1H), 2.96–2.74 (m, 2H), 2.46 (dd, <i>J</i> = 14.2, 6.9 Hz, 1H), 2.37–2.27 (m, 1H), 2.25–1.98 (m, 7H), 1.64–1.49 (m, 4H), 1.38–1.24 (m, 1H), 1.15 (dt, <i>J</i> = 8.2, 7.1 Hz, 3H), 0.89 (d, <i>J</i> = 62.8 Hz, 1H, dr <b>60</b>:40), 0.69 (d, <i>J</i> = 52.6 Hz, 1H, dr 60:<b>40</b>), 0.32 (dt, <i>J</i> = 17.8, 5.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 166.85, 166.83, 161.95, 161.69, 156.18, 155.88, 136.29, 136.20, 130.95, 130.50, 129.23, 129.13, 127.69, 127.56, 124.62, 124.40, 121.90, 121.85, 120.74, 120.58, 115.31, 115.13, 113.95, 113.82, 112.01, 111.90, 102.62, 60.90, 60.56, 59.87, 59.81, 55.32, 54.77, 50.85, 48.21, 48.08, 45.64, 45.60, 40.24, 40.17, 40.09, 39.74, 33.47, 33.42, 30.86, 20.19, 18.92, 17.04, 16.55, 15.72, 14.17, 14.15, 10.91, 9.23. HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 22.572 and 27.023 min, purity >99%, dr 45:55 (absorbance at 254 nm). HRMS (C<sub>33</sub>H<sub>39</sub>O<sub>4</sub>N<sub>3</sub> + H<sup>+</sup>): calcd, 542.30133; found, 542.29988 (error −3.6 ppm). The two diastereoisomers <b>58a</b> and <b>58b</b> were resolved and separated by preparative chiral HPLC (Chiralpak AD-H 21 mm × 250 mm × 5 μm): mobile phase: gradient from 10 to 40% 2-PrOH in hexanes; temperature: 25 °C; flow rate: 15–18 mL/min; injection volume: 3 mL (∼15–20 mg/mL sample concentration); detection at λ 230 and 254 nm with the support of ELS detector. <b>58a</b> eluted first; HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 28.905 min, purity >99%, de >99% (absorbance at 254 nm). <b>58b</b> eluted second; HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 20% 2-PrOH in hexanes; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 34.205 min, purity >99%, de >99% (absorbance at 254 nm).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(4-((1<i>S</i>,5<i>S</i>,9<i>R</i>)-9-Hydroxy-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)butyl)-1<i>H</i>-indole-2-carboxamide (<b>61</b>)</h4><div class="NLM_p last">The reaction was performed following the same procure described for <b>57</b>, starting from (1<i>S</i>,5<i>S</i>,9<i>R</i>)-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ol (<b>59</b>; 40 mg, 0.17 mmol). The desired product was purified by flash chromatography eluting with 20% DMA and obtained as a white solid (20 mg, 26% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.57 (ddt, <i>J</i> = 9.0, 8.0, 1.0 Hz, 2H), 7.41 (dt, <i>J</i> = 8.2, 0.8 Hz, 2H), 7.24–6.94 (m, 4H), 6.89–6.73 (m, 2H), 6.66–6.58 (m, 1H), 4.25 (m, 1H), 4.07 (s, 1H), 3.74 (d, <i>J</i> = 0.5 Hz, 2H), 3.46 (d, <i>J</i> = 6.1 Hz, 1H), 3.44–3.25 (m, 3H), 2.96 (d, <i>J</i> = 9.8 Hz, 1H), 2.70 (br s, 3H), 2.48 (td, <i>J</i> = 13.5, 7.8 Hz, 2H), 2.31 (d, <i>J</i> = 12.8 Hz, 1H), 2.23–2.08 (m, 1H), 1.93–1.61 (m, <i>J</i> = 4.2, 3.2 Hz, 6H), 1.28 (br s, 1H). HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 50% 2-PrOH in hexanes + 0.1% DEA; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 29.790, purity >99%, ee >99% (absorbance at 254 nm). HRMS (C<sub>27</sub>H<sub>34</sub>O<sub>3</sub>N<sub>3</sub> + H<sup>+</sup>): calcd, 448.25947; found, 448.25979.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(4-((1<i>S</i>,5<i>S</i>,9<i>S</i>)-9-Hydroxy-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)butyl)-1<i>H</i>-indole-2-carboxamide (<b>62</b>)</h4><div class="NLM_p last">The reaction was performed following the same procedure described for <b>57</b>, starting from (1<i>S</i>,5<i>S</i>,9<i>S</i>)-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ol (<b>60</b>; 40 mg, 0.17 mmol). The desired product was purified by flash chromatography eluting with 20% DMA and obtained as a white solid (20 mg, 26% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.62–7.53 (m, 2H), 7.42 (t, <i>J</i> = 8.3 Hz, 2H), 7.25–7.12 (m, 2H), 7.12–6.80 (m, 4H), 6.40 (m, 1H), 4.30 (m, 1H), 4.07 (s, 1H), 3.75 (s, 2H), 3.49–3.37 (m, 4H), 2.98 (br s, 1H), 2.20–1.93 (m, 7H), 1.73–1.66 (m, 5H), 1.28 (br s, 2H). HPLC analysis method: Chiralpak AD-H analytical column (4.5 mm × 250 mm—5 μm particle size); mobile phase: isocratic 50% 2-PrOH in hexanes + 0.1% DEA; flow rate: 1 mL/min; injection volume: 20 μL; sample concentration: ∼1 mg/mL; multiple DAD λ absorbance signals measured in the range of 210–280 nm, Rt 32.837, purity >99%, ee >99% (absorbance at 254 nm). HRMS (C<sub>27</sub>H<sub>34</sub>O<sub>3</sub>N<sub>3</sub> + H<sup>+</sup>): calcd, 448.25947; found, 448.25982.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethan-1-ol (<b>63</b>)</h4><div class="NLM_p last">A solution of 1-(2,3-dichlorophenyl)piperazine hydrochloride (500 mg, 1.87 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.29 g, 9.34 mmol) in ACN (30 mL) was stirred for 25 min under gentle heating, followed by dropwise addition of 2-bromoethan-1-ol (257 mg, 2.06 mmol) and cat. KI. The suspension was stirred under reflux overnight and filtered, and the solvent was evaporated under vacuum to afford the crude material. The desired product was purified by flash chromatography eluting with 100% EtOAc and obtained as yellow oil (310 mg, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.21–7.10 (m, 2H), 6.96 (dd, <i>J</i> = 6.7, 2.8 Hz, 1H), 3.72–3.62 (m, 2H), 3.08 (br s, 4H), 2.71 (br s, 4H), 2.67–2.60 (m, 2H).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl 4-Methylbenzenesulfonate (<b>64</b>)</h4><div class="NLM_p last"><i>p</i>-Toluenesulfonyl chloride (<i>p</i>-TsCl, 200 mg, 1.05 mmol) was added portionwise to a solution of <b>63</b> (240 mg, 0.87 mmol) and DIPEA (0.310 mL, 225 mg, 1.74 mmol) in DCM (15 mL). The mixture was stirred at RT overnight, the solvent was evaporated under vacuum, and the crude residue was purified by flash chromatography eluting with hex/EtOAc (1/1). The desired product was obtained as a white solid (135 mg, 36% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 7.9 Hz, 2H), 7.34 (d, <i>J</i> = 7.9 Hz, 2H), 7.18–7.08 (m, 2H), 6.91 (dd, <i>J</i> = 6.8, 2.9 Hz, 1H), 4.16 (t, <i>J</i> = 5.7 Hz, 2H), 3.06–2.99 (br s, 4H), 2.72 (t, <i>J</i> = 5.8 Hz, 2H), 2.61 (br s, 4H), 2.44 (s, 3H).</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Ethyl (<i>Z</i>)-2-((1<i>S</i>,5<i>S</i>)-2-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonan-9-ylidene)acetate (<b>65</b>)</h4><div class="NLM_p last">A suspension of <b>56</b> (50 mg, 0.175 mmol), <b>64</b> (71.5 mg, 0.166 mmol), and NaHCO<sub>3</sub> (100 mg, 1.2 mmol) in ACN (7 mL) was heated and stirred in a sealed vessel for 6 h. The reaction mixture was filtered, the solvent was evaporated under vacuum, and the residue was purified by flash chromatography eluting with 10% DMA. The desired product was obtained as yellow oil (40 mg, 43% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.33–7.14 (m, 3H), 7.14–7.05 (m, 1H), 6.92 (m, 2H), 6.65 (m, 1H), 5.48 (s, 1H), 4.08 (dq, <i>J</i> = 21.4, 7.1 Hz, 2H), 3.34–3.21 (m, 2H), 3.08 (br s, 4H), 2.97–2.70 (m, 10H), 2.56–2.42 (m, 1H), 2.22–1.98 (m, 4H), 1.74 (m, 1H), 1.65 (s, 1H), 1.19 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 168.38, 167.92, 158.33, 152.58, 149.48, 134.91, 130.18, 129.03, 128.40, 125.82, 120.17, 119.71, 116.02, 115.67, 114.48, 111.42, 59.50, 57.16, 56.04, 54.80, 54.16, 52.08, 46.63, 41.34, 39.27, 31.73, 21.35, 14.54. The free base was converted into the corresponding oxalate salt. HRMS (C<sub>30</sub>H<sub>37</sub>N<sub>3</sub>O<sub>3</sub>Cl<sub>2</sub> + H<sup>+</sup>): calcd, 558.22847; found, 558.22925 (error 1.4 ppm). CHN (C<sub>30</sub>H<sub>37</sub>N<sub>3</sub>O<sub>3</sub>Cl<sub>2</sub> + 2.5H<sub>2</sub>C<sub>2</sub>O<sub>4</sub> + 2H<sub>2</sub>O) Calcd: C, 51.29; H, 5.66; N, 5.13. Found: C, 51.07; H, 5.28; N, 5.21. mp: salt decomposes above 110 °C.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Radioligand Binding Studies</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> hD<sub>2</sub>R, hD<sub>3</sub>R, and hD<sub>4</sub>R</h4><div class="NLM_p last">Radioligand binding assays were conducted similar to those previously described.<a onclick="showRef(event, 'ref45 ref67'); return false;" href="javascript:void(0);" class="ref ref45 ref67">(45,67)</a> HEK293 cells stably expressing human D<sub>2</sub>LR or D<sub>3</sub>R or D<sub>4.4</sub> were grown in a 50:50 mix of Dulbecco’s modified Eagle medium (DMEM) and Ham’s F12 culture media, supplemented with 20 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 0.1 mM nonessential amino acids, 1× antibiotic/antimycotic, 10% heat-inactivated fetal bovine serum (FBS), and 200 μg/mL hygromycin (Life Technologies, Grand Island, NY) and kept in an incubator at 37 °C and 5% CO<sub>2</sub>. Upon reaching 80–90% confluence, cells were harvested using premixed Earle’s balanced salt solution with 5 mM ethylenediaminetetraacetic acid (EDTA) (Life Technologies) and centrifuged at 3000 rpm for 10 min at 21 °C. The supernatant was removed, and the pellet was resuspended in 10 mL of hypotonic lysis buffer (5 mM MgCl<sub>2</sub>, 5 mM Tris, pH 7.4 at 4 °C) and centrifuged at 14,500 rpm (∼25,000<i>g</i>) for 30 min at 4 °C. The pellet was then resuspended in binding buffer. Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration. For [<sup>3</sup>H]-<i>N</i>-methylspiperone binding studies, membranes were diluted to 500 μg/mL, in fresh EBSS binding buffer made from 8.7 g/L Earle’s balanced salts without phenol red (US Biological, Salem, MA), 2.2 g/L sodium bicarbonate, pH to 7.4, and stored in a −80 °C freezer for later use. For [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT binding studies, membranes were harvested fresh; the binding buffer was made from 50 mM Tris, 10 mM MgCl<sub>2</sub>, and 1 mM EDTA, pH 7.4. On the test day, each test compound was diluted into half-log serial dilutions using the 30% dimethyl sulfoxide (DMSO) vehicle. When it was necessary to assist solubilization of the drugs at the highest tested concentration, 0.1% AcOH (final concentration v/v) was added alongside the vehicle. Membranes were diluted in fresh binding buffer. Radioligand competition experiments were conducted in 96-well plates containing 300 μL of fresh binding buffer, 50 μL of the diluted test compound, 100 μL of membranes (for [<sup>3</sup>H]-<i>N</i>-methylspiperone assays: 10–20, 10–20, and 20–30 μg/well total protein for hD<sub>2L</sub>R, hD<sub>3</sub>R, and hD<sub>4.4</sub>R, respectively; for [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT assays: 40–80 and 20–40 μg/well total protein for hD<sub>2L</sub>R and hD<sub>3</sub>R, respectively), and 50 μL of radioligand diluted in binding buffer ([<sup>3</sup>H]-<i>N</i>-methylspiperone: 0.4 nM final concentration for all the hD<sub>2</sub>-like receptor subtypes; [<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT: 1.5 nM final concentration for hD<sub>2</sub>L, and 0.5 nM final concentration for hD<sub>3</sub>; PerkinElmer). Aliquots of radioligand solution were also quantified accurately in each experiment replicate to determine how much radioactivity was added, taking into account the experimentally determined counter efficiency. Nonspecific binding was determined using 10 μM (+)-butaclamol (Sigma-Aldrich, St. Louis, MO), and total binding was determined with the 30% DMSO vehicle. All compound dilutions were tested in triplicate, and the reaction was incubated for 60 min ([<sup>3</sup>H]-<i>N</i>-methylspiperone assays) or 90 min ([<sup>3</sup>H]-(<i>R</i>)-(+)-7-OH-DPAT assays) at RT. The reaction was terminated by filtration through PerkinElmer UniFilter-96 GF/B, presoaked for the incubation time in 0.5% polyethylenimine, using a Brandel 96-well plates harvester manifold (Brandel Instruments, Gaithersburg, MD). The filters were washed thrice with 3 mL (3 Å—1 mL/well) of ice-cold binding buffer. PerkinElmer MicroScint 20 scintillation cocktail (65 μL) was added to each well, and filters were counted using a PerkinElmer MicroBeta microplate counter. IC<sub>50</sub> values for each compound were determined from dose–response curves, and <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a><i>K</i><sub>d</sub> values were determined <i>via</i> separate homologous competitive binding experiments. When a complete inhibition could not be achieved at the highest tested concentrations, <i>K</i><sub>i</sub> values have been extrapolated by constraining the bottom of the dose–response curves (=0% residual specific binding) in the nonlinear regression analysis. These analyses were performed using GraphPad Prism version 8 for Macintosh (GraphPad Software, San Diego, CA). All results were rounded to the third significant figure. <i>K</i><sub>i</sub> values were determined from at least three independent experiments and are reported as the mean ± SEM.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> hMOR</h4><div class="NLM_p last">Radioligand binding experiments were conducted, and the results were analyzed, as described above and similar to those previously reported.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> HEK293 cells stably expressing the hMOR were grown in a DMEM, supplemented with 10% FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 1% penicillin–streptomycin (or antibiotic/antimycotic), and hygromycin B (50 μg/mL). Upon reaching confluence, the cells were harvested and the membranes were prepared as detailed before. The binding buffer was made of 50 mM Tris and 5 mM MgCl<sub>2</sub> at pH 7.4. The experiments were performed in the presence of [<sup>3</sup>H]-DAMGO (final concentration 3 nM; PerkinElmer) and 30 μg/well of membranes (final concentration). The reactions were incubated for 60 min at RT and terminated by rapid filtration through PerkinElmer UniFilter-96 GF/B, presoaked for 60 min in 0.5% polyethylenimine. The nonspecific binding was determined using 10 μM C-TOP or cold DAMGO. The radioligand <i>K</i><sub>d</sub> was measured <i>via</i> radioligand saturation experiments.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> BRET Studies</h3><div class="NLM_p last">All reagents were purchased from Sigma-Aldrich-Merck unless otherwise stated. BRET experiments were performed in transiently transfected human embryonic kidney 293 T (HEK 293T) cells, as described previously.<a onclick="showRef(event, 'ref31 ref68'); return false;" href="javascript:void(0);" class="ref ref31 ref68">(31,68)</a> Briefly, cells were grown and maintained at 37 °C in 5% CO<sub>2</sub> in DMEM supplemented with 10% (v/v) FBS. Cells were seeded in 10 cm Petri dishes (2.5 × 10<sup>6</sup> cells per dish) and allowed to grow overnight in media at 37 °C, 5% CO<sub>2</sub>. The following day, cells were transiently transfected in media supplemented with antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin, Gibco) using a 1:6 total DNA to PEI (PolySciences Inc.) ratio. BRET constructs were as follows: 4 μg of Nb33-Venus and 1 μg of mMOR-Rluc8 for Nb33 recruitment, 2 μg of WT-Gα (i2 or oA), 1 μg of Gβ1-Venus(156–239), 1 μg of Gγ2-Venus(1–155), 1 μg of masGRK3ct-Rluc8, and 1 μg of receptor (SNAP-mMOR or hD3R) for GPA,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and 4 μg of arrestin-3-Venus, 2 μg of WT-GRK2, and 1 μg of mMOR-Rluc8 for arrestin-3 recruitment. Cells were then allowed to grow overnight at 37 °C, 5% CO<sub>2</sub>. The next day, cells were plated in Greiner poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated 96-well plates (SLS) in media and allowed to grow overnight. On the day of the assay (48 h post-transfection), cells were washed once with D-PBS (Lonza, SLS) and incubated in D-PBS for 30 min at 37 °C. For the antagonist-mode assays that require preincubation, the cells were washed once with D-PBS and incubated with ligands in D-PBS (supplemented with 10 mM glucose) at 37 °C, 5% CO<sub>2</sub> for 3 h prior to starting the assay. The Rluc substrate coelenterazine h (NanoLight) was added to each well (final concentration of 5 μM), and cells were incubated for 5 min at 37 °C. After 5 min, ligands (final concentration from 10 μM to 1 nM in D-PBS) were added to the plate and cells were incubated for a further 10 min at 37 °C before reading the plate in a PHERAstar FSX microplate reader (Venus and Rluc emission signals at 535 and 475 nm, respectively, BMG Labtech). The ratio of Venus/Rluc counts was used to quantify the BRET signal in each well. Data were normalized to the wells containing 10 μM DAMGO/quinpirole or no drug for maximal or minimal response, respectively, and as indicated in the figure legends. All experiments were performed in duplicate and at least three times independently. All data points represent the mean, and error bars represent the SEM and were fitted using the built-in log(agonist) versus response (three parameters) model in Prism 8.0 (GraphPad Software Inc., San Diego, CA).For agonist-mode assays, data were fitted to a three-parameter concentration–response model where EC<sub>50</sub> is the concentration of the agonist needed to elicit half the maximal response of the particular agonist, defined as <i>E</i><sub>max</sub>. For the antagonist-mode assays, data points were fitted using a three-parameter concentration–response model where IC<sub>50</sub> is the concentration required to inhibit half the maximum response of the agonist used at a particular concentration. Values of pEC<sub>50</sub> or pIC<sub>50</sub> ± error are given as the error has a Gaussian distribution, whereas the error associated with the antilog value does not. For some ligands for which the lower asymptote of the curve was not well defined within the concentration range (represented by a dotted line), the bottom was constrained to be equal to 0%.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Molecular Docking and CADD</h3><div class="NLM_p last">The receptor structures corresponding to PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CM4">6CM4</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a> were extracted from RCSB for the inactive-state D<sub>2</sub>R, inactive-state D<sub>3</sub>R, and active-state MOR, respectively. All the objects except the receptor protein subunit, the crystallized ligand, and in the case of active-state MOR, three crystallographic waters were deleted, and this was followed by the addition of hydrogens and optimization of the side-chain residues. Ligands were sketched, assigned formal charges, and energy-optimized prior to docking. The ligand docking box for potential grid docking was defined as the whole extracellular half of the protein, and all-atom docking was performed using the energy minimized structures for all ligands with a thoroughness value of 10. The best-scored docking solutions were further optimized by several rounds of minimization and Monte Carlo sampling of the ligand conformation, including the surrounding side-chain residues (within 5 Å of the ligand) and the three crystallographic waters in the MOR orthosteric sites. All the abovementioned molecular modeling operations were performed in ICM-Pro v3.8-5 molecular modeling package.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00611" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84443" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84443" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00611?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00611</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">PDB files of all the ligand/target complexes studied (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_002.zip" class="ext-link">ZIP</a>)</p></li><li><p class="inline">Analytical data summary of the products (combustion elemental analyses, HRMS–MS/MS, GC/MS, and HPLC), supporting table reporting biased agonism analysis at MOR signaling pathways, and supplemental figures of all the ligand/target complexes studied (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_001.csv">jm1c00611_si_001.csv (8.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_002.zip">jm1c00611_si_002.zip (1.85 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf">jm1c00611_si_003.pdf (5.97 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00611" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandro Bonifazi</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7306-0114" title="Orcid link">https://orcid.org/0000-0002-7306-0114</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6d7dad3c5c5d7d8d2c4d998d4d9d8dfd0d7ccdf84f6d8dfde98d1d9c0"><span class="__cf_email__" data-cfemail="8feee3eafcfceee1ebfde0a1ede0e1e6e9eef5e6bdcfe1e6e7a1e8e0f9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Hauck Newman</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9065-4072" title="Orcid link">https://orcid.org/0000-0001-9065-4072</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c0d02091b010d022c0502181e0d420205080d42020504420b031a"><span class="__cf_email__" data-cfemail="b9d8d7dcced4d8d7f9d0d7cdcbd897d7d0ddd897d7d0d197ded6cf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco O. Battiti</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Sanchez</span> - <span class="hlFld-Affiliation affiliation">Division
of Physiology, Pharmacology and Neuroscience, School of Life Sciences,
Queen’s Medical Centre, University
of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, Universities
of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saheem A. Zaidi</span> - <span class="hlFld-Affiliation affiliation">Bridge
Institute, Michelson Center for Convergent Bioscience, Department
of Chemistry, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Bow</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Synthesis Section, Molecular Targets and Medications Discovery
Branch, National Institute on Drug Abuse—Intramural Research
Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariia Makarova</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Synthesis Section, Molecular Targets and Medications Discovery
Branch, National Institute on Drug Abuse—Intramural Research
Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjing Cao</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anver Basha Shaik</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Section, Molecular Targets and Medications Discovery Branch,
National Institute on Drug Abuse—Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9894-5544" title="Orcid link">https://orcid.org/0000-0001-9894-5544</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agnieszka Sulima</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Synthesis Section, Molecular Targets and Medications Discovery
Branch, National Institute on Drug Abuse—Intramural Research
Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenner C. Rice</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Synthesis Section, Molecular Targets and Medications Discovery
Branch, National Institute on Drug Abuse—Intramural Research
Program, National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vsevolod Katritch</span> - <span class="hlFld-Affiliation affiliation">Bridge
Institute, Michelson Center for Convergent Bioscience, Department
of Chemistry, Department of Biological Sciences, University of Southern California, Los Angeles, California 90089, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3883-4505" title="Orcid link">https://orcid.org/0000-0003-3883-4505</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meritxell Canals</span> - <span class="hlFld-Affiliation affiliation">Division
of Physiology, Pharmacology and Neuroscience, School of Life Sciences,
Queen’s Medical Centre, University
of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, Universities
of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7942-5006" title="Orcid link">https://orcid.org/0000-0002-7942-5006</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Robert Lane</span> - <span class="hlFld-Affiliation affiliation">Division
of Physiology, Pharmacology and Neuroscience, School of Life Sciences,
Queen’s Medical Centre, University
of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, Universities
of Birmingham and Nottingham, Midlands NG2 7AG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7361-7875" title="Orcid link">https://orcid.org/0000-0002-7361-7875</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.B. and A.H.N. designed the project; A.B., F.O.B., and A.H.N. wrote the manuscript with input of all the authors; A.B., F.O.B., J.S., S.A.Z., A.S., K.C.R., V.K., M.C., J.R.L., and A.H.N. designed and supervised the experiments and data analysis; A.B., F.O.B., J.S., S.A.Z., E.B., M.M., J.C., A.B.S., and A.S. performed experiments.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This project was supported by the National Institute on Drug Abuse—Intramural Research Program (ZIADA000609; ZIADA000424), as well as grant funding R33DA038858 for V.K. The authors thank Drs. Ludovic Muller and Shelley Jackson from the Structural Biology Core at NIDA-IRP for high-resolution MS/MS analyses, Dr. Ning Sheng Cai from the Integrative Neurobiology Section at NIDA-IRP for assistance with cell lines and tissue culture protocols, and Dr. Arthur Jacobson from the Drug Design and Synthesis Section at NIDA-IRP for insightful suggestions to the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">D<sub>2-like</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2-like</sub> receptors</p></td></tr><tr><td class="NLM_term">OUD</td><td class="NLM_def"><p class="first last">opioid use disorders</p></td></tr><tr><td class="NLM_term">CADD</td><td class="NLM_def"><p class="first last">computer-aided drug design</p></td></tr><tr><td class="NLM_term">BRET</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">HEK 293 cells</td><td class="NLM_def"><p class="first last">human embryonic kidney 293 cells</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dichloromethane, methanol, and ammonium hydroxide</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HCTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(1<i>H</i>-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">STAB</td><td class="NLM_def"><p class="first last">sodium triacetoxyborohydride</p></td></tr><tr><td class="NLM_term">DMP</td><td class="NLM_def"><p class="first last">Dess–Martin periodinane</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">GPA</td><td class="NLM_def"><p class="first last">G-protein activation</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 69 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span> </span><span class="NLM_article-title">CDC/NCHS National
Vital Statistics System, Mortality. CDC WONDER</span>; <span class="NLM_publisher-name">US Department of Health and Human Services, CDC</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>. <a href="https://www.cdc.gov/nchs/nvss/deaths.htm" class="extLink">https://www.cdc.gov/nchs/nvss/deaths.htm</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDC%2FNCHS+National%0AVital+Statistics+System%2C+Mortality.+CDC+WONDER%3B+US+Department+of+Health+and+Human+Services%2C+CDC%3A+Atlanta%2C+GA.+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fnvss%2Fdeaths.htm+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCDC%252FNCHS%2520National%250AVital%2520Statistics%2520System%252C%2520Mortality.%2520CDC%2520WONDER%26pub%3DUS%2520Department%2520of%2520Health%2520and%2520Human%2520Services%252C%2520CDC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, L.</span></span> <a href="https://www.forbes.com/sites/lipiroy/2020/05/23/collision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse/#5cbc00837d3a" class="extLink">https://www.forbes.com/sites/lipiroy/2020/05/23/collision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse/#5cbc00837d3a</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roy%2C+L.+https%3A%2F%2Fwww.forbes.com%2Fsites%2Flipiroy%2F2020%2F05%2F23%2Fcollision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse%2F%235cbc00837d3a+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, Z.</span></span> <span> </span><span class="NLM_article-title">The escalation of the opioid epidemic due to COVID-19 and sesulting lessons about treatment alternatives</span>. <i>Am. J. Manag. Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">e202</span>– <span class="NLM_lpage">e204</span>, <span class="refDoi"> DOI: 10.37765/ajmc.2020.43386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.37765%2Fajmc.2020.43386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32672917" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=e202-e204&author=M.+J.+Silvaauthor=Z.+Kelly&title=The+escalation+of+the+opioid+epidemic+due+to+COVID-19+and+sesulting+lessons+about+treatment+alternatives&doi=10.37765%2Fajmc.2020.43386"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.37765%2Fajmc.2020.43386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.37765%252Fajmc.2020.43386%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DM.%2BJ.%26aulast%3DKelly%26aufirst%3DZ.%26atitle%3DThe%2520escalation%2520of%2520the%2520opioid%2520epidemic%2520due%2520to%2520COVID-19%2520and%2520sesulting%2520lessons%2520about%2520treatment%2520alternatives%26jtitle%3DAm.%2520J.%2520Manag.%2520Care%26date%3D2020%26volume%3D26%26spage%3De202%26epage%3De204%26doi%3D10.37765%2Fajmc.2020.43386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">NIH/NIDA</span>. <a href="https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis" class="extLink">https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH%2FNIDA.+https%3A%2F%2Fwww.drugabuse.gov%2Fdrugs-abuse%2Fopioids%2Fopioid-overdose-crisis+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vowles, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEntee, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julnes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Goes, D. N.</span></span> <span> </span><span class="NLM_article-title">Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1097/01.j.pain.0000460357.01998.f1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1097%2F01.j.pain.0000460357.01998.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=25785523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC2MnlvVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=569-576&author=K.+E.+Vowlesauthor=M.+L.+McEnteeauthor=P.+S.+Julnesauthor=T.+Froheauthor=J.+P.+Neyauthor=D.+N.+van+der+Goes&title=Rates+of+opioid+misuse%2C+abuse%2C+and+addiction+in+chronic+pain%3A+a+systematic+review+and+data+synthesis&doi=10.1097%2F01.j.pain.0000460357.01998.f1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis</span></div><div class="casAuthors">Vowles Kevin E; McEntee Mindy L; Julnes Peter Siyahhan; Frohe Tessa; Ney John P; van der Goes David N</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-576</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid use in chronic pain treatment is complex, as patients may derive both benefit and harm.  Identification of individuals currently using opioids in a problematic way is important given the substantial recent increases in prescription rates and consequent increases in morbidity and mortality.  The present review provides updated and expanded information regarding rates of problematic opioid use in chronic pain.  Because previous reviews have indicated substantial variability in this literature, several steps were taken to enhance precision and utility.  First, problematic use was coded using explicitly defined terms, referring to different patterns of use (ie, misuse, abuse, and addiction).  Second, average prevalence rates were calculated and weighted by sample size and study quality.  Third, the influence of differences in study methodology was examined.  In total, data from 38 studies were included.  Rates of problematic use were quite broad, ranging from <1% to 81% across studies.  Across most calculations, rates of misuse averaged between 21% and 29% (range, 95% confidence interval [CI]: 13%-38%).  Rates of addiction averaged between 8% and 12% (range, 95% CI: 3%-17%).  Abuse was reported in only a single study.  Only 1 difference emerged when study methods were examined, where rates of addiction were lower in studies that identified prevalence assessment as a primary, rather than secondary, objective.  Although significant variability remains in this literature, this review provides guidance regarding possible average rates of opioid misuse and addiction and also highlights areas in need of further clarification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRopnzK7CEDcdts4TFFB11gfW6udTcc2ebg8z4Jmu7AGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnlvVKhtA%253D%253D&md5=0ddbfbaad57261f02f7c5c72531df680</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F01.j.pain.0000460357.01998.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.j.pain.0000460357.01998.f1%26sid%3Dliteratum%253Aachs%26aulast%3DVowles%26aufirst%3DK.%2BE.%26aulast%3DMcEntee%26aufirst%3DM.%2BL.%26aulast%3DJulnes%26aufirst%3DP.%2BS.%26aulast%3DFrohe%26aufirst%3DT.%26aulast%3DNey%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%2BGoes%26aufirst%3DD.%2BN.%26atitle%3DRates%2520of%2520opioid%2520misuse%252C%2520abuse%252C%2520and%2520addiction%2520in%2520chronic%2520pain%253A%2520a%2520systematic%2520review%2520and%2520data%2520synthesis%26jtitle%3DPain%26date%3D2015%26volume%3D156%26spage%3D569%26epage%3D576%26doi%3D10.1097%2F01.j.pain.0000460357.01998.f1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhuri, P. K.</span>; <span class="NLM_string-name">Gfroerer, J. C.</span>; <span class="NLM_string-name">Davies, M. C.</span></span> <i>CBHSQ Data Review: Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States</i>, August <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+K.+Muhuri&author=J.+C.+Gfroerer&author=M.+C.+Davies&title=CBHSQ+Data+Review%3A+Associations+of+Nonmedical+Pain+Reliever+Use+and+Initiation+of+Heroin+Use+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DMuhuri%26aufirst%3DP.%2BK.%26jtitle%3DCBHSQ%2520Data%2520Review%253A%2520Associations%2520of%2520Nonmedical%2520Pain%2520Reliever%2520Use%2520and%2520Initiation%2520of%2520Heroin%2520Use%2520in%2520the%2520United%2520States%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surratt, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. P.</span></span> <span> </span><span class="NLM_article-title">The changing face of heroin use in the United States: a retrospective analysis of the past 50 years</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2014.366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1001%2Fjamapsychiatry.2014.366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=24871348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC2cjmslOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=821-826&author=T.+J.+Ciceroauthor=M.+S.+Ellisauthor=H.+L.+Surrattauthor=S.+P.+Kurtz&title=The+changing+face+of+heroin+use+in+the+United+States%3A+a+retrospective+analysis+of+the+past+50+years&doi=10.1001%2Fjamapsychiatry.2014.366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The changing face of heroin use in the United States: a retrospective analysis of the past 50 years</span></div><div class="casAuthors">Cicero Theodore J; Ellis Matthew S; Surratt Hilary L; Kurtz Steven P</div><div class="citationInfo"><span class="NLM_cas:title">JAMA psychiatry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">821-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Over the past several years, there have been a number of mainstream media reports that the abuse of heroin has migrated from low-income urban areas with large minority populations to more affluent suburban and rural areas with primarily white populations.  OBJECTIVE:  To examine the veracity of these anecdotal reports and define the relationship between the abuse of prescription opioids and the abuse of heroin.  DESIGN, SETTING, AND PARTICIPANTS:  Using a mixed-methods approach, we analyzed (1) data from an ongoing study that uses structured, self-administered surveys to gather retrospective data on past drug use patterns among patients entering substance abuse treatment programs across the country who received a primary (DSM-IV) diagnosis of heroin use/dependence (n = 2797) and (2) data from unstructured qualitative interviews with a subset of patients (n = 54) who completed the structured interview.  MAIN OUTCOMES AND MEASURES:  In addition to data on population demographics and current residential location, we used cross-tabulations to assess prevalence rates as a function of the decade of the initiation of abuse for (1) first opioid used (prescription opioid or heroin), (2) sex, (3) race/ethnicity, and (4) age at first use.  Respondents indicated in an open-ended format why they chose heroin as their primary drug and the interrelationship between their use of heroin and their use of prescription opioids.  RESULTS:  Approximately 85% of treatment-seeking patients approached to complete the Survey of Key Informants' Patients Program did so.  Respondents who began using heroin in the 1960s were predominantly young men (82.8%; mean age, 16.5 years) whose first opioid of abuse was heroin (80%).  However, more recent users were older (mean age, 22.9 years) men and women living in less urban areas (75.2%) who were introduced to opioids through prescription drugs (75.0%).  Whites and nonwhites were equally represented in those initiating use prior to the 1980s, but nearly 90% of respondents who began use in the last decade were white.  Although the "high" produced by heroin was described as a significant factor in its selection, it was often used because it was more readily accessible and much less expensive than prescription opioids.  CONCLUSION AND RELEVANCE:  Our data show that the demographic composition of heroin users entering treatment has shifted over the last 50 years such that heroin use has changed from an inner-city, minority-centered problem to one that has a more widespread geographical distribution, involving primarily white men and women in their late 20s living outside of large urban areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRW_x_4-GpCCmyYR5VtavbzfW6udTcc2ebg8z4Jmu7AGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjmslOqug%253D%253D&md5=aa2bef62f31eecb7aec411ff07180385</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2014.366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2014.366%26sid%3Dliteratum%253Aachs%26aulast%3DCicero%26aufirst%3DT.%2BJ.%26aulast%3DEllis%26aufirst%3DM.%2BS.%26aulast%3DSurratt%26aufirst%3DH.%2BL.%26aulast%3DKurtz%26aufirst%3DS.%2BP.%26atitle%3DThe%2520changing%2520face%2520of%2520heroin%2520use%2520in%2520the%2520United%2520States%253A%2520a%2520retrospective%2520analysis%2520of%2520the%2520past%252050%2520years%26jtitle%3DJAMA%2520Psychiatry%26date%3D2014%26volume%3D71%26spage%3D821%26epage%3D826%26doi%3D10.1001%2Fjamapsychiatry.2014.366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahhas, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniulaityte, R.</span></span> <span> </span><span class="NLM_article-title">Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2015.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.drugalcdep.2015.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26785634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC28nitVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=127-134&author=R.+G.+Carlsonauthor=R.+W.+Nahhasauthor=S.+S.+Martinsauthor=R.+Daniulaityte&title=Predictors+of+transition+to+heroin+use+among+initially+non-opioid+dependent+illicit+pharmaceutical+opioid+users%3A+A+natural+history+study&doi=10.1016%2Fj.drugalcdep.2015.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study</span></div><div class="casAuthors">Carlson Robert G; Nahhas Ramzi W; Martins Silvia S; Daniulaityte Raminta</div><div class="citationInfo"><span class="NLM_cas:title">Drug and alcohol dependence</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Increases in illicit pharmaceutical opioid (PO) use have been associated with risk for transition to heroin use.  We identify predictors of transition to heroin use among young, illicit PO users with no history of opioid dependence or heroin use at baseline.  METHODS:  Respondent-driven sampling recruited 383 participants; 362 returned for at least one biannual structured interview over 36 months.  Cox regression was used to test for associations between lagged predictors and hazard of transition to heroin use.  Potential predictors were based on those suggested in the literature.  We also computed population attributable risk (PAR) and the rate of heroin transition.  RESULTS:  Over 36 months, 27 (7.5%) participants initiated heroin use; all were white, and the rate of heroin initiation was 2.8% per year (95% CI=1.9%-4.1%).  Mean length of PO at first reported heroin use was 6.2 years (SD=1.9).  Lifetime PO dependence (AHR=2.39, 95% CI=1.07-5.48; PAR=32%, 95% CI=-2% to 64%), early age of PO initiation (AHR=3.08, 95%; CI=1.26-7.47; PAR=30%, 95% CI=2%-59%), using illicit POs to get high but not to self-medicate a health problem (AHR=4.83, 95% CI=2.11-11.0; PAR=38%, 95% CI=12%-65%), and ever using PO non-orally most often (AHR=6.57, 95% CI=2.81-17.2; PAR=63%, 95% CI=31%-86%) were significant predictors.  CONCLUSION:  This is one of the first prospective studies to test observations from previous cross-sectional and retrospective research on the relationship between illicit PO use and heroin initiation among young, initially non-opioid dependent PO users.  The results provide insights into targets for the design of urgently needed prevention interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaLgGnk3do_EeosoOnpOLfW6udTcc2ebr8kypH0SLhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nitVWktw%253D%253D&md5=0978c5e92cac5c8646f648ae65f5244c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2015.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2015.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BG.%26aulast%3DNahhas%26aufirst%3DR.%2BW.%26aulast%3DMartins%26aufirst%3DS.%2BS.%26aulast%3DDaniulaityte%26aufirst%3DR.%26atitle%3DPredictors%2520of%2520transition%2520to%2520heroin%2520use%2520among%2520initially%2520non-opioid%2520dependent%2520illicit%2520pharmaceutical%2520opioid%2520users%253A%2520A%2520natural%2520history%2520study%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2016%26volume%3D160%26spage%3D127%26epage%3D134%26doi%3D10.1016%2Fj.drugalcdep.2015.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">NIDA’s medication development priorities in response to the opioid crisis: ten most wanted</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0292-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-018-0292-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30538289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BB3cngvVOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=657-659&author=K.+Rasmussenauthor=D.+A.+Whiteauthor=J.+B.+Acri&title=NIDA%E2%80%99s+medication+development+priorities+in+response+to+the+opioid+crisis%3A+ten+most+wanted&doi=10.1038%2Fs41386-018-0292-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted</span></div><div class="casAuthors">Rasmussen Kurt; White David A; Acri Jane B</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHtoX-sKxKlNTiMd2aNQVUfW6udTcc2eZiNPshBTsJC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cngvVOruw%253D%253D&md5=798c0fdeee2c7543009f32f638b2f97e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0292-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0292-5%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DD.%2BA.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DNIDA%25E2%2580%2599s%2520medication%2520development%2520priorities%2520in%2520response%2520to%2520the%2520opioid%2520crisis%253A%2520ten%2520most%2520wanted%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D657%26epage%3D659%26doi%3D10.1038%2Fs41386-018-0292-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0lhnoX9WKa9L6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+receptor+antagonist+%28GSK598809%29+potentiates+the+hypertensive+effects+of+cocaine+in+conscious%2C+freely-moving+dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0lh55Lmg5o0SFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonist%2520%2528GSK598809%2529%2520potentiates%2520the%2520hypertensive%2520effects%2520of%2520cocaine%2520in%2520conscious%252C%2520freely-moving%2520dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span> <span> </span><span class="NLM_article-title">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">107597</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.neuropharm.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30974107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=107597&author=C.+J.+Jordanauthor=B.+Humburgauthor=M.+Riceauthor=G.-H.+Biauthor=Z.-B.+Youauthor=A.+B.+Shaikauthor=J.+Caoauthor=A.+Bonifaziauthor=A.+Gadianoauthor=R.+Raisauthor=B.+Slusherauthor=A.+H.+Newmanauthor=Z.-X.+Xi&title=The+highly+selective+dopamine+D3R+antagonist%2C+R-VK4-40+attenuates+oxycodone+reward+and+augments+analgesia+in+rodents&doi=10.1016%2Fj.neuropharm.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree; Rice, Myra; Bi, Guo-Hua; You, Zhi-Bing; Shaik, Anver Basha; Cao, Jianjing; Bonifazi, Alessandro; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107597</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the effects of R-VK4-40, a highly selective D3R receptor antagonist, on the rewarding and analgesic effects of oxycodone, the most commonly abused prescription opioid, in rats and mice.  Systemic administration of R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward in rats.  Pretreatment with R-VK4-40 also dose-dependently lowered break-points for oxycodone under a progressive-ratio schedule.  To det. whether a DA-dependent mechanism underlies the impact of D3 antagonism in reducing opioid reward, we used optogenetic approaches to examine intracranial self-stimulation (ICSS) maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice.  Pretreatment with R-VK4-40 blocked oxycodone-enhanced brain-stimulation reward.  By itself, R-VK4-40 produced a modest dose-dependent redn. in optical ICSS.  Pretreatment with R-VK4-40 did not compromise the antinociceptive effects of oxycodone in rats, and R-VK4-40 alone produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.  Together, these findings suggest R-VK4-40 may permit a lower dose of prescription opioids for pain management, potentially mitigating tolerance and dependence, while diminishing reward potency.  Hence, development of R-VK4-40 as a therapy for the treatment of opioid use disorders and/or pain is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoec47hB7NVR7Vg90H21EOLACvtfcHk0lh55Lmg5o0SFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI&md5=2619b493c3addad36e8ec504f41b25c7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.-X.%26atitle%3DThe%2520highly%2520selective%2520dopamine%2520D3R%2520antagonist%252C%2520R-VK4-40%2520attenuates%2520oxycodone%2520reward%2520and%2520augments%2520analgesia%2520in%2520rodents%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26spage%3D107597%26doi%3D10.1016%2Fj.neuropharm.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415-1424&author=Z.-B.+Youauthor=G.-H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0ljzXORBoq3SXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26epage%3D1424%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.-B.+Youauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0ljzXORBoq3SXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorndike, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span> <span> </span><span class="NLM_article-title">Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.259390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fjpet.119.259390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31562201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2019&pages=602-614&author=C.+J.+Jordanauthor=B.+A.+Humburgauthor=E.+B.+Thorndikeauthor=A.+B.+Shaikauthor=Z.-X.+Xiauthor=M.+H.+Baumannauthor=A.+H.+Newmanauthor=C.+W.+Schindler&title=Newly+developed+dopamine+D3+receptor+antagonists%2C+R-VK4-40+and+R-VK4-116%2C+do+not+potentiate+cardiovascular+effects+of+cocaine+or+oxycodone+in+rats&doi=10.1124%2Fjpet.119.259390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Newly developed Dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree A.; Thorndike, Eric B.; Shaik, Anver Basha; Xi, Zheng-Xiong; Baumann, Michael H.; Newman, Amy Hauck; Schindler, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid and cocaine abuse are major public health burdens.  Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder.  Dopamine D3 receptor (D3R) antagonists have shown promise in attenuating opioid and cocaine reward and mitigating relapse in preclin. models.  However, translation of D3R antagonists to the clinic has been hampered by reports that the D3R antagonists GSK598,809 (5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole) and SB-277,011A (2-(2-((1r,4r)-4-(2-oxo-2-(quinolin-4-yl)ethyl)cyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile) have adverse cardiovascular effects in the presence of cocaine.  Recently, we developed two structurally novel D3R antagonists, R-VK4-40 and R-VK4-116, which are highly selective for D3R and display translational potential for treatment of opioid use disorder.  Here, we tested whether R-VK4-40 ((R)-N-(4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) and R-VK4-116 ((R)-N-(4-(4-(3-Chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) have unwanted cardiovascular effects in the presence of oxycodone, a prescription opioid, or cocaine in freely moving rats fitted with surgically implanted telemetry transmitters.  We also examd. cardiovascular effects of the D3R antagonist, SB-277,011A, and L-741,626 (1-((1H-indol-3-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol), a dopamine D2 receptor-selective antagonist, for comparison.  Consistent with prior reports, SB-277,011A increased blood pressure, heart rate, and locomotor activity alone and in the presence of cocaine.  L-741,626 increased blood pressure and heart rate.  In contrast, R-VK4-40 alone dose-dependently reduced blood pressure and heart rate and attenuated oxycodone-induced increases in blood pressure and oxycodone or cocaine-induced increases in heart rate.  Similarly, R-VK4-116 alone dose-dependently reduced cocaine-induced increases in blood pressure and heart rate.  These results highlight the safety of new D3R antagonists and support the continued development of R-VK4-40 and R-VK4-116 for the treatment of opioid and cocaine use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvUfnNpZtkLVg90H21EOLACvtfcHk0lg1vl__eyDudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D&md5=5fe7b8a11ae2083e6d78b2123bdd6fde</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.259390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.259390%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%2BA.%26aulast%3DThorndike%26aufirst%3DE.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DNewly%2520developed%2520dopamine%2520D3%2520receptor%2520antagonists%252C%2520R-VK4-40%2520and%2520R-VK4-116%252C%2520do%2520not%2520potentiate%2520cardiovascular%2520effects%2520of%2520cocaine%2520or%2520oxycodone%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D371%26spage%3D602%26epage%3D614%26doi%3D10.1124%2Fjpet.119.259390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsch, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portenoy, R. K.</span></span> <span> </span><span class="NLM_article-title">Opioids and the treatment of chronic pain: controversies, current status, and future directions</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1037/a0013628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1037%2Fa0013628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=18837637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BD1cnksFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=405-416&author=A.+Rosenblumauthor=L.+A.+Marschauthor=H.+Josephauthor=R.+K.+Portenoy&title=Opioids+and+the+treatment+of+chronic+pain%3A+controversies%2C+current+status%2C+and+future+directions&doi=10.1037%2Fa0013628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids and the treatment of chronic pain: controversies, current status, and future directions</span></div><div class="casAuthors">Rosenblum Andrew; Marsch Lisa A; Joseph Herman; Portenoy Russell K</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-16</span>
        ISSN:<span class="NLM_cas:issn">1064-1297</span>.
    </div><div class="casAbstract">Opioids have been regarded for millennia as among the most effective drugs for the treatment of pain.  Their use in the management of acute severe pain and chronic pain related to advanced medical illness is considered the standard of care in most of the world.  In contrast, the long-term administration of an opioid for the treatment of chronic noncancer pain continues to be controversial.  Concerns related to effectiveness, safety, and abuse liability have evolved over decades, sometimes driving a more restrictive perspective and sometimes leading to a greater willingness to endorse this treatment.  The past several decades in the United States have been characterized by attitudes that have shifted repeatedly in response to clinical and epidemiological observations, and events in the legal and regulatory communities.  The interface between the legitimate medical use of opioids to provide analgesia and the phenomena associated with abuse and addiction continues to challenge the clinical community, leading to uncertainty about the appropriate role of these drugs in the treatment of pain.  This narrative review briefly describes the neurobiology of opioids and then focuses on the complex issues at this interface between analgesia and abuse, including terminology, clinical challenges, and the potential for new agents, such as buprenorphine, to influence practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_kTYYpznRzOkdrW1FkXG-fW6udTcc2eZPo1oJgJ_mwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnksFGgsA%253D%253D&md5=cbbbc8151dd35cc18a0287a00cfd2137</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1037%2Fa0013628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252Fa0013628%26sid%3Dliteratum%253Aachs%26aulast%3DRosenblum%26aufirst%3DA.%26aulast%3DMarsch%26aufirst%3DL.%2BA.%26aulast%3DJoseph%26aufirst%3DH.%26aulast%3DPortenoy%26aufirst%3DR.%2BK.%26atitle%3DOpioids%2520and%2520the%2520treatment%2520of%2520chronic%2520pain%253A%2520controversies%252C%2520current%2520status%252C%2520and%2520future%2520directions%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2008%26volume%3D16%26spage%3D405%26epage%3D416%26doi%3D10.1037%2Fa0013628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoll, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beakley, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchikanti, L.</span></span> <span> </span><span class="NLM_article-title">Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">S93</span>– <span class="NLM_lpage">S109</span>, <span class="refDoi"> DOI: 10.36076/ppj.2017.s109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.36076%2Fppj.2017.s109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=S93-S109&author=A.+D.+Kayeauthor=M.+R.+Jonesauthor=A.+M.+Kayeauthor=J.+G.+Ripollauthor=V.+Galanauthor=B.+D.+Beakleyauthor=F.+Calixtoauthor=J.+L.+Boldenauthor=R.+D.+Urmanauthor=L.+Manchikanti&title=Prescription+opioid+abuse+in+chronic+pain%3A+an+updated+review+of+opioid+abuse+predictors+and+strategies+to+curb+opioid+abuse%3A+part+1&doi=10.36076%2Fppj.2017.s109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.36076%2Fppj.2017.s109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.36076%252Fppj.2017.s109%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DA.%2BD.%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DKaye%26aufirst%3DA.%2BM.%26aulast%3DRipoll%26aufirst%3DJ.%2BG.%26aulast%3DGalan%26aufirst%3DV.%26aulast%3DBeakley%26aufirst%3DB.%2BD.%26aulast%3DCalixto%26aufirst%3DF.%26aulast%3DBolden%26aufirst%3DJ.%2BL.%26aulast%3DUrman%26aufirst%3DR.%2BD.%26aulast%3DManchikanti%26aufirst%3DL.%26atitle%3DPrescription%2520opioid%2520abuse%2520in%2520chronic%2520pain%253A%2520an%2520updated%2520review%2520of%2520opioid%2520abuse%2520predictors%2520and%2520strategies%2520to%2520curb%2520opioid%2520abuse%253A%2520part%25201%26jtitle%3DPain%2520Physician%26date%3D2017%26volume%3D2%26spage%3DS93%26epage%3DS109%26doi%3D10.36076%2Fppj.2017.s109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scuteri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, G.</span></span> <span> </span><span class="NLM_article-title">Opioids resistance in chronic pain management</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.2174/1570159x14666161101092822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2174%2F1570159X14666161101092822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=28503117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=444-456&author=L.+Morroneauthor=D.+Scuteriauthor=L.+Rombolaauthor=H.+Mizoguchiauthor=G.+Bagetta&title=Opioids+resistance+in+chronic+pain+management&doi=10.2174%2F1570159x14666161101092822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids Resistance in Chronic Pain Management</span></div><div class="casAuthors">Morrone, Luigi A.; Scuteri, Damiana; Rombola, Laura; Mizoguchi, Hirokazu; Bagetta, Giacinto</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-456</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Chronic pain management represents a serious healthcare problem worldwide.  Chronic pain affects approx. 20% of the adult European population and is more frequent in women and older people.  Unfortunately, its management in the community remains generally unsatisfactory and rarely under the control of currently available analgesics.  Opioids have been used as analgesics for a long history and are among the most used drugs; however, while there is no debate over their short term use for pain management, limited evidence supports their efficacy of long-term treatment for chronic noncancer pain.  Therapy with opioids is hampered by inter-individual variability and serious side effects and some opioids often result ineffective in the treatment of chronic pain and their use is controversial.  Accordingly, for a better control of chronic pain a deeper knowledge of the mol. mechanisms underlying resistance to opiates is mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt-0LCXx1xEbVg90H21EOLACvtfcHk0lgTUEz2Pb_Opg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2iurw%253D&md5=e4b7ec166e89c8859fa88e9408471d96</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1570159X14666161101092822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X14666161101092822%26sid%3Dliteratum%253Aachs%26aulast%3DMorrone%26aufirst%3DL.%26aulast%3DScuteri%26aufirst%3DD.%26aulast%3DRombola%26aufirst%3DL.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DBagetta%26aufirst%3DG.%26atitle%3DOpioids%2520resistance%2520in%2520chronic%2520pain%2520management%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26spage%3D444%26epage%3D456%26doi%3D10.2174%2F1570159x14666161101092822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Bias factor and therapeutic window correlate to predict safer opioid analgesics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1175.e13</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.cell.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29149605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1165-1175.e13&author=C.+L.+Schmidauthor=N.+M.+Kennedyauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Yueauthor=J.+Morgenweckauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=Bias+factor+and+therapeutic+window+correlate+to+predict+safer+opioid+analgesics&doi=10.1016%2Fj.cell.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics</span></div><div class="casAuthors">Schmid, Cullen L.; Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Morgenweck, Jenny; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1175.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Biased agonism has been proposed as a means to sep. desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets.  Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit βarrestin proteins.  By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compds. spanning a wide range of signaling bias.  We find that β-arrestin-biased compds., such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfthQaadgklLVg90H21EOLACvtfcHk0ljHz6fE7iF1dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE&md5=6d3f21c03fb40bc83adbe62c3ea331fc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBias%2520factor%2520and%2520therapeutic%2520window%2520correlate%2520to%2520predict%2520safer%2520opioid%2520analgesics%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1165%26epage%3D1175.e13%26doi%3D10.1016%2Fj.cell.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Canabal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Toward directing opioid receptor signaling to refine opioid therapeutics</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2019.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.biopsych.2019.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31806082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlehtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2020&pages=15-21&author=T.+W.+Grimauthor=A.+Acevedo-Canabalauthor=L.+M.+Bohn&title=Toward+directing+opioid+receptor+signaling+to+refine+opioid+therapeutics&doi=10.1016%2Fj.biopsych.2019.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics</span></div><div class="casAuthors">Grim, Travis W.; Acevedo-Canabal, Agnes; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The mu opioid receptor (MOR) is a diversely regulated target for the alleviation of pain in the clin. setting.  However, untoward side effects such as tolerance, dependence, respiratory suppression, constipation, and abuse liability detract from the general activation of these receptors.  Studies in genetically modified rodent models suggest that activating G protein signaling pathways while avoiding phosphorylation of the receptor or recruitment of β-arrestin scaffolding proteins could preserve the analgesic properties of MOR agonists while avoiding certain side effects.  With the development of novel MOR "biased" agonists, which lead to preferential activation of G protein pathways over receptor phosphorylation, internalization, or interaction with other effectors, this hypothesis can be tested in a native, physiol. setting.  Overall, it is clear that the MOR is not a simple on-off switch and that the diverse means by which the receptor can be regulated may present an opportunity to refine therapeutics for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgAHNYSLwmLrVg90H21EOLACvtfcHk0ljHz6fE7iF1dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlehtLrP&md5=da81307c1e611b5c293bd5db953898b5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2019.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2019.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DAcevedo-Canabal%26aufirst%3DA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DToward%2520directing%2520opioid%2520receptor%2520signaling%2520to%2520refine%2520opioid%2520therapeutics%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26volume%3D87%26spage%3D15%26epage%3D21%26doi%3D10.1016%2Fj.biopsych.2019.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoots, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venniro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, Y.</span></span> <span> </span><span class="NLM_article-title">Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2085</span>, <span class="refDoi"> DOI: 10.1111/ejn.13955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1111%2Fejn.13955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29779230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC1MfltVCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=2075-2085&author=J.+M.+Bossertauthor=J.+K.+Hootsauthor=I.+Fredrikssonauthor=S.+Adhikaryauthor=M.+Zhangauthor=M.+Venniroauthor=Y.+Shaham&title=Role+of+mu%2C+but+not+delta+or+kappa%2C+opioid+receptors+in+context-induced+reinstatement+of+oxycodone+seeking&doi=10.1111%2Fejn.13955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking</span></div><div class="casAuthors">Bossert Jennifer M; Hoots Jennifer K; Fredriksson Ida; Adhikary Sweta; Zhang Michelle; Venniro Marco; Shaham Yavin</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2075-2085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Relapse to non-medical use of prescription opioids often occurs after exposure to places previously associated with drug use.  Here, we describe a rat model of context-induced reinstatement of oxycodone seeking after repeated cycles of drug self-administration and extinction-induced abstinence.  We also determined the role of mu, delta and kappa opioid receptors (MOR, DOR, KOR) in this reinstatement.  We trained rats to self-administer oxycodone for 6 h/day in context A; lever pressing was paired with a discrete cue.  Next, we extinguished the lever pressing in the presence of the discrete cue in context B and then tested the rats for reinstatement of oxycodone seeking in both contexts.  We retrained rats to self-administer oxycodone in context A, re-extinguished their lever pressing in context B and retested them for reinstatement in both contexts.  Prior to testing, we injected the rats with vehicle or antagonists of MOR (naltrexone; 0.5 or 1.0 mg/kg), DOR (naltrindole; 7.5 or 15 mg/kg) or KOR (LY2456302; 5 or 10 mg/kg).  We also tested the effect of naltrexone, naltrindole and LY2456302 on oxycodone self-administration under fixed-ratio-1 (FR1) and progressive ratio (PR) reinforcement schedules.  We observed context-induced reinstatement of oxycodone seeking after repeated cycles of drug self-administration and extinction.  Naltrexone, but not naltrindole or LY2456302, injections decreased this reinstatement.  Additionally, naltrexone increased oxycodone self-administration under the FR1 schedule and decreased oxycodone self-administration under the PR schedule; naltrindole and LY2456302 were ineffective.  Results demonstrate a critical role of MOR, but not DOR or KOR, in context-induced reinstatement of oxycodone seeking and oxycodone self-administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuqvBaKT2wzQvupmecNw_lfW6udTcc2eb5jrpf-UK0g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfltVCgsg%253D%253D&md5=9c444f57d0a5dbbd661cb61a76926d5c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fejn.13955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejn.13955%26sid%3Dliteratum%253Aachs%26aulast%3DBossert%26aufirst%3DJ.%2BM.%26aulast%3DHoots%26aufirst%3DJ.%2BK.%26aulast%3DFredriksson%26aufirst%3DI.%26aulast%3DAdhikary%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DVenniro%26aufirst%3DM.%26aulast%3DShaham%26aufirst%3DY.%26atitle%3DRole%2520of%2520mu%252C%2520but%2520not%2520delta%2520or%2520kappa%252C%2520opioid%2520receptors%2520in%2520context-induced%2520reinstatement%2520of%2520oxycodone%2520seeking%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2019%26volume%3D50%26spage%3D2075%26epage%3D2085%26doi%3D10.1111%2Fejn.13955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantouli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Canabal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">A G protein signaling-biased agonist at the mu-opioid receptor reverses morphine tolerance while preventing morphine withdrawal</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41386-019-0491-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-019-0491-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31443104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12gsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=416-425&author=T.+W.+Grimauthor=C.+L.+Schmidauthor=E.+L.+Stahlauthor=F.+Pantouliauthor=J.-H.+Hoauthor=A.+Acevedo-Canabalauthor=N.+M.+Kennedyauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=A+G+protein+signaling-biased+agonist+at+the+mu-opioid+receptor+reverses+morphine+tolerance+while+preventing+morphine+withdrawal&doi=10.1038%2Fs41386-019-0491-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal</span></div><div class="casAuthors">Grim, Travis W.; Schmid, Cullen L.; Stahl, Edward L.; Pantouli, Fani; Ho, Jo-Hao; Acevedo-Canabal, Agnes; Kennedy, Nicole M.; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-425</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">It has been demonstrated that opioid agonists that preferentially act at μ-opioid receptors to activate G protein signaling over βarrestin 2 recruitment produce antinociception with less respiratory suppression.  However, most of the adverse effects assocd. with opioid therapeutics are realized after extended dosing.  Therefore, we tested the onset of tolerance and dependence, and assessed for neurochem. changes assocd. with prolonged treatment with the biased agonist SR-17018.  When chronically administered to mice, SR-17018 does not lead to hot plate antinociceptive tolerance, receptor desensitization in periaqueductal gray, nor a super-sensitization of adenylyl cyclase in the striatum, which are hallmarks of opioid neuronal adaptations that are seen with morphine.  Interestingly, substitution with SR-17018 in morphine-tolerant mice restores morphine potency and efficacy, whereas the onset of opioid withdrawal is prevented.  This is in contrast to buprenorphine, which can suppress withdrawal, but produces and maintains morphine antinociceptive tolerance.  Biased agonists of this nature may therefore be useful for the treatment of opioid dependence while restoring opioid antinociceptive sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWBdsWXtDfrVg90H21EOLACvtfcHk0lhgLhWBp_ofyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12gsrrM&md5=72ca93a6cdfc8fb26e821ccea132115d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41386-019-0491-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-019-0491-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DPantouli%26aufirst%3DF.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DAcevedo-Canabal%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DA%2520G%2520protein%2520signaling-biased%2520agonist%2520at%2520the%2520mu-opioid%2520receptor%2520reverses%2520morphine%2520tolerance%2520while%2520preventing%2520morphine%2520withdrawal%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D416%26epage%3D425%26doi%3D10.1038%2Fs41386-019-0491-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8895</span>– <span class="NLM_lpage">8907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12isr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8895-8907&author=N.+M.+Kennedyauthor=C.+L.+Schmidauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Yueauthor=Y.+T.+Chenauthor=M.+D.+Cameronauthor=L.+M.+Bohnauthor=T.+D.+Bannister&title=Optimization+of+a+series+of+mu+opioid+receptor+%28MOR%29+agonists+with+high+G+protein+signaling+bias&doi=10.1021%2Facs.jmedchem.8b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias</span></div><div class="casAuthors">Kennedy, Nicole M.; Schmid, Cullen L.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Chen, Yen Ting; Cameron, Michael D.; Bohn, Laura M.; Bannister, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8895-8907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While mu opioid receptor (MOR) agonists are esp. effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear sepn. of analgesia from many problematic side effects.  Recently, MOR agonists that induce minimal βarrestin-mediated signaling were extensively investigated because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis.  Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents.  It was recently shown that, within a chem. series, the degree of bias correlates linearly with the magnitude of the respiratory safety index.  Herein, the synthesis and optimization of (piperidinyl)benzimidazolone MOR agonists I (R1 = H, 4-Cl, 5-Me, 5-CN, 5,6-Cl2, etc.; R2 = H, Me; R3 = Ph, 2-ClC6H4, 2-F-4-BrC6H3, etc.) and analogs that display a wide range of bias (G/βarr2) is described.  The structural features affecting potency and maximizing bias were identified and many compds. were shown to have desirable properties, such as long half-lives and high brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7BvhzTWgOLVg90H21EOLACvtfcHk0lhdcl1eliWbdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12isr7I&md5=7ebd89b52ecdb593170b4151f1e5cccd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01136%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%2520mu%2520opioid%2520receptor%2520%2528MOR%2529%2520agonists%2520with%2520high%2520G%2520protein%2520signaling%2520bias%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8895%26epage%3D8907%26doi%3D10.1021%2Facs.jmedchem.8b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imam, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassabian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span> <span> </span><span class="NLM_article-title">Intracerebroventricular administration of CYX-6, a potent mu-opioid receptor agonist, a delta- and kappa-opioid receptor antagonist and a biased ligand at mu, delta & kappa-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>871</i></span>,  <span class="NLM_fpage">172918</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2020.172918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.ejphar.2020.172918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31958457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFehsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=871&publication_year=2020&pages=172918&author=M.+Z.+Imamauthor=A.+Kuoauthor=S.+Ghassabianauthor=Y.+Caiauthor=Y.+Qinauthor=T.+Liauthor=M.+T.+Smith&title=Intracerebroventricular+administration+of+CYX-6%2C+a+potent+mu-opioid+receptor+agonist%2C+a+delta-+and+kappa-opioid+receptor+antagonist+and+a+biased+ligand+at+mu%2C+delta+%26+kappa-opioid+receptors%2C+evokes+antinociception+with+minimal+constipation+and+respiratory+depression+in+rats+in+contrast+to+morphine&doi=10.1016%2Fj.ejphar.2020.172918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine</span></div><div class="casAuthors">Imam, Mohammad Zafar; Kuo, Andy; Ghassabian, Sussan; Cai, Yunxin; Qin, Yajuan; Li, Tingyou; Smith, Maree T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">871</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172918</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mu opioid receptor (MOPr) agonists are thought to produce analgesia via modulation of G-protein-coupled intracellular signalling pathways whereas the β-arrestin2 pathway is proposed to mediate opioid-related adverse effects.  Here, we report the antinociception, constipation and respiratory depressant profile of CYX-6, a potent MOPr agonist that is also a delta and a kappa opioid receptor (DOPr/KOPr) antagonist and that lacks β-arrestin2 recruitment at each of the MOPr, DOPr and the KOPr.  In anesthetized male Sprague Dawley rats, an intracerebroventricular (i.c.v.) guide cannula was stereotaxically implanted.  After 5-7 days post-surgical recovery, rats received a single i.c.v. bolus dose of CYX-6 (3-30 nmol), morphine (100 nmol) or vehicle.  Antinociception was assessed using the warm water tail flick test (52.5 ± 0.5°C).  Constipation was assessed using the charcoal meal gut motility test and the castor oil-induced diarrhoea test.  Respiratory depression was measured by whole-body plethysmog. in awake, freely moving animals, upon exposure to a hypercapnic gas mixt. (8% CO2, 21% O2 and 71% N2).  The intrinsic pharmacol. of CYX-6 given by the i.c.v. route in rats showed that it produced dose-dependent antinociception.  It also produced respiratory stimulation rather than depression and it had a minimal effect on intestinal motility in contrast to the pos. control, morphine.  CYX-6 is an endomorphin-2 analog that dissocs. antinociception from constipation and respiratory depression in rats.  Our findings provide useful insight to inform the discovery and development of novel opioid analgesics with a superior tolerability profile compared with morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6tkHb8Z7Ll7Vg90H21EOLACvtfcHk0lhdcl1eliWbdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFehsLY%253D&md5=a92653c75b0e20f14d29c836739df17c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2020.172918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2020.172918%26sid%3Dliteratum%253Aachs%26aulast%3DImam%26aufirst%3DM.%2BZ.%26aulast%3DKuo%26aufirst%3DA.%26aulast%3DGhassabian%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26atitle%3DIntracerebroventricular%2520administration%2520of%2520CYX-6%252C%2520a%2520potent%2520mu-opioid%2520receptor%2520agonist%252C%2520a%2520delta-%2520and%2520kappa-opioid%2520receptor%2520antagonist%2520and%2520a%2520biased%2520ligand%2520at%2520mu%252C%2520delta%2520%2526%2520kappa-opioid%2520receptors%252C%2520evokes%2520antinociception%2520with%2520minimal%2520constipation%2520and%2520respiratory%2520depression%2520in%2520rats%2520in%2520contrast%2520to%2520morphine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D871%26spage%3D172918%26doi%3D10.1016%2Fj.ejphar.2020.172918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sianati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08162-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41467-018-08162-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30664663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367&author=A.+Kliewerauthor=F.+Schmiedelauthor=S.+Sianatiauthor=A.+Baileyauthor=J.+T.+Batemanauthor=E.+S.+Levittauthor=J.+T.+Williamsauthor=M.+J.+Christieauthor=S.+Schulz&title=Phosphorylation-deficient+G-protein-biased+mu-opioid+receptors+improve+analgesia+and+diminish+tolerance+but+worsen+opioid+side+effects&doi=10.1038%2Fs41467-018-08162-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span></div><div class="casAuthors">Kliewer, A.; Schmiedel, F.; Sianati, S.; Bailey, A.; Bateman, J. T.; Levitt, E. S.; Williams, J. T.; Christie, M. J.; Schulz, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops.  The mol. mechanisms initiating tolerance have remained unresolved to date.  We have previously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is controlled by carboxyl-terminal phosphorylation.  Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit beta-arrestins.  Desensitization is inhibited in locus coeruleus neurons of mutant mice.  Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished.  Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that beta-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased mu-agonists are still likely to elicit severe adverse effects.  In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEj4ARbzSS7Vg90H21EOLACvtfcHk0lih6q06o0NcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D&md5=19fa2354d75d29b28503d21f63754d45</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08162-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08162-1%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DSianati%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBateman%26aufirst%3DJ.%2BT.%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DPhosphorylation-deficient%2520G-protein-biased%2520mu-opioid%2520receptors%2520improve%2520analgesia%2520and%2520diminish%2520tolerance%2520but%2520worsen%2520opioid%2520side%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D367%26doi%3D10.1038%2Fs41467-018-08162-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montandon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victoria, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, R. L.</span></span> <span> </span><span class="NLM_article-title">G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1097/aln.0000000000000984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1097%2FALN.0000000000000984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26675532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=641-650&author=G.+Montandonauthor=J.+Renauthor=N.+C.+Victoriaauthor=H.+Liuauthor=K.+Wickmanauthor=J.+J.+Greerauthor=R.+L.+Horner&title=G-protein-gated+inwardly+rectifying+potassium+channels+modulate+respiratory+depression+by+opioids&doi=10.1097%2Faln.0000000000000984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids</span></div><div class="casAuthors">Montandon, Gaspard; Ren, Jun; Victoria, Nicole C.; Liu, Hattie; Wickman, Kevin; Greer, John J.; Horner, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">641-650</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Drugs acting on μ-opioid receptors (MORs) are widely used as analgesics but present side effects including life-threatening respiratory depression.  MORs are G-protein-coupled receptors inhibiting neuronal activity through calcium channels, adenylyl cyclase, and/or G-protein-gated inwardly rectifying potassium (GIRK) channels.  The pathways underlying MOR-dependent inhibition of rhythmic breathing are unknown.  Methods: By using a combination of genetic, pharmacol., and physiol. tools in rodents in vivo, the authors aimed to identify the role of GIRK channels in MOR-mediated inhibition of respiratory circuits.  Results: GIRK channels were expressed in the ventrolateral medulla, a neuronal population regulating rhythmic breathing, and GIRK channel activation with flupirtine reduced respiratory rate in rats (percentage of baseline rate in mean ± SD: 79.4 ± 7.4%, n = 7), wild-type mice (82.6 ± 3.8%, n = 3), but not in mice lacking the GIRK2 subunit, an integral subunit of neuronal GIRK channels (GIRK2, 101.0 ± 1.9%, n = 3).  Application of the MOR agonist [D-Ala, N-MePhe, Gly-ol]-enkephalin (DAMGO) to the ventrolateral medulla depressed respiratory rate, an effect partially reversed by the GIRK channel blocker Tertiapin-Q (baseline: 42.1 ± 7.4 breath/min, Damgo: 26.1 ± 13.4 breath/min, Tertiapin-Q + Damgo: 33.9 ± 9.8 breath/min, n = 4).  Importantly, DAMGO applied to the ventrolateral medulla failed to reduce rhythmic breathing in GIRK2 mice (percentage of baseline rate: 103.2 ± 12.1%, n = 4), whereas it considerably reduced rate in wild-type mice (62.5 ± 17.7% of baseline, n = 4).  Respiratory rate depression by systemic injection of the opioid analgesic fentanyl was markedly reduced in GIRK2 (percentage of baseline: 12.8 ± 15.8%, n = 5) compared with wild-type mice (72.9 ± 27.3%).  Conclusions: Overall, these results identify that GIRK channels contribute to respiratory inhibition by MOR, an essential step toward understanding respiratory depression by opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn3IRBnyEdBrVg90H21EOLACvtfcHk0lih6q06o0NcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFGlu7w%253D&md5=fda08f10b9a6c994c9535a1b1c6932e4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FALN.0000000000000984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0000000000000984%26sid%3Dliteratum%253Aachs%26aulast%3DMontandon%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DVictoria%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWickman%26aufirst%3DK.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DHorner%26aufirst%3DR.%2BL.%26atitle%3DG-protein-gated%2520inwardly%2520rectifying%2520potassium%2520channels%2520modulate%2520respiratory%2520depression%2520by%2520opioids%26jtitle%3DAnesthesiology%26date%3D2016%26volume%3D124%26spage%3D641%26epage%3D650%26doi%3D10.1097%2Faln.0000000000000984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdala, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span> <span> </span><span class="NLM_article-title">mu opioid receptor activation hyperpolarizes respiratory-controlling Kolliker-Fuse neurons and suppresses post-inspiratory drive</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">4453</span>– <span class="NLM_lpage">4469</span>, <span class="refDoi"> DOI: 10.1113/jp270822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1113%2FJP270822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26175072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2015&pages=4453-4469&author=E.+S.+Levittauthor=A.+P.+Abdalaauthor=J.+F.+R.+Patonauthor=J.+M.+Bissonnetteauthor=J.+T.+Williams&title=mu+opioid+receptor+activation+hyperpolarizes+respiratory-controlling+Kolliker-Fuse+neurons+and+suppresses+post-inspiratory+drive&doi=10.1113%2Fjp270822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">μ opioid receptor activation hyperpolarizes respiratory-controlling Koelliker-Fuse neurons and suppresses post-inspiratory drive</span></div><div class="casAuthors">Levitt, Erica S.; Abdala, Ana P.; Paton, Julian F. R.; Bissonnette, John M.; Williams, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4453-4469</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">1469-7793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Opioid-induced respiratory effects include aspiration and difficulty swallowing, suggesting impairment of the upper airways.  The pontine Koelliker-Fuse nucleus (KF) controls upper airway patency and regulates respiration, in particular the inspiratory/expiratory phase transition.  Given the importance of the KF in coordinating respiratory pattern, the mechanisms of μ opioid receptor activation in this nucleus were investigated at the systems and cellular level.  In anesthetized, vagi-intact rats, injection of opioid agonists DAMGO or [Met5]enkephalin (ME) into the KF reduced respiratory frequency and amplitude.  The μ opioid agonist DAMGO applied directly into the KF of the in situ arterially perfused working heart-brainstem prepn. of rat resulted in robust apneusis (lengthened low amplitude inspiration due to loss of post-inspiratory drive) that was rapidly reversed by the opioid antagonist naloxone.  In brain slice prepns., activation of μ opioid receptors on KF neurons hyperpolarized a distinct population (61%) of neurons.  As expected, the opioid-induced hyperpolarization reduced the excitability of the neuron in response to either current injection or local application of glutamate.  In voltage-clamp recordings the outward current produced by the opioid agonist ME was concn. dependent, reversed at the potassium equil. potential and was blocked by BaCl2, characteristics of a G protein-coupled inwardly rectifying potassium (GIRK) conductance.  The clin. used drug morphine produced an outward current in KF neurons with similar potency to morphine-mediated currents in locus coeruleus brain slice prepns.  Thus, the population of KF neurons that are hyperpolarized by μ opioid agonists are likely mediators of the opioid-induced loss of post-inspiration and induction of apneusis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9jCfamKM7ArVg90H21EOLACvtfcHk0ljHm_He-SL8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLzI&md5=6ca013cbf8dd47b28a29db63cb679964</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1113%2FJP270822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252FJP270822%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DAbdala%26aufirst%3DA.%2BP.%26aulast%3DPaton%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBissonnette%26aufirst%3DJ.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26atitle%3Dmu%2520opioid%2520receptor%2520activation%2520hyperpolarizes%2520respiratory-controlling%2520Kolliker-Fuse%2520neurons%2520and%2520suppresses%2520post-inspiratory%2520drive%26jtitle%3DJ.%2520Physiol.%26date%3D2015%26volume%3D593%26spage%3D4453%26epage%3D4469%26doi%3D10.1113%2Fjp270822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbarali, H. I.</span></span> <span> </span><span class="NLM_article-title">Molecular physiology of enteric opioid receptors</span>. <i>Am. J. Gastroenterol. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/ajgsup.2014.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fajgsup.2014.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=25207608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyit7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=17-21&author=J.+J.+Galliganauthor=H.+I.+Akbarali&title=Molecular+physiology+of+enteric+opioid+receptors&doi=10.1038%2Fajgsup.2014.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Physiology of Enteric Opioid Receptors</span></div><div class="casAuthors">Galligan, James J.; Akbarali, Hamid I.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology Supplements</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-21</span>CODEN:
                <span class="NLM_cas:coden">AJGSAD</span>;
        ISSN:<span class="NLM_cas:issn">1948-9501</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Opioid drugs have powerful antidiarrheal effects and many patients taking these drugs for chronic pain relief experience chronic constipation that can progress to opioid-induced bowel dysfunction.  Three classes of opioid receptors are expressed by enteric neurons: μ-, δ-, and κ-opioid receptors (MOR, DOR, and KOR).  MOR and DOR couple to inhibition of adenylate cylase and nerve terminal Ca2+ channels and activation of K+ channels.  These effects reduce neuronal activity and neurotransmitter release.  KOR couples to inhibition of Ca2+ channels and inhibition of neurotransmitter release.  In the human gastrointestinal tract, MOR, DOR, and KOR link to inhibition of acetylcholine release from enteric interneurons and purine/nitric oxide release from inhibitory motorneurons.  These actions inhibit propulsive motility.  MOR and DOR also link to inhibition of submucosal secretomotor neurons, reducing active Cl- secretion and passive water movement into the colonic lumen.  These effects account for the constipation caused by opioid receptor agonists.  Tolerance develops to the analgesic effects of opioid receptor agonists but not to the constipating actions.  This may be due to differential β-arrestin-2-dependent opioid receptor desensitization and internalization in enteric nerves in the colon compared with the small intestine and in neuronal pain pathways.  Further studies of differential opioid receptor desensitization and tolerance in subsets of enteric neurons may identify new drugs or other treatment strategies of opioid-induced bowel dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQvx-dYsVoLVg90H21EOLACvtfcHk0ljHm_He-SL8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyit7vJ&md5=b5cda786613426030de1af4ee56ff0eb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fajgsup.2014.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajgsup.2014.5%26sid%3Dliteratum%253Aachs%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DAkbarali%26aufirst%3DH.%2BI.%26atitle%3DMolecular%2520physiology%2520of%2520enteric%2520opioid%2520receptors%26jtitle%3DAm.%2520J.%2520Gastroenterol.%2520Suppl.%26date%3D2014%26volume%3D2%26spage%3D17%26epage%3D21%26doi%3D10.1038%2Fajgsup.2014.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Morphine-induced respiratory depression is independent of beta-arrestin2 signalling</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">2923</span>– <span class="NLM_lpage">2931</span>, <span class="refDoi"> DOI: 10.1111/bph.15004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1111%2Fbph.15004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32052419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFersLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2020&pages=2923-2931&author=A.+Kliewerauthor=A.+Gillisauthor=R.+Hillauthor=F.+Schmiedelauthor=C.+Baileyauthor=E.+Kellyauthor=G.+Hendersonauthor=M.+J.+Christieauthor=S.+Schulz&title=Morphine-induced+respiratory+depression+is+independent+of+beta-arrestin2+signalling&doi=10.1111%2Fbph.15004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine-induced respiratory depression is independent of β-arrestin2 signalling</span></div><div class="casAuthors">Kliewer, Andrea; Gillis, Alexander; Hill, Rob; Schmidel, Frank; Bailey, Chris; Kelly, Eamonn; Henderson, Graeme; Christie, MacDonald J.; Schulz, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2923-2931</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPCRs can signal through both G proteins and β-arrestin2.  For the μ-opioid receptor, early exptl. evidence from a single study suggested that G protein signalling mediates analgesia, whereas β-arrestin2 signalling mediates respiratory depression and constipation.  Consequently, for more than a decade, much research effort has been focused on developing biased μ-opioid agonists that preferentially target G protein signalling over β-arrestin signalling, as it was believed that such drugs would be analgesics devoid of respiratory depressant activity.  The present study was set up to re-examine opioid-induced respiratory depression in β-arrestin2 knockout mice.  To this end, a consortium was formed consisting of three different labs. located in different countries to evaluate independently opioid-induced respiratory depression.  Our consensus results unequivocally demonstrate that the prototypical μ-opioid agonist morphine as well as the potent opioid fentanyl do indeed induce respiratory depression and constipation in β-arrestin2 knockout mice in a dose-dependent manner indistinguishable from that obsd. in wild-type mice.  Our findings do not support the original suggestion that β-arrestin2 signalling plays a key role in opioid-induced respiratory depression and call into question the concept of developing G protein-biased μ-opioid receptor agonists as a strategy for the development of safer opioid analgesic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtInyxD8GRBbVg90H21EOLACvtfcHk0ljHm_He-SL8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFersLw%253D&md5=7913eb638bb57db9a7ed8d43aab61d48</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fbph.15004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.15004%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DGillis%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DHenderson%26aufirst%3DG.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DMorphine-induced%2520respiratory%2520depression%2520is%2520independent%2520of%2520beta-arrestin2%2520signalling%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D177%26spage%3D2923%26epage%3D2931%26doi%3D10.1111%2Fbph.15004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imam, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassabian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span> <span> </span><span class="NLM_article-title">Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.neuropharm.2017.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29273520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCkurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=238-255&author=M.+Z.+Imamauthor=A.+Kuoauthor=S.+Ghassabianauthor=M.+T.+Smith&title=Progress+in+understanding+mechanisms+of+opioid-induced+gastrointestinal+adverse+effects+and+respiratory+depression&doi=10.1016%2Fj.neuropharm.2017.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression</span></div><div class="casAuthors">Imam, Mohammad Zafar; Kuo, Andy; Ghassabian, Sussan; Smith, Maree T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238-255</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Opioids evoke analgesia through activation of opioid receptors (predominantly the μ opioid receptor) in the central nervous system.  Opioid receptors are abundant in multiple regions of the central nervous system and the peripheral nervous system including enteric neurons.  Opioid-related adverse effects such as constipation, nausea, and vomiting pose challenges for compliance and continuation of the therapy for chronic pain management.  In the post-operative setting opioid-induced depression of respiration can be fatal.  These crit. limitations warrant a better understanding of their underpinning cellular and mol. mechanisms to inform the design of novel opioid analgesic mols. that are devoid of these unwanted side-effects.  Research efforts on opioid receptor signalling in the past decade suggest that differential signalling pathways and downstream mols. preferentially mediate distinct pharmacol. effects.  Addnl., interaction among opioid receptors and, between opioid receptor and non-opioid receptors to form signalling complexes shows that opioid-induced receptor signalling is potentially more complicated than previously thought.  This complexity provides an opportunity to identify and probe relationships between selective signalling pathway specificity and in vivo prodn. of opioid-related adverse effects.  In this review, we focus on current knowledge of the mechanisms thought to transduce opioid-induced gastrointestinal adverse effects (constipation, nausea, vomiting) and respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG2tqBIUlp0LVg90H21EOLACvtfcHk0lh00c1Shg61FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCkurzI&md5=92e24f72e063c55d83163e12abc89c7a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DImam%26aufirst%3DM.%2BZ.%26aulast%3DKuo%26aufirst%3DA.%26aulast%3DGhassabian%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26atitle%3DProgress%2520in%2520understanding%2520mechanisms%2520of%2520opioid-induced%2520gastrointestinal%2520adverse%2520effects%2520and%2520respiratory%2520depression%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D131%26spage%3D238%26epage%3D255%26doi%3D10.1016%2Fj.neuropharm.2017.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzwanker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katte, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsey, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">eaaz3140</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaz3140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1126%2Fscisignal.aaz3140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32234959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=A.+Gillisauthor=A.+B.+Gondinauthor=A.+Kliewerauthor=J.+Sanchezauthor=H.+D.+Limauthor=C.+Alameinauthor=P.+Manandharauthor=M.+Santiagoauthor=S.+Fritzwankerauthor=F.+Schmiedelauthor=T.+A.+Katteauthor=T.+Reekieauthor=N.+L.+Grimseyauthor=M.+Kassiouauthor=B.+Kellamauthor=C.+Kraselauthor=M.+L.+Hallsauthor=M.+Connorauthor=J.+R.+Laneauthor=S.+Schulzauthor=M.+J.+Christieauthor=M.+Canals&title=Low+intrinsic+efficacy+for+G+protein+activation+can+explain+the+improved+side+effect+profiles+of+new+opioid+agonists&doi=10.1126%2Fscisignal.aaz3140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaz3140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaz3140%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DA.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DAlamein%26aufirst%3DC.%26aulast%3DManandhar%26aufirst%3DP.%26aulast%3DSantiago%26aufirst%3DM.%26aulast%3DFritzwanker%26aufirst%3DS.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DKatte%26aufirst%3DT.%2BA.%26aulast%3DReekie%26aufirst%3DT.%26aulast%3DGrimsey%26aufirst%3DN.%2BL.%26aulast%3DKassiou%26aufirst%3DM.%26aulast%3DKellam%26aufirst%3DB.%26aulast%3DKrasel%26aufirst%3DC.%26aulast%3DHalls%26aufirst%3DM.%2BL.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DLow%2520intrinsic%2520efficacy%2520for%2520G%2520protein%2520activation%2520can%2520explain%2520the%2520improved%2520side%2520effect%2520profiles%2520of%2520new%2520opioid%2520agonists%26jtitle%3DSci.%2520Signaling%26date%3D2020%26volume%3D13%26doi%3D10.1126%2Fscisignal.aaz3140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">Abuse potential of biased mu opioid receptor agonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.tips.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30343727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=916-919&author=S.+S.+Negusauthor=K.+B.+Freeman&title=Abuse+potential+of+biased+mu+opioid+receptor+agonists&doi=10.1016%2Fj.tips.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse Potential of Biased Mu Opioid Receptor Agonists</span></div><div class="casAuthors">Negus, S. Stevens; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">916-919</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics.  The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans.  Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0Xf3TNu4LrVg90H21EOLACvtfcHk0li-jXQthKhAWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF&md5=b33e27478c5d58a4232fffad6de7412f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DAbuse%2520potential%2520of%2520biased%2520mu%2520opioid%2520receptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26spage%3D916%26epage%3D919%26doi%3D10.1016%2Fj.tips.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altarifi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchhala, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbarali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1177/0269881116689257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1177%2F0269881116689257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=28142305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=730-739&author=A.+A.+Altarifiauthor=B.+Davidauthor=K.+H.+Muchhalaauthor=B.+E.+Bloughauthor=H.+Akbaraliauthor=S.+S.+Negus&title=Effects+of+acute+and+repeated+treatment+with+the+biased+mu+opioid+receptor+agonist+TRV130+%28oliceridine%29+on+measures+of+antinociception%2C+gastrointestinal+function%2C+and+abuse+liability+in+rodents&doi=10.1177%2F0269881116689257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents</span></div><div class="casAuthors">Altarifi, Ahmad A.; David, Bethany; Muchhala, Karan H.; Blough, Bruce E.; Akbarali, Hamid; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein vs. β-arrestin signaling pathways coupled to MORs.  Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists.  This study compared the effects of acute and repeated TRV130 administration on measures of antinociception, gastrointestinal function, and abuse liability in rodents.  We hypothesized that TRV130 would produce robust and sustained antinociception and abuse-related effects during repeated treatment, but that tolerance would develop to gastrointestinal inhibition.  Antinociception was assessed using a warm-water tail-withdrawal procedure in mice.  Gastrointestinal function was assessed in mice using an in vivo measure of fecal output and in vitro assays of colonic propulsion and of colon and ileum circular muscle contraction.  Abuse liability was assessed in rats using an intracranial self-stimulation (ICSS) procedure. (+)-TRV130 was administered with acute and repeated dosing regimens, and (-)-TRV130 was also examd. in the ICSS procedure to assess stereoselectivity.  Acute (+)-TRV130 treatment produced robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects.  Repeated (+)-TRV130 treatment failed to produce tolerance to antinociception or gastrointestinal inhibition, and abuse-related effects were enhanced by repeated treatment.  Effects of acute and repeated (+)-TRV130 in these procedures resemble effects of morphine, with the exception that TRV130 antinociception was more resistant to tolerance. (-)-TRV130 was inactive.  These results suggest that TRV130 retains undesirable constipating and abuse-related effects during repeated treatment despite its bias for G-protein signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gxveeteZ2rVg90H21EOLACvtfcHk0li-jXQthKhAWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyit7s%253D&md5=05a231e5e3b72369d45879688b2b4e02</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F0269881116689257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881116689257%26sid%3Dliteratum%253Aachs%26aulast%3DAltarifi%26aufirst%3DA.%2BA.%26aulast%3DDavid%26aufirst%3DB.%26aulast%3DMuchhala%26aufirst%3DK.%2BH.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DAkbarali%26aufirst%3DH.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520acute%2520and%2520repeated%2520treatment%2520with%2520the%2520biased%2520mu%2520opioid%2520receptor%2520agonist%2520TRV130%2520%2528oliceridine%2529%2520on%2520measures%2520of%2520antinociception%252C%2520gastrointestinal%2520function%252C%2520and%2520abuse%2520liability%2520in%2520rodents%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2017%26volume%3D31%26spage%3D730%26epage%3D739%26doi%3D10.1177%2F0269881116689257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin
Zamarripa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.drugalcdep.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30261403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOqu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2018&pages=158-162&author=C.+Austin%0AZamarripaauthor=S.+R.+Edwardsauthor=H.+N.+Qureshiauthor=J.+N.+Yiauthor=B.+E.+Bloughauthor=K.+B.+Freeman&title=The+G-protein+biased+mu-opioid+agonist%2C+TRV130%2C+produces+reinforcing+and+antinociceptive+effects+that+are+comparable+to+oxycodone+in+rats&doi=10.1016%2Fj.drugalcdep.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats</span></div><div class="casAuthors">Austin Zamarripa, C.; Edwards, Shelley R.; Qureshi, Hina N.; Yi, John N.; Blough, Bruce E.; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">158-162</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Mu-opioid agonists (e.g., oxycodone) are highly effective therapeutics for pain.  However, they also produce reinforcing effects that increase their likelihood of abuse.  Recent strategies in drug development have focused on opioids with biased receptor-signaling profiles that favor activation of specific intracellular pathways over others with the aim of increasing therapeutic selectivity.  TRV130, a mu agonist biased towards G-protein signaling, produces antinociceptive effects comparable to the mu agonist, morphine, but exhibits reduced side effects.  However, in terms of abuse potential, we know of no published preclin. data investigating the effects of TRV130 as a reinforcer.  In the present study, we assessed the relative reinforcing effects of TRV130 and oxycodone, a commonly-prescribed mu agonist, in rats self-administering the drugs under a progressive-ratio (PR) schedule of reinforcement.  In addn., we assessed the relative potency and efficacy of TRV130 and oxycodone in rats in a test of thermal antinociception (Hot Plate).  For self-administration, male Sprague-Dawley rats (n = 7) self-administered i.v. infusions of TRV130 or oxycodone (0.01-0.32 mg/kg/inj) under a PR schedule of reinforcement.  For the Hot-Plate test, male rats (n = 7) received s.c. injections of TRV130 (0.1-3.2 mg/kg/inj) or oxycodone (0.1-5.6 mg/kg/inj), and nociceptive response latencies were measured.  TRV130 and oxycodone were equi-potent and equi-effective in self-administration and thermal antinociception.  This study demonstrates that TRV130 produces reinforcing and antinociceptive effects that are quant. similar to oxycodone, and that a biased-signaling profile does not necessarily reduce abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraKkZQtR8C27Vg90H21EOLACvtfcHk0lgKQMsQgKwzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOqu7vK&md5=aa098a7b54d32678bcf21a1e1cba4e8e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%2BZamarripa%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DS.%2BR.%26aulast%3DQureshi%26aufirst%3DH.%2BN.%26aulast%3DYi%26aufirst%3DJ.%2BN.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DThe%2520G-protein%2520biased%2520mu-opioid%2520agonist%252C%2520TRV130%252C%2520produces%2520reinforcing%2520and%2520antinociceptive%2520effects%2520that%2520are%2520comparable%2520to%2520oxycodone%2520in%2520rats%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2018%26volume%3D192%26spage%3D158%26epage%3D162%26doi%3D10.1016%2Fj.drugalcdep.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jullié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Zastrow, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Opioid pharmacology under the microscope</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1124/mol.119.119321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fmol.119.119321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32198210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFemtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2020&pages=425-432&author=D.+Julli%C3%A9author=A.+B.+Gondinauthor=M.+E.+Von+Zastrowauthor=M.+Canals&title=Opioid+pharmacology+under+the+microscope&doi=10.1124%2Fmol.119.119321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid pharmacology under the microscope</span></div><div class="casAuthors">Jullie, Damien; Gondin, Arisbel B.; von Zastrow, Mark; Canals, Meritxell</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The powerful analgesic effects of opioid drugs have captivated the interest of physicians and scientists for millennia, and the ability of opioid drugs to produce serious undesired effects has been recognized for a similar period of time.  Many of these develop progressively with prolonged or repeated drug use and then persist, motivating particular interest in understanding how opioid drugs initiate adaptive or maladaptive modifications in neural function or regulation.  Exciting advances have been made over the past several years in elucidating drug-induced changes at mol., cellular, and physiol. scales of anal.  The present review will highlight some recent cellular studies that we believe bridge across scales and will focus on optical imaging approaches that put opioid drug action "under the microscope".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwZPW2Rk2nqbVg90H21EOLACvtfcHk0lgKQMsQgKwzCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFemtbbL&md5=1ffa0196d32d0d2159f824ba12f10dc5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.119321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.119321%26sid%3Dliteratum%253Aachs%26aulast%3DJulli%25C3%25A9%26aufirst%3DD.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DVon%2BZastrow%26aufirst%3DM.%2BE.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DOpioid%2520pharmacology%2520under%2520the%2520microscope%26jtitle%3DMol.%2520Pharmacol.%26date%3D2020%26volume%3D98%26spage%3D425%26epage%3D432%26doi%3D10.1124%2Fmol.119.119321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, H.</span></span> <span> </span><span class="NLM_article-title">A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1213/ane.0b013e3181605add</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1213%2Fane.0b013e3181605add" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=18227300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FntFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=451-462&author=T.+H.+Stanleyauthor=T.+D.+Eganauthor=H.+Van+Aken&title=A+tribute+to+Dr.+Paul+A.+J.+Janssen%3A+entrepreneur+extraordinaire%2C+innovative+scientist%2C+and+significant+contributor+to+anesthesiology&doi=10.1213%2Fane.0b013e3181605add"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology</span></div><div class="casAuthors">Stanley Theodore H; Egan Talmage D; Van Aken Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia and analgesia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-62, table of contents</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dr.  Paul Janssen was the founder of Janssen Pharmaceutica and the developer of over 80 pharmaceutical compounds that proved useful in human, botanical, and veterinary medicine.  He and his coworkers synthesized the fentanyl family of drugs, many other potent analgesics, droperidol, etomidate, and numerous other important medicines that were extremely useful in psychiatry, parasitology, gastroenterology, cardiology, virology, and immunology.  Anesthesiology and medicine as a whole have benefited a great deal from his resourcefulness, creativity, and entrepreneurial spirit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmcHm4NWcm443yKPtYViAGfW6udTcc2eZK5DgdmvHUbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FntFWhuw%253D%253D&md5=482dd39d8a7f26112483110a5859961e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1213%2Fane.0b013e3181605add&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252Fane.0b013e3181605add%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DT.%2BH.%26aulast%3DEgan%26aufirst%3DT.%2BD.%26aulast%3DVan%2BAken%26aufirst%3DH.%26atitle%3DA%2520tribute%2520to%2520Dr.%2520Paul%2520A.%2520J.%2520Janssen%253A%2520entrepreneur%2520extraordinaire%252C%2520innovative%2520scientist%252C%2520and%2520significant%2520contributor%2520to%2520anesthesiology%26jtitle%3DAnesth.%2520Analg.%26date%3D2008%26volume%3D106%26spage%3D451%26epage%3D462%26doi%3D10.1213%2Fane.0b013e3181605add" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span> <span> </span><span class="NLM_article-title">New mu-opioid receptor agonists with piperazine moiety</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1320</span>, <span class="refDoi"> DOI: 10.1248/cpb.49.1314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1248%2Fcpb.49.1314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=11605661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1Cktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=1314-1320&author=T.+Komotoauthor=T.+Okadaauthor=S.+Satoauthor=Y.+Niinoauthor=T.+Okaauthor=T.+Sakamoto&title=New+mu-opioid+receptor+agonists+with+piperazine+moiety&doi=10.1248%2Fcpb.49.1314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">New μ-opioid receptor agonists with piperazine moiety</span></div><div class="casAuthors">Komoto, Teruo; Okada, Tomomi; Sato, Susumu; Niino, Yasuhiro; Oka, Tetsuo; Sakamoto, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1314-1320</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">New μ-opioid receptor (MOR) agonists contg. piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated.  Among the synthesized compds., 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKh67O1fK4rVg90H21EOLACvtfcHk0ljPURF8kRb7FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1Cktrk%253D&md5=e44081f644e24ad71278aab1de61dcdf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1248%2Fcpb.49.1314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.49.1314%26sid%3Dliteratum%253Aachs%26aulast%3DKomoto%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DNiino%26aufirst%3DY.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DT.%26atitle%3DNew%2520mu-opioid%2520receptor%2520agonists%2520with%2520piperazine%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2001%26volume%3D49%26spage%3D1314%26epage%3D1320%26doi%3D10.1248%2Fcpb.49.1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jevtić, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penjišević, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostić-Rajačić, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic route towards potential bivalent ligands possessing opioid and D2/D3 pharmacophores</span>. <i>J. Serb. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.2298/jsc181002105j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2298%2FJSC181002105J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyqsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=639-647&author=I.+Jevti%C4%87author=J.+Penji%C5%A1evi%C4%87author=M.+Ivanovi%C4%87author=S.+Kosti%C4%87-Raja%C4%8Di%C4%87&title=Synthetic+route+towards+potential+bivalent+ligands+possessing+opioid+and+D2%2FD3+pharmacophores&doi=10.2298%2Fjsc181002105j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic route towards potential bivalent ligands possessing opioid and D2/D3 pharmacophores</span></div><div class="casAuthors">Jevtic, Ivana I.; Penjisevic, Jelena Z.; Ivanovic, Milovan D.; Kostic-Rajacic, Sladana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Serbian Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">JSCSEN</span>;
        ISSN:<span class="NLM_cas:issn">0352-5139</span>.
    
            (<span class="NLM_cas:orgname">Serbian Chemical Society</span>)
        </div><div class="casAbstract">A scalable, cost-efficient and simple synthetic pathway towards potential bivalent opioid/dopamine receptor ligands was developed and optimized.  Three novel compds. that contain both opioid and dopamine pharmacophores linked by the four methylene group chain were synthesized in 33, 35 and 39% overall yield after a four-step synthetic route starting from three com. available N-aryl piperazines.  The anilino piperidine precursor was easily prepd. in three steps, as previously published, starting from 4-piperidone.  The synthesis presented in this paper could be of interest for heterocyclic and general org. chem.  The newly designed compds. possessing two pharmacophores, opioid and D2/D3, are potentially useful pharmacol. probes.  Of particular interest would be the simultaneous binding to both opioid and D2/D3 receptors, and the resulting pharmacol. responses may be useful for the further understanding of tolerance and dependence phenomena in opioid clin. use and/or abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomlRtv_iMN1rVg90H21EOLACvtfcHk0ljPURF8kRb7FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyqsb3L&md5=32c4c8b7581b6d93fb6c4ab298f55e0e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2298%2FJSC181002105J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2298%252FJSC181002105J%26sid%3Dliteratum%253Aachs%26aulast%3DJevti%25C4%2587%26aufirst%3DI.%26aulast%3DPenji%25C5%25A1evi%25C4%2587%26aufirst%3DJ.%26aulast%3DIvanovi%25C4%2587%26aufirst%3DM.%26aulast%3DKosti%25C4%2587-Raja%25C4%258Di%25C4%2587%26aufirst%3DS.%26atitle%3DSynthetic%2520route%2520towards%2520potential%2520bivalent%2520ligands%2520possessing%2520opioid%2520and%2520D2%252FD3%2520pharmacophores%26jtitle%3DJ.%2520Serb.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D84%26spage%3D639%26epage%3D647%26doi%3D10.2298%2Fjsc181002105j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jevtić, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penjišević, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savić-Vujović, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srebro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vučković, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostić-Rajačić, S.</span></span> <span> </span><span class="NLM_article-title">mi-Opioid/D2 dopamine receptor pharmacophore containing ligands: Synthesis and pharmacological evaluation</span>. <i>J. Serb. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.2298/jsc190912118j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2298%2FJSC190912118J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GlsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=711-720&author=I.+Jevti%C4%87author=J.+Penji%C5%A1evi%C4%87author=K.+Savi%C4%87-Vujovi%C4%87author=D.+Srebroauthor=S.+Vu%C4%8Dkovi%C4%87author=M.+Ivanovi%C4%87author=S.+Kosti%C4%87-Raja%C4%8Di%C4%87&title=mi-Opioid%2FD2+dopamine+receptor+pharmacophore+containing+ligands%3A+Synthesis+and+pharmacological+evaluation&doi=10.2298%2Fjsc190912118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">μ-opioid/D2 dopamine receptor pharmacophore containing ligands: synthesis and pharmacological evaluation</span></div><div class="casAuthors">Jevtic, Ivana I.; Penjisevic, Jelena Z.; Savic-Vujovic, Katarina R.; Srebro, Dragana P.; Vuckovic, Sonja M.; Ivanovic, Milovan D.; Kostic-Rajacic, Sladana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Serbian Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">711-720</span>CODEN:
                <span class="NLM_cas:coden">JSCSEN</span>;
        ISSN:<span class="NLM_cas:issn">1820-7421</span>.
    
            (<span class="NLM_cas:orgname">Serbian Chemical Society</span>)
        </div><div class="casAbstract">Herein, the synthesis and pharmacol. evaluation of 13 novel compds., designed as potential heterobivalent ligands for μ-opioid receptor (MOR) and dopamine D2 receptors (D2DAR), are reported.  The compds. consisted of anilido piperidine and N-aryl piperazine moieties, joined by a variable-length methylene linker.  The two moieties represent MOR and D2DAR pharmacophores, resp.  The synthesis encompassed four steps, securing the final products in 28-42 % overall yields.  The approach has a considerable synthetic potential, providing access to various related structures.  Pharmacol. tests involved in vitro competitive assay for D2DAR using [3H] spiperon, as a std. radioligand, and in vivo antinociceptive tests for MOR.  The measured dopamine affinities were modest to low, while antinociceptive activity was completely absent.  Therefore, the compds. of the general structure prepd. in this research are unlikely to be useful as opioid-dopamine receptor heterobivalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0E8S6_kOJebVg90H21EOLACvtfcHk0lgemwrE1iR1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GlsrbM&md5=74487b8b08067d67340706b133d3b7c2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2298%2FJSC190912118J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2298%252FJSC190912118J%26sid%3Dliteratum%253Aachs%26aulast%3DJevti%25C4%2587%26aufirst%3DI.%26aulast%3DPenji%25C5%25A1evi%25C4%2587%26aufirst%3DJ.%26aulast%3DSavi%25C4%2587-Vujovi%25C4%2587%26aufirst%3DK.%26aulast%3DSrebro%26aufirst%3DD.%26aulast%3DVu%25C4%258Dkovi%25C4%2587%26aufirst%3DS.%26aulast%3DIvanovi%25C4%2587%26aufirst%3DM.%26aulast%3DKosti%25C4%2587-Raja%25C4%258Di%25C4%2587%26aufirst%3DS.%26atitle%3Dmi-Opioid%252FD2%2520dopamine%2520receptor%2520pharmacophore%2520containing%2520ligands%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DJ.%2520Serb.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D85%26spage%3D711%26epage%3D720%26doi%3D10.2298%2Fjsc190912118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">14288</span>– <span class="NLM_lpage">14297</span>, <span class="refDoi"> DOI: 10.3390/molecules171214288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.3390%2Fmolecules171214288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=23208464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=14288-14297&author=X.+Baoauthor=D.+Liuauthor=Y.+Jinauthor=Y.+Yang&title=A+facile+synthesis+for+novel+loperamide+analogs+as+potential+%CE%BC+opioid+receptor+agonists&doi=10.3390%2Fmolecules171214288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists</span></div><div class="casAuthors">Bao, Xiaofeng; Liu, Duliang; Jin, Yanyan; Yang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14288-14297</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A facile synthesis for novel loperamide analogs as potential μ-opioids is described.  The synthetic procedure for compd. I, which contains two 4-phenylpiperidine scaffolds, was optimized, and this compd. was synthesized in excellent yield.  Addnl., a mild and highly efficient protocol for the synthesis of compds. II (R = F, Br) was described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW38kzjYeYZLVg90H21EOLACvtfcHk0lgemwrE1iR1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhtbbM&md5=0a8f5d47357df2ce9f98a5bec1ada433</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3390%2Fmolecules171214288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules171214288%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DA%2520facile%2520synthesis%2520for%2520novel%2520loperamide%2520analogs%2520as%2520potential%2520%25CE%25BC%2520opioid%2520receptor%2520agonists%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D14288%26epage%3D14297%26doi%3D10.3390%2Fmolecules171214288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4215</span>– <span class="NLM_lpage">4219</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.4215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1073%2Fpnas.73.11.4215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=186791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4215-4219&author=A.+P.+Feinbergauthor=I.+Creeseauthor=S.+H.+Snyder&title=The+opiate+receptor%3A+a+model+explaining+structure-activity+relationships+of+opiate+agonists+and+antagonists&doi=10.1073%2Fpnas.73.11.4215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The opiate receptor:  A model explaining structure-activity relations of opiate agonists and antagonists</span></div><div class="casAuthors">Feinberg, Andrew P.; Creese, Ian; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4215-19</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A model of the opiate receptor is proposed which explains structure-activity relationships of opiate drugs, including the unique potency of certain opiates such as etonitazene, fentanyl, phenazocine, and oripavines; the role of N-allyl substituents in conferring antagonist properties; and chem. features that afford pure antagonists.  The model indicates mol. mechanisms for interconversion of the opiate receptor between respective states that bind agonists or antagonists with high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcp-YfSxhKX7Vg90H21EOLACvtfcHk0lgu_U9QY7JoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D&md5=13320bdc14257c1f4c0fe84ad05e1421</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4215%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520opiate%2520receptor%253A%2520a%2520model%2520explaining%2520structure-activity%2520relationships%2520of%2520opiate%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4215%26epage%3D4219%26doi%3D10.1073%2Fpnas.73.11.4215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huysentruyt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risseeuw, M. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Craenenbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of bivalent ligands targeting dopamine D2-like receptors and the mu-opioid receptor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1002%2Fcmdc.201700787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29451744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Ohs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=944-956&author=M.+Qianauthor=L.+Vasudevanauthor=J.+Huysentruytauthor=M.+D.+P.+Risseeuwauthor=C.+Stoveauthor=P.+M.+L.+Vanderheydenauthor=K.+Van+Craenenbroeckauthor=S.+Van+Calenbergh&title=Design%2C+synthesis%2C+and+biological+evaluation+of+bivalent+ligands+targeting+dopamine+D2-like+receptors+and+the+mu-opioid+receptor&doi=10.1002%2Fcmdc.201700787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Bivalent Ligands Targeting Dopamine D2-Like Receptors and the μ-Opioid Receptor</span></div><div class="casAuthors">Qian, Mingcheng; Vasudevan, Lakshmi; Huysentruyt, Jelle; Risseeuw, Martijn D. P.; Stove, Christophe; Vanderheyden, Patrick M. L.; Van Craenenbroeck, Kathleen; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">944-956</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Currently, there is mounting evidence that intermol. receptor-receptor interactions may result in altered receptor recognition, pharmacol. and signaling.  Heterobivalent ligands have been proven useful as mol. probes for confirming and targeting heteromeric receptors.  This report describes the design and synthesis of novel heterobivalent ligands for dopamine D2-like receptors (D2-likeR) and the μ-opioid receptor (μOR) and their evaluation using ligand binding and functional assays.  Interestingly, we identified a potent bivalent ligand that contains a short 18-atom linker and combines good potency with high efficacy both in β-arrestin 2 recruitment for μOR and MAPK-P for D4R.  Furthermore, this compd. was characterized by a biphasic competition binding curve for the D4R-μOR heterodimer, indicative of a bivalent binding mode.  As this compd. possibly bridges the D4R-μOR heterodimer, it could be used as a pharmacol. tool to further investigate the interactions of D4R and μOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC2Yyud3OdY7Vg90H21EOLACvtfcHk0lgu_U9QY7JoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Ohs78%253D&md5=84c1b8350ba27a7c348b7f2e7db8a181</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700787%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DM.%26aulast%3DVasudevan%26aufirst%3DL.%26aulast%3DHuysentruyt%26aufirst%3DJ.%26aulast%3DRisseeuw%26aufirst%3DM.%2BD.%2BP.%26aulast%3DStove%26aufirst%3DC.%26aulast%3DVanderheyden%26aufirst%3DP.%2BM.%2BL.%26aulast%3DVan%2BCraenenbroeck%26aufirst%3DK.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520bivalent%2520ligands%2520targeting%2520dopamine%2520D2-like%2520receptors%2520and%2520the%2520mu-opioid%2520receptor%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D944%26epage%3D956%26doi%3D10.1002%2Fcmdc.201700787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+medicinal+chemistry+lectureship%3A+designing+bivalent+or+bitopic+molecules+for+G-protein+coupled+receptors.+The+whole+is+greater+than+the+sum+of+its+parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0lgrAoCTwQOw7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520medicinal%2520chemistry%2520lectureship%253A%2520designing%2520bivalent%2520or%2520bitopic%2520molecules%2520for%2520G-protein%2520coupled%2520receptors.%2520The%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520its%2520parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgrAoCTwQOw7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and synthesis of bitopic ligands as D3 receptor (D3R) selective agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+significance+of+chirality+in+drug+design+and+synthesis+of+bitopic+ligands+as+D3+receptor+%28D3R%29+selective+agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0lgaC8i2jeGWaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520synthesis%2520of%2520bitopic%2520ligands%2520as%2520D3%2520receptor%2520%2528D3R%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">Exception that proves the rule: investigation of privileged stereochemistry in designing dopamine D3R bitopic agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1956</span>– <span class="NLM_lpage">1964</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00660</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00660" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1956-1964&author=F.+O.+Battitiauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=Exception+that+proves+the+rule%3A+investigation+of+privileged+stereochemistry+in+designing+dopamine+D3R+bitopic+agonists&doi=10.1021%2Facsmedchemlett.9b00660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D3R Bitopic Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1956-1964</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, starting from our selective D3R agonist FOB02-04A (5)(I), we investigated the chem. space around the linker portion of the mol. via insertion of a hydroxyl substituent and ring-expansion of the trans-cyclopropyl moiety into a trans-cyclohexyl scaffold.  Moreover, to further elucidate the importance of the primary pharmacophore stereochem. in the design of bitopic ligands, we inves47942005Ntigated the chiral requirements of (+)-PD128907 ((+)-(4aR,10bR)-2)(II) by synthesizing and resolving bitopic analogs in all the cis and trans combinations of its 9-methoxy-3,4,4a,10b-tetrahydro-2H,5H-chromeno[4,3-b][1,4] oxazine scaffold.  Despite the lack of success in obtaining new analogs with improved biol. profiles, in comparison to our current leads, a "neg." result due to a poor or simply not improved biol. profile is fundamental toward better understanding chem. space and optimal stereochem. for target recognition.  Herein, we identified essential structural information to understand the differences between orthosteric and bitopic ligand-receptor binding interactions, discriminate D3R active and inactive states, and assist multitarget receptor recognition.  Exploring stereochem. complexity and developing extended D3R SAR from this new library complements previously described SAR and inspires future structural and computational biol. investigation.  Moreover, the expansion of chem. space characterization for D3R agonism may be utilized in machine learning and artificial intelligence (AI)-based drug design, in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokM-YxOh1X7LVg90H21EOLACvtfcHk0lgaC8i2jeGWaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOntL8%253D&md5=c8b00bebd54a25f0fa1f8df6c0209253</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00660%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DException%2520that%2520proves%2520the%2520rule%253A%2520investigation%2520of%2520privileged%2520stereochemistry%2520in%2520designing%2520dopamine%2520D3R%2520bitopic%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1956%26epage%3D1964%26doi%3D10.1021%2Facsmedchemlett.9b00660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0liwoybrxYKmRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. S.</span></span> <span> </span><span class="NLM_article-title">Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides</span>. <i>Perspect. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.4137/pmc.s3898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.4137%2Fpmc.s3898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=20212915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisl2rs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1-10&author=J.+S.+Goldberg&title=Stereochemical+basis+for+a+unified+structure+activity+theory+of+aromatic+and+heterocyclic+rings+in+selected+opioids+and+opioid+peptides&doi=10.4137%2Fpmc.s3898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides</span></div><div class="casAuthors">Goldberg, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PMCEAZ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">This paper presents a novel unified theory of the structure activity relationship of opioids and opioid peptides.  It is hypothesized that a virtual or known heterocyclic ring exists in all opioids which have activity in humans, and this ring occupies relative to the arom. ring of the drug, approx. the same plane in space as the piperidine ring of morphine.  Since the rings of morphine are rigid, and the arom. and piperidine rings are crit. structural components for morphine's analgesic properties, the rigid morphine mol. allows for approxns. of the arom. and heterocyclic relationships in subsequent drug models where bond rotations are common.  This hypothesis and five propositions are supported by stereochem. and exptl. observations.  Proposition #1 The structure of morphine provides a template.  Proposition #2 Steric hindrance of some centric portion of the piperidine ring explains antagonist properties of naloxone, naltrexone and alvimopam.  Proposition #3 Methadone has an active conformation which contains a virtual heterocyclic ring which explains its analgesic activity and racemic properties.  Proposition #4 The piperidine ring of fentanyl can assume the morphine position under conditions of nitrogen inversion.  Proposition #5 The first 3 amino acid sequences of beta endorphin (-try-gly-gly) and the active opioid dipeptide, -tyr-pro, (as a result of a peptide turn and zwitterion bonding) form a virtual piperazine-like ring which is similar in size, shape and location to the heterocyclic rings of morphine, meperidine, and methadone.  Potential flaws in this theory are discussed.  This theory could be important for future analgesic drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUbEcf6oKYrVg90H21EOLACvtfcHk0liwoybrxYKmRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisl2rs70%253D&md5=93019d829fa6878650dd8a369902e6e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4137%2Fpmc.s3898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252Fpmc.s3898%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26atitle%3DStereochemical%2520basis%2520for%2520a%2520unified%2520structure%2520activity%2520theory%2520of%2520aromatic%2520and%2520heterocyclic%2520rings%2520in%2520selected%2520opioids%2520and%2520opioid%2520peptides%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2010%26volume%3D4%26spage%3D1%26epage%3D10%26doi%3D10.4137%2Fpmc.s3898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0li0Rftzf6uLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Subtle modifications to the indole-2-carboxamide motif of the negative allosteric modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) yield dramatic changes in pharmacological activity at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00192</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00192" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSrtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=371-377&author=A.+Kopinathanauthor=C.+Draper-Joyceauthor=M.+Szaboauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=J.+R.+Laneauthor=B.+Capuano&title=Subtle+modifications+to+the+indole-2-carboxamide+motif+of+the+negative+allosteric+modulator+N-%28%28trans%29-4-%282-%287-Cyano-3%2C4-dihydroisoquinolin-2%281+H%29-yl%29ethyl%29cyclohexyl%29-1+H-indole-2-carboxamide+%28SB269652%29+yield+dramatic+changes+in+pharmacological+activity+at+the+dopamine+D2+receptor&doi=10.1021%2Facs.jmedchem.8b00192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D2 Receptor</span></div><div class="casAuthors">Kopinathan, Anitha; Draper-Joyce, Christopher; Szabo, Monika; Christopoulos, Arthur; Scammells, Peter J.; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">371-377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SB269652 (I) is a neg. allosteric modulator of the dopamine D2 receptor.  Herein, we present the design, synthesis, and pharmacol. evaluation of "second generation" analogs of I whereby subtle modifications to the indole-2-carboxamide motif confer dramatic changes in functional affinity (5000-fold increase), cooperativity (100-fold increase), and a novel action to modulate dopamine efficacy.  Thus, structural changes to this region of I allows the generation of a novel set of analogs with distinct pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKb0oWUyeKLVg90H21EOLACvtfcHk0li0Rftzf6uLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSrtr7F&md5=5921911ef17a94e8b83913423d62d408</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00192%26sid%3Dliteratum%253Aachs%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DDraper-Joyce%26aufirst%3DC.%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DSubtle%2520modifications%2520to%2520the%2520indole-2-carboxamide%2520motif%2520of%2520the%2520negative%2520allosteric%2520modulator%2520N-%2528%2528trans%2529-4-%25282-%25287-Cyano-3%252C4-dihydroisoquinolin-2%25281%2520H%2529-yl%2529ethyl%2529cyclohexyl%2529-1%2520H-indole-2-carboxamide%2520%2528SB269652%2529%2520yield%2520dramatic%2520changes%2520in%2520pharmacological%2520activity%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D371%26epage%3D377%26doi%3D10.1021%2Facs.jmedchem.8b00192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1208</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-19642-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41598-018-19642-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29352161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1208&author=C.+J.+Draper-Joyceauthor=R.+K.+Vermaauthor=M.+Michinoauthor=J.+Shonbergauthor=A.+Kopinathanauthor=C.+Klein+Herenbrinkauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=A.+M.+Abramyanauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+action+of+a+negative+allosteric+modulator+at+the+dopamine+D2+receptor+is+dependent+upon+sodium+ions&doi=10.1038%2Fs41598-018-19642-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span></div><div class="casAuthors">Draper-Joyce Christopher J; Klein Herenbrink Carmen; Thal David M; Christopoulos Arthur; Lane J Robert; Verma Ravi Kumar; Michino Mayako; Abramyan Ara M; Shi Lei; Michino Mayako; Shonberg Jeremy; Kopinathan Anitha; Scammells Peter J; Capuano Ben; Javitch Jonathan A; Javitch Jonathan A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium ions (Na(+)) allosterically modulate the binding of orthosteric agonists and antagonists to many class A G protein-coupled receptors, including the dopamine D2 receptor (D2R).  Experimental and computational evidences have revealed that this effect is mediated by the binding of Na(+) to a conserved site located beneath the orthosteric binding site (OBS).  SB269652 acts as a negative allosteric modulator (NAM) of the D2R that adopts an extended bitopic pose, in which the tetrahydroisoquinoline moiety interacts with the OBS and the indole-2-carboxamide moiety occupies a secondary binding pocket (SBP).  In this study, we find that the presence of a Na(+) within the conserved Na(+)-binding pocket is required for the action of SB269652.  Using fragments of SB269652 and novel full-length analogues, we show that Na(+) is required for the high affinity binding of the tetrahydroisoquinoline moiety within the OBS, and that the interaction of the indole-2-carboxamide moiety with the SBP determines the degree of Na(+)-sensitivity.  Thus, we extend our understanding of the mode of action of this novel class of NAM by showing it acts synergistically with Na(+) to modulate the binding of orthosteric ligands at the D2R, providing opportunities for fine-tuning of modulatory effects in future allosteric drug design efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvIHTTptFmHTToTC3aBaesfW6udTcc2eZMW5N1vwzfRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D&md5=7126d1cd2e69be311c508c596d81cc2f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-19642-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-19642-1%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520action%2520of%2520a%2520negative%2520allosteric%2520modulator%2520at%2520the%2520dopamine%2520D2%2520receptor%2520is%2520dependent%2520upon%2520sodium%2520ions%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D1208%26doi%3D10.1038%2Fs41598-018-19642-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1005948</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1371%2Fjournal.pcbi.1005948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29337986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=R.+K.+Vermaauthor=A.+M.+Abramyanauthor=M.+Michinoauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=L.+Shi&title=The+E2.65A+mutation+disrupts+dynamic+binding+poses+of+SB269652+at+the+dopamine+D2+and+D3+receptors&doi=10.1371%2Fjournal.pcbi.1005948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span></div><div class="casAuthors">Verma, Ravi Kumar; Abramyan, Ara M.; Michino, Mayako; Free, R. Benjamin; Sibley, David R.; Javitch, Jonathan A.; Lane, J. Robert; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005948/1-e1005948/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The dopamine D2 and D3 receptors (D2R and D3R) are important targets for antipsychotics and for the treatment of drug abuse.  SB269652, a bitopic ligand that simultaneously binds both the orthosteric binding site (OBS) and a secondary binding pocket (SBP) in both D2R and D3R, was found to be a neg. allosteric modulator.  Previous studies identified Glu2.65 in the SBP to be a key determinant of both the affinity of SB269652 and the magnitude of its cooperativity with orthosteric ligands, as the E2.  A mutation decreased both of these parameters.  However, the proposed hydrogen bond (H-bond) between Glu2.65 and the indole moiety of SB269652 is not a strong interaction, and a structure activity relationship study of SB269652 indicates that this H-bond may not be the only element that dets. its allosteric properties.  To understand the structural basis of the obsd. phenotype of E2.65A, we carried out mol. dynamics simulations with a cumulative length of ∼77 μs of D2R and D3R wild-type and their E2.65A mutants bound to SB269652.  In combination with Markov state model anal. and by characterizing the equil. of ligand binding modes in different conditions, we found that in both D2R and D3R, whereas the tetrahydroisoquinoline moiety of SB269652 is stably bound in the OBS, the indole-2-carboxamide moiety is dynamic and only intermittently forms H-bonds with Glu2.65.  Our results also indicate that the E2.65A mutation significantly affects the overall shape and size of the SBP, as well as the conformation of the N terminus.  Thus, our findings suggest that the key role of Glu2.65 in mediating the allosteric properties of SB269652 extends beyond a direct interaction with SB269652, and provide structural insights for rational design of SB269652 derivs. that may retain its allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1JueDgCVDrVg90H21EOLACvtfcHk0lhWF72oovRNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ&md5=e7ff0bcc58a78f0292a5c1f1c820c151</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005948%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520E2.65A%2520mutation%2520disrupts%2520dynamic%2520binding%2520poses%2520of%2520SB269652%2520at%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1005948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyriac, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span> <span> </span><span class="NLM_article-title">N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1021/jm900095y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900095y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2559-2570&author=A.+H.+Newmanauthor=P.+Grundtauthor=G.+Cyriacauthor=J.+R.+Deschampsauthor=M.+Taylorauthor=R.+Kumarauthor=D.+Hoauthor=R.+R.+Luedtke&title=N-%284-%284-%282%2C3-dichloro-+or+2-methoxyphenyl%29piperazin-1-yl%29butyl%29heterobiarylcarboxamides+with+functionalized+linking+chains+as+high+affinity+and+enantioselective+D3+receptor+antagonists&doi=10.1021%2Fjm900095y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists</span></div><div class="casAuthors">Newman, Amy Hauck; Grundt, Peter; Cyriac, George; Deschamps, Jeffrey R.; Taylor, Michelle; Kumar, Rakesh; Ho, David; Luedtke, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2559-2570</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present report, the D3 receptor pharmacophore is modified in the 2,3-diCl- and 2-OCH3-phenylpiperazine class of compds. with the goal to improve D3 receptor affinity and selectivity.  This extension of structure-activity relationships (SAR) has resulted in the identification of the first enantioselective D3 antagonists (R- and S-22) to be reported, wherein enantioselectivity is more pronounced at D3 than at D2, and that a binding region on the second extracellular loop (E2) may play a role in both enantioselectivity and D3 receptor selectivity.  Moreover, we have discovered some of the most D3-selective compds. reported to date that show high affinity (Ki = 1 nM) for D3 and ∼400-fold selectivity over the D2 receptor subtype.  Several of these analogs showed exquisite selectivity for D3 receptors over >60 other receptors, further underscoring their value as in vivo research tools.  These lead compds. also have appropriate phys. characteristics for in vivo exploration and therefore will be useful in detg. how intrinsic activity at D3 receptors tested in vitro is related to behaviors in animal models of addiction and other neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbxvbF2dNX7Vg90H21EOLACvtfcHk0libQx7IGr09PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt7s%253D&md5=665731381e379cec45ef058cd6c45d0e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm900095y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900095y%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCyriac%26aufirst%3DG.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DD.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26atitle%3DN-%25284-%25284-%25282%252C3-dichloro-%2520or%25202-methoxyphenyl%2529piperazin-1-yl%2529butyl%2529heterobiarylcarboxamides%2520with%2520functionalized%2520linking%2520chains%2520as%2520high%2520affinity%2520and%2520enantioselective%2520D3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2559%26epage%3D2570%26doi%3D10.1021%2Fjm900095y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Paulis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogren, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensadn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csoregh, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystal structure and anti-dopaminergic properties of eticlopride (FLB 131)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaL28Xhs1ygsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1985&pages=273-276&author=T.+De%0APaulisauthor=H.+Hallauthor=S.+O.+Ogrenauthor=A.+Wagnerauthor=B.+Stensadnauthor=I.+Csoregh&title=Synthesis%2C+crystal+structure+and+anti-dopaminergic+properties+of+eticlopride+%28FLB+131%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystal structure and antidopaminergic properties of eticlopride (FLB 131)</span></div><div class="casAuthors">De Paulis, Tomas; Hall, Haakan; Oegren, Sven Ove; Waegner, Anna; Stensland, Birgitta; Csoeregh, Ingeborg</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-6</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The title pyrrolidinylmethylsalicylamide I (R = Et) was prepd. by treating methoxysalicylic acid II (R1 = OH, R2 = H) with with SO2Cl2 and then SOCl2 to give II (R1, R2 = Cl) which was treated with S(-)-aminomethyl-N-ethylpyrrolidine to give I.  I was 10 times more potent than haloperidol, both in displacing 3H-spiperone from striatal homogenate of rat brain, and in antagonizing apomorphine-induced hyperactivity in rats.  The x-ray crystal structure of I is given.  I (R = Me) was also prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFtgvcxXHxTrVg90H21EOLACvtfcHk0libQx7IGr09PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xhs1ygsr0%253D&md5=9ceeea4811c8da0f09548dbb056fcfad</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DOgren%26aufirst%3DS.%2BO.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DStensadn%26aufirst%3DB.%26aulast%3DCsoregh%26aufirst%3DI.%26atitle%3DSynthesis%252C%2520crystal%2520structure%2520and%2520anti-dopaminergic%2520properties%2520of%2520eticlopride%2520%2528FLB%2520131%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1985%26volume%3D20%26spage%3D273%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periasamy, M.</span></span> <span> </span><span class="NLM_article-title">Metalation of iminium ions formed in the reaction of tertiary amines with TiCl4</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1021/ol990745d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol990745d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaK1MXlsFSku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=857-859&author=P.+Bharathiauthor=M.+Periasamy&title=Metalation+of+iminium+ions+formed+in+the+reaction+of+tertiary+amines+with+TiCl4&doi=10.1021%2Fol990745d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metalation of Iminium Ions Formed in the Reaction of Tertiary Amines with TiCl4</span></div><div class="casAuthors">Bharathi, Pandi; Periasamy, Mariappan</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">857-859</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TiCl4 reacts with trialkylamines at 0-25° to give iminium ions that on metalation followed by reaction with diaryl ketones, produce α,β-unsatd. aldehydes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4YbX7rxxfc7Vg90H21EOLACvtfcHk0ljmkckThIqTKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsFSku74%253D&md5=ebe1664c943e15ecbf75463f06c916b2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fol990745d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol990745d%26sid%3Dliteratum%253Aachs%26aulast%3DBharathi%26aufirst%3DP.%26aulast%3DPeriasamy%26aufirst%3DM.%26atitle%3DMetalation%2520of%2520iminium%2520ions%2520formed%2520in%2520the%2520reaction%2520of%2520tertiary%2520amines%2520with%2520TiCl4%26jtitle%3DOrg.%2520Lett.%26date%3D1999%26volume%3D1%26spage%3D857%26epage%3D859%26doi%3D10.1021%2Fol990745d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiebel, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuvelis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dersch, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3765</span>– <span class="NLM_lpage">3776</span>, <span class="refDoi"> DOI: 10.1021/jm061325e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061325e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVymsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3765-3776&author=A.-C.+Hiebelauthor=Y.+S.+Leeauthor=E.+Bilskyauthor=D.+Giuvelisauthor=J.+R.+Deschampsauthor=D.+A.+Parrishauthor=M.+D.+Acetoauthor=E.+L.+Mayauthor=L.+S.+Harrisauthor=A.+Coopauthor=C.+M.+Derschauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=K.+Chengauthor=A.+E.+Jacobsonauthor=K.+C.+Rice&title=Probes+for+narcotic+receptor+mediated+phenomena.+34.+Synthesis+and+structure-activity+relationships+of+a+potent+mu-agonist+delta-antagonist+and+an+exceedingly+potent+antinociceptive+in+the+enantiomeric+C9-substituted+5-%283-hydroxyphenyl%29-N-phenylethylmorphan+series&doi=10.1021%2Fjm061325e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent μ-Agonist δ-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphan Series</span></div><div class="casAuthors">Hiebel, Anne-Cecile; Lee, Yong Sok; Bilsky, Edward; Giuvelis, Denise; Deschamps, Jeffrey R.; Parrish, Damon A.; Aceto, Mario D.; May, Everette L.; Harris, Louis S.; Coop, Andrew; Dersch, Christina M.; Partilla, John S.; Rothman, Richard B.; Cheng, Kejun; Jacobson, Arthur E.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3765-3776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic azabicyclononanylphenols (phenylmorphans) such as I and II (R = HO, H; R1 = H, Me) are prepd.; both enantiomeric phenylmorphans are prepd. and tested for their selectivities for the μ-, κ-, and δ-opioid receptors, while the antagonism or agonism at the μ-, δ-, and κ-opioid receptors of I and II (R = HO, H; R1 = H, Me) is detd.  A racemic (methoxyphenyl)azabicyclononanone is resolved with D- and L-tartaric acid to provide the starting materials for the prepn. of the phenylmorphans tested.  I and II (R = HO, H; R1 = H, Me) are tested against opioid receptors in vitro and in rats.  II (R = HO; R1 = H) binds the μ-opioid receptor with a Ki value of 0.19 nM, acting as a μ-agonist 500-1000 times as potent as morphine; I acts as μ-opioid agonist and a μ-, δ-, and κ-opioid antagonist, binding the μ-opioid receptor with a Ki value of 0.19 nM.  II (R = H; R1 = Me) binds the μ-opioid receptor with a Ki value of 0.63 nM.  II (R = HO; R1 = H) is the most potent phenylmorphan antinociceptive agent known.  The structures of I and II (R = HO, H; R1 = H, Me) are detd. by d. functional theor. (B3LYP/6-31G*) calcns.; the barriers to rotation of the Ph ring about the bond connecting it to the azabicyclononane ring are calcd.  The spatial arrangement of the nitrogen atom and the 9β-OH substituent in II (R = HO; R1 = H) may facilitate the alignment of a putative water chain enabling proton transfer to a nearby proton acceptor group upon binding to the μ-opioid receptor.  The structures of three of the nonracemic phenylmorphans are detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5nkbpaomPbVg90H21EOLACvtfcHk0ljmkckThIqTKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVymsLk%253D&md5=2d839c563a12b1f511fec2a08983d695</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm061325e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061325e%26sid%3Dliteratum%253Aachs%26aulast%3DHiebel%26aufirst%3DA.-C.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DBilsky%26aufirst%3DE.%26aulast%3DGiuvelis%26aufirst%3DD.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DParrish%26aufirst%3DD.%2BA.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DMay%26aufirst%3DE.%2BL.%26aulast%3DHarris%26aufirst%3DL.%2BS.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DDersch%26aufirst%3DC.%2BM.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DProbes%2520for%2520narcotic%2520receptor%2520mediated%2520phenomena.%252034.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%2520a%2520potent%2520mu-agonist%2520delta-antagonist%2520and%2520an%2520exceedingly%2520potent%2520antinociceptive%2520in%2520the%2520enantiomeric%2520C9-substituted%25205-%25283-hydroxyphenyl%2529-N-phenylethylmorphan%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3765%26epage%3D3776%26doi%3D10.1021%2Fjm061325e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and potent dopamine D2 receptor Go-protein biased agonists</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=52-65&author=A.+Bonifaziauthor=H.+Yanoauthor=A.+M.+Guerreroauthor=V.+Kumarauthor=A.+F.+Hoffmanauthor=C.+R.+Lupicaauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+and+potent+dopamine+D2+receptor+Go-protein+biased+agonists&doi=10.1021%2Facsptsci.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Guerrero, Adrian M.; Kumar, Vivek; Hoffman, Alexander F.; Lupica, Carl R.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of functionally biased and physiol. beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D2 receptor (D2R) targeted mols. that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders.  Here we describe the synthesis of a novel series of D2R agonists linking the D2R unbiased agonist sumanirole with privileged secondary mol. fragments.  The resulting ligands demonstrate improved D2R affinity and selectivity over sumanirole.  Extensive in vitro functional studies and bias factor anal. led to the identification of a novel class of highly potent Go-protein biased full D2R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, resp.  Intracellular electrophysiol. recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D2Rs, which may be beneficial in the treatment of dyskinesias assocd. with dopamine system dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNIFl-FnvXCrVg90H21EOLACvtfcHk0ljBQNNfZRF9wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D&md5=5b67e76002f6ceb85293c961f698722a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520potent%2520dopamine%2520D2%2520receptor%2520Go-protein%2520biased%2520agonists%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facsptsci.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laeremans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into micro-opioid receptor activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/nature14886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fnature14886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26245379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=315-321&author=W.+Huangauthor=A.+Manglikauthor=A.+J.+Venkatakrishnanauthor=T.+Laeremansauthor=E.+N.+Feinbergauthor=A.+L.+Sanbornauthor=H.+E.+Katoauthor=K.+E.+Livingstonauthor=T.+S.+Thorsenauthor=R.+C.+Klingauthor=S.+Granierauthor=P.+Gmeinerauthor=S.+M.+Husbandsauthor=J.+R.+Traynorauthor=W.+I.+Weisauthor=J.+Steyaertauthor=R.+O.+Drorauthor=B.+K.+Kobilka&title=Structural+insights+into+micro-opioid+receptor+activation&doi=10.1038%2Fnature14886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into μ-opioid receptor activation</span></div><div class="casAuthors">Huang, Weijiao; Manglik, Aashish; Venkatakrishnan, A. J.; Laeremans, Toon; Feinberg, Evan N.; Sanborn, Adrian L.; Kato, Hideaki E.; Livingston, Kathryn E.; Thorsen, Thor S.; Kling, Ralf C.; Granier, Sebastien; Gmeiner, Peter; Husbands, Stephen M.; Traynor, John R.; Weis, William I.; Steyaert, Jan; Dror, Ron O.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">315-321</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the μ-opioid receptor (μOR) is responsible for the efficacy of the most effective analgesics.  To shed light on the structural basis for μOR activation, here we report a 2.1 Å X-ray crystal structure of the murine μOR bound to the morphinan agonist BU72 and a G protein mimetic camelid antibody fragment Nb39 (nanobody 39).  The BU72-stabilized changes in the μOR binding pocket are subtle and differ from those obsd. for agonist-bound structures of the β2-adrenergic receptor (β2AR) and the M2 muscarinic receptor (M2R).  Comparison with active β2AR reveals a common rearrangement in the packing of three conserved amino acids in the core of the μOR, and mol. dynamics simulations illustrate how the ligand-binding pocket is conformationally linked to this conserved triad.  Addnl., an extensive polar network between the ligand-binding pocket and the cytoplasmic domains appears to play a similar role in signal propagation for all three G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFUN1wheV07Vg90H21EOLACvtfcHk0ljJT0ltN7QS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtbzM&md5=b9af3e1351b04539379532c127c02651</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature14886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14886%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DLaeremans%26aufirst%3DT.%26aulast%3DFeinberg%26aufirst%3DE.%2BN.%26aulast%3DSanborn%26aufirst%3DA.%2BL.%26aulast%3DKato%26aufirst%3DH.%2BE.%26aulast%3DLivingston%26aufirst%3DK.%2BE.%26aulast%3DThorsen%26aufirst%3DT.%2BS.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DGranier%26aufirst%3DS.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520micro-opioid%2520receptor%2520activation%26jtitle%3DNature%26date%3D2015%26volume%3D524%26spage%3D315%26epage%3D321%26doi%3D10.1038%2Fnature14886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Flexible protein-ligand docking by global energy optimization in internal coordinates</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/(sici)1097-0134(1997)1+<215::aid-prot29>3.0.co;2-q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1002%2F%28SICI%291097-0134%281997%291%2B%3C215%3A%3AAID-PROT29%3E3.0.CO%3B2-Q" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=215-220&author=M.+Totrovauthor=R.+Abagyan&title=Flexible+protein-ligand+docking+by+global+energy+optimization+in+internal+coordinates&doi=10.1002%2F%28sici%291097-0134%281997%291%2B%3C215%3A%3Aaid-prot29%3E3.0.co%3B2-q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0134%281997%291%2B%3C215%3A%3AAID-PROT29%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0134%25281997%25291%252B%253C215%253A%253AAID-PROT29%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DFlexible%2520protein-ligand%2520docking%2520by%2520global%2520energy%2520optimization%2520in%2520internal%2520coordinates%26jtitle%3DProteins%26date%3D1997%26volume%3D29%26spage%3D215%26epage%3D220%26doi%3D10.1002%2F%28sici%291097-0134%281997%291%2B%3C215%3A%3Aaid-prot29%3E3.0.co%3B2-q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaluna, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D4 receptor-selective compounds reveal structure-activity relationships that engender agonist efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3722</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3722-3740&author=T.+M.+Keckauthor=R.+B.+Freeauthor=M.+M.+Dayauthor=S.+L.+Brownauthor=M.+S.+Maddalunaauthor=G.+Fountainauthor=C.+Cooperauthor=B.+Fallonauthor=M.+Holmesauthor=C.+T.+Stangauthor=R.+Burkhardtauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=D.+R.+Sibleyauthor=C.+Wuauthor=C.+A.+Boateng&title=Dopamine+D4+receptor-selective+compounds+reveal+structure-activity+relationships+that+engender+agonist+efficacy&doi=10.1021%2Facs.jmedchem.9b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy</span></div><div class="casAuthors">Keck, Thomas M.; Free, R. Benjamin; Day, Marilyn M.; Brown, Sonvia L.; Maddaluna, Michele S.; Fountain, Griffin; Cooper, Charles; Fallon, Brooke; Holmes, Matthew; Stang, Christopher T.; Burkhardt, Russell; Bonifazi, Alessandro; Ellenberger, Michael P.; Newman, Amy H.; Sibley, David R.; Wu, Chun; Boateng, Comfort A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3722-3740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making.  Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders.  To identify new D4R-selective ligands, and to understand the mol. determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)-N-(m-tolyl)acetamide).  Compds. were profiled using radioligand binding displacement assays, β-arrestin recruitment assays, cAMP inhibition assays, and mol. dynamics computational modeling.  We identified several novel D4R-selective (Ki ≤ 4.3 nM and >100-fold vs other D2-like receptors) compds. with diverse partial agonist and antagonist profiles, falling into three structural groups.  These compds. highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtBRYg7sp8rVg90H21EOLACvtfcHk0ljJT0ltN7QS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D&md5=f3f03df2f50a91030295d32d6b692f1c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00231%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDay%26aufirst%3DM.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DMaddaluna%26aufirst%3DM.%2BS.%26aulast%3DFountain%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DFallon%26aufirst%3DB.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DStang%26aufirst%3DC.%2BT.%26aulast%3DBurkhardt%26aufirst%3DR.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26atitle%3DDopamine%2520D4%2520receptor-selective%2520compounds%2520reveal%2520structure-activity%2520relationships%2520that%2520engender%2520agonist%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3722%26epage%3D3740%26doi%3D10.1021%2Facs.jmedchem.9b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volpe, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, G. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellon, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colatsky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropp, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbois, S. L.</span></span> <span> </span><span class="NLM_article-title">Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2010.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.yrtph.2010.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=21215785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Wit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=385-390&author=D.+A.+Volpeauthor=G.+A.+M.+Tobinauthor=R.+D.+Mellonauthor=A.+G.+Katkiauthor=R.+J.+Parkerauthor=T.+Colatskyauthor=T.+J.+Kroppauthor=S.+L.+Verbois&title=Uniform+assessment+and+ranking+of+opioid+mu+receptor+binding+constants+for+selected+opioid+drugs&doi=10.1016%2Fj.yrtph.2010.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs</span></div><div class="casAuthors">Volpe, Donna A.; McMahon Tobin, Grainne A.; Mellon, R. Daniel; Katki, Aspandiar G.; Parker, Robert J.; Colatsky, Thomas; Kropp, Timothy J.; Verbois, S. Leigh</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-390</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The safe disposal of unused opioid drugs is an area of regulatory concern.  While toilet flushing is recommended for some drugs to prevent accidental exposure, there is a need for data that can support a more consistent disposal policy based on an assessment of relative risk.  For drugs acting at the Mu-opioid receptor (MOR), published measurements of binding affinity (Ki) are incomplete and inconsistent due to differences in methodol. and assay system, leading to a wide range of values for the same drug thus precluding a simple and meaningful relative ranking of drug potency.  Expts. were conducted to obtain Ki's for 19 approved opioid drugs using a single binding assay in a cell membrane prepn. expressing recombinant human MOR.  The Ki values obtained ranged from 0.1380 nM (sufentanil) to 12.486 μM (tramadol).  The drugs were sepd. into three categories based upon their Ki values: Ki > 100 nM (tramadol, codeine, meperidine, propoxyphene and pentazocine), Ki = 1-100 nM (hydrocodone, oxycodone, diphenoxylate, alfentanil, methadone, nalbuphine, fentanyl and morphine) and Ki < 1 nM (butorphanol, levorphanol, oxymorphone, hydromorphone, buprenorphine and sufentanil).  These data add to the understanding of the pharmacol. of opioid drugs and support the development of a more consistent labeling policies regarding safe disposal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVz_1KaclTerVg90H21EOLACvtfcHk0liVYj4SOHWN-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Wit7c%253D&md5=5b5583510504e30657f282b94921da2d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2010.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2010.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DVolpe%26aufirst%3DD.%2BA.%26aulast%3DTobin%26aufirst%3DG.%2BA.%2BM.%26aulast%3DMellon%26aufirst%3DR.%2BD.%26aulast%3DKatki%26aufirst%3DA.%2BG.%26aulast%3DParker%26aufirst%3DR.%2BJ.%26aulast%3DColatsky%26aufirst%3DT.%26aulast%3DKropp%26aufirst%3DT.%2BJ.%26aulast%3DVerbois%26aufirst%3DS.%2BL.%26atitle%3DUniform%2520assessment%2520and%2520ranking%2520of%2520opioid%2520mu%2520receptor%2520binding%2520constants%2520for%2520selected%2520opioid%2520drugs%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2011%26volume%3D59%26spage%3D385%26epage%3D390%26doi%3D10.1016%2Fj.yrtph.2010.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billing, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wish, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó-Anguera, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span> <span> </span><span class="NLM_article-title">Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2744</span>, <span class="refDoi"> DOI: 10.1172/jci126912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1172%2FJCI126912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30913037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BB3cbot1yitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=2730-2744&author=N.-S.+Caiauthor=C.+Quirozauthor=J.+Bonaventuraauthor=A.+Bonifaziauthor=T.+O.+Coleauthor=J.+Purksauthor=A.+S.+Billingauthor=E.+Masseyauthor=M.+Wagnerauthor=E.+D.+Wishauthor=X.+Guitartauthor=W.+Reaauthor=S.+Lamauthor=E.+Morenoauthor=V.+Casad%C3%B3-Angueraauthor=A.+D.+Greenblattauthor=A.+E.+Jacobsonauthor=K.+C.+Riceauthor=V.+Casad%C3%B3author=A.+H.+Newmanauthor=J.+W.+Winkelmanauthor=M.+Michaelidesauthor=E.+Weintraubauthor=N.+D.+Volkowauthor=A.+M.+Belcherauthor=S.+Ferr%C3%A9&title=Opioid-galanin+receptor+heteromers+mediate+the+dopaminergic+effects+of+opioids&doi=10.1172%2Fjci126912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids</span></div><div class="casAuthors">Cai Ning-Sheng; Quiroz Cesar; Guitart Xavier; Rea William; Ferre Sergi; Bonaventura Jordi; Lam Sherry; Michaelides Michael; Bonifazi Alessandro; Newman Amy H; Cole Thomas O; Greenblatt Aaron D; Weintraub Eric; Belcher Annabelle M; Purks Julia; Winkelman John W; Billing Amy S; Massey Ebonie; Wagner Michael; Wish Eric D; Moreno Estefania; Casado-Anguera Veronica; Casado Vicent; Jacobson Arthur E; Rice Kenner C; Volkow Nora D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2730-2744</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Identifying non-addictive opioid medications is a high priority in medical sciences, but μ-opioid receptors mediate both the analgesic and addictive effects of opioids.  We found a significant pharmacodynamic difference between morphine and methadone that is determined entirely by heteromerization of μ-opioid receptors with galanin Gal1 receptors, rendering a profound decrease in the potency of methadone.  This was explained by methadone's weaker proficiency to activate the dopaminergic system as compared to morphine and predicted a dissociation of therapeutic versus euphoric effects of methadone, which was corroborated by a significantly lower incidence of self-report of "high" in methadone-maintained patients.  These results suggest that μ-opioid-Gal1 receptor heteromers mediate the dopaminergic effects of opioids that may lead to a lower addictive liability of opioids with selective low potency for the μ-opioid-Gal1 receptor heteromer, exemplified by methadone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzhYYvOBe1ng5nADWVYHg1fW6udTcc2eYcUG02R0EFsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbot1yitw%253D%253D&md5=0362b240a45fdbab876cb8d439fcc766</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1172%2FJCI126912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI126912%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DN.-S.%26aulast%3DQuiroz%26aufirst%3DC.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DT.%2BO.%26aulast%3DPurks%26aufirst%3DJ.%26aulast%3DBilling%26aufirst%3DA.%2BS.%26aulast%3DMassey%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DWish%26aufirst%3DE.%2BD.%26aulast%3DGuitart%26aufirst%3DX.%26aulast%3DRea%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DCasad%25C3%25B3-Anguera%26aufirst%3DV.%26aulast%3DGreenblatt%26aufirst%3DA.%2BD.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWinkelman%26aufirst%3DJ.%2BW.%26aulast%3DMichaelides%26aufirst%3DM.%26aulast%3DWeintraub%26aufirst%3DE.%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DBelcher%26aufirst%3DA.%2BM.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DOpioid-galanin%2520receptor%2520heteromers%2520mediate%2520the%2520dopaminergic%2520effects%2520of%2520opioids%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26spage%3D2730%26epage%3D2744%26doi%3D10.1172%2Fjci126912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhfh4OMFCuHCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sounier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laeremans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déméné, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Propagation of conformational changes during mu-opioid receptor activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1038/nature14680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fnature14680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26245377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=375-378&author=R.+Sounierauthor=C.+Masauthor=J.+Steyaertauthor=T.+Laeremansauthor=A.+Manglikauthor=W.+Huangauthor=B.+K.+Kobilkaauthor=H.+D%C3%A9m%C3%A9n%C3%A9author=S.+Granier&title=Propagation+of+conformational+changes+during+mu-opioid+receptor+activation&doi=10.1038%2Fnature14680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Propagation of conformational changes during μ-opioid receptor activation</span></div><div class="casAuthors">Sounier, Remy; Mas, Camille; Steyaert, Jan; Laeremans, Toon; Manglik, Aashish; Huang, Weijiao; Kobilka, Brian K.; Demene, Helene; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">375-378</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">μ-Opioid receptors (μORs) are G-protein-coupled receptors that are activated by a structurally diverse spectrum of natural and synthetic agonists including endogenous endorphin peptides, morphine and methadone.  The recent structures of the μOR in inactive and agonist-induced active states (W. Huang et al., 2015) provide snapshots of the receptor at the beginning and end of a signalling event, but little is known about the dynamic sequence of events that span these two states.  Here we use soln.-state NMR to examine the process of μOR activation using a purified receptor (mouse sequence) prepn. in an amphiphile membrane-like environment.  We obtain spectra of the μOR in the absence of ligand, and in the presence of the high-affinity agonist BU 72 alone, or with BU 72 and a G protein mimetic nanobody.  Our results show that conformational changes in transmembrane segments 5 and 6 (TM5 and TM6), which are required for the full engagement of a G protein, are almost completely dependent on the presence of both the agonist and the G protein mimetic nanobody, revealing a weak allosteric coupling between the agonist-binding pocket and the G-protein-coupling interface (TM5 and TM6), similar to that obsd. for the β2-adrenergic receptor.  Unexpectedly, in the presence of agonist alone, we find larger spectral changes involving intracellular loop 1 and helix 8 compared to changes in TM5 and TM6.  These results suggest that one or both of these domains may play a role in the initial interaction with the G protein, and that TM5 and TM6 are only engaged later in the process of complex formation.  The initial interactions between the G protein and intracellular loop 1 and/or helix 8 may be involved in G-protein coupling specificity, as has been suggested for other family A G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonzj6Bmj4e5LVg90H21EOLACvtfcHk0lh9F43rzltKLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FN&md5=0dd0dedcce583a52b4adc3084726a862</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature14680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14680%26sid%3Dliteratum%253Aachs%26aulast%3DSounier%26aufirst%3DR.%26aulast%3DMas%26aufirst%3DC.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DLaeremans%26aufirst%3DT.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DD%25C3%25A9m%25C3%25A9n%25C3%25A9%26aufirst%3DH.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DPropagation%2520of%2520conformational%2520changes%2520during%2520mu-opioid%2520receptor%2520activation%26jtitle%3DNature%26date%3D2015%26volume%3D524%26spage%3D375%26epage%3D378%26doi%3D10.1038%2Fnature14680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0lh9F43rzltKLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Central nervous system multiparameter optimization desirability: application in drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=767-775&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Central+nervous+system+multiparameter+optimization+desirability%3A+application+in+drug+discovery&doi=10.1021%2Facschemneuro.6b00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">767-775</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant progress has been made in prospectively designing mols. using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the anal. reported herein of a second wave of drug candidates that originated after the development and implementation of this tool.  This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochem. properties.  The CNS MPO tool has helped to increase the percentage of compds. nominated for clin. development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA).  The use of this tool has played a role in reducing the no. of compds. submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicol. into First in Human studies.  Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compds. nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46WD7qMaX6bVg90H21EOLACvtfcHk0lglyGYxv_wxAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D&md5=061c3aef6c88758cbaee1a2abb34796a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00029%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DCentral%2520nervous%2520system%2520multiparameter%2520optimization%2520desirability%253A%2520application%2520in%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D767%26epage%3D775%26doi%3D10.1021%2Facschemneuro.6b00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Investigation of novel primary and secondary pharmacophores and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9061</span>– <span class="NLM_lpage">9077</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9061-9077&author=A.+B.+Shaikauthor=V.+Kumarauthor=A.+Bonifaziauthor=A.+M.+Guerreroauthor=S.+L.+Cemajauthor=A.+Gadianoauthor=J.+Lamauthor=Z.-X.+Xiauthor=R.+Raisauthor=B.+S.+Slusherauthor=A.+H.+Newman&title=Investigation+of+novel+primary+and+secondary+pharmacophores+and+3-substitution+in+the+linking+chain+of+a+series+of+highly+selective+and+bitopic+dopamine+D3+receptor+antagonists+and+partial+agonists&doi=10.1021%2Facs.jmedchem.9b00607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D3 Receptor Antagonists and Partial Agonists</span></div><div class="casAuthors">Shaik, Anver Basha; Kumar, Vivek; Bonifazi, Alessandro; Guerrero, Adrian M.; Cemaj, Sophie L.; Gadiano, Alexandra; Lam, Jenny; Xi, Zheng-Xiong; Rais, Rana; Slusher, Barbara S.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9061-9077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptors (D3R) play a crit. role in neuropsychiatric conditions including substance use disorders (SUD).  Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogs as high affinity and selective D3R lead mols. for the treatment of opioid use disorders (OUD).  Further optimization led to a series of analogs that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP).  Among the 3-F-compds., 9b demonstrated the highest D3R binding affinity (Ki = 0.756 nM) and was 327-fold selective for D3R over D2R.  In addn., modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examd.  Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure R- and S-enantiomers of the four lead compds.  Off-target binding affinities, functional efficacies, and metabolic profiles revealed crit. structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR79XdHJXFkbVg90H21EOLACvtfcHk0lglyGYxv_wxAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO&md5=0b8b1d8d76d17164a4ab7ba0e17ea2c2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00607%26sid%3Dliteratum%253Aachs%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DInvestigation%2520of%2520novel%2520primary%2520and%2520secondary%2520pharmacophores%2520and%25203-substitution%2520in%2520the%2520linking%2520chain%2520of%2520a%2520series%2520of%2520highly%2520selective%2520and%2520bitopic%2520dopamine%2520D3%2520receptor%2520antagonists%2520and%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9061%26epage%3D9077%26doi%3D10.1021%2Facs.jmedchem.9b00607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10842</span>, <span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein%0AHerenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0lgkNCbqaxlGLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuravi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digby, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, N. A.</span></span> <span> </span><span class="NLM_article-title">The c-terminus of GRK3 indicates rapid dissociation of G protein heterotrimers</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2009.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.cellsig.2009.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=19258039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslKkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=1015-1021&author=B.+Hollinsauthor=S.+Kuraviauthor=G.+J.+Digbyauthor=N.+A.+Lambert&title=The+c-terminus+of+GRK3+indicates+rapid+dissociation+of+G+protein+heterotrimers&doi=10.1016%2Fj.cellsig.2009.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The C-terminus of GRK3 indicates rapid dissociation of G protein heterotrimers</span></div><div class="casAuthors">Hollins, Bettye; Kuravi, Sudhakiranmayi; Digby, Gregory J.; Lambert, Nevin A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1021</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signals mediated by heterotrimeric G proteins often develop over the course of tens of milliseconds, and could require either conformational rearrangement or complete phys. dissocn. of Gαβγ heterotrimers.  Although it is known that some active heterotrimers are dissocd. (into Gα and Gβγ) at steady-state, it is not clear that dissocn. occurs quickly enough to participate in rapid signaling.  Here we show that fusion proteins contg. the c-terminus of GPCR kinase 3 (GRK3ct) and either the fluorescent protein cerulean or Renilla luciferase bind to venus-labeled Gβγ dimers (Gβγ-V), resulting in Foerster or bioluminescence resonance energy transfer (FRET or BRET).  GRK3ct fusion proteins are freely-diffusible, and do not form preassembled complexes with G proteins.  GRK3ct fusion proteins bind to free Gβγ-V dimers but not to rearranged heterotrimers, and thus can report G protein dissocn. with high temporal resoln.  We find that heterotrimer dissocn. can occur in living cells in less than 100 ms.  Under the conditions of these expts. diffusion and collision of masGRK3ct fusion proteins and Gβγ-V were not rate-limiting.  These results indicate that G protein heterotrimers can dissoc. quickly enough to participate in rapid signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5hN_doIS7Vg90H21EOLACvtfcHk0lgkNCbqaxlGLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslKkt7g%253D&md5=1f154d0e658dc3620b0cc7a3129dbf6a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2009.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2009.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DHollins%26aufirst%3DB.%26aulast%3DKuravi%26aufirst%3DS.%26aulast%3DDigby%26aufirst%3DG.%2BJ.%26aulast%3DLambert%26aufirst%3DN.%2BA.%26atitle%3DThe%2520c-terminus%2520of%2520GRK3%2520indicates%2520rapid%2520dissociation%2520of%2520G%2520protein%2520heterotrimers%26jtitle%3DCell.%2520Signalling%26date%3D2009%26volume%3D21%26spage%3D1015%26epage%3D1021%26doi%3D10.1016%2Fj.cellsig.2009.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug design based on structural modification of canonical synthons inspired by agonists, antagonists, and partial agonists selectively targeting the MOR and D<sub>3</sub>R. Orange boxes denote bivalent templates, and green boxes denote bitopic templates. Variables <b>A</b>, <b>B</b>, and <b>C</b> correspond to the aromatic substitutions seen in compounds <b>1</b>, <b>2</b>, <b>7</b>, <b>10</b>, or <b>11</b>. The general <b>Ar</b> group corresponds to the aromatic substituents in compounds <b>7</b>, <b>9</b>, <b>10</b>, and <b>11</b>. General <b>R</b><sup><b>1</b></sup> and <b>R</b><sup><b>2</b></sup> groups represent H, Me, or OH or (O). Variables <b>Y</b> and <b>Z</b> represent C or N, and variable <b>X</b> is H, OMe, or OH or (O).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Appropriate primary or secondary amine, K<sub>2</sub>CO<sub>3</sub>, and acetonitrile (ACN), 130 °C, overnight, 8–53%; (b) Me<sub>2</sub>NH·HCl, K<sub>2</sub>CO<sub>3</sub>, and ACN, 130 °C, overnight, 79%; (c) HBr 48% in H<sub>2</sub>O, 100 °C, overnight; (d) <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (EDC), 1-hydroxybenzotriazole hydrate (HOBt), 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a><i>N</i>,<i>N</i>-diisopropylethylamine (Hünig’s base, DIPEA), and dichloromethane (DCM), 25 °C, overnight, 6%; and (e) ethyl magnesium bromide (EtMgBr) 3 M in diethyl ether (Et<sub>2</sub>O), toluene, 0 to 110 °C, 3 h, 59%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 1-(2,3-Dichlorophenyl)piperazine, 2-(6-chloro-1-<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), and DCM, 25 °C, 3 h, 59%; (b) trifluoroacetic acid (TFA) and DCM, 25 °C, 24 h; and (c) 4-bromo-2,2-diphenylbutanenitrile, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight, 3% (over two steps).</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Appropriate secondary amine, K<sub>2</sub>CO<sub>3</sub>, DIPEA (for <b>23</b> and <b>24</b>), ACN, and <i>tert</i>-butyl methyl ether (TBME), reflux, 24 h, 16–91%; (b) 2 N NaOH in H<sub>2</sub>O, 25 °C, 5 min, 100%; (c) Dess–Martin periodinane (DMP), DCM, 0 to 25 °C, 1 h, 60%; and (d) appropriate primary or secondary amine, catalytic acetic acid (cat. AcOH), sodium triacetoxyborohydride (STAB), and 1,2-dichloroethane (DCE), 25 °C, 2.5 h, 12–100%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, cat. KI, ACN, 82 °C, overnight; (b) hydrazine (NH<sub>2</sub>NH<sub>2</sub>) and ethanol (EtOH), 80 °C, 3 h, 94% (over 2 steps); and (c) <i>N</i>,<i>N</i>-dimethyl-4-oxo-2,2-diphenylbutanamide (<b>26</b>), cat. AcOH, STAB, and DCE, 25 °C, 2.5 h, 46%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight; (b) NH<sub>2</sub>NH<sub>2</sub> and EtOH, 80 °C, 3 h, 36% (over two steps); and (c) K<sub>2</sub>CO<sub>3</sub> and ACN, 130 °C, overnight, 10–23%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Bromobutyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, and ACN, 82 °C, overnight, 85%; (b) TFA and DCM, 25 °C, 3 h; (c) HCTU and DCM, 25 °C, 48 h, 26%; (d) NH<sub>2</sub>NH<sub>2</sub> and EtOH, 80 °C, 3 h; and (e) cat. AcOH, STAB, and DCE, 25 °C, 12 h, 21% (over two steps).</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) LAH and tetrahydrofuran (THF), 0 to 25 °C, 15 h, 40%; (b) 2-chloroacetyl chloride, DIPEA, and THF, 0 to 25 °C, 1 h; (c) cat. KI, K<sub>2</sub>CO<sub>3</sub> and ACN, 82 °C, 3 h, 74% (over two steps); (d) TFA and DCM, 25 °C, 2 h; (e) HCTU, DIPEA, and DCM, 25 °C, 3 h, 15% (over two steps); (f) methyl chloroformate, DIPEA, and DCM, 25 °C, 1 h; (g) LAH and THF, 0 to 25 °C, 56% (over two steps); and (h) propionyl chloride, DIPEA, and DCM, 40 °C, overnight, 29%.</p></p></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 8. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Cat. AcOH, STAB, and DCE, 25 °C, 4 h; (b) TFA and DCM, 25 °C, overnight, 8.5% (over two steps).</p></p></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 9. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Titanium tetrachloride (TiCl<sub>4</sub>), triethylamine (TEA), and DCM, 0 to 25 °C, overnight, 58%; (b) 4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butan-1-amine, cat. AcOH, STAB, and DCE, 25 °C, 4 h, 88%; (c) H<sub>2</sub> (50 psi), Pd/C (20% wt), and EtOH, 25 °C, 12 h; (d) HBr 33% in AcOH; 118 °C, 48 h, 13–31%; (e) 1-(2-chloro-3-ethylphenyl)piperazine,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> cat. AcOH, STAB, and DCE, 25 °C, 4 h, 88%; and (f) H<sub>2</sub> (30 psi), Pd/C (20% wt), and EtOAc/EtOH (2:1), 25 °C, 3 h, 75%.</p></p></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 10. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>N</i>-(4-Oxobutyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> cat. AcOH, STAB, and DCE, 25 °C, 1.5 h, 26–88%; (b) <i>trans</i>-<i>N</i>-(2-(2-formylcyclopropyl)ethyl)-1<i>H</i>-indole-2-carboxamide,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> cat. AcOH, STAB, and DCE, 25 °C, 1.5 h, 65%; and (c) preparative enantioselective high-performance liquid chromatography (HPLC), ChiralPak AD-H column.</p></p></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 11. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 2-Bromoethan-1-ol, K<sub>2</sub>CO<sub>3</sub>, cat. KI, and ACN, 82 °C, overnight, 60%; (b) <i>p</i>-toluenesulfonyl chloride (<i>p</i>-TsCl), DIPEA, and DCM, 25 °C, overnight, 36%; (c) NaHCO<sub>3</sub> and ACN, 82 °C, 6 h, 43%.</p></p></figure><figure data-id="fig2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of <b>5</b> (orange sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) binding mode of <b>3</b> (green sticks) inside the MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding modes of <b>23</b> (green) and <b>5</b> (orange) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) docking mode of <b>23</b> (green) and <b>13</b> (orange) inside the MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of <b>14</b> (orange sticks) and <b>28</b> (green sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Binding mode of <b>40</b> (orange sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>65</b> (orange sticks) and <b>10</b> (green sticks) inside the (A) D<sub>3</sub>R (cyan; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>) and (B) MOR (white; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/medium/jm1c00611_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Functional profiles of selected MOR–D<sub>3</sub>R hybrids. Each panel shows a different signaling readout: (A) Nb33 recruitment at the MOR, (B) MOR-mediated Gα<sub>i2</sub> protein activation, (C) antagonism at the MOR using GPA in the presence of 100 nM DAMGO, (D) arrestin-3 recruitment at the MOR in the presence of overexpressed GRK2, (E) D<sub>3</sub>R-mediated Gα<sub>oA</sub> protein activation, and (F) antagonism at the D<sub>3</sub>R using GPA in the presence of 3 nM quinpirole. In order to ensure that test ligands achieved maximal receptor occupancy possible before agonist addition, all ligands were added to the cells 3 h prior to activating the D<sub>3</sub>R with quinpirole and measuring BRET signals with the exception of <b>5</b>. Dotted lines represent fits where the bottom asymptote was constrained to be 0%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.1c00611/20210602/images/large/jm1c00611_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00611&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44714" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44714" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 69 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span> </span><span class="NLM_article-title">CDC/NCHS National
Vital Statistics System, Mortality. CDC WONDER</span>; <span class="NLM_publisher-name">US Department of Health and Human Services, CDC</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>. <a href="https://www.cdc.gov/nchs/nvss/deaths.htm" class="extLink">https://www.cdc.gov/nchs/nvss/deaths.htm</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDC%2FNCHS+National%0AVital+Statistics+System%2C+Mortality.+CDC+WONDER%3B+US+Department+of+Health+and+Human+Services%2C+CDC%3A+Atlanta%2C+GA.+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fnvss%2Fdeaths.htm+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DCDC%252FNCHS%2520National%250AVital%2520Statistics%2520System%252C%2520Mortality.%2520CDC%2520WONDER%26pub%3DUS%2520Department%2520of%2520Health%2520and%2520Human%2520Services%252C%2520CDC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, L.</span></span> <a href="https://www.forbes.com/sites/lipiroy/2020/05/23/collision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse/#5cbc00837d3a" class="extLink">https://www.forbes.com/sites/lipiroy/2020/05/23/collision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse/#5cbc00837d3a</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Roy%2C+L.+https%3A%2F%2Fwww.forbes.com%2Fsites%2Flipiroy%2F2020%2F05%2F23%2Fcollision-of-crises-how-covid-19-will-propel-drug-overdose-from-bad-to-worse%2F%235cbc00837d3a+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, Z.</span></span> <span> </span><span class="NLM_article-title">The escalation of the opioid epidemic due to COVID-19 and sesulting lessons about treatment alternatives</span>. <i>Am. J. Manag. Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">e202</span>– <span class="NLM_lpage">e204</span>, <span class="refDoi"> DOI: 10.37765/ajmc.2020.43386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.37765%2Fajmc.2020.43386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32672917" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=e202-e204&author=M.+J.+Silvaauthor=Z.+Kelly&title=The+escalation+of+the+opioid+epidemic+due+to+COVID-19+and+sesulting+lessons+about+treatment+alternatives&doi=10.37765%2Fajmc.2020.43386"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.37765%2Fajmc.2020.43386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.37765%252Fajmc.2020.43386%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DM.%2BJ.%26aulast%3DKelly%26aufirst%3DZ.%26atitle%3DThe%2520escalation%2520of%2520the%2520opioid%2520epidemic%2520due%2520to%2520COVID-19%2520and%2520sesulting%2520lessons%2520about%2520treatment%2520alternatives%26jtitle%3DAm.%2520J.%2520Manag.%2520Care%26date%3D2020%26volume%3D26%26spage%3De202%26epage%3De204%26doi%3D10.37765%2Fajmc.2020.43386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">NIH/NIDA</span>. <a href="https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis" class="extLink">https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis</a> (accessed Feb 10, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH%2FNIDA.+https%3A%2F%2Fwww.drugabuse.gov%2Fdrugs-abuse%2Fopioids%2Fopioid-overdose-crisis+%28accessed+Feb+10%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vowles, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEntee, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julnes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Goes, D. N.</span></span> <span> </span><span class="NLM_article-title">Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1097/01.j.pain.0000460357.01998.f1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1097%2F01.j.pain.0000460357.01998.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=25785523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC2MnlvVKhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=569-576&author=K.+E.+Vowlesauthor=M.+L.+McEnteeauthor=P.+S.+Julnesauthor=T.+Froheauthor=J.+P.+Neyauthor=D.+N.+van+der+Goes&title=Rates+of+opioid+misuse%2C+abuse%2C+and+addiction+in+chronic+pain%3A+a+systematic+review+and+data+synthesis&doi=10.1097%2F01.j.pain.0000460357.01998.f1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis</span></div><div class="casAuthors">Vowles Kevin E; McEntee Mindy L; Julnes Peter Siyahhan; Frohe Tessa; Ney John P; van der Goes David N</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-576</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid use in chronic pain treatment is complex, as patients may derive both benefit and harm.  Identification of individuals currently using opioids in a problematic way is important given the substantial recent increases in prescription rates and consequent increases in morbidity and mortality.  The present review provides updated and expanded information regarding rates of problematic opioid use in chronic pain.  Because previous reviews have indicated substantial variability in this literature, several steps were taken to enhance precision and utility.  First, problematic use was coded using explicitly defined terms, referring to different patterns of use (ie, misuse, abuse, and addiction).  Second, average prevalence rates were calculated and weighted by sample size and study quality.  Third, the influence of differences in study methodology was examined.  In total, data from 38 studies were included.  Rates of problematic use were quite broad, ranging from <1% to 81% across studies.  Across most calculations, rates of misuse averaged between 21% and 29% (range, 95% confidence interval [CI]: 13%-38%).  Rates of addiction averaged between 8% and 12% (range, 95% CI: 3%-17%).  Abuse was reported in only a single study.  Only 1 difference emerged when study methods were examined, where rates of addiction were lower in studies that identified prevalence assessment as a primary, rather than secondary, objective.  Although significant variability remains in this literature, this review provides guidance regarding possible average rates of opioid misuse and addiction and also highlights areas in need of further clarification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRopnzK7CEDcdts4TFFB11gfW6udTcc2ebZtnEm2zsTJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnlvVKhtA%253D%253D&md5=0ddbfbaad57261f02f7c5c72531df680</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F01.j.pain.0000460357.01998.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.j.pain.0000460357.01998.f1%26sid%3Dliteratum%253Aachs%26aulast%3DVowles%26aufirst%3DK.%2BE.%26aulast%3DMcEntee%26aufirst%3DM.%2BL.%26aulast%3DJulnes%26aufirst%3DP.%2BS.%26aulast%3DFrohe%26aufirst%3DT.%26aulast%3DNey%26aufirst%3DJ.%2BP.%26aulast%3Dvan%2Bder%2BGoes%26aufirst%3DD.%2BN.%26atitle%3DRates%2520of%2520opioid%2520misuse%252C%2520abuse%252C%2520and%2520addiction%2520in%2520chronic%2520pain%253A%2520a%2520systematic%2520review%2520and%2520data%2520synthesis%26jtitle%3DPain%26date%3D2015%26volume%3D156%26spage%3D569%26epage%3D576%26doi%3D10.1097%2F01.j.pain.0000460357.01998.f1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muhuri, P. K.</span>; <span class="NLM_string-name">Gfroerer, J. C.</span>; <span class="NLM_string-name">Davies, M. C.</span></span> <i>CBHSQ Data Review: Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States</i>, August <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+K.+Muhuri&author=J.+C.+Gfroerer&author=M.+C.+Davies&title=CBHSQ+Data+Review%3A+Associations+of+Nonmedical+Pain+Reliever+Use+and+Initiation+of+Heroin+Use+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DMuhuri%26aufirst%3DP.%2BK.%26jtitle%3DCBHSQ%2520Data%2520Review%253A%2520Associations%2520of%2520Nonmedical%2520Pain%2520Reliever%2520Use%2520and%2520Initiation%2520of%2520Heroin%2520Use%2520in%2520the%2520United%2520States%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surratt, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. P.</span></span> <span> </span><span class="NLM_article-title">The changing face of heroin use in the United States: a retrospective analysis of the past 50 years</span>. <i>JAMA Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1001/jamapsychiatry.2014.366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1001%2Fjamapsychiatry.2014.366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=24871348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC2cjmslOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=821-826&author=T.+J.+Ciceroauthor=M.+S.+Ellisauthor=H.+L.+Surrattauthor=S.+P.+Kurtz&title=The+changing+face+of+heroin+use+in+the+United+States%3A+a+retrospective+analysis+of+the+past+50+years&doi=10.1001%2Fjamapsychiatry.2014.366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The changing face of heroin use in the United States: a retrospective analysis of the past 50 years</span></div><div class="casAuthors">Cicero Theodore J; Ellis Matthew S; Surratt Hilary L; Kurtz Steven P</div><div class="citationInfo"><span class="NLM_cas:title">JAMA psychiatry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">821-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Over the past several years, there have been a number of mainstream media reports that the abuse of heroin has migrated from low-income urban areas with large minority populations to more affluent suburban and rural areas with primarily white populations.  OBJECTIVE:  To examine the veracity of these anecdotal reports and define the relationship between the abuse of prescription opioids and the abuse of heroin.  DESIGN, SETTING, AND PARTICIPANTS:  Using a mixed-methods approach, we analyzed (1) data from an ongoing study that uses structured, self-administered surveys to gather retrospective data on past drug use patterns among patients entering substance abuse treatment programs across the country who received a primary (DSM-IV) diagnosis of heroin use/dependence (n = 2797) and (2) data from unstructured qualitative interviews with a subset of patients (n = 54) who completed the structured interview.  MAIN OUTCOMES AND MEASURES:  In addition to data on population demographics and current residential location, we used cross-tabulations to assess prevalence rates as a function of the decade of the initiation of abuse for (1) first opioid used (prescription opioid or heroin), (2) sex, (3) race/ethnicity, and (4) age at first use.  Respondents indicated in an open-ended format why they chose heroin as their primary drug and the interrelationship between their use of heroin and their use of prescription opioids.  RESULTS:  Approximately 85% of treatment-seeking patients approached to complete the Survey of Key Informants' Patients Program did so.  Respondents who began using heroin in the 1960s were predominantly young men (82.8%; mean age, 16.5 years) whose first opioid of abuse was heroin (80%).  However, more recent users were older (mean age, 22.9 years) men and women living in less urban areas (75.2%) who were introduced to opioids through prescription drugs (75.0%).  Whites and nonwhites were equally represented in those initiating use prior to the 1980s, but nearly 90% of respondents who began use in the last decade were white.  Although the "high" produced by heroin was described as a significant factor in its selection, it was often used because it was more readily accessible and much less expensive than prescription opioids.  CONCLUSION AND RELEVANCE:  Our data show that the demographic composition of heroin users entering treatment has shifted over the last 50 years such that heroin use has changed from an inner-city, minority-centered problem to one that has a more widespread geographical distribution, involving primarily white men and women in their late 20s living outside of large urban areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRW_x_4-GpCCmyYR5VtavbzfW6udTcc2eZgY7C1wKVLO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjmslOqug%253D%253D&md5=aa2bef62f31eecb7aec411ff07180385</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjamapsychiatry.2014.366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamapsychiatry.2014.366%26sid%3Dliteratum%253Aachs%26aulast%3DCicero%26aufirst%3DT.%2BJ.%26aulast%3DEllis%26aufirst%3DM.%2BS.%26aulast%3DSurratt%26aufirst%3DH.%2BL.%26aulast%3DKurtz%26aufirst%3DS.%2BP.%26atitle%3DThe%2520changing%2520face%2520of%2520heroin%2520use%2520in%2520the%2520United%2520States%253A%2520a%2520retrospective%2520analysis%2520of%2520the%2520past%252050%2520years%26jtitle%3DJAMA%2520Psychiatry%26date%3D2014%26volume%3D71%26spage%3D821%26epage%3D826%26doi%3D10.1001%2Fjamapsychiatry.2014.366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahhas, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniulaityte, R.</span></span> <span> </span><span class="NLM_article-title">Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2015.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.drugalcdep.2015.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26785634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC28nitVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2016&pages=127-134&author=R.+G.+Carlsonauthor=R.+W.+Nahhasauthor=S.+S.+Martinsauthor=R.+Daniulaityte&title=Predictors+of+transition+to+heroin+use+among+initially+non-opioid+dependent+illicit+pharmaceutical+opioid+users%3A+A+natural+history+study&doi=10.1016%2Fj.drugalcdep.2015.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study</span></div><div class="casAuthors">Carlson Robert G; Nahhas Ramzi W; Martins Silvia S; Daniulaityte Raminta</div><div class="citationInfo"><span class="NLM_cas:title">Drug and alcohol dependence</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Increases in illicit pharmaceutical opioid (PO) use have been associated with risk for transition to heroin use.  We identify predictors of transition to heroin use among young, illicit PO users with no history of opioid dependence or heroin use at baseline.  METHODS:  Respondent-driven sampling recruited 383 participants; 362 returned for at least one biannual structured interview over 36 months.  Cox regression was used to test for associations between lagged predictors and hazard of transition to heroin use.  Potential predictors were based on those suggested in the literature.  We also computed population attributable risk (PAR) and the rate of heroin transition.  RESULTS:  Over 36 months, 27 (7.5%) participants initiated heroin use; all were white, and the rate of heroin initiation was 2.8% per year (95% CI=1.9%-4.1%).  Mean length of PO at first reported heroin use was 6.2 years (SD=1.9).  Lifetime PO dependence (AHR=2.39, 95% CI=1.07-5.48; PAR=32%, 95% CI=-2% to 64%), early age of PO initiation (AHR=3.08, 95%; CI=1.26-7.47; PAR=30%, 95% CI=2%-59%), using illicit POs to get high but not to self-medicate a health problem (AHR=4.83, 95% CI=2.11-11.0; PAR=38%, 95% CI=12%-65%), and ever using PO non-orally most often (AHR=6.57, 95% CI=2.81-17.2; PAR=63%, 95% CI=31%-86%) were significant predictors.  CONCLUSION:  This is one of the first prospective studies to test observations from previous cross-sectional and retrospective research on the relationship between illicit PO use and heroin initiation among young, initially non-opioid dependent PO users.  The results provide insights into targets for the design of urgently needed prevention interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaLgGnk3do_EeosoOnpOLfW6udTcc2eaQlpRWsUt0D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nitVWktw%253D%253D&md5=0978c5e92cac5c8646f648ae65f5244c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2015.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2015.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BG.%26aulast%3DNahhas%26aufirst%3DR.%2BW.%26aulast%3DMartins%26aufirst%3DS.%2BS.%26aulast%3DDaniulaityte%26aufirst%3DR.%26atitle%3DPredictors%2520of%2520transition%2520to%2520heroin%2520use%2520among%2520initially%2520non-opioid%2520dependent%2520illicit%2520pharmaceutical%2520opioid%2520users%253A%2520A%2520natural%2520history%2520study%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2016%26volume%3D160%26spage%3D127%26epage%3D134%26doi%3D10.1016%2Fj.drugalcdep.2015.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">NIDA’s medication development priorities in response to the opioid crisis: ten most wanted</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0292-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-018-0292-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30538289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BB3cngvVOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=657-659&author=K.+Rasmussenauthor=D.+A.+Whiteauthor=J.+B.+Acri&title=NIDA%E2%80%99s+medication+development+priorities+in+response+to+the+opioid+crisis%3A+ten+most+wanted&doi=10.1038%2Fs41386-018-0292-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted</span></div><div class="casAuthors">Rasmussen Kurt; White David A; Acri Jane B</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-659</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHtoX-sKxKlNTiMd2aNQVUfW6udTcc2eaQlpRWsUt0D7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cngvVOruw%253D%253D&md5=798c0fdeee2c7543009f32f638b2f97e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0292-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0292-5%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DD.%2BA.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DNIDA%25E2%2580%2599s%2520medication%2520development%2520priorities%2520in%2520response%2520to%2520the%2520opioid%2520crisis%253A%2520ten%2520most%2520wanted%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D657%26epage%3D659%26doi%3D10.1038%2Fs41386-018-0292-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5361</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm501512b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501512b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5361-5380&author=T.+M.+Keckauthor=W.+S.+Johnauthor=P.+W.+Czotyauthor=M.+A.+Naderauthor=A.+H.+Newman&title=Identifying+medication+targets+for+psychostimulant+addiction%3A+unraveling+the+dopamine+D3+receptor+hypothesis&doi=10.1021%2Fjm501512b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis</span></div><div class="casAuthors">Keck, Thomas M.; John, William S.; Czoty, Paul W.; Nader, Michael A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5361-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a target for developing medications to treat substance use disorders.  D3R-selective compds. with high affinity and varying efficacies have been discovered, providing crit. research tools for cell-based studies that have been translated to in vivo models of drug abuse.  D3R antagonists and partial agonists have shown esp. promising results in rodent models of relapse-like behavior, including stress-, drug-, and cue-induced reinstatement of drug seeking.  However, to date, translation to human studies has been limited.  Herein, we present an overview and illustrate some of the pitfalls and challenges of developing novel D3R-selective compds. toward clin. utility, esp. for treatment of cocaine abuse.  Future research and development of D3R-selective antagonists and partial agonists for substance abuse remains critically important but will also require further evaluation and development of translational animal models to det. the best time in the addiction cycle to target D3Rs for optimal therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVPGvcTvN87Vg90H21EOLACvtfcHk0ljTmpRc6sj7cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGgu74%253D&md5=99f531d840ad7f94d0eeadeb6fd48100</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501512b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501512b%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DJohn%26aufirst%3DW.%2BS.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DIdentifying%2520medication%2520targets%2520for%2520psychostimulant%2520addiction%253A%2520unraveling%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5361%26epage%3D5380%26doi%3D10.1021%2Fjm501512b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acri, J. B.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fjpet.115.224121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26177654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=484-492&author=N.+M.+Appelauthor=S.-H.+Liauthor=T.+H.+Holmesauthor=J.+B.+Acri&title=Dopamine+D3+receptor+antagonist+%28GSK598809%29+potentiates+the+hypertensive+effects+of+cocaine+in+conscious%2C+freely-moving+dogs&doi=10.1124%2Fjpet.115.224121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs</span></div><div class="casAuthors">Appel, Nathan M.; Li, Shou-Hua; Holmes, Tyson H.; Acri, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">484-492</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The chronic and relapsing nature of addiction presents unique challenges for ensuring the safety of a potential medication.  A patient may use cocaine, for example, while taking the medication or take more medication than prescribed.  Thus, a potential medication must be safe and not exacerbate the effects of cocaine.  Multiple published studies support antagonism of brain dopamine D3 receptor function as a potential mechanism of action for an anti-addiction medication.  Dopamine D3 receptors are widely distributed outside the central nervous system, however; for example, dopamine D3 receptors in the kidneys are implicated in regulating blood pressure.  The selective dopamine D3 receptor antagonist GSK598809 [1-(2-fluoro-4- trifluoromethyl-phenyl)-3-{3-[4-methyl-5-(4-methyl-oxazol-5- yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-propyl}-3-aza-bicyclo[3.1.0] hexane] has been proposed as a medication to treat cocaine and other substance use disorders.  The US Food and Drug Administration has established guidelines recommending safety studies to investigate potential undesirable pharmacodynamic effects of a substance in relation to exposure in the therapeutic range and above.  Hence, we assessed the interaction between this selective dopamine D3 receptor antagonist and cocaine on hemodynamics and cardiac function in freely-moving, telemetered dogs before conducting a clin. trial.  GSK598809 increased the hemodynamic effect of cocaine in this model.  Thus, the increase in blood pressure after i.v. cocaine was greater in animals that had been pretreated with GSK598809 compared with vehicle.  This finding suggests that GSK598809 in particular, and perhaps dopamine D3 receptor antagonists as a class, may produce unacceptable cardiovascular risks as medications to treat cocaine use disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWq20sTq43bVg90H21EOLACvtfcHk0lhiQwiuyCRMCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbvJ&md5=6fd994c95c5bee2dd486b4c340564c73</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224121%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DS.-H.%26aulast%3DHolmes%26aufirst%3DT.%2BH.%26aulast%3DAcri%26aufirst%3DJ.%2BB.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonist%2520%2528GSK598809%2529%2520potentiates%2520the%2520hypertensive%2520effects%2520of%2520cocaine%2520in%2520conscious%252C%2520freely-moving%2520dogs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D484%26epage%3D492%26doi%3D10.1124%2Fjpet.115.224121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span> <span> </span><span class="NLM_article-title">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">107597</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.neuropharm.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30974107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&pages=107597&author=C.+J.+Jordanauthor=B.+Humburgauthor=M.+Riceauthor=G.-H.+Biauthor=Z.-B.+Youauthor=A.+B.+Shaikauthor=J.+Caoauthor=A.+Bonifaziauthor=A.+Gadianoauthor=R.+Raisauthor=B.+Slusherauthor=A.+H.+Newmanauthor=Z.-X.+Xi&title=The+highly+selective+dopamine+D3R+antagonist%2C+R-VK4-40+attenuates+oxycodone+reward+and+augments+analgesia+in+rodents&doi=10.1016%2Fj.neuropharm.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree; Rice, Myra; Bi, Guo-Hua; You, Zhi-Bing; Shaik, Anver Basha; Cao, Jianjing; Bonifazi, Alessandro; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107597</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the effects of R-VK4-40, a highly selective D3R receptor antagonist, on the rewarding and analgesic effects of oxycodone, the most commonly abused prescription opioid, in rats and mice.  Systemic administration of R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward in rats.  Pretreatment with R-VK4-40 also dose-dependently lowered break-points for oxycodone under a progressive-ratio schedule.  To det. whether a DA-dependent mechanism underlies the impact of D3 antagonism in reducing opioid reward, we used optogenetic approaches to examine intracranial self-stimulation (ICSS) maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice.  Pretreatment with R-VK4-40 blocked oxycodone-enhanced brain-stimulation reward.  By itself, R-VK4-40 produced a modest dose-dependent redn. in optical ICSS.  Pretreatment with R-VK4-40 did not compromise the antinociceptive effects of oxycodone in rats, and R-VK4-40 alone produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.  Together, these findings suggest R-VK4-40 may permit a lower dose of prescription opioids for pain management, potentially mitigating tolerance and dependence, while diminishing reward potency.  Hence, development of R-VK4-40 as a therapy for the treatment of opioid use disorders and/or pain is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoec47hB7NVR7Vg90H21EOLACvtfcHk0lhiQwiuyCRMCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI&md5=2619b493c3addad36e8ec504f41b25c7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.-X.%26atitle%3DThe%2520highly%2520selective%2520dopamine%2520D3R%2520antagonist%252C%2520R-VK4-40%2520attenuates%2520oxycodone%2520reward%2520and%2520augments%2520analgesia%2520in%2520rodents%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26spage%3D107597%26doi%3D10.1016%2Fj.neuropharm.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415-1424&author=Z.-B.+Youauthor=G.-H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0lhPG8tkhrw9_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DBi%26aufirst%3DG.-H.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26epage%3D1424%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.-B.+Youauthor=Z.-X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0lhktpBn_nW0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.-B.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorndike, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span> <span> </span><span class="NLM_article-title">Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.259390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fjpet.119.259390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31562201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2019&pages=602-614&author=C.+J.+Jordanauthor=B.+A.+Humburgauthor=E.+B.+Thorndikeauthor=A.+B.+Shaikauthor=Z.-X.+Xiauthor=M.+H.+Baumannauthor=A.+H.+Newmanauthor=C.+W.+Schindler&title=Newly+developed+dopamine+D3+receptor+antagonists%2C+R-VK4-40+and+R-VK4-116%2C+do+not+potentiate+cardiovascular+effects+of+cocaine+or+oxycodone+in+rats&doi=10.1124%2Fjpet.119.259390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Newly developed Dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree A.; Thorndike, Eric B.; Shaik, Anver Basha; Xi, Zheng-Xiong; Baumann, Michael H.; Newman, Amy Hauck; Schindler, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid and cocaine abuse are major public health burdens.  Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder.  Dopamine D3 receptor (D3R) antagonists have shown promise in attenuating opioid and cocaine reward and mitigating relapse in preclin. models.  However, translation of D3R antagonists to the clinic has been hampered by reports that the D3R antagonists GSK598,809 (5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole) and SB-277,011A (2-(2-((1r,4r)-4-(2-oxo-2-(quinolin-4-yl)ethyl)cyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile) have adverse cardiovascular effects in the presence of cocaine.  Recently, we developed two structurally novel D3R antagonists, R-VK4-40 and R-VK4-116, which are highly selective for D3R and display translational potential for treatment of opioid use disorder.  Here, we tested whether R-VK4-40 ((R)-N-(4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) and R-VK4-116 ((R)-N-(4-(4-(3-Chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) have unwanted cardiovascular effects in the presence of oxycodone, a prescription opioid, or cocaine in freely moving rats fitted with surgically implanted telemetry transmitters.  We also examd. cardiovascular effects of the D3R antagonist, SB-277,011A, and L-741,626 (1-((1H-indol-3-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol), a dopamine D2 receptor-selective antagonist, for comparison.  Consistent with prior reports, SB-277,011A increased blood pressure, heart rate, and locomotor activity alone and in the presence of cocaine.  L-741,626 increased blood pressure and heart rate.  In contrast, R-VK4-40 alone dose-dependently reduced blood pressure and heart rate and attenuated oxycodone-induced increases in blood pressure and oxycodone or cocaine-induced increases in heart rate.  Similarly, R-VK4-116 alone dose-dependently reduced cocaine-induced increases in blood pressure and heart rate.  These results highlight the safety of new D3R antagonists and support the continued development of R-VK4-40 and R-VK4-116 for the treatment of opioid and cocaine use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvUfnNpZtkLVg90H21EOLACvtfcHk0lhktpBn_nW0-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D&md5=5fe7b8a11ae2083e6d78b2123bdd6fde</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.259390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.259390%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%2BA.%26aulast%3DThorndike%26aufirst%3DE.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DNewly%2520developed%2520dopamine%2520D3%2520receptor%2520antagonists%252C%2520R-VK4-40%2520and%2520R-VK4-116%252C%2520do%2520not%2520potentiate%2520cardiovascular%2520effects%2520of%2520cocaine%2520or%2520oxycodone%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D371%26spage%3D602%26epage%3D614%26doi%3D10.1124%2Fjpet.119.259390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsch, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portenoy, R. K.</span></span> <span> </span><span class="NLM_article-title">Opioids and the treatment of chronic pain: controversies, current status, and future directions</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1037/a0013628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1037%2Fa0013628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=18837637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BD1cnksFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=405-416&author=A.+Rosenblumauthor=L.+A.+Marschauthor=H.+Josephauthor=R.+K.+Portenoy&title=Opioids+and+the+treatment+of+chronic+pain%3A+controversies%2C+current+status%2C+and+future+directions&doi=10.1037%2Fa0013628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids and the treatment of chronic pain: controversies, current status, and future directions</span></div><div class="casAuthors">Rosenblum Andrew; Marsch Lisa A; Joseph Herman; Portenoy Russell K</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">405-16</span>
        ISSN:<span class="NLM_cas:issn">1064-1297</span>.
    </div><div class="casAbstract">Opioids have been regarded for millennia as among the most effective drugs for the treatment of pain.  Their use in the management of acute severe pain and chronic pain related to advanced medical illness is considered the standard of care in most of the world.  In contrast, the long-term administration of an opioid for the treatment of chronic noncancer pain continues to be controversial.  Concerns related to effectiveness, safety, and abuse liability have evolved over decades, sometimes driving a more restrictive perspective and sometimes leading to a greater willingness to endorse this treatment.  The past several decades in the United States have been characterized by attitudes that have shifted repeatedly in response to clinical and epidemiological observations, and events in the legal and regulatory communities.  The interface between the legitimate medical use of opioids to provide analgesia and the phenomena associated with abuse and addiction continues to challenge the clinical community, leading to uncertainty about the appropriate role of these drugs in the treatment of pain.  This narrative review briefly describes the neurobiology of opioids and then focuses on the complex issues at this interface between analgesia and abuse, including terminology, clinical challenges, and the potential for new agents, such as buprenorphine, to influence practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_kTYYpznRzOkdrW1FkXG-fW6udTcc2ebExgSDC7OrMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnksFGgsA%253D%253D&md5=cbbbc8151dd35cc18a0287a00cfd2137</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1037%2Fa0013628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252Fa0013628%26sid%3Dliteratum%253Aachs%26aulast%3DRosenblum%26aufirst%3DA.%26aulast%3DMarsch%26aufirst%3DL.%2BA.%26aulast%3DJoseph%26aufirst%3DH.%26aulast%3DPortenoy%26aufirst%3DR.%2BK.%26atitle%3DOpioids%2520and%2520the%2520treatment%2520of%2520chronic%2520pain%253A%2520controversies%252C%2520current%2520status%252C%2520and%2520future%2520directions%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2008%26volume%3D16%26spage%3D405%26epage%3D416%26doi%3D10.1037%2Fa0013628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripoll, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beakley, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urman, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manchikanti, L.</span></span> <span> </span><span class="NLM_article-title">Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">S93</span>– <span class="NLM_lpage">S109</span>, <span class="refDoi"> DOI: 10.36076/ppj.2017.s109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.36076%2Fppj.2017.s109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=S93-S109&author=A.+D.+Kayeauthor=M.+R.+Jonesauthor=A.+M.+Kayeauthor=J.+G.+Ripollauthor=V.+Galanauthor=B.+D.+Beakleyauthor=F.+Calixtoauthor=J.+L.+Boldenauthor=R.+D.+Urmanauthor=L.+Manchikanti&title=Prescription+opioid+abuse+in+chronic+pain%3A+an+updated+review+of+opioid+abuse+predictors+and+strategies+to+curb+opioid+abuse%3A+part+1&doi=10.36076%2Fppj.2017.s109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.36076%2Fppj.2017.s109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.36076%252Fppj.2017.s109%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DA.%2BD.%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DKaye%26aufirst%3DA.%2BM.%26aulast%3DRipoll%26aufirst%3DJ.%2BG.%26aulast%3DGalan%26aufirst%3DV.%26aulast%3DBeakley%26aufirst%3DB.%2BD.%26aulast%3DCalixto%26aufirst%3DF.%26aulast%3DBolden%26aufirst%3DJ.%2BL.%26aulast%3DUrman%26aufirst%3DR.%2BD.%26aulast%3DManchikanti%26aufirst%3DL.%26atitle%3DPrescription%2520opioid%2520abuse%2520in%2520chronic%2520pain%253A%2520an%2520updated%2520review%2520of%2520opioid%2520abuse%2520predictors%2520and%2520strategies%2520to%2520curb%2520opioid%2520abuse%253A%2520part%25201%26jtitle%3DPain%2520Physician%26date%3D2017%26volume%3D2%26spage%3DS93%26epage%3DS109%26doi%3D10.36076%2Fppj.2017.s109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scuteri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagetta, G.</span></span> <span> </span><span class="NLM_article-title">Opioids resistance in chronic pain management</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.2174/1570159x14666161101092822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2174%2F1570159X14666161101092822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=28503117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=444-456&author=L.+Morroneauthor=D.+Scuteriauthor=L.+Rombolaauthor=H.+Mizoguchiauthor=G.+Bagetta&title=Opioids+resistance+in+chronic+pain+management&doi=10.2174%2F1570159x14666161101092822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids Resistance in Chronic Pain Management</span></div><div class="casAuthors">Morrone, Luigi A.; Scuteri, Damiana; Rombola, Laura; Mizoguchi, Hirokazu; Bagetta, Giacinto</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-456</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Chronic pain management represents a serious healthcare problem worldwide.  Chronic pain affects approx. 20% of the adult European population and is more frequent in women and older people.  Unfortunately, its management in the community remains generally unsatisfactory and rarely under the control of currently available analgesics.  Opioids have been used as analgesics for a long history and are among the most used drugs; however, while there is no debate over their short term use for pain management, limited evidence supports their efficacy of long-term treatment for chronic noncancer pain.  Therapy with opioids is hampered by inter-individual variability and serious side effects and some opioids often result ineffective in the treatment of chronic pain and their use is controversial.  Accordingly, for a better control of chronic pain a deeper knowledge of the mol. mechanisms underlying resistance to opiates is mandatory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt-0LCXx1xEbVg90H21EOLACvtfcHk0ljswSwNbPaQJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2iurw%253D&md5=e4b7ec166e89c8859fa88e9408471d96</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1570159X14666161101092822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X14666161101092822%26sid%3Dliteratum%253Aachs%26aulast%3DMorrone%26aufirst%3DL.%26aulast%3DScuteri%26aufirst%3DD.%26aulast%3DRombola%26aufirst%3DL.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DBagetta%26aufirst%3DG.%26atitle%3DOpioids%2520resistance%2520in%2520chronic%2520pain%2520management%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26spage%3D444%26epage%3D456%26doi%3D10.2174%2F1570159x14666161101092822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Bias factor and therapeutic window correlate to predict safer opioid analgesics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1175.e13</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.cell.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29149605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=1165-1175.e13&author=C.+L.+Schmidauthor=N.+M.+Kennedyauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Yueauthor=J.+Morgenweckauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=Bias+factor+and+therapeutic+window+correlate+to+predict+safer+opioid+analgesics&doi=10.1016%2Fj.cell.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics</span></div><div class="casAuthors">Schmid, Cullen L.; Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Morgenweck, Jenny; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1165-1175.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Biased agonism has been proposed as a means to sep. desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets.  Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit βarrestin proteins.  By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compds. spanning a wide range of signaling bias.  We find that β-arrestin-biased compds., such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfthQaadgklLVg90H21EOLACvtfcHk0lg-_x_FFs3TKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhs7vE&md5=6d3f21c03fb40bc83adbe62c3ea331fc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBias%2520factor%2520and%2520therapeutic%2520window%2520correlate%2520to%2520predict%2520safer%2520opioid%2520analgesics%26jtitle%3DCell%26date%3D2017%26volume%3D171%26spage%3D1165%26epage%3D1175.e13%26doi%3D10.1016%2Fj.cell.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Canabal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Toward directing opioid receptor signaling to refine opioid therapeutics</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2019.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.biopsych.2019.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31806082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlehtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2020&pages=15-21&author=T.+W.+Grimauthor=A.+Acevedo-Canabalauthor=L.+M.+Bohn&title=Toward+directing+opioid+receptor+signaling+to+refine+opioid+therapeutics&doi=10.1016%2Fj.biopsych.2019.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics</span></div><div class="casAuthors">Grim, Travis W.; Acevedo-Canabal, Agnes; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The mu opioid receptor (MOR) is a diversely regulated target for the alleviation of pain in the clin. setting.  However, untoward side effects such as tolerance, dependence, respiratory suppression, constipation, and abuse liability detract from the general activation of these receptors.  Studies in genetically modified rodent models suggest that activating G protein signaling pathways while avoiding phosphorylation of the receptor or recruitment of β-arrestin scaffolding proteins could preserve the analgesic properties of MOR agonists while avoiding certain side effects.  With the development of novel MOR "biased" agonists, which lead to preferential activation of G protein pathways over receptor phosphorylation, internalization, or interaction with other effectors, this hypothesis can be tested in a native, physiol. setting.  Overall, it is clear that the MOR is not a simple on-off switch and that the diverse means by which the receptor can be regulated may present an opportunity to refine therapeutics for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgAHNYSLwmLrVg90H21EOLACvtfcHk0lg-_x_FFs3TKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlehtLrP&md5=da81307c1e611b5c293bd5db953898b5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2019.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2019.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DAcevedo-Canabal%26aufirst%3DA.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DToward%2520directing%2520opioid%2520receptor%2520signaling%2520to%2520refine%2520opioid%2520therapeutics%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26volume%3D87%26spage%3D15%26epage%3D21%26doi%3D10.1016%2Fj.biopsych.2019.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoots, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venniro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaham, Y.</span></span> <span> </span><span class="NLM_article-title">Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2085</span>, <span class="refDoi"> DOI: 10.1111/ejn.13955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1111%2Fejn.13955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29779230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC1MfltVCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=2075-2085&author=J.+M.+Bossertauthor=J.+K.+Hootsauthor=I.+Fredrikssonauthor=S.+Adhikaryauthor=M.+Zhangauthor=M.+Venniroauthor=Y.+Shaham&title=Role+of+mu%2C+but+not+delta+or+kappa%2C+opioid+receptors+in+context-induced+reinstatement+of+oxycodone+seeking&doi=10.1111%2Fejn.13955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking</span></div><div class="casAuthors">Bossert Jennifer M; Hoots Jennifer K; Fredriksson Ida; Adhikary Sweta; Zhang Michelle; Venniro Marco; Shaham Yavin</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2075-2085</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Relapse to non-medical use of prescription opioids often occurs after exposure to places previously associated with drug use.  Here, we describe a rat model of context-induced reinstatement of oxycodone seeking after repeated cycles of drug self-administration and extinction-induced abstinence.  We also determined the role of mu, delta and kappa opioid receptors (MOR, DOR, KOR) in this reinstatement.  We trained rats to self-administer oxycodone for 6 h/day in context A; lever pressing was paired with a discrete cue.  Next, we extinguished the lever pressing in the presence of the discrete cue in context B and then tested the rats for reinstatement of oxycodone seeking in both contexts.  We retrained rats to self-administer oxycodone in context A, re-extinguished their lever pressing in context B and retested them for reinstatement in both contexts.  Prior to testing, we injected the rats with vehicle or antagonists of MOR (naltrexone; 0.5 or 1.0 mg/kg), DOR (naltrindole; 7.5 or 15 mg/kg) or KOR (LY2456302; 5 or 10 mg/kg).  We also tested the effect of naltrexone, naltrindole and LY2456302 on oxycodone self-administration under fixed-ratio-1 (FR1) and progressive ratio (PR) reinforcement schedules.  We observed context-induced reinstatement of oxycodone seeking after repeated cycles of drug self-administration and extinction.  Naltrexone, but not naltrindole or LY2456302, injections decreased this reinstatement.  Additionally, naltrexone increased oxycodone self-administration under the FR1 schedule and decreased oxycodone self-administration under the PR schedule; naltrindole and LY2456302 were ineffective.  Results demonstrate a critical role of MOR, but not DOR or KOR, in context-induced reinstatement of oxycodone seeking and oxycodone self-administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuqvBaKT2wzQvupmecNw_lfW6udTcc2eYrkNV3HicSBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfltVCgsg%253D%253D&md5=9c444f57d0a5dbbd661cb61a76926d5c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fejn.13955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejn.13955%26sid%3Dliteratum%253Aachs%26aulast%3DBossert%26aufirst%3DJ.%2BM.%26aulast%3DHoots%26aufirst%3DJ.%2BK.%26aulast%3DFredriksson%26aufirst%3DI.%26aulast%3DAdhikary%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DVenniro%26aufirst%3DM.%26aulast%3DShaham%26aufirst%3DY.%26atitle%3DRole%2520of%2520mu%252C%2520but%2520not%2520delta%2520or%2520kappa%252C%2520opioid%2520receptors%2520in%2520context-induced%2520reinstatement%2520of%2520oxycodone%2520seeking%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2019%26volume%3D50%26spage%3D2075%26epage%3D2085%26doi%3D10.1111%2Fejn.13955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantouli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Canabal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">A G protein signaling-biased agonist at the mu-opioid receptor reverses morphine tolerance while preventing morphine withdrawal</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41386-019-0491-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41386-019-0491-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31443104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12gsrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=416-425&author=T.+W.+Grimauthor=C.+L.+Schmidauthor=E.+L.+Stahlauthor=F.+Pantouliauthor=J.-H.+Hoauthor=A.+Acevedo-Canabalauthor=N.+M.+Kennedyauthor=M.+D.+Cameronauthor=T.+D.+Bannisterauthor=L.+M.+Bohn&title=A+G+protein+signaling-biased+agonist+at+the+mu-opioid+receptor+reverses+morphine+tolerance+while+preventing+morphine+withdrawal&doi=10.1038%2Fs41386-019-0491-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal</span></div><div class="casAuthors">Grim, Travis W.; Schmid, Cullen L.; Stahl, Edward L.; Pantouli, Fani; Ho, Jo-Hao; Acevedo-Canabal, Agnes; Kennedy, Nicole M.; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">416-425</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">It has been demonstrated that opioid agonists that preferentially act at μ-opioid receptors to activate G protein signaling over βarrestin 2 recruitment produce antinociception with less respiratory suppression.  However, most of the adverse effects assocd. with opioid therapeutics are realized after extended dosing.  Therefore, we tested the onset of tolerance and dependence, and assessed for neurochem. changes assocd. with prolonged treatment with the biased agonist SR-17018.  When chronically administered to mice, SR-17018 does not lead to hot plate antinociceptive tolerance, receptor desensitization in periaqueductal gray, nor a super-sensitization of adenylyl cyclase in the striatum, which are hallmarks of opioid neuronal adaptations that are seen with morphine.  Interestingly, substitution with SR-17018 in morphine-tolerant mice restores morphine potency and efficacy, whereas the onset of opioid withdrawal is prevented.  This is in contrast to buprenorphine, which can suppress withdrawal, but produces and maintains morphine antinociceptive tolerance.  Biased agonists of this nature may therefore be useful for the treatment of opioid dependence while restoring opioid antinociceptive sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWBdsWXtDfrVg90H21EOLACvtfcHk0liC-TPc-8_DLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12gsrrM&md5=72ca93a6cdfc8fb26e821ccea132115d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41386-019-0491-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-019-0491-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DPantouli%26aufirst%3DF.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DAcevedo-Canabal%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DA%2520G%2520protein%2520signaling-biased%2520agonist%2520at%2520the%2520mu-opioid%2520receptor%2520reverses%2520morphine%2520tolerance%2520while%2520preventing%2520morphine%2520withdrawal%26jtitle%3DNeuropsychopharmacology%26date%3D2020%26volume%3D45%26spage%3D416%26epage%3D425%26doi%3D10.1038%2Fs41386-019-0491-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8895</span>– <span class="NLM_lpage">8907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12isr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8895-8907&author=N.+M.+Kennedyauthor=C.+L.+Schmidauthor=N.+C.+Rossauthor=K.+M.+Lovellauthor=Z.+Yueauthor=Y.+T.+Chenauthor=M.+D.+Cameronauthor=L.+M.+Bohnauthor=T.+D.+Bannister&title=Optimization+of+a+series+of+mu+opioid+receptor+%28MOR%29+agonists+with+high+G+protein+signaling+bias&doi=10.1021%2Facs.jmedchem.8b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias</span></div><div class="casAuthors">Kennedy, Nicole M.; Schmid, Cullen L.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Chen, Yen Ting; Cameron, Michael D.; Bohn, Laura M.; Bannister, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8895-8907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While mu opioid receptor (MOR) agonists are esp. effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear sepn. of analgesia from many problematic side effects.  Recently, MOR agonists that induce minimal βarrestin-mediated signaling were extensively investigated because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis.  Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents.  It was recently shown that, within a chem. series, the degree of bias correlates linearly with the magnitude of the respiratory safety index.  Herein, the synthesis and optimization of (piperidinyl)benzimidazolone MOR agonists I (R1 = H, 4-Cl, 5-Me, 5-CN, 5,6-Cl2, etc.; R2 = H, Me; R3 = Ph, 2-ClC6H4, 2-F-4-BrC6H3, etc.) and analogs that display a wide range of bias (G/βarr2) is described.  The structural features affecting potency and maximizing bias were identified and many compds. were shown to have desirable properties, such as long half-lives and high brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI7BvhzTWgOLVg90H21EOLACvtfcHk0lh7_j9tRwcaPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12isr7I&md5=7ebd89b52ecdb593170b4151f1e5cccd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01136%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DN.%2BM.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DRoss%26aufirst%3DN.%2BC.%26aulast%3DLovell%26aufirst%3DK.%2BM.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%2520mu%2520opioid%2520receptor%2520%2528MOR%2529%2520agonists%2520with%2520high%2520G%2520protein%2520signaling%2520bias%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8895%26epage%3D8907%26doi%3D10.1021%2Facs.jmedchem.8b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imam, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassabian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span> <span> </span><span class="NLM_article-title">Intracerebroventricular administration of CYX-6, a potent mu-opioid receptor agonist, a delta- and kappa-opioid receptor antagonist and a biased ligand at mu, delta & kappa-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>871</i></span>,  <span class="NLM_fpage">172918</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2020.172918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.ejphar.2020.172918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=31958457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFehsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=871&publication_year=2020&pages=172918&author=M.+Z.+Imamauthor=A.+Kuoauthor=S.+Ghassabianauthor=Y.+Caiauthor=Y.+Qinauthor=T.+Liauthor=M.+T.+Smith&title=Intracerebroventricular+administration+of+CYX-6%2C+a+potent+mu-opioid+receptor+agonist%2C+a+delta-+and+kappa-opioid+receptor+antagonist+and+a+biased+ligand+at+mu%2C+delta+%26+kappa-opioid+receptors%2C+evokes+antinociception+with+minimal+constipation+and+respiratory+depression+in+rats+in+contrast+to+morphine&doi=10.1016%2Fj.ejphar.2020.172918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine</span></div><div class="casAuthors">Imam, Mohammad Zafar; Kuo, Andy; Ghassabian, Sussan; Cai, Yunxin; Qin, Yajuan; Li, Tingyou; Smith, Maree T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">871</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172918</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mu opioid receptor (MOPr) agonists are thought to produce analgesia via modulation of G-protein-coupled intracellular signalling pathways whereas the β-arrestin2 pathway is proposed to mediate opioid-related adverse effects.  Here, we report the antinociception, constipation and respiratory depressant profile of CYX-6, a potent MOPr agonist that is also a delta and a kappa opioid receptor (DOPr/KOPr) antagonist and that lacks β-arrestin2 recruitment at each of the MOPr, DOPr and the KOPr.  In anesthetized male Sprague Dawley rats, an intracerebroventricular (i.c.v.) guide cannula was stereotaxically implanted.  After 5-7 days post-surgical recovery, rats received a single i.c.v. bolus dose of CYX-6 (3-30 nmol), morphine (100 nmol) or vehicle.  Antinociception was assessed using the warm water tail flick test (52.5 ± 0.5°C).  Constipation was assessed using the charcoal meal gut motility test and the castor oil-induced diarrhoea test.  Respiratory depression was measured by whole-body plethysmog. in awake, freely moving animals, upon exposure to a hypercapnic gas mixt. (8% CO2, 21% O2 and 71% N2).  The intrinsic pharmacol. of CYX-6 given by the i.c.v. route in rats showed that it produced dose-dependent antinociception.  It also produced respiratory stimulation rather than depression and it had a minimal effect on intestinal motility in contrast to the pos. control, morphine.  CYX-6 is an endomorphin-2 analog that dissocs. antinociception from constipation and respiratory depression in rats.  Our findings provide useful insight to inform the discovery and development of novel opioid analgesics with a superior tolerability profile compared with morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6tkHb8Z7Ll7Vg90H21EOLACvtfcHk0lh7_j9tRwcaPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFehsLY%253D&md5=a92653c75b0e20f14d29c836739df17c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2020.172918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2020.172918%26sid%3Dliteratum%253Aachs%26aulast%3DImam%26aufirst%3DM.%2BZ.%26aulast%3DKuo%26aufirst%3DA.%26aulast%3DGhassabian%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26atitle%3DIntracerebroventricular%2520administration%2520of%2520CYX-6%252C%2520a%2520potent%2520mu-opioid%2520receptor%2520agonist%252C%2520a%2520delta-%2520and%2520kappa-opioid%2520receptor%2520antagonist%2520and%2520a%2520biased%2520ligand%2520at%2520mu%252C%2520delta%2520%2526%2520kappa-opioid%2520receptors%252C%2520evokes%2520antinociception%2520with%2520minimal%2520constipation%2520and%2520respiratory%2520depression%2520in%2520rats%2520in%2520contrast%2520to%2520morphine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D871%26spage%3D172918%26doi%3D10.1016%2Fj.ejphar.2020.172918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sianati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08162-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41467-018-08162-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30664663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367&author=A.+Kliewerauthor=F.+Schmiedelauthor=S.+Sianatiauthor=A.+Baileyauthor=J.+T.+Batemanauthor=E.+S.+Levittauthor=J.+T.+Williamsauthor=M.+J.+Christieauthor=S.+Schulz&title=Phosphorylation-deficient+G-protein-biased+mu-opioid+receptors+improve+analgesia+and+diminish+tolerance+but+worsen+opioid+side+effects&doi=10.1038%2Fs41467-018-08162-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span></div><div class="casAuthors">Kliewer, A.; Schmiedel, F.; Sianati, S.; Bailey, A.; Bateman, J. T.; Levitt, E. S.; Williams, J. T.; Christie, M. J.; Schulz, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops.  The mol. mechanisms initiating tolerance have remained unresolved to date.  We have previously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is controlled by carboxyl-terminal phosphorylation.  Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit beta-arrestins.  Desensitization is inhibited in locus coeruleus neurons of mutant mice.  Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished.  Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that beta-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased mu-agonists are still likely to elicit severe adverse effects.  In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEj4ARbzSS7Vg90H21EOLACvtfcHk0lhZ3R725loaSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D&md5=19fa2354d75d29b28503d21f63754d45</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08162-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08162-1%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DSianati%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBateman%26aufirst%3DJ.%2BT.%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DPhosphorylation-deficient%2520G-protein-biased%2520mu-opioid%2520receptors%2520improve%2520analgesia%2520and%2520diminish%2520tolerance%2520but%2520worsen%2520opioid%2520side%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D367%26doi%3D10.1038%2Fs41467-018-08162-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montandon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victoria, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, R. L.</span></span> <span> </span><span class="NLM_article-title">G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1097/aln.0000000000000984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1097%2FALN.0000000000000984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26675532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=641-650&author=G.+Montandonauthor=J.+Renauthor=N.+C.+Victoriaauthor=H.+Liuauthor=K.+Wickmanauthor=J.+J.+Greerauthor=R.+L.+Horner&title=G-protein-gated+inwardly+rectifying+potassium+channels+modulate+respiratory+depression+by+opioids&doi=10.1097%2Faln.0000000000000984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids</span></div><div class="casAuthors">Montandon, Gaspard; Ren, Jun; Victoria, Nicole C.; Liu, Hattie; Wickman, Kevin; Greer, John J.; Horner, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">641-650</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Drugs acting on μ-opioid receptors (MORs) are widely used as analgesics but present side effects including life-threatening respiratory depression.  MORs are G-protein-coupled receptors inhibiting neuronal activity through calcium channels, adenylyl cyclase, and/or G-protein-gated inwardly rectifying potassium (GIRK) channels.  The pathways underlying MOR-dependent inhibition of rhythmic breathing are unknown.  Methods: By using a combination of genetic, pharmacol., and physiol. tools in rodents in vivo, the authors aimed to identify the role of GIRK channels in MOR-mediated inhibition of respiratory circuits.  Results: GIRK channels were expressed in the ventrolateral medulla, a neuronal population regulating rhythmic breathing, and GIRK channel activation with flupirtine reduced respiratory rate in rats (percentage of baseline rate in mean ± SD: 79.4 ± 7.4%, n = 7), wild-type mice (82.6 ± 3.8%, n = 3), but not in mice lacking the GIRK2 subunit, an integral subunit of neuronal GIRK channels (GIRK2, 101.0 ± 1.9%, n = 3).  Application of the MOR agonist [D-Ala, N-MePhe, Gly-ol]-enkephalin (DAMGO) to the ventrolateral medulla depressed respiratory rate, an effect partially reversed by the GIRK channel blocker Tertiapin-Q (baseline: 42.1 ± 7.4 breath/min, Damgo: 26.1 ± 13.4 breath/min, Tertiapin-Q + Damgo: 33.9 ± 9.8 breath/min, n = 4).  Importantly, DAMGO applied to the ventrolateral medulla failed to reduce rhythmic breathing in GIRK2 mice (percentage of baseline rate: 103.2 ± 12.1%, n = 4), whereas it considerably reduced rate in wild-type mice (62.5 ± 17.7% of baseline, n = 4).  Respiratory rate depression by systemic injection of the opioid analgesic fentanyl was markedly reduced in GIRK2 (percentage of baseline: 12.8 ± 15.8%, n = 5) compared with wild-type mice (72.9 ± 27.3%).  Conclusions: Overall, these results identify that GIRK channels contribute to respiratory inhibition by MOR, an essential step toward understanding respiratory depression by opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn3IRBnyEdBrVg90H21EOLACvtfcHk0lhZ3R725loaSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFGlu7w%253D&md5=fda08f10b9a6c994c9535a1b1c6932e4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1097%2FALN.0000000000000984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0000000000000984%26sid%3Dliteratum%253Aachs%26aulast%3DMontandon%26aufirst%3DG.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DVictoria%26aufirst%3DN.%2BC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWickman%26aufirst%3DK.%26aulast%3DGreer%26aufirst%3DJ.%2BJ.%26aulast%3DHorner%26aufirst%3DR.%2BL.%26atitle%3DG-protein-gated%2520inwardly%2520rectifying%2520potassium%2520channels%2520modulate%2520respiratory%2520depression%2520by%2520opioids%26jtitle%3DAnesthesiology%26date%3D2016%26volume%3D124%26spage%3D641%26epage%3D650%26doi%3D10.1097%2Faln.0000000000000984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdala, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span> <span> </span><span class="NLM_article-title">mu opioid receptor activation hyperpolarizes respiratory-controlling Kolliker-Fuse neurons and suppresses post-inspiratory drive</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">4453</span>– <span class="NLM_lpage">4469</span>, <span class="refDoi"> DOI: 10.1113/jp270822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1113%2FJP270822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26175072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2015&pages=4453-4469&author=E.+S.+Levittauthor=A.+P.+Abdalaauthor=J.+F.+R.+Patonauthor=J.+M.+Bissonnetteauthor=J.+T.+Williams&title=mu+opioid+receptor+activation+hyperpolarizes+respiratory-controlling+Kolliker-Fuse+neurons+and+suppresses+post-inspiratory+drive&doi=10.1113%2Fjp270822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">μ opioid receptor activation hyperpolarizes respiratory-controlling Koelliker-Fuse neurons and suppresses post-inspiratory drive</span></div><div class="casAuthors">Levitt, Erica S.; Abdala, Ana P.; Paton, Julian F. R.; Bissonnette, John M.; Williams, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4453-4469</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">1469-7793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Opioid-induced respiratory effects include aspiration and difficulty swallowing, suggesting impairment of the upper airways.  The pontine Koelliker-Fuse nucleus (KF) controls upper airway patency and regulates respiration, in particular the inspiratory/expiratory phase transition.  Given the importance of the KF in coordinating respiratory pattern, the mechanisms of μ opioid receptor activation in this nucleus were investigated at the systems and cellular level.  In anesthetized, vagi-intact rats, injection of opioid agonists DAMGO or [Met5]enkephalin (ME) into the KF reduced respiratory frequency and amplitude.  The μ opioid agonist DAMGO applied directly into the KF of the in situ arterially perfused working heart-brainstem prepn. of rat resulted in robust apneusis (lengthened low amplitude inspiration due to loss of post-inspiratory drive) that was rapidly reversed by the opioid antagonist naloxone.  In brain slice prepns., activation of μ opioid receptors on KF neurons hyperpolarized a distinct population (61%) of neurons.  As expected, the opioid-induced hyperpolarization reduced the excitability of the neuron in response to either current injection or local application of glutamate.  In voltage-clamp recordings the outward current produced by the opioid agonist ME was concn. dependent, reversed at the potassium equil. potential and was blocked by BaCl2, characteristics of a G protein-coupled inwardly rectifying potassium (GIRK) conductance.  The clin. used drug morphine produced an outward current in KF neurons with similar potency to morphine-mediated currents in locus coeruleus brain slice prepns.  Thus, the population of KF neurons that are hyperpolarized by μ opioid agonists are likely mediators of the opioid-induced loss of post-inspiration and induction of apneusis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9jCfamKM7ArVg90H21EOLACvtfcHk0lhQFedY1f7PUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLzI&md5=6ca013cbf8dd47b28a29db63cb679964</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1113%2FJP270822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252FJP270822%26sid%3Dliteratum%253Aachs%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DAbdala%26aufirst%3DA.%2BP.%26aulast%3DPaton%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DBissonnette%26aufirst%3DJ.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26atitle%3Dmu%2520opioid%2520receptor%2520activation%2520hyperpolarizes%2520respiratory-controlling%2520Kolliker-Fuse%2520neurons%2520and%2520suppresses%2520post-inspiratory%2520drive%26jtitle%3DJ.%2520Physiol.%26date%3D2015%26volume%3D593%26spage%3D4453%26epage%3D4469%26doi%3D10.1113%2Fjp270822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbarali, H. I.</span></span> <span> </span><span class="NLM_article-title">Molecular physiology of enteric opioid receptors</span>. <i>Am. J. Gastroenterol. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1038/ajgsup.2014.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fajgsup.2014.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=25207608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyit7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=17-21&author=J.+J.+Galliganauthor=H.+I.+Akbarali&title=Molecular+physiology+of+enteric+opioid+receptors&doi=10.1038%2Fajgsup.2014.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Physiology of Enteric Opioid Receptors</span></div><div class="casAuthors">Galligan, James J.; Akbarali, Hamid I.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology Supplements</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-21</span>CODEN:
                <span class="NLM_cas:coden">AJGSAD</span>;
        ISSN:<span class="NLM_cas:issn">1948-9501</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Opioid drugs have powerful antidiarrheal effects and many patients taking these drugs for chronic pain relief experience chronic constipation that can progress to opioid-induced bowel dysfunction.  Three classes of opioid receptors are expressed by enteric neurons: μ-, δ-, and κ-opioid receptors (MOR, DOR, and KOR).  MOR and DOR couple to inhibition of adenylate cylase and nerve terminal Ca2+ channels and activation of K+ channels.  These effects reduce neuronal activity and neurotransmitter release.  KOR couples to inhibition of Ca2+ channels and inhibition of neurotransmitter release.  In the human gastrointestinal tract, MOR, DOR, and KOR link to inhibition of acetylcholine release from enteric interneurons and purine/nitric oxide release from inhibitory motorneurons.  These actions inhibit propulsive motility.  MOR and DOR also link to inhibition of submucosal secretomotor neurons, reducing active Cl- secretion and passive water movement into the colonic lumen.  These effects account for the constipation caused by opioid receptor agonists.  Tolerance develops to the analgesic effects of opioid receptor agonists but not to the constipating actions.  This may be due to differential β-arrestin-2-dependent opioid receptor desensitization and internalization in enteric nerves in the colon compared with the small intestine and in neuronal pain pathways.  Further studies of differential opioid receptor desensitization and tolerance in subsets of enteric neurons may identify new drugs or other treatment strategies of opioid-induced bowel dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQvx-dYsVoLVg90H21EOLACvtfcHk0lhQFedY1f7PUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyit7vJ&md5=b5cda786613426030de1af4ee56ff0eb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fajgsup.2014.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajgsup.2014.5%26sid%3Dliteratum%253Aachs%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DAkbarali%26aufirst%3DH.%2BI.%26atitle%3DMolecular%2520physiology%2520of%2520enteric%2520opioid%2520receptors%26jtitle%3DAm.%2520J.%2520Gastroenterol.%2520Suppl.%26date%3D2014%26volume%3D2%26spage%3D17%26epage%3D21%26doi%3D10.1038%2Fajgsup.2014.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Morphine-induced respiratory depression is independent of beta-arrestin2 signalling</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">2923</span>– <span class="NLM_lpage">2931</span>, <span class="refDoi"> DOI: 10.1111/bph.15004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1111%2Fbph.15004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32052419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFersLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2020&pages=2923-2931&author=A.+Kliewerauthor=A.+Gillisauthor=R.+Hillauthor=F.+Schmiedelauthor=C.+Baileyauthor=E.+Kellyauthor=G.+Hendersonauthor=M.+J.+Christieauthor=S.+Schulz&title=Morphine-induced+respiratory+depression+is+independent+of+beta-arrestin2+signalling&doi=10.1111%2Fbph.15004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine-induced respiratory depression is independent of β-arrestin2 signalling</span></div><div class="casAuthors">Kliewer, Andrea; Gillis, Alexander; Hill, Rob; Schmidel, Frank; Bailey, Chris; Kelly, Eamonn; Henderson, Graeme; Christie, MacDonald J.; Schulz, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2923-2931</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPCRs can signal through both G proteins and β-arrestin2.  For the μ-opioid receptor, early exptl. evidence from a single study suggested that G protein signalling mediates analgesia, whereas β-arrestin2 signalling mediates respiratory depression and constipation.  Consequently, for more than a decade, much research effort has been focused on developing biased μ-opioid agonists that preferentially target G protein signalling over β-arrestin signalling, as it was believed that such drugs would be analgesics devoid of respiratory depressant activity.  The present study was set up to re-examine opioid-induced respiratory depression in β-arrestin2 knockout mice.  To this end, a consortium was formed consisting of three different labs. located in different countries to evaluate independently opioid-induced respiratory depression.  Our consensus results unequivocally demonstrate that the prototypical μ-opioid agonist morphine as well as the potent opioid fentanyl do indeed induce respiratory depression and constipation in β-arrestin2 knockout mice in a dose-dependent manner indistinguishable from that obsd. in wild-type mice.  Our findings do not support the original suggestion that β-arrestin2 signalling plays a key role in opioid-induced respiratory depression and call into question the concept of developing G protein-biased μ-opioid receptor agonists as a strategy for the development of safer opioid analgesic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtInyxD8GRBbVg90H21EOLACvtfcHk0lhQFedY1f7PUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFersLw%253D&md5=7913eb638bb57db9a7ed8d43aab61d48</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fbph.15004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.15004%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DGillis%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DHenderson%26aufirst%3DG.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DMorphine-induced%2520respiratory%2520depression%2520is%2520independent%2520of%2520beta-arrestin2%2520signalling%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2020%26volume%3D177%26spage%3D2923%26epage%3D2931%26doi%3D10.1111%2Fbph.15004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imam, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassabian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. T.</span></span> <span> </span><span class="NLM_article-title">Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.neuropharm.2017.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29273520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCkurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=238-255&author=M.+Z.+Imamauthor=A.+Kuoauthor=S.+Ghassabianauthor=M.+T.+Smith&title=Progress+in+understanding+mechanisms+of+opioid-induced+gastrointestinal+adverse+effects+and+respiratory+depression&doi=10.1016%2Fj.neuropharm.2017.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression</span></div><div class="casAuthors">Imam, Mohammad Zafar; Kuo, Andy; Ghassabian, Sussan; Smith, Maree T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238-255</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Opioids evoke analgesia through activation of opioid receptors (predominantly the μ opioid receptor) in the central nervous system.  Opioid receptors are abundant in multiple regions of the central nervous system and the peripheral nervous system including enteric neurons.  Opioid-related adverse effects such as constipation, nausea, and vomiting pose challenges for compliance and continuation of the therapy for chronic pain management.  In the post-operative setting opioid-induced depression of respiration can be fatal.  These crit. limitations warrant a better understanding of their underpinning cellular and mol. mechanisms to inform the design of novel opioid analgesic mols. that are devoid of these unwanted side-effects.  Research efforts on opioid receptor signalling in the past decade suggest that differential signalling pathways and downstream mols. preferentially mediate distinct pharmacol. effects.  Addnl., interaction among opioid receptors and, between opioid receptor and non-opioid receptors to form signalling complexes shows that opioid-induced receptor signalling is potentially more complicated than previously thought.  This complexity provides an opportunity to identify and probe relationships between selective signalling pathway specificity and in vivo prodn. of opioid-related adverse effects.  In this review, we focus on current knowledge of the mechanisms thought to transduce opioid-induced gastrointestinal adverse effects (constipation, nausea, vomiting) and respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG2tqBIUlp0LVg90H21EOLACvtfcHk0ljNtV_qT1-vww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCkurzI&md5=92e24f72e063c55d83163e12abc89c7a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DImam%26aufirst%3DM.%2BZ.%26aulast%3DKuo%26aufirst%3DA.%26aulast%3DGhassabian%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26atitle%3DProgress%2520in%2520understanding%2520mechanisms%2520of%2520opioid-induced%2520gastrointestinal%2520adverse%2520effects%2520and%2520respiratory%2520depression%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D131%26spage%3D238%26epage%3D255%26doi%3D10.1016%2Fj.neuropharm.2017.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alamein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manandhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzwanker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katte, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsey, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">eaaz3140</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaz3140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1126%2Fscisignal.aaz3140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32234959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=A.+Gillisauthor=A.+B.+Gondinauthor=A.+Kliewerauthor=J.+Sanchezauthor=H.+D.+Limauthor=C.+Alameinauthor=P.+Manandharauthor=M.+Santiagoauthor=S.+Fritzwankerauthor=F.+Schmiedelauthor=T.+A.+Katteauthor=T.+Reekieauthor=N.+L.+Grimseyauthor=M.+Kassiouauthor=B.+Kellamauthor=C.+Kraselauthor=M.+L.+Hallsauthor=M.+Connorauthor=J.+R.+Laneauthor=S.+Schulzauthor=M.+J.+Christieauthor=M.+Canals&title=Low+intrinsic+efficacy+for+G+protein+activation+can+explain+the+improved+side+effect+profiles+of+new+opioid+agonists&doi=10.1126%2Fscisignal.aaz3140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaz3140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaz3140%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DA.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DH.%2BD.%26aulast%3DAlamein%26aufirst%3DC.%26aulast%3DManandhar%26aufirst%3DP.%26aulast%3DSantiago%26aufirst%3DM.%26aulast%3DFritzwanker%26aufirst%3DS.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DKatte%26aufirst%3DT.%2BA.%26aulast%3DReekie%26aufirst%3DT.%26aulast%3DGrimsey%26aufirst%3DN.%2BL.%26aulast%3DKassiou%26aufirst%3DM.%26aulast%3DKellam%26aufirst%3DB.%26aulast%3DKrasel%26aufirst%3DC.%26aulast%3DHalls%26aufirst%3DM.%2BL.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DLow%2520intrinsic%2520efficacy%2520for%2520G%2520protein%2520activation%2520can%2520explain%2520the%2520improved%2520side%2520effect%2520profiles%2520of%2520new%2520opioid%2520agonists%26jtitle%3DSci.%2520Signaling%26date%3D2020%26volume%3D13%26doi%3D10.1126%2Fscisignal.aaz3140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">Abuse potential of biased mu opioid receptor agonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.tips.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30343727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=916-919&author=S.+S.+Negusauthor=K.+B.+Freeman&title=Abuse+potential+of+biased+mu+opioid+receptor+agonists&doi=10.1016%2Fj.tips.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse Potential of Biased Mu Opioid Receptor Agonists</span></div><div class="casAuthors">Negus, S. Stevens; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">916-919</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics.  The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans.  Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg0Xf3TNu4LrVg90H21EOLACvtfcHk0ljHRMH4zuGBgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKisr%252FF&md5=b33e27478c5d58a4232fffad6de7412f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DAbuse%2520potential%2520of%2520biased%2520mu%2520opioid%2520receptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2018%26volume%3D39%26spage%3D916%26epage%3D919%26doi%3D10.1016%2Fj.tips.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altarifi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muchhala, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbarali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1177/0269881116689257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1177%2F0269881116689257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=28142305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=730-739&author=A.+A.+Altarifiauthor=B.+Davidauthor=K.+H.+Muchhalaauthor=B.+E.+Bloughauthor=H.+Akbaraliauthor=S.+S.+Negus&title=Effects+of+acute+and+repeated+treatment+with+the+biased+mu+opioid+receptor+agonist+TRV130+%28oliceridine%29+on+measures+of+antinociception%2C+gastrointestinal+function%2C+and+abuse+liability+in+rodents&doi=10.1177%2F0269881116689257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents</span></div><div class="casAuthors">Altarifi, Ahmad A.; David, Bethany; Muchhala, Karan H.; Blough, Bruce E.; Akbarali, Hamid; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein vs. β-arrestin signaling pathways coupled to MORs.  Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists.  This study compared the effects of acute and repeated TRV130 administration on measures of antinociception, gastrointestinal function, and abuse liability in rodents.  We hypothesized that TRV130 would produce robust and sustained antinociception and abuse-related effects during repeated treatment, but that tolerance would develop to gastrointestinal inhibition.  Antinociception was assessed using a warm-water tail-withdrawal procedure in mice.  Gastrointestinal function was assessed in mice using an in vivo measure of fecal output and in vitro assays of colonic propulsion and of colon and ileum circular muscle contraction.  Abuse liability was assessed in rats using an intracranial self-stimulation (ICSS) procedure. (+)-TRV130 was administered with acute and repeated dosing regimens, and (-)-TRV130 was also examd. in the ICSS procedure to assess stereoselectivity.  Acute (+)-TRV130 treatment produced robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects.  Repeated (+)-TRV130 treatment failed to produce tolerance to antinociception or gastrointestinal inhibition, and abuse-related effects were enhanced by repeated treatment.  Effects of acute and repeated (+)-TRV130 in these procedures resemble effects of morphine, with the exception that TRV130 antinociception was more resistant to tolerance. (-)-TRV130 was inactive.  These results suggest that TRV130 retains undesirable constipating and abuse-related effects during repeated treatment despite its bias for G-protein signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gxveeteZ2rVg90H21EOLACvtfcHk0ljHRMH4zuGBgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyit7s%253D&md5=05a231e5e3b72369d45879688b2b4e02</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F0269881116689257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881116689257%26sid%3Dliteratum%253Aachs%26aulast%3DAltarifi%26aufirst%3DA.%2BA.%26aulast%3DDavid%26aufirst%3DB.%26aulast%3DMuchhala%26aufirst%3DK.%2BH.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DAkbarali%26aufirst%3DH.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DEffects%2520of%2520acute%2520and%2520repeated%2520treatment%2520with%2520the%2520biased%2520mu%2520opioid%2520receptor%2520agonist%2520TRV130%2520%2528oliceridine%2529%2520on%2520measures%2520of%2520antinociception%252C%2520gastrointestinal%2520function%252C%2520and%2520abuse%2520liability%2520in%2520rodents%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2017%26volume%3D31%26spage%3D730%26epage%3D739%26doi%3D10.1177%2F0269881116689257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin
Zamarripa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span> <span> </span><span class="NLM_article-title">The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.drugalcdep.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30261403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOqu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2018&pages=158-162&author=C.+Austin%0AZamarripaauthor=S.+R.+Edwardsauthor=H.+N.+Qureshiauthor=J.+N.+Yiauthor=B.+E.+Bloughauthor=K.+B.+Freeman&title=The+G-protein+biased+mu-opioid+agonist%2C+TRV130%2C+produces+reinforcing+and+antinociceptive+effects+that+are+comparable+to+oxycodone+in+rats&doi=10.1016%2Fj.drugalcdep.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats</span></div><div class="casAuthors">Austin Zamarripa, C.; Edwards, Shelley R.; Qureshi, Hina N.; Yi, John N.; Blough, Bruce E.; Freeman, Kevin B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">158-162</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Mu-opioid agonists (e.g., oxycodone) are highly effective therapeutics for pain.  However, they also produce reinforcing effects that increase their likelihood of abuse.  Recent strategies in drug development have focused on opioids with biased receptor-signaling profiles that favor activation of specific intracellular pathways over others with the aim of increasing therapeutic selectivity.  TRV130, a mu agonist biased towards G-protein signaling, produces antinociceptive effects comparable to the mu agonist, morphine, but exhibits reduced side effects.  However, in terms of abuse potential, we know of no published preclin. data investigating the effects of TRV130 as a reinforcer.  In the present study, we assessed the relative reinforcing effects of TRV130 and oxycodone, a commonly-prescribed mu agonist, in rats self-administering the drugs under a progressive-ratio (PR) schedule of reinforcement.  In addn., we assessed the relative potency and efficacy of TRV130 and oxycodone in rats in a test of thermal antinociception (Hot Plate).  For self-administration, male Sprague-Dawley rats (n = 7) self-administered i.v. infusions of TRV130 or oxycodone (0.01-0.32 mg/kg/inj) under a PR schedule of reinforcement.  For the Hot-Plate test, male rats (n = 7) received s.c. injections of TRV130 (0.1-3.2 mg/kg/inj) or oxycodone (0.1-5.6 mg/kg/inj), and nociceptive response latencies were measured.  TRV130 and oxycodone were equi-potent and equi-effective in self-administration and thermal antinociception.  This study demonstrates that TRV130 produces reinforcing and antinociceptive effects that are quant. similar to oxycodone, and that a biased-signaling profile does not necessarily reduce abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraKkZQtR8C27Vg90H21EOLACvtfcHk0lg318qO01Uohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOqu7vK&md5=aa098a7b54d32678bcf21a1e1cba4e8e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%2BZamarripa%26aufirst%3DC.%26aulast%3DEdwards%26aufirst%3DS.%2BR.%26aulast%3DQureshi%26aufirst%3DH.%2BN.%26aulast%3DYi%26aufirst%3DJ.%2BN.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26atitle%3DThe%2520G-protein%2520biased%2520mu-opioid%2520agonist%252C%2520TRV130%252C%2520produces%2520reinforcing%2520and%2520antinociceptive%2520effects%2520that%2520are%2520comparable%2520to%2520oxycodone%2520in%2520rats%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2018%26volume%3D192%26spage%3D158%26epage%3D162%26doi%3D10.1016%2Fj.drugalcdep.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jullié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Zastrow, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Opioid pharmacology under the microscope</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1124/mol.119.119321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1124%2Fmol.119.119321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=32198210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFemtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2020&pages=425-432&author=D.+Julli%C3%A9author=A.+B.+Gondinauthor=M.+E.+Von+Zastrowauthor=M.+Canals&title=Opioid+pharmacology+under+the+microscope&doi=10.1124%2Fmol.119.119321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid pharmacology under the microscope</span></div><div class="casAuthors">Jullie, Damien; Gondin, Arisbel B.; von Zastrow, Mark; Canals, Meritxell</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The powerful analgesic effects of opioid drugs have captivated the interest of physicians and scientists for millennia, and the ability of opioid drugs to produce serious undesired effects has been recognized for a similar period of time.  Many of these develop progressively with prolonged or repeated drug use and then persist, motivating particular interest in understanding how opioid drugs initiate adaptive or maladaptive modifications in neural function or regulation.  Exciting advances have been made over the past several years in elucidating drug-induced changes at mol., cellular, and physiol. scales of anal.  The present review will highlight some recent cellular studies that we believe bridge across scales and will focus on optical imaging approaches that put opioid drug action "under the microscope".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwZPW2Rk2nqbVg90H21EOLACvtfcHk0lg318qO01Uohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFemtbbL&md5=1ffa0196d32d0d2159f824ba12f10dc5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.119.119321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.119.119321%26sid%3Dliteratum%253Aachs%26aulast%3DJulli%25C3%25A9%26aufirst%3DD.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DVon%2BZastrow%26aufirst%3DM.%2BE.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DOpioid%2520pharmacology%2520under%2520the%2520microscope%26jtitle%3DMol.%2520Pharmacol.%26date%3D2020%26volume%3D98%26spage%3D425%26epage%3D432%26doi%3D10.1124%2Fmol.119.119321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, H.</span></span> <span> </span><span class="NLM_article-title">A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1213/ane.0b013e3181605add</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1213%2Fane.0b013e3181605add" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=18227300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FntFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=451-462&author=T.+H.+Stanleyauthor=T.+D.+Eganauthor=H.+Van+Aken&title=A+tribute+to+Dr.+Paul+A.+J.+Janssen%3A+entrepreneur+extraordinaire%2C+innovative+scientist%2C+and+significant+contributor+to+anesthesiology&doi=10.1213%2Fane.0b013e3181605add"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology</span></div><div class="casAuthors">Stanley Theodore H; Egan Talmage D; Van Aken Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia and analgesia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-62, table of contents</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dr.  Paul Janssen was the founder of Janssen Pharmaceutica and the developer of over 80 pharmaceutical compounds that proved useful in human, botanical, and veterinary medicine.  He and his coworkers synthesized the fentanyl family of drugs, many other potent analgesics, droperidol, etomidate, and numerous other important medicines that were extremely useful in psychiatry, parasitology, gastroenterology, cardiology, virology, and immunology.  Anesthesiology and medicine as a whole have benefited a great deal from his resourcefulness, creativity, and entrepreneurial spirit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmcHm4NWcm443yKPtYViAGfW6udTcc2eZqOZGkKB0lBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FntFWhuw%253D%253D&md5=482dd39d8a7f26112483110a5859961e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1213%2Fane.0b013e3181605add&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252Fane.0b013e3181605add%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DT.%2BH.%26aulast%3DEgan%26aufirst%3DT.%2BD.%26aulast%3DVan%2BAken%26aufirst%3DH.%26atitle%3DA%2520tribute%2520to%2520Dr.%2520Paul%2520A.%2520J.%2520Janssen%253A%2520entrepreneur%2520extraordinaire%252C%2520innovative%2520scientist%252C%2520and%2520significant%2520contributor%2520to%2520anesthesiology%26jtitle%3DAnesth.%2520Analg.%26date%3D2008%26volume%3D106%26spage%3D451%26epage%3D462%26doi%3D10.1213%2Fane.0b013e3181605add" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span> <span> </span><span class="NLM_article-title">New mu-opioid receptor agonists with piperazine moiety</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1320</span>, <span class="refDoi"> DOI: 10.1248/cpb.49.1314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1248%2Fcpb.49.1314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=11605661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1Cktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=1314-1320&author=T.+Komotoauthor=T.+Okadaauthor=S.+Satoauthor=Y.+Niinoauthor=T.+Okaauthor=T.+Sakamoto&title=New+mu-opioid+receptor+agonists+with+piperazine+moiety&doi=10.1248%2Fcpb.49.1314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">New μ-opioid receptor agonists with piperazine moiety</span></div><div class="casAuthors">Komoto, Teruo; Okada, Tomomi; Sato, Susumu; Niino, Yasuhiro; Oka, Tetsuo; Sakamoto, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1314-1320</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">New μ-opioid receptor (MOR) agonists contg. piperazine and homopiperazine moieties in the structures were synthesized and their affinities to and agonist potencies on MOR were evaluated.  Among the synthesized compds., 4-[4-(2-methoxyphenyl)piperazin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide showed the highest affinity to the human MOR expressed in Chinese hamster ovary (CHO)-K1 cells, and the highest agonist potency on the MOR in isolated guinea-pig ileum prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKh67O1fK4rVg90H21EOLACvtfcHk0lj6L61CgcPyNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1Cktrk%253D&md5=e44081f644e24ad71278aab1de61dcdf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1248%2Fcpb.49.1314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.49.1314%26sid%3Dliteratum%253Aachs%26aulast%3DKomoto%26aufirst%3DT.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DNiino%26aufirst%3DY.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DT.%26atitle%3DNew%2520mu-opioid%2520receptor%2520agonists%2520with%2520piperazine%2520moiety%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2001%26volume%3D49%26spage%3D1314%26epage%3D1320%26doi%3D10.1248%2Fcpb.49.1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jevtić, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penjišević, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostić-Rajačić, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic route towards potential bivalent ligands possessing opioid and D2/D3 pharmacophores</span>. <i>J. Serb. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">647</span>, <span class="refDoi"> DOI: 10.2298/jsc181002105j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2298%2FJSC181002105J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyqsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=639-647&author=I.+Jevti%C4%87author=J.+Penji%C5%A1evi%C4%87author=M.+Ivanovi%C4%87author=S.+Kosti%C4%87-Raja%C4%8Di%C4%87&title=Synthetic+route+towards+potential+bivalent+ligands+possessing+opioid+and+D2%2FD3+pharmacophores&doi=10.2298%2Fjsc181002105j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic route towards potential bivalent ligands possessing opioid and D2/D3 pharmacophores</span></div><div class="casAuthors">Jevtic, Ivana I.; Penjisevic, Jelena Z.; Ivanovic, Milovan D.; Kostic-Rajacic, Sladana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Serbian Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">JSCSEN</span>;
        ISSN:<span class="NLM_cas:issn">0352-5139</span>.
    
            (<span class="NLM_cas:orgname">Serbian Chemical Society</span>)
        </div><div class="casAbstract">A scalable, cost-efficient and simple synthetic pathway towards potential bivalent opioid/dopamine receptor ligands was developed and optimized.  Three novel compds. that contain both opioid and dopamine pharmacophores linked by the four methylene group chain were synthesized in 33, 35 and 39% overall yield after a four-step synthetic route starting from three com. available N-aryl piperazines.  The anilino piperidine precursor was easily prepd. in three steps, as previously published, starting from 4-piperidone.  The synthesis presented in this paper could be of interest for heterocyclic and general org. chem.  The newly designed compds. possessing two pharmacophores, opioid and D2/D3, are potentially useful pharmacol. probes.  Of particular interest would be the simultaneous binding to both opioid and D2/D3 receptors, and the resulting pharmacol. responses may be useful for the further understanding of tolerance and dependence phenomena in opioid clin. use and/or abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomlRtv_iMN1rVg90H21EOLACvtfcHk0lj6L61CgcPyNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyqsb3L&md5=32c4c8b7581b6d93fb6c4ab298f55e0e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2298%2FJSC181002105J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2298%252FJSC181002105J%26sid%3Dliteratum%253Aachs%26aulast%3DJevti%25C4%2587%26aufirst%3DI.%26aulast%3DPenji%25C5%25A1evi%25C4%2587%26aufirst%3DJ.%26aulast%3DIvanovi%25C4%2587%26aufirst%3DM.%26aulast%3DKosti%25C4%2587-Raja%25C4%258Di%25C4%2587%26aufirst%3DS.%26atitle%3DSynthetic%2520route%2520towards%2520potential%2520bivalent%2520ligands%2520possessing%2520opioid%2520and%2520D2%252FD3%2520pharmacophores%26jtitle%3DJ.%2520Serb.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D84%26spage%3D639%26epage%3D647%26doi%3D10.2298%2Fjsc181002105j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jevtić, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penjišević, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savić-Vujović, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srebro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vučković, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanović, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostić-Rajačić, S.</span></span> <span> </span><span class="NLM_article-title">mi-Opioid/D2 dopamine receptor pharmacophore containing ligands: Synthesis and pharmacological evaluation</span>. <i>J. Serb. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.2298/jsc190912118j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.2298%2FJSC190912118J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GlsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=711-720&author=I.+Jevti%C4%87author=J.+Penji%C5%A1evi%C4%87author=K.+Savi%C4%87-Vujovi%C4%87author=D.+Srebroauthor=S.+Vu%C4%8Dkovi%C4%87author=M.+Ivanovi%C4%87author=S.+Kosti%C4%87-Raja%C4%8Di%C4%87&title=mi-Opioid%2FD2+dopamine+receptor+pharmacophore+containing+ligands%3A+Synthesis+and+pharmacological+evaluation&doi=10.2298%2Fjsc190912118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">μ-opioid/D2 dopamine receptor pharmacophore containing ligands: synthesis and pharmacological evaluation</span></div><div class="casAuthors">Jevtic, Ivana I.; Penjisevic, Jelena Z.; Savic-Vujovic, Katarina R.; Srebro, Dragana P.; Vuckovic, Sonja M.; Ivanovic, Milovan D.; Kostic-Rajacic, Sladana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Serbian Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">711-720</span>CODEN:
                <span class="NLM_cas:coden">JSCSEN</span>;
        ISSN:<span class="NLM_cas:issn">1820-7421</span>.
    
            (<span class="NLM_cas:orgname">Serbian Chemical Society</span>)
        </div><div class="casAbstract">Herein, the synthesis and pharmacol. evaluation of 13 novel compds., designed as potential heterobivalent ligands for μ-opioid receptor (MOR) and dopamine D2 receptors (D2DAR), are reported.  The compds. consisted of anilido piperidine and N-aryl piperazine moieties, joined by a variable-length methylene linker.  The two moieties represent MOR and D2DAR pharmacophores, resp.  The synthesis encompassed four steps, securing the final products in 28-42 % overall yields.  The approach has a considerable synthetic potential, providing access to various related structures.  Pharmacol. tests involved in vitro competitive assay for D2DAR using [3H] spiperon, as a std. radioligand, and in vivo antinociceptive tests for MOR.  The measured dopamine affinities were modest to low, while antinociceptive activity was completely absent.  Therefore, the compds. of the general structure prepd. in this research are unlikely to be useful as opioid-dopamine receptor heterobivalent ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0E8S6_kOJebVg90H21EOLACvtfcHk0lgURnqUGBHoXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GlsrbM&md5=74487b8b08067d67340706b133d3b7c2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2298%2FJSC190912118J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2298%252FJSC190912118J%26sid%3Dliteratum%253Aachs%26aulast%3DJevti%25C4%2587%26aufirst%3DI.%26aulast%3DPenji%25C5%25A1evi%25C4%2587%26aufirst%3DJ.%26aulast%3DSavi%25C4%2587-Vujovi%25C4%2587%26aufirst%3DK.%26aulast%3DSrebro%26aufirst%3DD.%26aulast%3DVu%25C4%258Dkovi%25C4%2587%26aufirst%3DS.%26aulast%3DIvanovi%25C4%2587%26aufirst%3DM.%26aulast%3DKosti%25C4%2587-Raja%25C4%258Di%25C4%2587%26aufirst%3DS.%26atitle%3Dmi-Opioid%252FD2%2520dopamine%2520receptor%2520pharmacophore%2520containing%2520ligands%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DJ.%2520Serb.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D85%26spage%3D711%26epage%3D720%26doi%3D10.2298%2Fjsc190912118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">14288</span>– <span class="NLM_lpage">14297</span>, <span class="refDoi"> DOI: 10.3390/molecules171214288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.3390%2Fmolecules171214288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=23208464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=14288-14297&author=X.+Baoauthor=D.+Liuauthor=Y.+Jinauthor=Y.+Yang&title=A+facile+synthesis+for+novel+loperamide+analogs+as+potential+%CE%BC+opioid+receptor+agonists&doi=10.3390%2Fmolecules171214288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists</span></div><div class="casAuthors">Bao, Xiaofeng; Liu, Duliang; Jin, Yanyan; Yang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14288-14297</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A facile synthesis for novel loperamide analogs as potential μ-opioids is described.  The synthetic procedure for compd. I, which contains two 4-phenylpiperidine scaffolds, was optimized, and this compd. was synthesized in excellent yield.  Addnl., a mild and highly efficient protocol for the synthesis of compds. II (R = F, Br) was described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW38kzjYeYZLVg90H21EOLACvtfcHk0lgURnqUGBHoXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhtbbM&md5=0a8f5d47357df2ce9f98a5bec1ada433</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3390%2Fmolecules171214288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules171214288%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DA%2520facile%2520synthesis%2520for%2520novel%2520loperamide%2520analogs%2520as%2520potential%2520%25CE%25BC%2520opioid%2520receptor%2520agonists%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D14288%26epage%3D14297%26doi%3D10.3390%2Fmolecules171214288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4215</span>– <span class="NLM_lpage">4219</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.4215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1073%2Fpnas.73.11.4215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=186791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4215-4219&author=A.+P.+Feinbergauthor=I.+Creeseauthor=S.+H.+Snyder&title=The+opiate+receptor%3A+a+model+explaining+structure-activity+relationships+of+opiate+agonists+and+antagonists&doi=10.1073%2Fpnas.73.11.4215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The opiate receptor:  A model explaining structure-activity relations of opiate agonists and antagonists</span></div><div class="casAuthors">Feinberg, Andrew P.; Creese, Ian; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4215-19</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A model of the opiate receptor is proposed which explains structure-activity relationships of opiate drugs, including the unique potency of certain opiates such as etonitazene, fentanyl, phenazocine, and oripavines; the role of N-allyl substituents in conferring antagonist properties; and chem. features that afford pure antagonists.  The model indicates mol. mechanisms for interconversion of the opiate receptor between respective states that bind agonists or antagonists with high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcp-YfSxhKX7Vg90H21EOLACvtfcHk0lgJ8yZM4hQTxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D&md5=13320bdc14257c1f4c0fe84ad05e1421</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4215%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520opiate%2520receptor%253A%2520a%2520model%2520explaining%2520structure-activity%2520relationships%2520of%2520opiate%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4215%26epage%3D4219%26doi%3D10.1073%2Fpnas.73.11.4215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huysentruyt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risseeuw, M. D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Craenenbroeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of bivalent ligands targeting dopamine D2-like receptors and the mu-opioid receptor</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">944</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1002%2Fcmdc.201700787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29451744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Ohs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=944-956&author=M.+Qianauthor=L.+Vasudevanauthor=J.+Huysentruytauthor=M.+D.+P.+Risseeuwauthor=C.+Stoveauthor=P.+M.+L.+Vanderheydenauthor=K.+Van+Craenenbroeckauthor=S.+Van+Calenbergh&title=Design%2C+synthesis%2C+and+biological+evaluation+of+bivalent+ligands+targeting+dopamine+D2-like+receptors+and+the+mu-opioid+receptor&doi=10.1002%2Fcmdc.201700787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Bivalent Ligands Targeting Dopamine D2-Like Receptors and the μ-Opioid Receptor</span></div><div class="casAuthors">Qian, Mingcheng; Vasudevan, Lakshmi; Huysentruyt, Jelle; Risseeuw, Martijn D. P.; Stove, Christophe; Vanderheyden, Patrick M. L.; Van Craenenbroeck, Kathleen; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">944-956</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Currently, there is mounting evidence that intermol. receptor-receptor interactions may result in altered receptor recognition, pharmacol. and signaling.  Heterobivalent ligands have been proven useful as mol. probes for confirming and targeting heteromeric receptors.  This report describes the design and synthesis of novel heterobivalent ligands for dopamine D2-like receptors (D2-likeR) and the μ-opioid receptor (μOR) and their evaluation using ligand binding and functional assays.  Interestingly, we identified a potent bivalent ligand that contains a short 18-atom linker and combines good potency with high efficacy both in β-arrestin 2 recruitment for μOR and MAPK-P for D4R.  Furthermore, this compd. was characterized by a biphasic competition binding curve for the D4R-μOR heterodimer, indicative of a bivalent binding mode.  As this compd. possibly bridges the D4R-μOR heterodimer, it could be used as a pharmacol. tool to further investigate the interactions of D4R and μOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC2Yyud3OdY7Vg90H21EOLACvtfcHk0lgJ8yZM4hQTxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Ohs78%253D&md5=84c1b8350ba27a7c348b7f2e7db8a181</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700787%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DM.%26aulast%3DVasudevan%26aufirst%3DL.%26aulast%3DHuysentruyt%26aufirst%3DJ.%26aulast%3DRisseeuw%26aufirst%3DM.%2BD.%2BP.%26aulast%3DStove%26aufirst%3DC.%26aulast%3DVanderheyden%26aufirst%3DP.%2BM.%2BL.%26aulast%3DVan%2BCraenenbroeck%26aufirst%3DK.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520bivalent%2520ligands%2520targeting%2520dopamine%2520D2-like%2520receptors%2520and%2520the%2520mu-opioid%2520receptor%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D944%26epage%3D956%26doi%3D10.1002%2Fcmdc.201700787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+medicinal+chemistry+lectureship%3A+designing+bivalent+or+bitopic+molecules+for+G-protein+coupled+receptors.+The+whole+is+greater+than+the+sum+of+its+parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0lh9bJvVomZIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520medicinal%2520chemistry%2520lectureship%253A%2520designing%2520bivalent%2520or%2520bitopic%2520molecules%2520for%2520G-protein%2520coupled%2520receptors.%2520The%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520its%2520parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lh9bJvVomZIQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and synthesis of bitopic ligands as D3 receptor (D3R) selective agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+significance+of+chirality+in+drug+design+and+synthesis+of+bitopic+ligands+as+D3+receptor+%28D3R%29+selective+agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0lhF3jlQgMcIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520synthesis%2520of%2520bitopic%2520ligands%2520as%2520D3%2520receptor%2520%2528D3R%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">Exception that proves the rule: investigation of privileged stereochemistry in designing dopamine D3R bitopic agonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1956</span>– <span class="NLM_lpage">1964</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00660</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00660" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlOntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1956-1964&author=F.+O.+Battitiauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=Exception+that+proves+the+rule%3A+investigation+of+privileged+stereochemistry+in+designing+dopamine+D3R+bitopic+agonists&doi=10.1021%2Facsmedchemlett.9b00660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Exception That Proves the Rule: Investigation of Privileged Stereochemistry in Designing Dopamine D3R Bitopic Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1956-1964</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, starting from our selective D3R agonist FOB02-04A (5)(I), we investigated the chem. space around the linker portion of the mol. via insertion of a hydroxyl substituent and ring-expansion of the trans-cyclopropyl moiety into a trans-cyclohexyl scaffold.  Moreover, to further elucidate the importance of the primary pharmacophore stereochem. in the design of bitopic ligands, we inves47942005Ntigated the chiral requirements of (+)-PD128907 ((+)-(4aR,10bR)-2)(II) by synthesizing and resolving bitopic analogs in all the cis and trans combinations of its 9-methoxy-3,4,4a,10b-tetrahydro-2H,5H-chromeno[4,3-b][1,4] oxazine scaffold.  Despite the lack of success in obtaining new analogs with improved biol. profiles, in comparison to our current leads, a "neg." result due to a poor or simply not improved biol. profile is fundamental toward better understanding chem. space and optimal stereochem. for target recognition.  Herein, we identified essential structural information to understand the differences between orthosteric and bitopic ligand-receptor binding interactions, discriminate D3R active and inactive states, and assist multitarget receptor recognition.  Exploring stereochem. complexity and developing extended D3R SAR from this new library complements previously described SAR and inspires future structural and computational biol. investigation.  Moreover, the expansion of chem. space characterization for D3R agonism may be utilized in machine learning and artificial intelligence (AI)-based drug design, in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokM-YxOh1X7LVg90H21EOLACvtfcHk0lhF3jlQgMcIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlOntL8%253D&md5=c8b00bebd54a25f0fa1f8df6c0209253</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00660%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DException%2520that%2520proves%2520the%2520rule%253A%2520investigation%2520of%2520privileged%2520stereochemistry%2520in%2520designing%2520dopamine%2520D3R%2520bitopic%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1956%26epage%3D1964%26doi%3D10.1021%2Facsmedchemlett.9b00660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0lgCWGyDLD3D-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. S.</span></span> <span> </span><span class="NLM_article-title">Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides</span>. <i>Perspect. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.4137/pmc.s3898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.4137%2Fpmc.s3898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=20212915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisl2rs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=1-10&author=J.+S.+Goldberg&title=Stereochemical+basis+for+a+unified+structure+activity+theory+of+aromatic+and+heterocyclic+rings+in+selected+opioids+and+opioid+peptides&doi=10.4137%2Fpmc.s3898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemical basis for a unified structure activity theory of aromatic and heterocyclic rings in selected opioids and opioid peptides</span></div><div class="casAuthors">Goldberg, Joel S.</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PMCEAZ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">This paper presents a novel unified theory of the structure activity relationship of opioids and opioid peptides.  It is hypothesized that a virtual or known heterocyclic ring exists in all opioids which have activity in humans, and this ring occupies relative to the arom. ring of the drug, approx. the same plane in space as the piperidine ring of morphine.  Since the rings of morphine are rigid, and the arom. and piperidine rings are crit. structural components for morphine's analgesic properties, the rigid morphine mol. allows for approxns. of the arom. and heterocyclic relationships in subsequent drug models where bond rotations are common.  This hypothesis and five propositions are supported by stereochem. and exptl. observations.  Proposition #1 The structure of morphine provides a template.  Proposition #2 Steric hindrance of some centric portion of the piperidine ring explains antagonist properties of naloxone, naltrexone and alvimopam.  Proposition #3 Methadone has an active conformation which contains a virtual heterocyclic ring which explains its analgesic activity and racemic properties.  Proposition #4 The piperidine ring of fentanyl can assume the morphine position under conditions of nitrogen inversion.  Proposition #5 The first 3 amino acid sequences of beta endorphin (-try-gly-gly) and the active opioid dipeptide, -tyr-pro, (as a result of a peptide turn and zwitterion bonding) form a virtual piperazine-like ring which is similar in size, shape and location to the heterocyclic rings of morphine, meperidine, and methadone.  Potential flaws in this theory are discussed.  This theory could be important for future analgesic drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUbEcf6oKYrVg90H21EOLACvtfcHk0lgCWGyDLD3D-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisl2rs70%253D&md5=93019d829fa6878650dd8a369902e6e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4137%2Fpmc.s3898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252Fpmc.s3898%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26atitle%3DStereochemical%2520basis%2520for%2520a%2520unified%2520structure%2520activity%2520theory%2520of%2520aromatic%2520and%2520heterocyclic%2520rings%2520in%2520selected%2520opioids%2520and%2520opioid%2520peptides%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2010%26volume%3D4%26spage%3D1%26epage%3D10%26doi%3D10.4137%2Fpmc.s3898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0lgC9Wl5Q0bkyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span> <span> </span><span class="NLM_article-title">Subtle modifications to the indole-2-carboxamide motif of the negative allosteric modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) yield dramatic changes in pharmacological activity at the dopamine D2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00192</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00192" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSrtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=371-377&author=A.+Kopinathanauthor=C.+Draper-Joyceauthor=M.+Szaboauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=J.+R.+Laneauthor=B.+Capuano&title=Subtle+modifications+to+the+indole-2-carboxamide+motif+of+the+negative+allosteric+modulator+N-%28%28trans%29-4-%282-%287-Cyano-3%2C4-dihydroisoquinolin-2%281+H%29-yl%29ethyl%29cyclohexyl%29-1+H-indole-2-carboxamide+%28SB269652%29+yield+dramatic+changes+in+pharmacological+activity+at+the+dopamine+D2+receptor&doi=10.1021%2Facs.jmedchem.8b00192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D2 Receptor</span></div><div class="casAuthors">Kopinathan, Anitha; Draper-Joyce, Christopher; Szabo, Monika; Christopoulos, Arthur; Scammells, Peter J.; Lane, J. Robert; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">371-377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">SB269652 (I) is a neg. allosteric modulator of the dopamine D2 receptor.  Herein, we present the design, synthesis, and pharmacol. evaluation of "second generation" analogs of I whereby subtle modifications to the indole-2-carboxamide motif confer dramatic changes in functional affinity (5000-fold increase), cooperativity (100-fold increase), and a novel action to modulate dopamine efficacy.  Thus, structural changes to this region of I allows the generation of a novel set of analogs with distinct pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKb0oWUyeKLVg90H21EOLACvtfcHk0lgC9Wl5Q0bkyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSrtr7F&md5=5921911ef17a94e8b83913423d62d408</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00192%26sid%3Dliteratum%253Aachs%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DDraper-Joyce%26aufirst%3DC.%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DSubtle%2520modifications%2520to%2520the%2520indole-2-carboxamide%2520motif%2520of%2520the%2520negative%2520allosteric%2520modulator%2520N-%2528%2528trans%2529-4-%25282-%25287-Cyano-3%252C4-dihydroisoquinolin-2%25281%2520H%2529-yl%2529ethyl%2529cyclohexyl%2529-1%2520H-indole-2-carboxamide%2520%2528SB269652%2529%2520yield%2520dramatic%2520changes%2520in%2520pharmacological%2520activity%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D371%26epage%3D377%26doi%3D10.1021%2Facs.jmedchem.8b00192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Draper-Joyce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopinathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1208</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-19642-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fs41598-018-19642-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29352161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1208&author=C.+J.+Draper-Joyceauthor=R.+K.+Vermaauthor=M.+Michinoauthor=J.+Shonbergauthor=A.+Kopinathanauthor=C.+Klein+Herenbrinkauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=A.+M.+Abramyanauthor=D.+M.+Thalauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=L.+Shiauthor=J.+R.+Lane&title=The+action+of+a+negative+allosteric+modulator+at+the+dopamine+D2+receptor+is+dependent+upon+sodium+ions&doi=10.1038%2Fs41598-018-19642-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions</span></div><div class="casAuthors">Draper-Joyce Christopher J; Klein Herenbrink Carmen; Thal David M; Christopoulos Arthur; Lane J Robert; Verma Ravi Kumar; Michino Mayako; Abramyan Ara M; Shi Lei; Michino Mayako; Shonberg Jeremy; Kopinathan Anitha; Scammells Peter J; Capuano Ben; Javitch Jonathan A; Javitch Jonathan A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sodium ions (Na(+)) allosterically modulate the binding of orthosteric agonists and antagonists to many class A G protein-coupled receptors, including the dopamine D2 receptor (D2R).  Experimental and computational evidences have revealed that this effect is mediated by the binding of Na(+) to a conserved site located beneath the orthosteric binding site (OBS).  SB269652 acts as a negative allosteric modulator (NAM) of the D2R that adopts an extended bitopic pose, in which the tetrahydroisoquinoline moiety interacts with the OBS and the indole-2-carboxamide moiety occupies a secondary binding pocket (SBP).  In this study, we find that the presence of a Na(+) within the conserved Na(+)-binding pocket is required for the action of SB269652.  Using fragments of SB269652 and novel full-length analogues, we show that Na(+) is required for the high affinity binding of the tetrahydroisoquinoline moiety within the OBS, and that the interaction of the indole-2-carboxamide moiety with the SBP determines the degree of Na(+)-sensitivity.  Thus, we extend our understanding of the mode of action of this novel class of NAM by showing it acts synergistically with Na(+) to modulate the binding of orthosteric ligands at the D2R, providing opportunities for fine-tuning of modulatory effects in future allosteric drug design efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvIHTTptFmHTToTC3aBaesfW6udTcc2ebLrphTzf4VXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvisFerug%253D%253D&md5=7126d1cd2e69be311c508c596d81cc2f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-19642-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-19642-1%26sid%3Dliteratum%253Aachs%26aulast%3DDraper-Joyce%26aufirst%3DC.%2BJ.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKopinathan%26aufirst%3DA.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520action%2520of%2520a%2520negative%2520allosteric%2520modulator%2520at%2520the%2520dopamine%2520D2%2520receptor%2520is%2520dependent%2520upon%2520sodium%2520ions%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D1208%26doi%3D10.1038%2Fs41598-018-19642-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1005948</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1371%2Fjournal.pcbi.1005948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=29337986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=R.+K.+Vermaauthor=A.+M.+Abramyanauthor=M.+Michinoauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=L.+Shi&title=The+E2.65A+mutation+disrupts+dynamic+binding+poses+of+SB269652+at+the+dopamine+D2+and+D3+receptors&doi=10.1371%2Fjournal.pcbi.1005948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors</span></div><div class="casAuthors">Verma, Ravi Kumar; Abramyan, Ara M.; Michino, Mayako; Free, R. Benjamin; Sibley, David R.; Javitch, Jonathan A.; Lane, J. Robert; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005948/1-e1005948/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The dopamine D2 and D3 receptors (D2R and D3R) are important targets for antipsychotics and for the treatment of drug abuse.  SB269652, a bitopic ligand that simultaneously binds both the orthosteric binding site (OBS) and a secondary binding pocket (SBP) in both D2R and D3R, was found to be a neg. allosteric modulator.  Previous studies identified Glu2.65 in the SBP to be a key determinant of both the affinity of SB269652 and the magnitude of its cooperativity with orthosteric ligands, as the E2.  A mutation decreased both of these parameters.  However, the proposed hydrogen bond (H-bond) between Glu2.65 and the indole moiety of SB269652 is not a strong interaction, and a structure activity relationship study of SB269652 indicates that this H-bond may not be the only element that dets. its allosteric properties.  To understand the structural basis of the obsd. phenotype of E2.65A, we carried out mol. dynamics simulations with a cumulative length of ∼77 μs of D2R and D3R wild-type and their E2.65A mutants bound to SB269652.  In combination with Markov state model anal. and by characterizing the equil. of ligand binding modes in different conditions, we found that in both D2R and D3R, whereas the tetrahydroisoquinoline moiety of SB269652 is stably bound in the OBS, the indole-2-carboxamide moiety is dynamic and only intermittently forms H-bonds with Glu2.65.  Our results also indicate that the E2.65A mutation significantly affects the overall shape and size of the SBP, as well as the conformation of the N terminus.  Thus, our findings suggest that the key role of Glu2.65 in mediating the allosteric properties of SB269652 extends beyond a direct interaction with SB269652, and provide structural insights for rational design of SB269652 derivs. that may retain its allosteric properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg1JueDgCVDrVg90H21EOLACvtfcHk0liMZ08bEAa6Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1OhsL%252FJ&md5=e7ff0bcc58a78f0292a5c1f1c820c151</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005948%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DAbramyan%26aufirst%3DA.%2BM.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DThe%2520E2.65A%2520mutation%2520disrupts%2520dynamic%2520binding%2520poses%2520of%2520SB269652%2520at%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1005948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyriac, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span> <span> </span><span class="NLM_article-title">N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1021/jm900095y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900095y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2559-2570&author=A.+H.+Newmanauthor=P.+Grundtauthor=G.+Cyriacauthor=J.+R.+Deschampsauthor=M.+Taylorauthor=R.+Kumarauthor=D.+Hoauthor=R.+R.+Luedtke&title=N-%284-%284-%282%2C3-dichloro-+or+2-methoxyphenyl%29piperazin-1-yl%29butyl%29heterobiarylcarboxamides+with+functionalized+linking+chains+as+high+affinity+and+enantioselective+D3+receptor+antagonists&doi=10.1021%2Fjm900095y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists</span></div><div class="casAuthors">Newman, Amy Hauck; Grundt, Peter; Cyriac, George; Deschamps, Jeffrey R.; Taylor, Michelle; Kumar, Rakesh; Ho, David; Luedtke, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2559-2570</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present report, the D3 receptor pharmacophore is modified in the 2,3-diCl- and 2-OCH3-phenylpiperazine class of compds. with the goal to improve D3 receptor affinity and selectivity.  This extension of structure-activity relationships (SAR) has resulted in the identification of the first enantioselective D3 antagonists (R- and S-22) to be reported, wherein enantioselectivity is more pronounced at D3 than at D2, and that a binding region on the second extracellular loop (E2) may play a role in both enantioselectivity and D3 receptor selectivity.  Moreover, we have discovered some of the most D3-selective compds. reported to date that show high affinity (Ki = 1 nM) for D3 and ∼400-fold selectivity over the D2 receptor subtype.  Several of these analogs showed exquisite selectivity for D3 receptors over >60 other receptors, further underscoring their value as in vivo research tools.  These lead compds. also have appropriate phys. characteristics for in vivo exploration and therefore will be useful in detg. how intrinsic activity at D3 receptors tested in vitro is related to behaviors in animal models of addiction and other neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbxvbF2dNX7Vg90H21EOLACvtfcHk0liTe39POPmZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt7s%253D&md5=665731381e379cec45ef058cd6c45d0e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm900095y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900095y%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCyriac%26aufirst%3DG.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DD.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26atitle%3DN-%25284-%25284-%25282%252C3-dichloro-%2520or%25202-methoxyphenyl%2529piperazin-1-yl%2529butyl%2529heterobiarylcarboxamides%2520with%2520functionalized%2520linking%2520chains%2520as%2520high%2520affinity%2520and%2520enantioselective%2520D3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2559%26epage%3D2570%26doi%3D10.1021%2Fjm900095y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Paulis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogren, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensadn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csoregh, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystal structure and anti-dopaminergic properties of eticlopride (FLB 131)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaL28Xhs1ygsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1985&pages=273-276&author=T.+De%0APaulisauthor=H.+Hallauthor=S.+O.+Ogrenauthor=A.+Wagnerauthor=B.+Stensadnauthor=I.+Csoregh&title=Synthesis%2C+crystal+structure+and+anti-dopaminergic+properties+of+eticlopride+%28FLB+131%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystal structure and antidopaminergic properties of eticlopride (FLB 131)</span></div><div class="casAuthors">De Paulis, Tomas; Hall, Haakan; Oegren, Sven Ove; Waegner, Anna; Stensland, Birgitta; Csoeregh, Ingeborg</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-6</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The title pyrrolidinylmethylsalicylamide I (R = Et) was prepd. by treating methoxysalicylic acid II (R1 = OH, R2 = H) with with SO2Cl2 and then SOCl2 to give II (R1, R2 = Cl) which was treated with S(-)-aminomethyl-N-ethylpyrrolidine to give I.  I was 10 times more potent than haloperidol, both in displacing 3H-spiperone from striatal homogenate of rat brain, and in antagonizing apomorphine-induced hyperactivity in rats.  The x-ray crystal structure of I is given.  I (R = Me) was also prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFtgvcxXHxTrVg90H21EOLACvtfcHk0liTe39POPmZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xhs1ygsr0%253D&md5=9ceeea4811c8da0f09548dbb056fcfad</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DOgren%26aufirst%3DS.%2BO.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DStensadn%26aufirst%3DB.%26aulast%3DCsoregh%26aufirst%3DI.%26atitle%3DSynthesis%252C%2520crystal%2520structure%2520and%2520anti-dopaminergic%2520properties%2520of%2520eticlopride%2520%2528FLB%2520131%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1985%26volume%3D20%26spage%3D273%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharathi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periasamy, M.</span></span> <span> </span><span class="NLM_article-title">Metalation of iminium ions formed in the reaction of tertiary amines with TiCl4</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1021/ol990745d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol990745d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaK1MXlsFSku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=857-859&author=P.+Bharathiauthor=M.+Periasamy&title=Metalation+of+iminium+ions+formed+in+the+reaction+of+tertiary+amines+with+TiCl4&doi=10.1021%2Fol990745d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metalation of Iminium Ions Formed in the Reaction of Tertiary Amines with TiCl4</span></div><div class="casAuthors">Bharathi, Pandi; Periasamy, Mariappan</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">857-859</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TiCl4 reacts with trialkylamines at 0-25° to give iminium ions that on metalation followed by reaction with diaryl ketones, produce α,β-unsatd. aldehydes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4YbX7rxxfc7Vg90H21EOLACvtfcHk0lix_KdrIfQx0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsFSku74%253D&md5=ebe1664c943e15ecbf75463f06c916b2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fol990745d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol990745d%26sid%3Dliteratum%253Aachs%26aulast%3DBharathi%26aufirst%3DP.%26aulast%3DPeriasamy%26aufirst%3DM.%26atitle%3DMetalation%2520of%2520iminium%2520ions%2520formed%2520in%2520the%2520reaction%2520of%2520tertiary%2520amines%2520with%2520TiCl4%26jtitle%3DOrg.%2520Lett.%26date%3D1999%26volume%3D1%26spage%3D857%26epage%3D859%26doi%3D10.1021%2Fol990745d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiebel, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuvelis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dersch, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3765</span>– <span class="NLM_lpage">3776</span>, <span class="refDoi"> DOI: 10.1021/jm061325e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061325e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVymsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3765-3776&author=A.-C.+Hiebelauthor=Y.+S.+Leeauthor=E.+Bilskyauthor=D.+Giuvelisauthor=J.+R.+Deschampsauthor=D.+A.+Parrishauthor=M.+D.+Acetoauthor=E.+L.+Mayauthor=L.+S.+Harrisauthor=A.+Coopauthor=C.+M.+Derschauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=K.+Chengauthor=A.+E.+Jacobsonauthor=K.+C.+Rice&title=Probes+for+narcotic+receptor+mediated+phenomena.+34.+Synthesis+and+structure-activity+relationships+of+a+potent+mu-agonist+delta-antagonist+and+an+exceedingly+potent+antinociceptive+in+the+enantiomeric+C9-substituted+5-%283-hydroxyphenyl%29-N-phenylethylmorphan+series&doi=10.1021%2Fjm061325e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent μ-Agonist δ-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-phenylethylmorphan Series</span></div><div class="casAuthors">Hiebel, Anne-Cecile; Lee, Yong Sok; Bilsky, Edward; Giuvelis, Denise; Deschamps, Jeffrey R.; Parrish, Damon A.; Aceto, Mario D.; May, Everette L.; Harris, Louis S.; Coop, Andrew; Dersch, Christina M.; Partilla, John S.; Rothman, Richard B.; Cheng, Kejun; Jacobson, Arthur E.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3765-3776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic azabicyclononanylphenols (phenylmorphans) such as I and II (R = HO, H; R1 = H, Me) are prepd.; both enantiomeric phenylmorphans are prepd. and tested for their selectivities for the μ-, κ-, and δ-opioid receptors, while the antagonism or agonism at the μ-, δ-, and κ-opioid receptors of I and II (R = HO, H; R1 = H, Me) is detd.  A racemic (methoxyphenyl)azabicyclononanone is resolved with D- and L-tartaric acid to provide the starting materials for the prepn. of the phenylmorphans tested.  I and II (R = HO, H; R1 = H, Me) are tested against opioid receptors in vitro and in rats.  II (R = HO; R1 = H) binds the μ-opioid receptor with a Ki value of 0.19 nM, acting as a μ-agonist 500-1000 times as potent as morphine; I acts as μ-opioid agonist and a μ-, δ-, and κ-opioid antagonist, binding the μ-opioid receptor with a Ki value of 0.19 nM.  II (R = H; R1 = Me) binds the μ-opioid receptor with a Ki value of 0.63 nM.  II (R = HO; R1 = H) is the most potent phenylmorphan antinociceptive agent known.  The structures of I and II (R = HO, H; R1 = H, Me) are detd. by d. functional theor. (B3LYP/6-31G*) calcns.; the barriers to rotation of the Ph ring about the bond connecting it to the azabicyclononane ring are calcd.  The spatial arrangement of the nitrogen atom and the 9β-OH substituent in II (R = HO; R1 = H) may facilitate the alignment of a putative water chain enabling proton transfer to a nearby proton acceptor group upon binding to the μ-opioid receptor.  The structures of three of the nonracemic phenylmorphans are detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU5nkbpaomPbVg90H21EOLACvtfcHk0lix_KdrIfQx0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVymsLk%253D&md5=2d839c563a12b1f511fec2a08983d695</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm061325e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061325e%26sid%3Dliteratum%253Aachs%26aulast%3DHiebel%26aufirst%3DA.-C.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DBilsky%26aufirst%3DE.%26aulast%3DGiuvelis%26aufirst%3DD.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DParrish%26aufirst%3DD.%2BA.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DMay%26aufirst%3DE.%2BL.%26aulast%3DHarris%26aufirst%3DL.%2BS.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DDersch%26aufirst%3DC.%2BM.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DProbes%2520for%2520narcotic%2520receptor%2520mediated%2520phenomena.%252034.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%2520a%2520potent%2520mu-agonist%2520delta-antagonist%2520and%2520an%2520exceedingly%2520potent%2520antinociceptive%2520in%2520the%2520enantiomeric%2520C9-substituted%25205-%25283-hydroxyphenyl%2529-N-phenylethylmorphan%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3765%26epage%3D3776%26doi%3D10.1021%2Fjm061325e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupica, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and potent dopamine D2 receptor Go-protein biased agonists</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=52-65&author=A.+Bonifaziauthor=H.+Yanoauthor=A.+M.+Guerreroauthor=V.+Kumarauthor=A.+F.+Hoffmanauthor=C.+R.+Lupicaauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+and+potent+dopamine+D2+receptor+Go-protein+biased+agonists&doi=10.1021%2Facsptsci.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Guerrero, Adrian M.; Kumar, Vivek; Hoffman, Alexander F.; Lupica, Carl R.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-65</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of functionally biased and physiol. beneficial ligands directed toward G-protein coupled receptors (GPCRs) has provided the impetus to design dopamine D2 receptor (D2R) targeted mols. that may be therapeutically advantageous for the treatment of certain neuropsychiatric or basal ganglia related disorders.  Here we describe the synthesis of a novel series of D2R agonists linking the D2R unbiased agonist sumanirole with privileged secondary mol. fragments.  The resulting ligands demonstrate improved D2R affinity and selectivity over sumanirole.  Extensive in vitro functional studies and bias factor anal. led to the identification of a novel class of highly potent Go-protein biased full D2R agonists with more than 10-fold and 1000-fold bias selectivity toward activation of specific G-protein subtypes and β-arrestin, resp.  Intracellular electrophysiol. recordings from midbrain dopamine neurons demonstrated that Go-protein selective agonists can elicit prolonged ligand-induced GIRK activity via D2Rs, which may be beneficial in the treatment of dyskinesias assocd. with dopamine system dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNIFl-FnvXCrVg90H21EOLACvtfcHk0lgMdGI1XoGVyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvF2nuw%253D%253D&md5=5b67e76002f6ceb85293c961f698722a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DLupica%26aufirst%3DC.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520potent%2520dopamine%2520D2%2520receptor%2520Go-protein%2520biased%2520agonists%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26spage%3D52%26epage%3D65%26doi%3D10.1021%2Facsptsci.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laeremans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into micro-opioid receptor activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/nature14886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fnature14886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26245379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=315-321&author=W.+Huangauthor=A.+Manglikauthor=A.+J.+Venkatakrishnanauthor=T.+Laeremansauthor=E.+N.+Feinbergauthor=A.+L.+Sanbornauthor=H.+E.+Katoauthor=K.+E.+Livingstonauthor=T.+S.+Thorsenauthor=R.+C.+Klingauthor=S.+Granierauthor=P.+Gmeinerauthor=S.+M.+Husbandsauthor=J.+R.+Traynorauthor=W.+I.+Weisauthor=J.+Steyaertauthor=R.+O.+Drorauthor=B.+K.+Kobilka&title=Structural+insights+into+micro-opioid+receptor+activation&doi=10.1038%2Fnature14886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into μ-opioid receptor activation</span></div><div class="casAuthors">Huang, Weijiao; Manglik, Aashish; Venkatakrishnan, A. J.; Laeremans, Toon; Feinberg, Evan N.; Sanborn, Adrian L.; Kato, Hideaki E.; Livingston, Kathryn E.; Thorsen, Thor S.; Kling, Ralf C.; Granier, Sebastien; Gmeiner, Peter; Husbands, Stephen M.; Traynor, John R.; Weis, William I.; Steyaert, Jan; Dror, Ron O.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">315-321</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the μ-opioid receptor (μOR) is responsible for the efficacy of the most effective analgesics.  To shed light on the structural basis for μOR activation, here we report a 2.1 Å X-ray crystal structure of the murine μOR bound to the morphinan agonist BU72 and a G protein mimetic camelid antibody fragment Nb39 (nanobody 39).  The BU72-stabilized changes in the μOR binding pocket are subtle and differ from those obsd. for agonist-bound structures of the β2-adrenergic receptor (β2AR) and the M2 muscarinic receptor (M2R).  Comparison with active β2AR reveals a common rearrangement in the packing of three conserved amino acids in the core of the μOR, and mol. dynamics simulations illustrate how the ligand-binding pocket is conformationally linked to this conserved triad.  Addnl., an extensive polar network between the ligand-binding pocket and the cytoplasmic domains appears to play a similar role in signal propagation for all three G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFUN1wheV07Vg90H21EOLACvtfcHk0lgMdGI1XoGVyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtbzM&md5=b9af3e1351b04539379532c127c02651</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnature14886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14886%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DLaeremans%26aufirst%3DT.%26aulast%3DFeinberg%26aufirst%3DE.%2BN.%26aulast%3DSanborn%26aufirst%3DA.%2BL.%26aulast%3DKato%26aufirst%3DH.%2BE.%26aulast%3DLivingston%26aufirst%3DK.%2BE.%26aulast%3DThorsen%26aufirst%3DT.%2BS.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DGranier%26aufirst%3DS.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520micro-opioid%2520receptor%2520activation%26jtitle%3DNature%26date%3D2015%26volume%3D524%26spage%3D315%26epage%3D321%26doi%3D10.1038%2Fnature14886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Flexible protein-ligand docking by global energy optimization in internal coordinates</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/(sici)1097-0134(1997)1+<215::aid-prot29>3.0.co;2-q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1002%2F%28SICI%291097-0134%281997%291%2B%3C215%3A%3AAID-PROT29%3E3.0.CO%3B2-Q" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=215-220&author=M.+Totrovauthor=R.+Abagyan&title=Flexible+protein-ligand+docking+by+global+energy+optimization+in+internal+coordinates&doi=10.1002%2F%28sici%291097-0134%281997%291%2B%3C215%3A%3Aaid-prot29%3E3.0.co%3B2-q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0134%281997%291%2B%3C215%3A%3AAID-PROT29%3E3.0.CO%3B2-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0134%25281997%25291%252B%253C215%253A%253AAID-PROT29%253E3.0.CO%253B2-Q%26sid%3Dliteratum%253Aachs%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DFlexible%2520protein-ligand%2520docking%2520by%2520global%2520energy%2520optimization%2520in%2520internal%2520coordinates%26jtitle%3DProteins%26date%3D1997%26volume%3D29%26spage%3D215%26epage%3D220%26doi%3D10.1002%2F%28sici%291097-0134%281997%291%2B%3C215%3A%3Aaid-prot29%3E3.0.co%3B2-q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaluna, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D4 receptor-selective compounds reveal structure-activity relationships that engender agonist efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3722</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00231</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00231" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3722-3740&author=T.+M.+Keckauthor=R.+B.+Freeauthor=M.+M.+Dayauthor=S.+L.+Brownauthor=M.+S.+Maddalunaauthor=G.+Fountainauthor=C.+Cooperauthor=B.+Fallonauthor=M.+Holmesauthor=C.+T.+Stangauthor=R.+Burkhardtauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=D.+R.+Sibleyauthor=C.+Wuauthor=C.+A.+Boateng&title=Dopamine+D4+receptor-selective+compounds+reveal+structure-activity+relationships+that+engender+agonist+efficacy&doi=10.1021%2Facs.jmedchem.9b00231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy</span></div><div class="casAuthors">Keck, Thomas M.; Free, R. Benjamin; Day, Marilyn M.; Brown, Sonvia L.; Maddaluna, Michele S.; Fountain, Griffin; Cooper, Charles; Fallon, Brooke; Holmes, Matthew; Stang, Christopher T.; Burkhardt, Russell; Bonifazi, Alessandro; Ellenberger, Michael P.; Newman, Amy H.; Sibley, David R.; Wu, Chun; Boateng, Comfort A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3722-3740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D4 receptor (D4R) plays important roles in cognition, attention, and decision making.  Novel D4R-selective ligands have promise in medication development for neuropsychiatric conditions, including Alzheimer's disease and substance use disorders.  To identify new D4R-selective ligands, and to understand the mol. determinants of agonist efficacy at D4R, we report a series of eighteen novel ligands based on the classical D4R agonist A-412997 (1, 2-(4-(pyridin-2-yl)piperidin-1-yl)-N-(m-tolyl)acetamide).  Compds. were profiled using radioligand binding displacement assays, β-arrestin recruitment assays, cAMP inhibition assays, and mol. dynamics computational modeling.  We identified several novel D4R-selective (Ki ≤ 4.3 nM and >100-fold vs other D2-like receptors) compds. with diverse partial agonist and antagonist profiles, falling into three structural groups.  These compds. highlight receptor-ligand interactions that control efficacy at D2-like receptors and may provide insights into targeted drug discovery, leading to a better understanding of the role of D4Rs in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtBRYg7sp8rVg90H21EOLACvtfcHk0lhLckgIBPgZEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFCiuro%253D&md5=f3f03df2f50a91030295d32d6b692f1c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00231%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDay%26aufirst%3DM.%2BM.%26aulast%3DBrown%26aufirst%3DS.%2BL.%26aulast%3DMaddaluna%26aufirst%3DM.%2BS.%26aulast%3DFountain%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DFallon%26aufirst%3DB.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DStang%26aufirst%3DC.%2BT.%26aulast%3DBurkhardt%26aufirst%3DR.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26atitle%3DDopamine%2520D4%2520receptor-selective%2520compounds%2520reveal%2520structure-activity%2520relationships%2520that%2520engender%2520agonist%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3722%26epage%3D3740%26doi%3D10.1021%2Facs.jmedchem.9b00231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volpe, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, G. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellon, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colatsky, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropp, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbois, S. L.</span></span> <span> </span><span class="NLM_article-title">Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs</span>. <i>Regul. Toxicol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1016/j.yrtph.2010.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.yrtph.2010.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=21215785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Wit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=385-390&author=D.+A.+Volpeauthor=G.+A.+M.+Tobinauthor=R.+D.+Mellonauthor=A.+G.+Katkiauthor=R.+J.+Parkerauthor=T.+Colatskyauthor=T.+J.+Kroppauthor=S.+L.+Verbois&title=Uniform+assessment+and+ranking+of+opioid+mu+receptor+binding+constants+for+selected+opioid+drugs&doi=10.1016%2Fj.yrtph.2010.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs</span></div><div class="casAuthors">Volpe, Donna A.; McMahon Tobin, Grainne A.; Mellon, R. Daniel; Katki, Aspandiar G.; Parker, Robert J.; Colatsky, Thomas; Kropp, Timothy J.; Verbois, S. Leigh</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Toxicology and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-390</span>CODEN:
                <span class="NLM_cas:coden">RTOPDW</span>;
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The safe disposal of unused opioid drugs is an area of regulatory concern.  While toilet flushing is recommended for some drugs to prevent accidental exposure, there is a need for data that can support a more consistent disposal policy based on an assessment of relative risk.  For drugs acting at the Mu-opioid receptor (MOR), published measurements of binding affinity (Ki) are incomplete and inconsistent due to differences in methodol. and assay system, leading to a wide range of values for the same drug thus precluding a simple and meaningful relative ranking of drug potency.  Expts. were conducted to obtain Ki's for 19 approved opioid drugs using a single binding assay in a cell membrane prepn. expressing recombinant human MOR.  The Ki values obtained ranged from 0.1380 nM (sufentanil) to 12.486 μM (tramadol).  The drugs were sepd. into three categories based upon their Ki values: Ki > 100 nM (tramadol, codeine, meperidine, propoxyphene and pentazocine), Ki = 1-100 nM (hydrocodone, oxycodone, diphenoxylate, alfentanil, methadone, nalbuphine, fentanyl and morphine) and Ki < 1 nM (butorphanol, levorphanol, oxymorphone, hydromorphone, buprenorphine and sufentanil).  These data add to the understanding of the pharmacol. of opioid drugs and support the development of a more consistent labeling policies regarding safe disposal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVz_1KaclTerVg90H21EOLACvtfcHk0lgb7cZdw_3KtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Wit7c%253D&md5=5b5583510504e30657f282b94921da2d</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2010.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2010.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DVolpe%26aufirst%3DD.%2BA.%26aulast%3DTobin%26aufirst%3DG.%2BA.%2BM.%26aulast%3DMellon%26aufirst%3DR.%2BD.%26aulast%3DKatki%26aufirst%3DA.%2BG.%26aulast%3DParker%26aufirst%3DR.%2BJ.%26aulast%3DColatsky%26aufirst%3DT.%26aulast%3DKropp%26aufirst%3DT.%2BJ.%26aulast%3DVerbois%26aufirst%3DS.%2BL.%26atitle%3DUniform%2520assessment%2520and%2520ranking%2520of%2520opioid%2520mu%2520receptor%2520binding%2520constants%2520for%2520selected%2520opioid%2520drugs%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2011%26volume%3D59%26spage%3D385%26epage%3D390%26doi%3D10.1016%2Fj.yrtph.2010.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiroz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billing, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wish, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó-Anguera, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkelman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span> <span> </span><span class="NLM_article-title">Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2744</span>, <span class="refDoi"> DOI: 10.1172/jci126912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1172%2FJCI126912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=30913037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A280%3ADC%252BB3cbot1yitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=2730-2744&author=N.-S.+Caiauthor=C.+Quirozauthor=J.+Bonaventuraauthor=A.+Bonifaziauthor=T.+O.+Coleauthor=J.+Purksauthor=A.+S.+Billingauthor=E.+Masseyauthor=M.+Wagnerauthor=E.+D.+Wishauthor=X.+Guitartauthor=W.+Reaauthor=S.+Lamauthor=E.+Morenoauthor=V.+Casad%C3%B3-Angueraauthor=A.+D.+Greenblattauthor=A.+E.+Jacobsonauthor=K.+C.+Riceauthor=V.+Casad%C3%B3author=A.+H.+Newmanauthor=J.+W.+Winkelmanauthor=M.+Michaelidesauthor=E.+Weintraubauthor=N.+D.+Volkowauthor=A.+M.+Belcherauthor=S.+Ferr%C3%A9&title=Opioid-galanin+receptor+heteromers+mediate+the+dopaminergic+effects+of+opioids&doi=10.1172%2Fjci126912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids</span></div><div class="casAuthors">Cai Ning-Sheng; Quiroz Cesar; Guitart Xavier; Rea William; Ferre Sergi; Bonaventura Jordi; Lam Sherry; Michaelides Michael; Bonifazi Alessandro; Newman Amy H; Cole Thomas O; Greenblatt Aaron D; Weintraub Eric; Belcher Annabelle M; Purks Julia; Winkelman John W; Billing Amy S; Massey Ebonie; Wagner Michael; Wish Eric D; Moreno Estefania; Casado-Anguera Veronica; Casado Vicent; Jacobson Arthur E; Rice Kenner C; Volkow Nora D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2730-2744</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Identifying non-addictive opioid medications is a high priority in medical sciences, but μ-opioid receptors mediate both the analgesic and addictive effects of opioids.  We found a significant pharmacodynamic difference between morphine and methadone that is determined entirely by heteromerization of μ-opioid receptors with galanin Gal1 receptors, rendering a profound decrease in the potency of methadone.  This was explained by methadone's weaker proficiency to activate the dopaminergic system as compared to morphine and predicted a dissociation of therapeutic versus euphoric effects of methadone, which was corroborated by a significantly lower incidence of self-report of "high" in methadone-maintained patients.  These results suggest that μ-opioid-Gal1 receptor heteromers mediate the dopaminergic effects of opioids that may lead to a lower addictive liability of opioids with selective low potency for the μ-opioid-Gal1 receptor heteromer, exemplified by methadone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzhYYvOBe1ng5nADWVYHg1fW6udTcc2eb8r9y_p-jgebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbot1yitw%253D%253D&md5=0362b240a45fdbab876cb8d439fcc766</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1172%2FJCI126912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI126912%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DN.-S.%26aulast%3DQuiroz%26aufirst%3DC.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DT.%2BO.%26aulast%3DPurks%26aufirst%3DJ.%26aulast%3DBilling%26aufirst%3DA.%2BS.%26aulast%3DMassey%26aufirst%3DE.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DWish%26aufirst%3DE.%2BD.%26aulast%3DGuitart%26aufirst%3DX.%26aulast%3DRea%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DCasad%25C3%25B3-Anguera%26aufirst%3DV.%26aulast%3DGreenblatt%26aufirst%3DA.%2BD.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWinkelman%26aufirst%3DJ.%2BW.%26aulast%3DMichaelides%26aufirst%3DM.%26aulast%3DWeintraub%26aufirst%3DE.%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DBelcher%26aufirst%3DA.%2BM.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DOpioid-galanin%2520receptor%2520heteromers%2520mediate%2520the%2520dopaminergic%2520effects%2520of%2520opioids%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26spage%3D2730%26epage%3D2744%26doi%3D10.1172%2Fjci126912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhmiLO5uXQusQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sounier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laeremans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déméné, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Propagation of conformational changes during mu-opioid receptor activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1038/nature14680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fnature14680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26245377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=375-378&author=R.+Sounierauthor=C.+Masauthor=J.+Steyaertauthor=T.+Laeremansauthor=A.+Manglikauthor=W.+Huangauthor=B.+K.+Kobilkaauthor=H.+D%C3%A9m%C3%A9n%C3%A9author=S.+Granier&title=Propagation+of+conformational+changes+during+mu-opioid+receptor+activation&doi=10.1038%2Fnature14680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Propagation of conformational changes during μ-opioid receptor activation</span></div><div class="casAuthors">Sounier, Remy; Mas, Camille; Steyaert, Jan; Laeremans, Toon; Manglik, Aashish; Huang, Weijiao; Kobilka, Brian K.; Demene, Helene; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">375-378</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">μ-Opioid receptors (μORs) are G-protein-coupled receptors that are activated by a structurally diverse spectrum of natural and synthetic agonists including endogenous endorphin peptides, morphine and methadone.  The recent structures of the μOR in inactive and agonist-induced active states (W. Huang et al., 2015) provide snapshots of the receptor at the beginning and end of a signalling event, but little is known about the dynamic sequence of events that span these two states.  Here we use soln.-state NMR to examine the process of μOR activation using a purified receptor (mouse sequence) prepn. in an amphiphile membrane-like environment.  We obtain spectra of the μOR in the absence of ligand, and in the presence of the high-affinity agonist BU 72 alone, or with BU 72 and a G protein mimetic nanobody.  Our results show that conformational changes in transmembrane segments 5 and 6 (TM5 and TM6), which are required for the full engagement of a G protein, are almost completely dependent on the presence of both the agonist and the G protein mimetic nanobody, revealing a weak allosteric coupling between the agonist-binding pocket and the G-protein-coupling interface (TM5 and TM6), similar to that obsd. for the β2-adrenergic receptor.  Unexpectedly, in the presence of agonist alone, we find larger spectral changes involving intracellular loop 1 and helix 8 compared to changes in TM5 and TM6.  These results suggest that one or both of these domains may play a role in the initial interaction with the G protein, and that TM5 and TM6 are only engaged later in the process of complex formation.  The initial interactions between the G protein and intracellular loop 1 and/or helix 8 may be involved in G-protein coupling specificity, as has been suggested for other family A G-protein-coupled receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonzj6Bmj4e5LVg90H21EOLACvtfcHk0lhmiLO5uXQusQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FN&md5=0dd0dedcce583a52b4adc3084726a862</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature14680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14680%26sid%3Dliteratum%253Aachs%26aulast%3DSounier%26aufirst%3DR.%26aulast%3DMas%26aufirst%3DC.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DLaeremans%26aufirst%3DT.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DD%25C3%25A9m%25C3%25A9n%25C3%25A9%26aufirst%3DH.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DPropagation%2520of%2520conformational%2520changes%2520during%2520mu-opioid%2520receptor%2520activation%26jtitle%3DNature%26date%3D2015%26volume%3D524%26spage%3D375%26epage%3D378%26doi%3D10.1038%2Fnature14680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">435-449</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The interplay among commonly used physicochem. properties in drug design was examd. and utilized to create a prospective design tool focused on the alignment of key druglike attributes.  Using a set of six physicochem. parameters ((a) lipophilicity, calcd. partition coeff. (ClogP); (b) calcd. distribution coeff. at pH = 7.4 (ClogD); (c) mol. wt. (MW); (d) topol. polar surface area (TPSA); (e) no. of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compds. (N = 11 303).  The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates.  This anal. suggests that this algorithm could potentially be used to identify compds. with a higher probability of successfully testing hypotheses in the clinic.  In addn., a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set.  The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chem. design space through a holistic assessment approach.  Based on six physicochem. properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compds. with increased probability of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3Mvkgm_X5bVg90H21EOLACvtfcHk0ljV_6N9GrGfeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVejtr8%253D&md5=e94998f65a420be6ee4dec4a987cb983</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Central nervous system multiparameter optimization desirability: application in drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=767-775&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Central+nervous+system+multiparameter+optimization+desirability%3A+application+in+drug+discovery&doi=10.1021%2Facschemneuro.6b00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">767-775</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant progress has been made in prospectively designing mols. using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the anal. reported herein of a second wave of drug candidates that originated after the development and implementation of this tool.  This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochem. properties.  The CNS MPO tool has helped to increase the percentage of compds. nominated for clin. development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA).  The use of this tool has played a role in reducing the no. of compds. submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicol. into First in Human studies.  Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compds. nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46WD7qMaX6bVg90H21EOLACvtfcHk0ljV_6N9GrGfeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D&md5=061c3aef6c88758cbaee1a2abb34796a</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00029%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DCentral%2520nervous%2520system%2520multiparameter%2520optimization%2520desirability%253A%2520application%2520in%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D767%26epage%3D775%26doi%3D10.1021%2Facschemneuro.6b00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Investigation of novel primary and secondary pharmacophores and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9061</span>– <span class="NLM_lpage">9077</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9061-9077&author=A.+B.+Shaikauthor=V.+Kumarauthor=A.+Bonifaziauthor=A.+M.+Guerreroauthor=S.+L.+Cemajauthor=A.+Gadianoauthor=J.+Lamauthor=Z.-X.+Xiauthor=R.+Raisauthor=B.+S.+Slusherauthor=A.+H.+Newman&title=Investigation+of+novel+primary+and+secondary+pharmacophores+and+3-substitution+in+the+linking+chain+of+a+series+of+highly+selective+and+bitopic+dopamine+D3+receptor+antagonists+and+partial+agonists&doi=10.1021%2Facs.jmedchem.9b00607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D3 Receptor Antagonists and Partial Agonists</span></div><div class="casAuthors">Shaik, Anver Basha; Kumar, Vivek; Bonifazi, Alessandro; Guerrero, Adrian M.; Cemaj, Sophie L.; Gadiano, Alexandra; Lam, Jenny; Xi, Zheng-Xiong; Rais, Rana; Slusher, Barbara S.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9061-9077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptors (D3R) play a crit. role in neuropsychiatric conditions including substance use disorders (SUD).  Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogs as high affinity and selective D3R lead mols. for the treatment of opioid use disorders (OUD).  Further optimization led to a series of analogs that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP).  Among the 3-F-compds., 9b demonstrated the highest D3R binding affinity (Ki = 0.756 nM) and was 327-fold selective for D3R over D2R.  In addn., modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examd.  Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure R- and S-enantiomers of the four lead compds.  Off-target binding affinities, functional efficacies, and metabolic profiles revealed crit. structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR79XdHJXFkbVg90H21EOLACvtfcHk0lhk7tfPnQu-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO&md5=0b8b1d8d76d17164a4ab7ba0e17ea2c2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00607%26sid%3Dliteratum%253Aachs%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DXi%26aufirst%3DZ.-X.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DInvestigation%2520of%2520novel%2520primary%2520and%2520secondary%2520pharmacophores%2520and%25203-substitution%2520in%2520the%2520linking%2520chain%2520of%2520a%2520series%2520of%2520highly%2520selective%2520and%2520bitopic%2520dopamine%2520D3%2520receptor%2520antagonists%2520and%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9061%26epage%3D9077%26doi%3D10.1021%2Facs.jmedchem.9b00607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10842</span>, <span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein%0AHerenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0lhk7tfPnQu-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuravi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digby, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, N. A.</span></span> <span> </span><span class="NLM_article-title">The c-terminus of GRK3 indicates rapid dissociation of G protein heterotrimers</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1021</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2009.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=10.1016%2Fj.cellsig.2009.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=19258039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslKkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=1015-1021&author=B.+Hollinsauthor=S.+Kuraviauthor=G.+J.+Digbyauthor=N.+A.+Lambert&title=The+c-terminus+of+GRK3+indicates+rapid+dissociation+of+G+protein+heterotrimers&doi=10.1016%2Fj.cellsig.2009.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The C-terminus of GRK3 indicates rapid dissociation of G protein heterotrimers</span></div><div class="casAuthors">Hollins, Bettye; Kuravi, Sudhakiranmayi; Digby, Gregory J.; Lambert, Nevin A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1021</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signals mediated by heterotrimeric G proteins often develop over the course of tens of milliseconds, and could require either conformational rearrangement or complete phys. dissocn. of Gαβγ heterotrimers.  Although it is known that some active heterotrimers are dissocd. (into Gα and Gβγ) at steady-state, it is not clear that dissocn. occurs quickly enough to participate in rapid signaling.  Here we show that fusion proteins contg. the c-terminus of GPCR kinase 3 (GRK3ct) and either the fluorescent protein cerulean or Renilla luciferase bind to venus-labeled Gβγ dimers (Gβγ-V), resulting in Foerster or bioluminescence resonance energy transfer (FRET or BRET).  GRK3ct fusion proteins are freely-diffusible, and do not form preassembled complexes with G proteins.  GRK3ct fusion proteins bind to free Gβγ-V dimers but not to rearranged heterotrimers, and thus can report G protein dissocn. with high temporal resoln.  We find that heterotrimer dissocn. can occur in living cells in less than 100 ms.  Under the conditions of these expts. diffusion and collision of masGRK3ct fusion proteins and Gβγ-V were not rate-limiting.  These results indicate that G protein heterotrimers can dissoc. quickly enough to participate in rapid signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5hN_doIS7Vg90H21EOLACvtfcHk0lgh0lrH5N38ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslKkt7g%253D&md5=1f154d0e658dc3620b0cc7a3129dbf6a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2009.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2009.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DHollins%26aufirst%3DB.%26aulast%3DKuravi%26aufirst%3DS.%26aulast%3DDigby%26aufirst%3DG.%2BJ.%26aulast%3DLambert%26aufirst%3DN.%2BA.%26atitle%3DThe%2520c-terminus%2520of%2520GRK3%2520indicates%2520rapid%2520dissociation%2520of%2520G%2520protein%2520heterotrimers%26jtitle%3DCell.%2520Signalling%26date%3D2009%26volume%3D21%26spage%3D1015%26epage%3D1021%26doi%3D10.1016%2Fj.cellsig.2009.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL','PDB','3PBL'); return false;">PDB: 3PBL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M','PDB','5C1M'); return false;">PDB: 5C1M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CM4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CM4','PDB','6CM4'); return false;">PDB: 6CM4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i68"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00611">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_75205"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00611?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00611</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_001.csv">CSV</a>)</p></li><li><p class="inline">PDB files of all the ligand/target complexes studied (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_002.zip">ZIP</a>)</p></li><li><p class="inline">Analytical data summary of the products (combustion elemental analyses, HRMS–MS/MS, GC/MS, and HPLC), supporting table reporting biased agonism analysis at MOR signaling pathways, and supplemental figures of all the ligand/target complexes studied (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_001.csv">jm1c00611_si_001.csv (8.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_002.zip">jm1c00611_si_002.zip (1.85 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00611/suppl_file/jm1c00611_si_003.pdf">jm1c00611_si_003.pdf (5.97 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00611%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00611" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679969123b8a1995","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
